{"items": "705", "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish", "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.", "feed": [{"title": "The 'Buy Everything' Market Is Over: Synopsys-Ansys Merger Provides Fertile Ground For This Stock Picker - Ansys  ( NASDAQ:ANSS ) , Advanced Micro Devices  ( NASDAQ:AMD ) ", "url": "https://www.benzinga.com/markets/equities/24/01/36685633/exclusive-the-buy-everything-market-is-over-synopsys-ansys-merger-provides-fertile-ground-for-th", "time_published": "20240118T205452", "authors": ["Neil Dennis"], "summary": "The Federal Reserve is driving the market bus. Rate cut expectations have been re-drawn, and the \"buy everything\" sentiment that powered equity indices higher in the final quarter of 2023 is over. This is now a stock picker's market.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/MarcChaikin_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}, {"topic": "Manufacturing", "relevance_score": "0.2"}], "overall_sentiment_score": 0.129835, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.162802", "ticker_sentiment_score": "0.281674", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.162802", "ticker_sentiment_score": "0.263153", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ANSS", "relevance_score": "0.318897", "ticker_sentiment_score": "0.110557", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNPS", "relevance_score": "0.392537", "ticker_sentiment_score": "0.214586", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.162802", "ticker_sentiment_score": "0.114804", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.08183", "ticker_sentiment_score": "0.081535", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.162802", "ticker_sentiment_score": "0.114804", "ticker_sentiment_label": "Neutral"}]}, {"title": "List Price Of Ozempic And Other Drugs Reportedly Rise: Here's What That Means For Consumers", "url": "https://www.forbes.com/sites/ariannajohnson/2024/01/18/list-price-of-ozempic-and-other-drugs-reportedly-rise-heres-what-that-means-for-consumers/", "time_published": "20240118T194930", "authors": ["Arianna Johnson"], "summary": "Almost 800 medications-including Ozempic and Mounjaro-had a median list price increase of 4.5% this month, according to a Wall Street Journal report, meaning copays may increase for consumers.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/651ed914b753a9b834db1a57/0x0.jpg?format=jpg&crop=3317,1864,x0,y171,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.061908, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.113329", "ticker_sentiment_score": "0.068214", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.056808", "ticker_sentiment_score": "0.046999", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.113329", "ticker_sentiment_score": "0.052573", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.056808", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.113329", "ticker_sentiment_score": "0.052573", "ticker_sentiment_label": "Neutral"}]}, {"title": "Medicare drug price negotiations hit critical phase", "url": "https://www.marketwatch.com/story/medicare-drug-price-negotiations-hit-critical-phase-1f52a7e2", "time_published": "20240118T153200", "authors": ["Eleanor Laise"], "summary": "The federal government is set to make its opening offers in Medicare drug price negotiations, as courts prepare to weigh in on the process.", "banner_image": "https://images.mktw.net/im-860220/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.007182, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.071357", "ticker_sentiment_score": "0.058455", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.071357", "ticker_sentiment_score": "0.072962", "ticker_sentiment_label": "Neutral"}]}, {"title": "AbbVie, Arch Capital, Gilead Sciences And A Telecom Giant On CNBC's 'Final Trades' - Arch Capital Group  ( NASDAQ:ACGL ) , AbbVie  ( NYSE:ABBV ) ", "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/01/36673096/abbvie-arch-capital-gilead-sciences-and-a-telecom-giant-on-cnbcs-final-trades", "time_published": "20240118T143618", "authors": ["Avi Kapoor"], "summary": "On CNBC's \"Halftime Report Final Trades,\" Rob Sechan of NewEdge Wealth said Gilead Sciences, Inc. GILD is an inexpensive way to give biotech exposure. Gilead Sciences, last month, said that it has purchased 15 million shares of HOOKIPA Pharma Inc HOOK for approximately $21.25 million, at $1.4167 ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/18/abbvie_shutterstock_2333939969.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.29847, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACGL", "relevance_score": "0.522333", "ticker_sentiment_score": "0.239132", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HOOK", "relevance_score": "0.277433", "ticker_sentiment_score": "0.352976", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABBV", "relevance_score": "0.522333", "ticker_sentiment_score": "0.571704", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.522333", "ticker_sentiment_score": "0.426395", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTS", "relevance_score": "0.140896", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VZ", "relevance_score": "0.522333", "ticker_sentiment_score": "0.496772", "ticker_sentiment_label": "Bullish"}]}, {"title": "Gilead Sciences  ( GILD )  Rises As Market Takes a Dip: Key Facts", "url": "https://www.zacks.com/stock/news/2211770/gilead-sciences-gild-rises-as-market-takes-a-dip-key-facts", "time_published": "20240117T230017", "authors": ["Zacks Equity Research"], "summary": "In the closing of the recent trading day, Gilead Sciences (GILD) stood at $86.48, denoting a +0.57% change from the preceding trading day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default254.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.95493"}], "overall_sentiment_score": 0.174179, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.549988", "ticker_sentiment_score": "0.190998", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Can AI and a supercomputer beat the markets? This is one of the hedge funds trying to find out.", "url": "https://www.marketwatch.com/story/can-ai-and-a-supercomputer-beat-the-markets-this-is-one-of-the-hedge-funds-trying-to-find-out-25283664", "time_published": "20240117T174700", "authors": ["Louis Goss"], "summary": "Castle Ridge is tiny and based in a hedge fund backwater. But Adrian de Valois Franklin is betting artificial intelligence will give it an edge.", "banner_image": "https://images.mktw.net/im-91318840/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.104532, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.063341", "ticker_sentiment_score": "0.053015", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.063341", "ticker_sentiment_score": "-0.051181", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cell Therapy Market Global Surge to Over USD 26.8 Billion by 2033, Fueled by Growing Demand in United States", "url": "https://www.benzinga.com/pressreleases/24/01/g36658512/cell-therapy-market-global-surge-to-over-usd-26-8-billion-by-2033-fueled-by-growing-demand-in-unit", "time_published": "20240117T132147", "authors": ["Globe Newswire"], "summary": "New York, Jan. 17, 2024 ( GLOBE NEWSWIRE ) -- According to Market.us, the global Cell Therapy Market size is forecasted to exceed USD 26.8 Billion by 2033, with a promising CAGR of 16.9% from 2024 to 2033.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.310463, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALLO", "relevance_score": "0.018802", "ticker_sentiment_score": "0.168923", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.018802", "ticker_sentiment_score": "0.187222", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.018802", "ticker_sentiment_score": "-0.142541", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.018802", "ticker_sentiment_score": "0.187222", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.056363", "ticker_sentiment_score": "0.182015", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ATRA", "relevance_score": "0.018802", "ticker_sentiment_score": "-0.142541", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSOI", "relevance_score": "0.037593", "ticker_sentiment_score": "0.167406", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.037593", "ticker_sentiment_score": "0.071135", "ticker_sentiment_label": "Neutral"}, {"ticker": "JCRRF", "relevance_score": "0.018802", "ticker_sentiment_score": "-0.142541", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.018802", "ticker_sentiment_score": "-0.142541", "ticker_sentiment_label": "Neutral"}]}, {"title": "$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/24/01/36612997/1000-invested-in-gilead-sciences-20-years-ago-would-be-worth-this-much-today", "time_published": "20240112T160048", "authors": ["Benzinga Insights"], "summary": "Gilead Sciences GILD has outperformed the market over the past 20 years by 5.26% on an annualized basis producing an average annual return of 12.66%. Currently, Gilead Sciences has a market capitalization of $107.43 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Gilead Sciences  ( GILD )  Increases Despite Market Slip: Here's What You Need to Know", "url": "https://www.zacks.com/stock/news/2209192/gilead-sciences-gild-increases-despite-market-slip-heres-what-you-need-to-know", "time_published": "20240111T230019", "authors": ["Zacks Equity Research"], "summary": "In the closing of the recent trading day, Gilead Sciences (GILD) stood at $85.39, denoting a +1.05% change from the preceding trading day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default122.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.216869, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.629492", "ticker_sentiment_score": "0.263205", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report", "url": "https://www.prnewswire.com/news-releases/clarivate-identifies-thirteen-potential-blockbuster-drugs-and-gamechangers-in-annual-drugs-to-watch-report-302027294.html", "time_published": "20240108T080000", "authors": ["Clarivate Plc"], "summary": "Therapeutic advancements for sickle cell disease, RSV, breast cancer, Crohn's and other ailments poised to advance patient health despite urgent challenges facing life science companies", "banner_image": "https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.242731, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLUE", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "III", "relevance_score": "0.020266", "ticker_sentiment_score": "0.240962", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.040519", "ticker_sentiment_score": "-0.030752", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.040519", "ticker_sentiment_score": "-0.030752", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.020266", "ticker_sentiment_score": "-0.125978", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLVT", "relevance_score": "0.239502", "ticker_sentiment_score": "0.270064", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.020266", "ticker_sentiment_score": "-0.125978", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIOVF", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.040519", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report", "url": "https://www.newswire.ca/news-releases/clarivate-identifies-thirteen-potential-blockbuster-drugs-and-gamechangers-in-annual-drugs-to-watch-report-802561925.html", "time_published": "20240108T080000", "authors": ["Clarivate Plc"], "summary": "Therapeutic advancements for sickle cell disease, RSV, breast cancer, Crohn's and other ailments poised to advance patient health despite urgent challenges facing life science companies", "banner_image": "https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg?p=facebook", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.242731, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLUE", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "III", "relevance_score": "0.020266", "ticker_sentiment_score": "0.240962", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.040519", "ticker_sentiment_score": "-0.030752", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.040519", "ticker_sentiment_score": "-0.030752", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.020266", "ticker_sentiment_score": "-0.125978", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLVT", "relevance_score": "0.239502", "ticker_sentiment_score": "0.270064", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.020266", "ticker_sentiment_score": "-0.125978", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIOVF", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.040519", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.020266", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Stock Falls Amid Market Uptick: What Investors Need to Know", "url": "https://www.zacks.com/stock/news/2206596/gilead-sciences-gild-stock-falls-amid-market-uptick-what-investors-need-to-know", "time_published": "20240105T230019", "authors": ["Zacks Equity Research"], "summary": "In the most recent trading session, Gilead Sciences (GILD) closed at $83.31, indicating a -1.38% shift from the previous trading day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default316.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928769"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.164789, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.504646", "ticker_sentiment_score": "0.212063", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns - Bristol-Myers Squibb  ( NYSE:BMY ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36473452/this-analyst-downgrades-bristol-myers-squibb-cautions-amid-product-launch-and-reven", "time_published": "20240103T172930", "authors": ["Vandana Singh"], "summary": "BofA Securities downgraded Bristol-Myers Squibb & Co BMY, noting that initially, the analyst believed that Bristol's loss of exclusivity ( LOEs ) for drugs like Eliquis and Opdivo was widely understood and it was anticipated that new product lineup would compensate for these losses and boost ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/03/bmy.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.241436, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BMY", "relevance_score": "0.56415", "ticker_sentiment_score": "0.197908", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.303175", "ticker_sentiment_score": "0.282842", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.303175", "ticker_sentiment_score": "0.282842", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": " ( GILD )  - Analyzing Gilead Sciences's Short Interest - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/short-sellers/24/01/36468482/gild-analyzing-gilead-sciencess-short-interest", "time_published": "20240103T133019", "authors": ["Benzinga Insights"], "summary": "Gilead Sciences's GILD short percent of float has risen 6.41% since its last report. The company recently reported that it has 18.50 million shares sold short, which is 1.66% of all regular shares that are available for trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.267332, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.221819", "ticker_sentiment_score": "0.155473", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Galapagos signs agreement to transfer Jyseleca\u00ae business to Alfasigma", "url": "https://www.globenewswire.com/news-release/2024/01/02/2802388/0/en/Galapagos-signs-agreement-to-transfer-Jyseleca-business-to-Alfasigma.html", "time_published": "20240102T060000", "authors": ["Galapagos NV"], "summary": "Mechelen, Belgium. 02 January 2024, 07:00 CET. Galapagos NV ( Euronext & NASDAQ: GLPG ) and Alfasigma S.p.A. today announced that they have signed an agreement to transfer Galapagos' Jyseleca\u00ae ( filgotinib ) business to Alfasigma, marking a significant milestone in Galapagos' transformation into ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/13b034e2-76d4-408b-bffb-c80d85420b03", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.232764, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GLPG", "relevance_score": "0.583156", "ticker_sentiment_score": "0.349798", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSOI", "relevance_score": "0.032382", "ticker_sentiment_score": "0.134818", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.032382", "ticker_sentiment_score": "0.151775", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Galapagos signs agreement to transfer Jyseleca\u00ae business to Alfasigma - Galapagos  ( NASDAQ:GLPG ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36446176/galapagos-signs-agreement-to-transfer-jyseleca-business-to-alfasigma", "time_published": "20240102T060000", "authors": ["Globe Newswire"], "summary": "Transaction expected to close in the first quarter of 2024, subject to customary closing conditions Michele Manto, Galapagos' Chief Commercial Officer, to join Alfasigma Mechelen, Belgium. 02 January 2024, 07:00 CET.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.228084, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GLPG", "relevance_score": "0.592249", "ticker_sentiment_score": "0.364126", "ticker_sentiment_label": "Bullish"}, {"ticker": "TSOI", "relevance_score": "0.031446", "ticker_sentiment_score": "0.125588", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.031446", "ticker_sentiment_score": "0.151309", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead Sciences  ( GILD )  Stock Moves -0.16%: What You Should Know", "url": "https://www.zacks.com/stock/news/2203937/gilead-sciences-gild-stock-moves--016-what-you-should-know", "time_published": "20231229T230018", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Gilead Sciences (GILD) closed at $81.01, marking a -0.16% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default357.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.165637, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.523451", "ticker_sentiment_score": "0.195074", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Harpoon Therapeutics Strengthens Leadership Team - Harpoon Therapeutics  ( NASDAQ:HARP ) ", "url": "https://www.benzinga.com/pressreleases/23/12/g36382813/harpoon-therapeutics-strengthens-leadership-team", "time_published": "20231226T123000", "authors": ["Globe Newswire"], "summary": "James Bucher, J.D. joins as Chief Legal Officer Wendy Chang promoted to Chief People Officer SOUTH SAN FRANCISCO, Calif., Dec. 26, 2023 ( GLOBE NEWSWIRE ) -- Harpoon Therapeutics, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.227417, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "WEN", "relevance_score": "0.049221", "ticker_sentiment_score": "0.187072", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EXEL", "relevance_score": "0.049221", "ticker_sentiment_score": "0.086826", "ticker_sentiment_label": "Neutral"}, {"ticker": "ELYM", "relevance_score": "0.049221", "ticker_sentiment_score": "0.086826", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.049221", "ticker_sentiment_score": "0.066801", "ticker_sentiment_label": "Neutral"}, {"ticker": "HARP", "relevance_score": "0.33433", "ticker_sentiment_score": "0.206455", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:GBP", "relevance_score": "0.049221", "ticker_sentiment_score": "0.086826", "ticker_sentiment_label": "Neutral"}]}, {"title": "Harpoon Therapeutics Strengthens Leadership Team", "url": "https://www.globenewswire.com/news-release/2023/12/26/2801063/0/en/Harpoon-Therapeutics-Strengthens-Leadership-Team.html", "time_published": "20231226T123000", "authors": ["Harpoon Therapeutics Inc."], "summary": "James Bucher, J.D. joins as Chief Legal Officer ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/7e618bf2-6d57-40b3-bdd8-00765a1ed497", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.905476"}], "overall_sentiment_score": 0.206841, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "WEN", "relevance_score": "0.040011", "ticker_sentiment_score": "0.183994", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EXEL", "relevance_score": "0.040011", "ticker_sentiment_score": "0.085583", "ticker_sentiment_label": "Neutral"}, {"ticker": "ELYM", "relevance_score": "0.040011", "ticker_sentiment_score": "0.085583", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.040011", "ticker_sentiment_score": "0.065714", "ticker_sentiment_label": "Neutral"}, {"ticker": "HARP", "relevance_score": "0.45283", "ticker_sentiment_score": "0.21039", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:GBP", "relevance_score": "0.040011", "ticker_sentiment_score": "0.085583", "ticker_sentiment_label": "Neutral"}]}, {"title": "$100 Invested In This Stock 20 Years Ago Would Be Worth $1,100 Today - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/23/12/36379733/100-invested-in-this-stock-20-years-ago-would-be-worth-1-100-today", "time_published": "20231225T180057", "authors": ["Benzinga Insights"], "summary": "Gilead Sciences GILD has outperformed the market over the past 20 years by 5.22% on an annualized basis producing an average annual return of 12.73%. Currently, Gilead Sciences has a market capitalization of $99.26 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "A Look Into Gilead Sciences Inc's Price Over Earnings - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/23/12/36364654/a-look-into-gilead-sciences-incs-price-over-earnings", "time_published": "20231222T160026", "authors": ["Benzinga Insights"], "summary": "Looking into the current session, Gilead Sciences Inc. GILD shares are trading at $79.75, after a 1.03% increase. Moreover, over the past month, the stock spiked by 5.79%, but in the past year, fell by 6.19%.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.149601, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.340915", "ticker_sentiment_score": "-0.046641", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nasdaq Gains 100 Points; CarMax Earnings Top Views - Clene  ( NASDAQ:CLNN ) , Annexon  ( NASDAQ:ANNX ) ", "url": "https://www.benzinga.com/news/earnings/23/12/36350420/nasdaq-gains-100-points-carmax-earnings-top-views", "time_published": "20231221T192303", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Thursday. The Dow traded up 0.37% to 37,218.15 while the NASDAQ rose 0.73% to 14,885.76. The S&P 500 also rose, gaining, 0.50% to 4,721.72. Materials shares jumped by 0.7% on Thursday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/21/image20.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.058145, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LGVN", "relevance_score": "0.123844", "ticker_sentiment_score": "-0.077903", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOOK", "relevance_score": "0.123844", "ticker_sentiment_score": "0.227132", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PBLA", "relevance_score": "0.184834", "ticker_sentiment_score": "0.352363", "ticker_sentiment_label": "Bullish"}, {"ticker": "AVGO", "relevance_score": "0.06211", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLNN", "relevance_score": "0.184834", "ticker_sentiment_score": "0.109269", "ticker_sentiment_label": "Neutral"}, {"ticker": "KMX", "relevance_score": "0.184834", "ticker_sentiment_score": "0.112789", "ticker_sentiment_label": "Neutral"}, {"ticker": "TGI", "relevance_score": "0.123844", "ticker_sentiment_score": "0.320759", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ANNX", "relevance_score": "0.244723", "ticker_sentiment_score": "0.140637", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.06211", "ticker_sentiment_score": "0.197164", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Crude Oil Moves Lower; Micron Issues Strong Forecast - DMK Pharmaceuticals  ( NASDAQ:DMK ) , Clene  ( NASDAQ:CLNN ) ", "url": "https://www.benzinga.com/news/earnings/23/12/36347681/crude-oil-moves-lower-micron-issues-strong-forecast", "time_published": "20231221T165953", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Thursday. The Dow traded up 0.58% to 37,296.40 while the NASDAQ rose 0.77% to 14,891.87. The S&P 500 also rose, gaining, 0.68% to 4,730.26. Health care shares jumped by 1% on Thursday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/21/crude_oil_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.062889, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LGVN", "relevance_score": "0.124486", "ticker_sentiment_score": "-0.078083", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOOK", "relevance_score": "0.124486", "ticker_sentiment_score": "0.227652", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PBLA", "relevance_score": "0.185781", "ticker_sentiment_score": "0.353559", "ticker_sentiment_label": "Bullish"}, {"ticker": "PRZO", "relevance_score": "0.124486", "ticker_sentiment_score": "0.139405", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVGO", "relevance_score": "0.062434", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DMK", "relevance_score": "0.185781", "ticker_sentiment_score": "0.282823", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CLNN", "relevance_score": "0.185781", "ticker_sentiment_score": "0.109678", "ticker_sentiment_label": "Neutral"}, {"ticker": "MU", "relevance_score": "0.124486", "ticker_sentiment_score": "0.37546", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.062434", "ticker_sentiment_score": "0.197188", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More", "url": "https://www.zacks.com/stock/news/2201158/biotech-stock-roundup-cgen-up-on-gild-deal-mrna-gains-on-study-data-more", "time_published": "20231221T163900", "authors": ["Zacks Equity Research"], "summary": "Compugen (CGEN) and Moderna (MRNA) are in the news on collaboration and study updates, respectively.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}], "overall_sentiment_score": 0.079368, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CGEN", "relevance_score": "0.392948", "ticker_sentiment_score": "0.207093", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.136113", "ticker_sentiment_score": "0.05447", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.310843", "ticker_sentiment_score": "0.156311", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.136113", "ticker_sentiment_score": "0.065648", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Is Immunotherapy-Focused Hookipa Pharma Stock Soaring Today? - HOOKIPA Pharma  ( NASDAQ:HOOK ) ", "url": "https://www.benzinga.com/general/biotech/23/12/36341713/why-is-immunotherapy-focused-hookipa-pharma-stock-soaring-today", "time_published": "20231221T160218", "authors": ["Vandana Singh"], "summary": "Gilead Sciences Inc GILD announced on Thursday that it has purchased 15 million shares of HOOKIPA Pharma Inc HOOK for approximately $21.25 million, at $1.4167 per share. In addition, HOOKIPA has the right to sell an additional approximately $8.75 million of common stock to Gilead as pro-rata ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/21/hook.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}], "overall_sentiment_score": 0.332915, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HOOK", "relevance_score": "0.443626", "ticker_sentiment_score": "0.481409", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.443626", "ticker_sentiment_score": "0.481409", "ticker_sentiment_label": "Bullish"}]}, {"title": "Dow Jumps 250 Points; US Weekly Jobless Claims Edge Higher - DMK Pharmaceuticals  ( NASDAQ:DMK ) , Clene  ( NASDAQ:CLNN ) ", "url": "https://www.benzinga.com/news/earnings/23/12/36344590/dow-jumps-250-points-us-weekly-jobless-claims-edge-higher", "time_published": "20231221T144830", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded higher this morning, with the Dow Jones gaining around 250 points on Thursday. Following the market opening Thursday, the Dow traded up 0.72% to 37,348.90 while the NASDAQ rose 0.96% to 14,919.80. The S&P 500 also rose, gaining, 0.78% to 4,734.96.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/21/image29.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.012056, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HOOK", "relevance_score": "0.160633", "ticker_sentiment_score": "0.260962", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AVGO", "relevance_score": "0.080728", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DMK", "relevance_score": "0.238913", "ticker_sentiment_score": "0.339212", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.080728", "ticker_sentiment_score": "0.201193", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NOGN", "relevance_score": "0.160633", "ticker_sentiment_score": "-0.145717", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLNN", "relevance_score": "0.238913", "ticker_sentiment_score": "0.133294", "ticker_sentiment_label": "Neutral"}]}, {"title": "HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences", "url": "https://www.globenewswire.com/news-release/2023/12/21/2799897/0/en/HOOKIPA-Pharma-Announces-21-25-Million-Equity-Investment-from-Gilead-Sciences.html", "time_published": "20231221T120100", "authors": ["HOOKIPA Pharma Inc"], "summary": "NEW YORK and VIENNA, Austria, Dec. 21, 2023 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( NASDAQ: HOOK, 'HOOKIPA' ) , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that Gilead Sciences ( 'Gilead' ) has purchased 15 million ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/62ba88bb-8adc-44c4-9fd7-3f6ca365c93d", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}], "overall_sentiment_score": 0.123305, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HOOK", "relevance_score": "0.130926", "ticker_sentiment_score": "0.050704", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.032871", "ticker_sentiment_score": "0.040987", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Stock Could Finally Have a Breakout Year. Here's Why.", "url": "https://www.barrons.com/amp/articles/gilead-stock-breakout-year-2024-1dbb7728", "time_published": "20231221T073000", "authors": ["Jacob Sonenshine"], "summary": "Investors have been waiting years for Gilead Sciences to finally recover from its blowup in 2016. Will 2024 be the year it finally does? It's hard to remember now, but Gilead was once the hottest of biotech stocks. That was back in the 2010s, when it cured hepatitis C.", "banner_image": "https://images.barrons.com/im-40882170/social", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.112154, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.140896", "ticker_sentiment_score": "0.209919", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead Sciences  ( GILD )  Stock Moves -1.13%: What You Should Know", "url": "https://www.zacks.com/stock/news/2200767/gilead-sciences-gild-stock-moves--113-what-you-should-know", "time_published": "20231220T225012", "authors": ["Zacks Equity Research"], "summary": "In the closing of the recent trading day, Gilead Sciences (GILD) stood at $78.59, denoting a -1.13% change from the preceding trading day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default79.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.201767, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.596978", "ticker_sentiment_score": "0.25759", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Is RedHill Biopharma  ( RDHL )  Stock Surging Today? - Redhill Biopharma  ( NASDAQ:RDHL ) ", "url": "https://www.benzinga.com/general/biotech/23/12/36327726/redhills-investigational-covid-19-drugs-combined-with-gileads-show-effect-against-ebola", "time_published": "20231220T180131", "authors": ["Vandana Singh"], "summary": "RedHill Biopharma Ltd RDHL says opaganib and RHB-107 ( upamostat ) demonstrated robust synergistic effects when combined individually with Gilead Sciences Inc GILD Veklury ( remdesivir ) in a new U.S. Army-funded and conducted Ebola virus in vitro study.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/20/rdhl.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.140235, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RDHL", "relevance_score": "0.395012", "ticker_sentiment_score": "0.08172", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.269776", "ticker_sentiment_score": "-0.032663", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead  ( GILD ) , Compugen Collaborate for Immunotherapy Program", "url": "https://www.zacks.com/stock/news/2200585/gilead-gild-compugen-collaborate-for-immunotherapy-program", "time_published": "20231220T153300", "authors": ["Zacks Equity Research"], "summary": "Gilead (GILD) enters into a license agreement with Compugen for its pre-clinical immunotherapy program.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.107957, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.24847", "ticker_sentiment_score": "0.143057", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHGI", "relevance_score": "0.125789", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CGEN", "relevance_score": "0.420483", "ticker_sentiment_score": "0.060363", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.365166", "ticker_sentiment_score": "0.092221", "ticker_sentiment_label": "Neutral"}]}, {"title": "RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola", "url": "https://www.prnewswire.com/news-releases/redhill-and-us-army-announce-opaganib-and-rhb-107-combinations-with-remdesivir-show-distinct-synergistic-effect-against-ebola-302020104.html", "time_published": "20231220T134500", "authors": ["RedHill Biopharma Ltd."], "summary": "RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.00727, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RDHL", "relevance_score": "0.126119", "ticker_sentiment_score": "0.023855", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.014071", "ticker_sentiment_score": "-0.153791", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GILD", "relevance_score": "0.028138", "ticker_sentiment_score": "-0.057413", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is American Century U.S. Quality Value ETF  ( VALQ )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2200357/is-american-century-us-quality-value-etf-valq-a-strong-etf-right-now", "time_published": "20231220T112006", "authors": ["Zacks Equity Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default103.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.319158, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.115787", "ticker_sentiment_score": "0.044463", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.115787", "ticker_sentiment_score": "0.044463", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.115787", "ticker_sentiment_score": "0.044463", "ticker_sentiment_label": "Neutral"}]}, {"title": "Compugen's stock rockets on deal with Gilead for anti-tumor drug", "url": "https://www.marketwatch.com/story/compugen-stock-rockets-on-anti-tumor-drug-deal-with-gilead-411f9617", "time_published": "20231219T155200", "authors": ["Steve Gelsi"], "summary": "Shares are halted for volatility but rise to highest levels since mid-2022 on resumed trading.", "banner_image": "https://images.mktw.net/im-771567/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.115759, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CGEN", "relevance_score": "0.726435", "ticker_sentiment_score": "0.185979", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.488777", "ticker_sentiment_score": "0.189445", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today? - Compugen  ( NASDAQ:CGEN ) ", "url": "https://www.benzinga.com/general/biotech/23/12/36302707/why-is-cancer-immunotherapy-focused-compugen-stock-is-trading-higher-today", "time_published": "20231219T153645", "authors": ["Vandana Singh"], "summary": "Gilead Sciences Inc GILD announced an agreement with Compugen Ltd CGEN to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the COM503 drug candidate.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/19/cgen.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.09063, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.285526", "ticker_sentiment_score": "0.153867", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CGEN", "relevance_score": "0.900307", "ticker_sentiment_score": "0.309158", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.285526", "ticker_sentiment_score": "0.248491", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": " ( GILD )  - Analyzing Gilead Sciences's Short Interest - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/short-sellers/23/12/36290043/gild-analyzing-gilead-sciencess-short-interest", "time_published": "20231218T193039", "authors": ["Benzinga Insights"], "summary": "Gilead Sciences's GILD short percent of float has fallen 4.29% since its last report. The company recently reported that it has 17.42 million shares sold short, which is 1.56% of all regular shares that are available for trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.239316, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.221819", "ticker_sentiment_score": "0.083071", "ticker_sentiment_label": "Neutral"}]}, {"title": "Patients Regain Weight After They Quit Using Ozempic Rival Zepbound. Here's Why That Makes Eli Lilly Stock an Even Better Buy.", "url": "https://www.fool.com/investing/2023/12/16/ozempic-zepbound-eli-lilly-stock-better-buy/", "time_published": "20231216T105500", "authors": ["Keith Speights"], "summary": "Lilly's weight loss drug appears to be on the way to becoming a megablockbuster.", "banner_image": "https://media.ycharts.com/charts/39a01a5a743922aa91d566a6a5310e4b.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.132674, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.513606", "ticker_sentiment_score": "0.204324", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.165409", "ticker_sentiment_score": "0.170712", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead  ( GILD )  Outperforms Industry in 6 Months: What Lies Ahead?", "url": "https://www.zacks.com/stock/news/2198930/gilead-gild-outperforms-industry-in-6-months-what-lies-ahead", "time_published": "20231215T174900", "authors": ["Zacks Equity Research"], "summary": "Gilead (GILD) gains 3.7% in six months as its oncology portfolio gains traction and its HIV business maintains momentum.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.130129, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.049019", "ticker_sentiment_score": "-0.024884", "ticker_sentiment_label": "Neutral"}, {"ticker": "BICEF", "relevance_score": "0.049019", "ticker_sentiment_score": "0.114683", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVAX", "relevance_score": "0.194242", "ticker_sentiment_score": "0.073547", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.194242", "ticker_sentiment_score": "0.095526", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRDA", "relevance_score": "0.146321", "ticker_sentiment_score": "0.062328", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.097854", "ticker_sentiment_score": "0.191681", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead Sciences  ( GILD )  Stock Sinks As Market Gains: Here's Why", "url": "https://www.zacks.com/stock/news/2198306/gilead-sciences-gild-stock-sinks-as-market-gains-heres-why", "time_published": "20231214T225004", "authors": ["Zacks Equity Research"], "summary": "In the closing of the recent trading day, Gilead Sciences (GILD) stood at $81.78, denoting a -1.58% change from the preceding trading day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default338.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.23112, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.659949", "ticker_sentiment_score": "0.300743", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Envista Holdings Corporation Appoints Three New Members to Leadership Team", "url": "https://www.prnewswire.com/news-releases/envista-holdings-corporation-appoints-three-new-members-to-leadership-team-302015992.html", "time_published": "20231214T211000", "authors": ["Envista Holdings Corporation"], "summary": "BREA, Calif., Dec. 14, 2023 /PRNewswire/ -- Envista Holdings Corporation ( NYSE: NVST ) today announced the expansion of its leadership team, with the recent appointments of Robert Befidi as President, Diagnostics. Suraj Satpathy as Chief Human Resources Officer. and Andrew Chen as Chief ...", "banner_image": "https://mma.prnewswire.com/media/1008600/Envista_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.382989, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.058047", "ticker_sentiment_score": "0.018019", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.058047", "ticker_sentiment_score": "0.029973", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.058047", "ticker_sentiment_score": "0.029973", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVST", "relevance_score": "0.656158", "ticker_sentiment_score": "0.569572", "ticker_sentiment_label": "Bullish"}, {"ticker": "JPM", "relevance_score": "0.058047", "ticker_sentiment_score": "0.029973", "ticker_sentiment_label": "Neutral"}, {"ticker": "DHR", "relevance_score": "0.058047", "ticker_sentiment_score": "0.018019", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pediatric Health Care Products and Services Market Set to Surge at 6.9% CAGR, to Reach USD 173.5 billion by 2031| Transparency Market Research, Inc.", "url": "https://www.benzinga.com/pressreleases/23/12/g36201229/pediatric-health-care-products-and-services-market-set-to-surge-at-6-9-cagr-to-reach-usd-173-5-bil", "time_published": "20231212T163000", "authors": ["Globe Newswire"], "summary": "Wilmington, Delaware, United States, Dec. 12, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The market for pediatric health care products and services is projected to thrive with an anticipated CAGR of 6.9% between 2023 and 2031.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.414749, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "NVS", "relevance_score": "0.067064", "ticker_sentiment_score": "0.230447", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.033562", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.033562", "ticker_sentiment_score": "0.195607", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCSG", "relevance_score": "0.033562", "ticker_sentiment_score": "0.269025", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.067064", "ticker_sentiment_score": "0.146108", "ticker_sentiment_label": "Neutral"}]}, {"title": "10 Best Tech Stocks For 2024", "url": "https://www.forbes.com/sites/investor-hub/article/best-tech-stocks-for-2024/", "time_published": "20231212T153842", "authors": ["CFP(R)", "Jason Kirsch"], "summary": "In this article, I look at the power and potential of technology stocks in shaping your investment portfolio. Read on to discover the compelling benefits of owning tech stocks, their dynamic nature, their ability to drive substantial growth and how to navigate the ever-evolving landscape in 2024.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/657878e2a81e6658ba680733/0x0.jpg?format=jpg&crop=1770,995,x0,y89,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.999767"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.432514, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "CPRT", "relevance_score": "0.054532", "ticker_sentiment_score": "0.144005", "ticker_sentiment_label": "Neutral"}, {"ticker": "DTST", "relevance_score": "0.021827", "ticker_sentiment_score": "0.231093", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.076288", "ticker_sentiment_score": "0.144951", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.054532", "ticker_sentiment_score": "0.139018", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRCX", "relevance_score": "0.032736", "ticker_sentiment_score": "0.248221", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.010915", "ticker_sentiment_score": "0.173467", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EA", "relevance_score": "0.097987", "ticker_sentiment_score": "0.218195", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TCTZF", "relevance_score": "0.065416", "ticker_sentiment_score": "0.210178", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "A Bull Market Is Coming: 1 Stock That Could Rocket 219% Higher in 2024, According to Wall Street", "url": "https://www.fool.com/investing/2023/12/12/a-bull-market-is-coming-1-stock-that-could-rocket/", "time_published": "20231212T102900", "authors": ["Cory Renauer"], "summary": "There's a huge gap between what the stock market and Wall Street analysts have to say about this often-overlooked growth stock.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F757793%2Finvestor-looks-at-financial-chart-on-laptop-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.104089, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GS", "relevance_score": "0.052685", "ticker_sentiment_score": "0.091005", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.052685", "ticker_sentiment_score": "-0.074158", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOVA", "relevance_score": "0.2589", "ticker_sentiment_score": "-0.029887", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences Battles Rising Threat of Drug Counterfeiting, Initiates Legal Actions - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/general/biotech/23/12/36179349/gilead-sciences-battles-rising-threat-of-drug-counterfeiting-initiates-legal-actions", "time_published": "20231211T171151", "authors": ["Vandana Singh"], "summary": "Gilead Sciences Inc GILD faces a severe threat from the rise in drug counterfeiting, a global issue highlighted by the World Health Organization's staggering estimate of up to $431 billion in counterfeit drugs annually.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/11/gilead.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.061031, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.375251", "ticker_sentiment_score": "-0.274068", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.375251", "ticker_sentiment_score": "0.36812", "ticker_sentiment_label": "Bullish"}]}, {"title": "Fraud in a bottle: How Big Pharma takes on criminals who make millions off counterfeit drugs", "url": "https://www.cnbc.com/2023/12/11/fraud-in-a-bottle-big-pharma-takes-on-counterfeit-drugs.html", "time_published": "20231211T140001", "authors": ["Contessa Brewer", "Scott Zamost"], "summary": "A CNBC investigation found criminal networks altering pill bottles of lifesaving drugs and then selling them back to pharmacies at large discounts.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107345437-1702070982673-1702064178880-PILL_FRAUD_FINAL_12_8_YOU_TUBE_R1.jpg?v=1702070985&w=750&h=422&vtcrop=y", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.009621, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.018243", "ticker_sentiment_score": "-0.078369", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.05469", "ticker_sentiment_score": "-0.068818", "ticker_sentiment_label": "Neutral"}]}, {"title": "This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks", "url": "https://www.fool.com/investing/2023/12/10/emerging-risk-problem-big-pharma-stocks/", "time_published": "20231210T184800", "authors": ["Alex Carchidi"], "summary": "Regulators are already on the case, and their findings will have financial impacts.", "banner_image": "https://g.foolcdn.com/editorial/images/757221/scientist-peers-into-microscope-in-laboratory.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.026577, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BMY", "relevance_score": "0.135094", "ticker_sentiment_score": "0.057097", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.090304", "ticker_sentiment_score": "0.027038", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Outpaces Stock Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2195772/gilead-sciences-gild-outpaces-stock-market-gains-what-you-should-know", "time_published": "20231208T225005", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Gilead Sciences (GILD) closed at $79.02, marking a +1.24% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default206.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.219503, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.576289", "ticker_sentiment_score": "0.31023", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Red Biotechnology Market to Reach $1,513.22 Billion, Globally, by 2030 at 10.7% CAGR: Coherent Market Insights", "url": "https://www.prnewswire.com/news-releases/red-biotechnology-market-to-reach-1-513-22-billion-globally-by-2030-at-10-7-cagr-coherent-market-insights-302009313.html", "time_published": "20231208T071400", "authors": ["Coherent Market Insights"], "summary": "BURLINGAME, Calif., Dec. 8, 2023 /PRNewswire/ -- According to Coherent Market Insights, The global red biotechnology market was valued at US$ 742.80 Billion in 2023 and is forecast to reach a value of US$ 1,513.22 Billion by 2030 at a CAGR of 10.7% between 2023 and 2030.", "banner_image": "https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.196644, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BAYZF", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Is Gilead  ( GILD )  Up 1.9% Since Last Earnings Report?", "url": "https://www.zacks.com/stock/news/2194972/why-is-gilead-gild-up-19-since-last-earnings-report", "time_published": "20231207T163057", "authors": ["Zacks Equity Research"], "summary": "Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default18.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99237"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.091552, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BPMC", "relevance_score": "0.135729", "ticker_sentiment_score": "0.022899", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.068112", "ticker_sentiment_score": "0.142095", "ticker_sentiment_label": "Neutral"}]}, {"title": "A Look Into Gilead Sciences Inc's Price Over Earnings - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/23/12/36135209/a-look-into-gilead-sciences-incs-price-over-earnings", "time_published": "20231207T150029", "authors": ["Benzinga Insights"], "summary": "Looking into the current session, Gilead Sciences Inc. GILD shares are trading at $79.44, after a 0.10% increase. Moreover, over the past month, the stock increased by 5.57%, but in the past year, fell by 10.01%.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.159004, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.340915", "ticker_sentiment_score": "-0.01236", "ticker_sentiment_label": "Neutral"}]}, {"title": "Merck's lung cancer drug combo fails to meet trial goal", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/mercks-lung-cancer-drug-combo-fails-meet-trial-goal-2023-12-07/", "time_published": "20231207T111300", "authors": ["Reuters"], "summary": "Dec 7 ( Reuters ) - Merck ( MRK.N ) said on Thursday its experimental therapy in combination with Keytruda to treat a type of lung cancer in previously treated patients did not meet the main goal in a mid-stage study.", "banner_image": "https://www.reuters.com/pf/resources/images/reuters/reuters-default.webp?d=165", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.194326, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.218817", "ticker_sentiment_score": "0.036954", "ticker_sentiment_label": "Neutral"}]}, {"title": "If You Invested $1000 In This Stock 20 Years Ago, You Would Have $11,000 Today - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/23/12/36113449/if-you-invested-1000-in-this-stock-20-years-ago-you-would-have-11-000-today", "time_published": "20231206T143037", "authors": ["Benzinga Insights"], "summary": "Gilead Sciences GILD has outperformed the market over the past 20 years by 5.36% on an annualized basis producing an average annual return of 12.88%. Currently, Gilead Sciences has a market capitalization of $98.54 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Hospital Infection Therapeutics Market to be Worth USD 14.4 billion by 2031| Transparency Market Research, Inc.", "url": "https://www.benzinga.com/pressreleases/23/12/g36087772/hospital-infection-therapeutics-market-to-be-worth-usd-14-4-billion-by-2031-transparency-market-re", "time_published": "20231205T120000", "authors": ["Globe Newswire"], "summary": "Wilmington, Delaware, United States, Dec. 05, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global hospital infection therapeutics market was estimated to have acquired US$ 11.3 billion in 2022.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.266143"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.122221, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HKMPF", "relevance_score": "0.044551", "ticker_sentiment_score": "0.128169", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.044551", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.044551", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.044551", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy\u00ae and IDE397 Combination in MTAP-Deletion Bladder Cancer", "url": "https://www.prnewswire.com/news-releases/ideaya-announces-clinical-study-collaboration-with-gilead-sciences-to-evaluate-trodelvy-and-ide397-combination-in-mtap-deletion-bladder-cancer-302003940.html", "time_published": "20231204T110000", "authors": ["IDEAYA Biosciences", "Inc."], "summary": "IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy\u00ae and IDE397 Combination ... PR ...", "banner_image": "https://mma.prnewswire.com/media/820568/IDEAYA_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.041402, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IDYA", "relevance_score": "0.174587", "ticker_sentiment_score": "0.061329", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.058615", "ticker_sentiment_score": "0.136018", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gene therapy market size to grow by USD 4,613.9 million from 2022 to 2027 | Growing research in gene therapy for ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/gene-therapy-market-size-to-grow-by-usd-4-613-9-million-from-2022-to-2027--growing-research-in-gene-therapy-for-cvds-and-orphan-diseases-is-the-major-market-trend--technavio-302002646.html", "time_published": "20231201T073500", "authors": [], "summary": "Gene therapy market size to grow by USD 4,613.9 million from 2022 to 2027 | Growing research in gene therapy for ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.290604, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GBIO", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "GIC", "relevance_score": "0.048523", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORTX", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSTX", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADVM", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "VYGR", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADAP", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGMO", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABEO", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Biotech Stocks You Can Buy and Hold for the Next Decade", "url": "https://www.fool.com/investing/2023/11/30/2-biotech-stocks-you-can-buy-and-hold-for-the-next/", "time_published": "20231130T133000", "authors": ["Prosper Junior Bakiny"], "summary": "These stocks aren't popular on the market right now, but investors shouldn't let that scare them off.", "banner_image": "https://g.foolcdn.com/editorial/images/755961/doctor-with-patient-talking.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}], "overall_sentiment_score": 0.168984, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.366832", "ticker_sentiment_score": "0.261516", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.366832", "ticker_sentiment_score": "0.174478", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "CAR T-Cell Therapies Under FDA Watch on Reports of Malignancies", "url": "https://www.zacks.com/stock/news/2190744/car-t-cell-therapies-under-fda-watch-on-reports-of-malignancies", "time_published": "20231129T133700", "authors": ["Ekta Bagri"], "summary": "The FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.01936, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TSVT", "relevance_score": "0.046724", "ticker_sentiment_score": "0.065389", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.093289", "ticker_sentiment_score": "0.057718", "ticker_sentiment_label": "Neutral"}, {"ticker": "LEGN", "relevance_score": "0.139534", "ticker_sentiment_score": "0.02006", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILEAD SCIENCES AWARDS OVER US$1.5 MILLION TO STRENGTHEN SUPPORT FOR COMMUNITY-LED HIV PROJECTS IN ASIA PACIFIC", "url": "https://www.prnewswire.com/apac/news-releases/gilead-sciences-awards-over-us1-5-million-to-strengthen-support-for-community-led-hiv-projects-in-asia-pacific-302000007.html", "time_published": "20231129T030000", "authors": ["Gilead Sciences", "Inc."], "summary": "GILEAD SCIENCES AWARDS OVER US$1.5 MILLION TO STRENGTHEN SUPPORT FOR COMMUNITY-LED HIV ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1775570/Gilead_Sciences_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.356349, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.197682", "ticker_sentiment_score": "0.235055", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "US FDA investigating safety risk of CAR-T cancer therapies", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-investigating-safety-risk-car-t-cancer-therapies-2023-11-28/", "time_published": "20231128T184200", "authors": ["Pratik Jain"], "summary": "Signage is seen outside of the Food and Drug Administration ( FDA ) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo Acquire Licensing Rights Nov 28 ( Reuters ) - The U.S.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/RAQCGVLRB5NEBN7F7E43VWZSTE.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.108946, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AUTL", "relevance_score": "0.113062", "ticker_sentiment_score": "-0.032092", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSVT", "relevance_score": "0.113062", "ticker_sentiment_score": "-0.077521", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.113062", "ticker_sentiment_score": "-0.247011", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.113062", "ticker_sentiment_score": "-0.247011", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "GSK Key Drugs & Vaccines Help Stock Outperform Industry YTD", "url": "https://www.zacks.com/stock/news/2189596/gsk-key-drugs-vaccines-help-stock-outperform-industry-ytd", "time_published": "20231127T134600", "authors": ["Zacks Equity Research"], "summary": "Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates are expected drive the stock in the future quarters.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/37920.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.14561, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.19331", "ticker_sentiment_score": "0.083423", "ticker_sentiment_label": "Neutral"}, {"ticker": "HLN", "relevance_score": "0.155201", "ticker_sentiment_score": "0.002599", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.672318", "ticker_sentiment_score": "0.375268", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.116725", "ticker_sentiment_score": "0.002242", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later", "url": "https://www.fool.com/investing/2023/11/26/3-fantastic-dividend-stocks-to-buy-sooner-rather-t/", "time_published": "20231126T115500", "authors": ["and Prosper Junior Bakiny", "Keith Speights", "David Jagielski"], "summary": "There's no time like the present to buy these stocks.", "banner_image": "https://g.foolcdn.com/editorial/images/755957/retired-woman-investing-laptop-401k-ira.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.995015"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.658903"}], "overall_sentiment_score": 0.300996, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.393634", "ticker_sentiment_score": "0.433055", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABBV", "relevance_score": "0.393634", "ticker_sentiment_score": "0.213478", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.225321", "ticker_sentiment_score": "0.13405", "ticker_sentiment_label": "Neutral"}]}, {"title": "Zacks Industry Outlook Highlights Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals", "url": "https://www.zacks.com/stock/news/2188966/zacks-industry-outlook-highlights-gilead-sciences-crispr-therapeutics-acadia-pharmaceuticals-dynavax-and-ligand-pharmaceuticals", "time_published": "20231124T141000", "authors": ["Zacks Equity Research"], "summary": "Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals are part of the Zacks Industry Outlook article.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c9/2325.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Earnings", "relevance_score": "0.947132"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.650727"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.225302, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LGND", "relevance_score": "0.064104", "ticker_sentiment_score": "0.045096", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.127795", "ticker_sentiment_score": "0.105904", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.021388", "ticker_sentiment_score": "0.138084", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.021388", "ticker_sentiment_score": "0.171316", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACAD", "relevance_score": "0.064104", "ticker_sentiment_score": "0.045096", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.0854", "ticker_sentiment_score": "0.090184", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.021388", "ticker_sentiment_score": "0.138084", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.021388", "ticker_sentiment_score": "0.106821", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.021388", "ticker_sentiment_score": "0.138084", "ticker_sentiment_label": "Neutral"}]}, {"title": "A Hollywood director took millions of dollars in Netflix funding and used it to trade options and crypto, report says. Here's a closer look at how he used the cash.", "url": "https://markets.businessinsider.com/news/stocks/netflix-director-trades-gilead-sciences-stock-spx-options-dogecoin-crypto-2023-11", "time_published": "20231123T150200", "authors": ["Theron Mohamed"], "summary": "Hollywood Director Used Netflix Cash for Gilead, S&P 500, Dogecoin Bets - Markets Insider ...", "banner_image": null, "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Blockchain", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.073688, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.524949", "ticker_sentiment_score": "-0.062134", "ticker_sentiment_label": "Neutral"}, {"ticker": "NYT", "relevance_score": "0.628066", "ticker_sentiment_score": "0.093633", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.141726", "ticker_sentiment_score": "0.015182", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:DOGE", "relevance_score": "0.344712", "ticker_sentiment_score": "0.335001", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Looking Into Gilead Sciences's Recent Short Interest - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/short-sellers/23/11/35922792/looking-into-gilead-sciencess-recent-short-interest", "time_published": "20231122T184526", "authors": ["Benzinga Insights"], "summary": "Gilead Sciences's GILD short percent of float has fallen 4.37% since its last report. The company recently reported that it has 19.50 million shares sold short, which is 1.75% of all regular shares that are available for trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.239316, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.221819", "ticker_sentiment_score": "0.083071", "ticker_sentiment_label": "Neutral"}]}, {"title": "Authorities warn that fake HIV drugs are found in Kenya despite a crackdown on counterfeits", "url": "https://apnews.com/article/kenya-us-hiv-counterfeit-medication-6420b710aa4f0e72f449410077e8103b", "time_published": "20231122T152500", "authors": ["EMMANUEL IGUNZA"], "summary": "NAIROBI, Kenya ( AP ) - Kenyan authorities issued a warning Wednesday about the sale of counterfeit HIV prevention drugs in the country, saying their \"safety, quality and efficacy cannot be assured.\"", "banner_image": "https://dims.apnews.com/dims4/default/7d2a8ac/2147483647/strip/true/crop/5200x3464+0+1/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F2b%2F98%2F933de2d2f6da9a53f902a9f5826d%2F4f80125da96b49f78d17502d1f78186e", "source": "Associated Press", "category_within_source": "Markets", "source_domain": "apnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.23279, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.147818", "ticker_sentiment_score": "-0.283542", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "5 Biotech Stocks Likely to Thrive as Industry Prospects Look Bright", "url": "https://www.zacks.com/commentary/2187656/5-biotech-stocks-likely-to-thrive-as-industry-prospects-look-bright", "time_published": "20231122T130700", "authors": ["Ekta Bagri"], "summary": "New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD, DVAX and LGND well amid volatility.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Earnings", "relevance_score": "0.947132"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.538269"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.227746, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LGND", "relevance_score": "0.044634", "ticker_sentiment_score": "0.125054", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.111281", "ticker_sentiment_score": "0.139072", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.022326", "ticker_sentiment_score": "0.061954", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.022326", "ticker_sentiment_score": "0.172148", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACAD", "relevance_score": "0.044634", "ticker_sentiment_score": "0.125054", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.066908", "ticker_sentiment_score": "0.125817", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.022326", "ticker_sentiment_score": "0.061954", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.022326", "ticker_sentiment_score": "0.154669", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.022326", "ticker_sentiment_score": "0.061954", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top 5 U.S. Giants for 2024 That Have Failed to Deliver in 2023", "url": "https://www.zacks.com/stock/news/2187699/top-5-us-giants-for-2024-that-have-failed-to-deliver-in-2023", "time_published": "20231122T130400", "authors": ["Nalak Das"], "summary": "We have narrowed our search to five U.S. corporate giants that have failed to deliver in 2023. These are: PEP, PG, MMM, XOM, GILD.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c5/37823.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.338378, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PEP", "relevance_score": "0.248259", "ticker_sentiment_score": "0.439284", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.207928", "ticker_sentiment_score": "0.307865", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MMM", "relevance_score": "0.08398", "ticker_sentiment_score": "0.301923", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PG", "relevance_score": "0.287923", "ticker_sentiment_score": "0.443436", "ticker_sentiment_label": "Bullish"}, {"ticker": "XOM", "relevance_score": "0.207928", "ticker_sentiment_score": "0.242843", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "$100 Invested In This Stock 20 Years Ago Would Be Worth $1,000 Today - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/23/11/35903134/100-invested-in-this-stock-20-years-ago-would-be-worth-1-000-today", "time_published": "20231121T183021", "authors": ["Benzinga Insights"], "summary": "Gilead Sciences GILD has outperformed the market over the past 20 years by 4.81% on an annualized basis producing an average annual return of 12.32%. Currently, Gilead Sciences has a market capitalization of $93.34 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics", "url": "https://www.zacks.com/stock/news/2187239/the-zacks-analyst-blog-highlights-gilead-sciences-legend-biotech-beigene-exact-sciences-and-sarepta-therapeutics", "time_published": "20231121T144300", "authors": ["Zacks Equity Research"], "summary": "Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics are part of the Zacks top Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/2227.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.159816, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BGNE", "relevance_score": "0.238133", "ticker_sentiment_score": "0.10029", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.199365", "ticker_sentiment_score": "0.201812", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LEGN", "relevance_score": "0.199365", "ticker_sentiment_score": "-0.060138", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXAS", "relevance_score": "0.238133", "ticker_sentiment_score": "-0.027896", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.238133", "ticker_sentiment_score": "0.077351", "ticker_sentiment_label": "Neutral"}]}, {"title": "These Stocks Are Exploding In November Rally", "url": "https://www.investors.com/research/these-stocks-explode-in-november-stock-market-rally/", "time_published": "20231121T130000", "authors": ["KIMBERLEY KOENIG", "Investor's Business Daily"], "summary": "The November stock market rally is picking up steam and expanding into more than just the Magnificent Seven stocks. We created an IBD MarketSmith screen that identified stocks that rocked the most in the past month. Each has gained over 50% for the month.", "banner_image": "https://www.investors.com/wp-content/uploads/2020/06/Stock-rocketchart-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.999822"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.148434, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.413425", "ticker_sentiment_score": "-0.360418", "ticker_sentiment_label": "Bearish"}, {"ticker": "VRTX", "relevance_score": "0.143843", "ticker_sentiment_score": "0.233455", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.143843", "ticker_sentiment_score": "-0.214803", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GDHG", "relevance_score": "0.214304", "ticker_sentiment_score": "-0.238604", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JAKK", "relevance_score": "0.143843", "ticker_sentiment_score": "0.219779", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Best Penny Stocks To Buy This Week? 4 To Watch Now", "url": "https://pennystocks.com/featured/2023/11/20/best-penny-stocks-to-buy-this-week-4-to-watch-now/", "time_published": "20231120T151726", "authors": ["J. Samuel"], "summary": "Whether you're looking at the \"Magnificent Seven stocks,\" or just the next round of penny stocks to watch, news & company events can quickly sway sentiment. This week is a short holiday week with Thursday's Thanksgiving Holiday and one of the \"Magnificent Seven\" could become a major catalyst.", "banner_image": "https://pennystocks.com/wp-content/uploads/2022/06/best-penny-stocks-to-buy-this-week.jpg", "source": "PennyStocks.com", "category_within_source": "n/a", "source_domain": "pennystocks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999995"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.284573, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.095264", "ticker_sentiment_score": "0.130306", "ticker_sentiment_label": "Neutral"}, {"ticker": "FBIO", "relevance_score": "0.031822", "ticker_sentiment_score": "0.11419", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOOK", "relevance_score": "0.095264", "ticker_sentiment_score": "0.006404", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.031822", "ticker_sentiment_score": "0.141902", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRON", "relevance_score": "0.095264", "ticker_sentiment_score": "0.174797", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AWON", "relevance_score": "0.031822", "ticker_sentiment_score": "0.164737", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.031822", "ticker_sentiment_score": "0.040484", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYTO", "relevance_score": "0.031822", "ticker_sentiment_score": "-0.05973", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024", "url": "https://www.zacks.com/stock/news/2186479/5-biotechnology-stocks-to-buy-for-a-stable-portfolio-in-2024", "time_published": "20231120T130200", "authors": ["Nalak Das"], "summary": "We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/49079.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.171573, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BGNE", "relevance_score": "0.210823", "ticker_sentiment_score": "0.181744", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.169378", "ticker_sentiment_score": "0.283412", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LEGN", "relevance_score": "0.169378", "ticker_sentiment_score": "-0.08", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXAS", "relevance_score": "0.210823", "ticker_sentiment_score": "-0.040019", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.210823", "ticker_sentiment_score": "0.107013", "ticker_sentiment_label": "Neutral"}]}, {"title": "HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus", "url": "https://www.globenewswire.com/news-release/2023/11/20/2783124/0/en/HOOKIPA-Pharma-Announces-FDA-Clearance-of-its-Investigational-New-Drug-Application-for-HB-500-for-the-Treatment-of-Human-Immunodeficiency-Virus.html", "time_published": "20231120T120100", "authors": ["HOOKIPA Pharma Inc"], "summary": "NEW YORK and VIENNA, Austria, Nov. 20, 2023 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( NASDAQ: HOOK, 'HOOKIPA' ) , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Company has received clearance from the U.S.", "banner_image": "https://ml.globenewswire.com/Resource/Download/62ba88bb-8adc-44c4-9fd7-3f6ca365c93d", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.079277, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HOOK", "relevance_score": "0.154951", "ticker_sentiment_score": "0.066168", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.038969", "ticker_sentiment_score": "0.056707", "ticker_sentiment_label": "Neutral"}]}, {"title": "HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus - HOOKIPA Pharma  ( NASDAQ:HOOK ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35869897/hookipa-pharma-announces-fda-clearance-of-its-investigational-new-drug-application-for-hb-500-for-", "time_published": "20231120T120100", "authors": ["Globe Newswire"], "summary": "Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. ( 'Gilead' ) , to be evaluated as a potential curative regimen for human immunodeficiency virus ( HIV ) Phase 1 trial to commence in the first half of 2024", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.076746, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HOOK", "relevance_score": "0.114682", "ticker_sentiment_score": "0.053041", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.038345", "ticker_sentiment_score": "-0.022637", "ticker_sentiment_label": "Neutral"}]}, {"title": "Major advertisers flee X, deepening crisis at Elon Musk's social media site | Business", "url": "https://www.cnn.com/2023/11/17/tech/lionsgate-suspends-advertising-x-musk", "time_published": "20231118T000900", "authors": ["Brian Fung", "Clare Duffy", "Samantha Delouya"], "summary": "Disney and Warner Bros. Discovery stop advertising on X as antisemitism crisis grows at Elon Musk's company ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/231117160935-x-app-file.jpg?c=16x9&q=w_800,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.137308, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.132733", "ticker_sentiment_score": "-0.124462", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCZ", "relevance_score": "0.132733", "ticker_sentiment_score": "0.001215", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.066598", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Lionsgate suspends all advertising on Elon Musk's X | Business", "url": "https://www.cnn.com/2023/11/17/tech/lionsgate-suspends-advertising-x-musk/index.html", "time_published": "20231117T202800", "authors": ["Brian Fung", "Clare Duffy"], "summary": "Lionsgate suspends all advertising on Elon Musk's X ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1145511643.jpg?c=16x9&q=w_800,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.195532, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.107016", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCZ", "relevance_score": "0.212115", "ticker_sentiment_score": "0.041948", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.107016", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "IBM to pause ad spending on X after its ads ran on pro-Nazi accounts | Business", "url": "https://www.cnn.com/2023/11/16/tech/ibm-to-pause-ad-spending-on-x/index.html", "time_published": "20231116T230000", "authors": ["Liam Reilly", "Clare Duffy"], "summary": "IBM suspends advertising on Elon Musk's X after its ad appeared next to pro-Nazi content ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/231116144305-ibm-silicon-valley-01202022.jpg?c=16x9&q=w_800,c_fill", "source": "CNN", "category_within_source": "Economy", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.106134, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.104002", "ticker_sentiment_score": "-0.007635", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCZ", "relevance_score": "0.052112", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.052112", "ticker_sentiment_score": "-0.002993", "ticker_sentiment_label": "Neutral"}]}, {"title": "IBM to pause ad spending on X after its ads ran on pro-Nazi accounts | Business", "url": "https://edition.cnn.com/2023/11/16/tech/ibm-to-pause-ad-spending-on-x/index.html", "time_published": "20231116T230000", "authors": ["Liam Reilly", "Clare Duffy"], "summary": "IBM to pause ad spending on X after its ads ran on pro-Nazi accounts CNN International ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/231116144305-ibm-silicon-valley-01202022.jpg?c=16x9&q=w_800,c_fill", "source": "CNN", "category_within_source": "Economy", "source_domain": "edition.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.106134, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.104002", "ticker_sentiment_score": "-0.007635", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCZ", "relevance_score": "0.052112", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.052112", "ticker_sentiment_score": "-0.002993", "ticker_sentiment_label": "Neutral"}]}, {"title": "Arcellx  ( ACLX )  Up 5% on Partnership Expansion With Gilead", "url": "https://www.zacks.com/stock/news/2185410/arcellx-aclx-up-5-on-partnership-expansion-with-gilead", "time_published": "20231116T151000", "authors": ["Zacks Equity Research"], "summary": "Arcellx (ACLX) and Gilead (GILD) expand their existing collaboration in cancer treatment. This deal is expected to close by year-end.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.033398, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.825924", "ticker_sentiment_score": "0.190773", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "APLS", "relevance_score": "0.439786", "ticker_sentiment_score": "-0.05066", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHVN", "relevance_score": "0.302243", "ticker_sentiment_score": "-0.015791", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHGI", "relevance_score": "0.153961", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.153961", "ticker_sentiment_score": "0.07588", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Jumps Another 160 Points Amid More Evidence Inflation Is Waning", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-jumps-another-200-points-amid-more-evidence-inflation-is-waning/", "time_published": "20231115T212900", "authors": ["RUSS BRITT", "Investor's Business Daily"], "summary": "Dow Jones Jumps Another 160 Points Amid More Evidence Inflation ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/03/Stock-cokefactory-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.999819"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.904684"}], "overall_sentiment_score": 0.067454, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.13409", "ticker_sentiment_score": "0.057942", "ticker_sentiment_label": "Neutral"}, {"ticker": "TGT", "relevance_score": "0.089629", "ticker_sentiment_score": "0.209037", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSSMY", "relevance_score": "0.089629", "ticker_sentiment_score": "0.013683", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.13409", "ticker_sentiment_score": "0.131262", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXPE", "relevance_score": "0.13409", "ticker_sentiment_score": "0.07734", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLBE", "relevance_score": "0.089629", "ticker_sentiment_score": "-0.237918", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GILD", "relevance_score": "0.089629", "ticker_sentiment_score": "0.049155", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYAOF", "relevance_score": "0.044885", "ticker_sentiment_score": "0.168915", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PLTR", "relevance_score": "0.13409", "ticker_sentiment_score": "0.015982", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences's Options: A Look at What the Big Money is Thinking - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/markets/options/23/11/35810554/gilead-sciencess-options-a-look-at-what-the-big-money-is-thinking", "time_published": "20231115T171653", "authors": ["Benzinga Insights"], "summary": "Financial giants have made a conspicuous bearish move on Gilead Sciences. Our analysis of options history for Gilead Sciences GILD revealed 12 unusual trades. Delving into the details, we found 41% of traders were bullish, while 58% showed bearish tendencies.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.098159, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.636698", "ticker_sentiment_score": "0.01476", "ticker_sentiment_label": "Neutral"}]}, {"title": "Small Caps Lead Stock Market As Retail Sector Shines, Except For These Laggards", "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-extends-gains-as-retail-sector-shines-except-for-these-laggards/", "time_published": "20231115T153900", "authors": ["Investor's Business Daily", "JUAN CARLOS ARANCIBIA"], "summary": "Small Caps Lead Stock Market As Retail Sector Shines, Except For ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/01/stock-target-02-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.99994"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.990678"}], "overall_sentiment_score": 0.041024, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AAP", "relevance_score": "0.163539", "ticker_sentiment_score": "-0.119815", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACLX", "relevance_score": "0.109455", "ticker_sentiment_score": "-0.148966", "ticker_sentiment_label": "Neutral"}, {"ticker": "TGT", "relevance_score": "0.21686", "ticker_sentiment_score": "0.166652", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "XPEV", "relevance_score": "0.109455", "ticker_sentiment_score": "-0.277216", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TSLA", "relevance_score": "0.109455", "ticker_sentiment_score": "-0.074189", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLBE", "relevance_score": "0.109455", "ticker_sentiment_score": "0.112617", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.109455", "ticker_sentiment_score": "-0.148966", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.109455", "ticker_sentiment_score": "0.199773", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "URBN", "relevance_score": "0.109455", "ticker_sentiment_score": "-0.113717", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top 2% Biotech Breaks Out On $285 Million Gilead Tie-Up", "url": "https://www.investors.com/news/technology/aclx-stock-breaks-out-after-inking-a-deal-with-gilead-kite/", "time_published": "20231115T150400", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "ACLX Stock Breaks Out After Inking A $285 Million Deal With ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/11/IT04-Arcellx-01-news.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.996023"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.050949, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.798255", "ticker_sentiment_score": "0.258298", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZTA", "relevance_score": "0.101582", "ticker_sentiment_score": "-0.312958", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GILD", "relevance_score": "0.201523", "ticker_sentiment_score": "-0.267769", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP", "url": "https://www.prnewswire.com/news-releases/arcellx-and-kite-announce-expansion-in-strategic-partnership-301988865.html", "time_published": "20231115T110000", "authors": ["Arcellx", "Inc."], "summary": "-- Arcellx to receive $200M equity investment at $61.68 per share and an $85 million upfront cash payment -- -- The companies expand the scope of their existing collaboration for CART-ddBCMA to include lymphomas --", "banner_image": "https://mma.prnewswire.com/media/1762478/Arcellx_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999986"}, {"topic": "Earnings", "relevance_score": "0.796627"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.128802, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.502117", "ticker_sentiment_score": "0.156171", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SHGI", "relevance_score": "0.159174", "ticker_sentiment_score": "0.053552", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.060035", "ticker_sentiment_score": "0.049113", "ticker_sentiment_label": "Neutral"}]}, {"title": "Analysts Offer Insights on Healthcare Companies: Gilead Sciences  ( GILD )  and Vertex  ( VERX ) ", "url": "https://markets.businessinsider.com/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-and-vertex-verx-1032808809", "time_published": "20231111T084853", "authors": ["Tipranks"], "summary": "Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Vertex (VERX) - Markets Insider ...", "banner_image": "https://markets.businessinsider.com/Images/FacebookIcon.jpg", "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.183506, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BCS", "relevance_score": "0.126784", "ticker_sentiment_score": "0.06595", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZM", "relevance_score": "0.126784", "ticker_sentiment_score": "0.098541", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANEB", "relevance_score": "0.126784", "ticker_sentiment_score": "0.100873", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOCN", "relevance_score": "0.126784", "ticker_sentiment_score": "0.098541", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACRV", "relevance_score": "0.126784", "ticker_sentiment_score": "0.100873", "ticker_sentiment_label": "Neutral"}, {"ticker": "KPRX", "relevance_score": "0.126784", "ticker_sentiment_score": "0.100873", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.47672", "ticker_sentiment_score": "0.231974", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ZI", "relevance_score": "0.126784", "ticker_sentiment_score": "0.098541", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biological threats exacerbated in Africa, Asia", "url": "https://www.financialexpress.com/opinion/biological-threats-exacerbated-in-africa-asia/3304827/", "time_published": "20231111T064803", "authors": ["Guest"], "summary": "Considering recent stages of the world's development, modern technology creates new threats emerging from developing biological technologies and outlines existing ones. Global division between already developed and developing countries is exacerbated.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/11/1-121.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.019218, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.0367", "ticker_sentiment_score": "-0.013628", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.0367", "ticker_sentiment_score": "-0.017545", "ticker_sentiment_label": "Neutral"}]}, {"title": "VRTX: Vertex Pharmaceuticals  ( VRTX )  Post-Earnings Analysis: Is It Time to Buy the Stock?", "url": "https://stocknews.com/news/vrtx-gild-otsky-cort-vertex-pharmaceuticals-vrtx-post-earnings-analysis-is-it-time-to-buy/", "time_published": "20231110T192932", "authors": ["StockNews.com Staff"], "summary": "VRTX: Vertex Pharmaceuticals ( VRTX ) Post-Earnings Analysis: Is It ... ...", "banner_image": "https://stocknews.com/wp-content/uploads/2022/07/shutterstock_1110645284.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.243089, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.568767", "ticker_sentiment_score": "0.3166", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CORT", "relevance_score": "0.048278", "ticker_sentiment_score": "0.124896", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.048278", "ticker_sentiment_score": "0.124896", "ticker_sentiment_label": "Neutral"}]}, {"title": "WHO's new COVID guidelines see fewer patients requiring hospitalization", "url": "https://www.marketwatch.com/story/whos-new-covid-guidelines-see-fewer-patients-requiring-hospitalization-f4703057", "time_published": "20231110T134300", "authors": ["Ciara Linnane"], "summary": "Groups previously deemed high-risk are now at moderate risk of getting severe disease or dying.", "banner_image": "https://images.mktw.net/im-594775/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.174407, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "0.265859", "ticker_sentiment_score": "0.121675", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.179121", "ticker_sentiment_score": "0.008884", "ticker_sentiment_label": "Neutral"}]}, {"title": "Market Rally Pauses As Yields Rebound: Weekly Review", "url": "https://www.investors.com/news/stock-market-rally-pauses-as-yields-rebound-datadog-affirm-among-earnings-winners-weekly-review/", "time_published": "20231110T120000", "authors": ["Investor's Business Daily", "IBD STAFF"], "summary": "The stock market rally saw the Dow Jones, S&P 500 and Nasdaq snap long win streaks, slashing or erasing weekly gains. The Russell 2000 tumbled amid weak breadth. Earnings generally remained positive.", "banner_image": "https://www.investors.com/wp-content/uploads/2017/01/INCOME_yield_013017_shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.997405"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": -0.017348, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "APP", "relevance_score": "0.046724", "ticker_sentiment_score": "0.091746", "ticker_sentiment_label": "Neutral"}, {"ticker": "CELH", "relevance_score": "0.046724", "ticker_sentiment_score": "0.114644", "ticker_sentiment_label": "Neutral"}, {"ticker": "FLYW", "relevance_score": "0.070036", "ticker_sentiment_score": "-0.032924", "ticker_sentiment_label": "Neutral"}, {"ticker": "TTD", "relevance_score": "0.046724", "ticker_sentiment_score": "-0.070037", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.070036", "ticker_sentiment_score": "0.075537", "ticker_sentiment_label": "Neutral"}, {"ticker": "DDOG", "relevance_score": "0.162489", "ticker_sentiment_score": "-0.016092", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOUR", "relevance_score": "0.070036", "ticker_sentiment_score": "-0.032924", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXON", "relevance_score": "0.046724", "ticker_sentiment_score": "-0.161943", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FN", "relevance_score": "0.046724", "ticker_sentiment_score": "0.060043", "ticker_sentiment_label": "Neutral"}, {"ticker": "DUOL", "relevance_score": "0.093289", "ticker_sentiment_score": "0.005589", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.093289", "ticker_sentiment_score": "0.006543", "ticker_sentiment_label": "Neutral"}, {"ticker": "DT", "relevance_score": "0.046724", "ticker_sentiment_score": "0.018995", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.070036", "ticker_sentiment_score": "-0.170289", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TSLA", "relevance_score": "0.070036", "ticker_sentiment_score": "-0.077475", "ticker_sentiment_label": "Neutral"}, {"ticker": "FANG", "relevance_score": "0.070036", "ticker_sentiment_score": "-0.170289", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GFS", "relevance_score": "0.046724", "ticker_sentiment_score": "0.013948", "ticker_sentiment_label": "Neutral"}, {"ticker": "TDG", "relevance_score": "0.093289", "ticker_sentiment_score": "0.02077", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.116461", "ticker_sentiment_score": "0.016621", "ticker_sentiment_label": "Neutral"}, {"ticker": "AOSL", "relevance_score": "0.046724", "ticker_sentiment_score": "0.013948", "ticker_sentiment_label": "Neutral"}, {"ticker": "MTSI", "relevance_score": "0.046724", "ticker_sentiment_score": "0.013948", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.093289", "ticker_sentiment_score": "0.042954", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNOW", "relevance_score": "0.046724", "ticker_sentiment_score": "0.018995", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.046724", "ticker_sentiment_score": "-0.127835", "ticker_sentiment_label": "Neutral"}, {"ticker": "NXPI", "relevance_score": "0.046724", "ticker_sentiment_score": "0.013948", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.070036", "ticker_sentiment_score": "0.006148", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSY", "relevance_score": "0.046724", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LCID", "relevance_score": "0.046724", "ticker_sentiment_score": "-0.127835", "ticker_sentiment_label": "Neutral"}, {"ticker": "POWI", "relevance_score": "0.046724", "ticker_sentiment_score": "0.013948", "ticker_sentiment_label": "Neutral"}, {"ticker": "DIOD", "relevance_score": "0.046724", "ticker_sentiment_score": "0.013948", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEP", "relevance_score": "0.046724", "ticker_sentiment_score": "0.114644", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.046724", "ticker_sentiment_score": "0.006", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARM", "relevance_score": "0.046724", "ticker_sentiment_score": "0.013948", "ticker_sentiment_label": "Neutral"}, {"ticker": "LI", "relevance_score": "0.046724", "ticker_sentiment_score": "0.073194", "ticker_sentiment_label": "Neutral"}, {"ticker": "AFRM", "relevance_score": "0.116461", "ticker_sentiment_score": "-0.038586", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.046724", "ticker_sentiment_score": "-0.127835", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.070036", "ticker_sentiment_score": "0.006148", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.070036", "ticker_sentiment_score": "-0.085312", "ticker_sentiment_label": "Neutral"}]}, {"title": "A Closer Look at Gilead Sciences's Options Market Dynamics - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/markets/options/23/11/35708450/a-closer-look-at-gilead-sciencess-options-market-dynamics", "time_published": "20231109T183252", "authors": ["Benzinga Insights"], "summary": "Deep-pocketed investors have adopted a bullish approach towards Gilead Sciences GILD, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.163116, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.549988", "ticker_sentiment_score": "0.209883", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates", "url": "https://www.zacks.com/stock/news/2181433/4-biotech-stocks-likely-to-outpace-q3-earnings-estimates", "time_published": "20231109T120500", "authors": ["Ekta Bagri"], "summary": "Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/53200.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.162975, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.431956", "ticker_sentiment_score": "0.165788", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SHGI", "relevance_score": "0.041394", "ticker_sentiment_score": "0.044537", "ticker_sentiment_label": "Neutral"}, {"ticker": "LEGN", "relevance_score": "0.283635", "ticker_sentiment_score": "0.121678", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRCL", "relevance_score": "0.204763", "ticker_sentiment_score": "0.141619", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.082677", "ticker_sentiment_score": "0.100716", "ticker_sentiment_label": "Neutral"}, {"ticker": "EYEN", "relevance_score": "0.359592", "ticker_sentiment_score": "0.096383", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.041394", "ticker_sentiment_score": "0.096085", "ticker_sentiment_label": "Neutral"}]}, {"title": "HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights", "url": "https://www.globenewswire.com/news-release/2023/11/09/2777198/0/en/HOOKIPA-Pharma-Reports-Third-Quarter-2023-Financial-Results-and-Recent-Business-Highlights.html", "time_published": "20231109T120100", "authors": ["HOOKIPA Pharma Inc"], "summary": "NEW YORK and VIENNA, Austria, Nov. 09, 2023 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( NASDAQ: HOOK, 'HOOKIPA' ) , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the third quarter ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/62ba88bb-8adc-44c4-9fd7-3f6ca365c93d", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}, {"topic": "Earnings", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.064573, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HOOK", "relevance_score": "0.118064", "ticker_sentiment_score": "0.026622", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.047371", "ticker_sentiment_score": "0.024943", "ticker_sentiment_label": "Neutral"}]}, {"title": "Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates - Assembly Biosciences  ( NASDAQ:ASMB ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35684422/assembly-biosciences-reports-third-quarter-2023-financial-results-and-recent-updates", "time_published": "20231108T210500", "authors": ["Globe Newswire"], "summary": "Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyond Now anticipate four development candidates from expanded pipeline in clinical development by the end of 2024 Named Anuj Gaggar, MD, PhD, as chief medical officer", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.085422, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ASMB", "relevance_score": "0.098862", "ticker_sentiment_score": "0.039536", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.049526", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead  ( GILD )  Q3 Earnings Beat, Trodelvy Fuels Oncology Sales", "url": "https://www.zacks.com/stock/news/2180900/gilead-gild-q3-earnings-beat-trodelvy-fuels-oncology-sales", "time_published": "20231108T145200", "authors": ["Zacks Equity Research"], "summary": "Gilead (GILD) reports better-than-expected results for the third quarter as Trodelvy boosts oncology sales and Biktarvy maintains momentum in the HIV franchise.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c9/2325.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.997845"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.139249, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DVAX", "relevance_score": "0.101012", "ticker_sentiment_score": "0.08384", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGND", "relevance_score": "0.101012", "ticker_sentiment_score": "0.092664", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.167554", "ticker_sentiment_score": "0.172633", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GSK", "relevance_score": "0.067441", "ticker_sentiment_score": "0.164042", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer - Assembly Biosciences  ( NASDAQ:ASMB ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35670938/assembly-biosciences-names-anuj-gaggar-md-phd-as-chief-medical-officer", "time_published": "20231108T130000", "authors": ["Globe Newswire"], "summary": "-- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 ( GLOBE NEWSWIRE ) -- Assembly Biosciences, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.120326, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ASMB", "relevance_score": "0.130571", "ticker_sentiment_score": "-0.127997", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.065506", "ticker_sentiment_score": "0.068172", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures: Five Stocks In Buy Areas From This Hot Sector", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-is-market-rally-due-for-pause-tesla-rivals-report/", "time_published": "20231108T030800", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Dow Jones Futures: Is Market Rally Due For A Pause? Tesla Rivals ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/01/Stock-DogJump-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.148134, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ARRY", "relevance_score": "0.090588", "ticker_sentiment_score": "-0.249486", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DDOG", "relevance_score": "0.323463", "ticker_sentiment_score": "0.144272", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPWK", "relevance_score": "0.120582", "ticker_sentiment_score": "0.156927", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDB", "relevance_score": "0.180012", "ticker_sentiment_score": "0.036076", "ticker_sentiment_label": "Neutral"}, {"ticker": "DT", "relevance_score": "0.180012", "ticker_sentiment_score": "0.007289", "ticker_sentiment_label": "Neutral"}, {"ticker": "LCID", "relevance_score": "0.060464", "ticker_sentiment_score": "-0.125454", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.150404", "ticker_sentiment_score": "0.151394", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NOW", "relevance_score": "0.150404", "ticker_sentiment_score": "0.066991", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.209365", "ticker_sentiment_score": "0.077777", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.090588", "ticker_sentiment_score": "-0.249486", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "UPST", "relevance_score": "0.090588", "ticker_sentiment_score": "-0.249486", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "UBER", "relevance_score": "0.060464", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.060464", "ticker_sentiment_score": "0.018005", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.030254", "ticker_sentiment_score": "0.186658", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead Sciences  ( GILD )  Q3 2023 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2023/11/07/gilead-sciences-gild-q3-2023-earnings-call-transcr/", "time_published": "20231108T021517", "authors": ["Motley Fool Transcribing"], "summary": "GILD earnings call for the period ending September 30, 2023.", "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.266143"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.250013, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.018108", "ticker_sentiment_score": "0.099955", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.004527", "ticker_sentiment_score": "0.085", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.004527", "ticker_sentiment_score": "0.158791", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GS", "relevance_score": "0.013582", "ticker_sentiment_score": "0.065942", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.004527", "ticker_sentiment_score": "-0.006494", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.004527", "ticker_sentiment_score": "0.099576", "ticker_sentiment_label": "Neutral"}]}, {"title": "After-Hours Selling to Challenge Winning Streak Wednesday", "url": "https://www.zacks.com/stock/news/2180387/after-hours-selling-to-challenge-winning-streak-wednesday", "time_published": "20231107T225700", "authors": ["Mark Vickery"], "summary": "Gilead, eBay and Rivian all beat on the bottom line in Q3, but all three are selling the news.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e9/13051.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.22669, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RIVN", "relevance_score": "0.291182", "ticker_sentiment_score": "0.105039", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.19661", "ticker_sentiment_score": "0.364399", "ticker_sentiment_label": "Bullish"}, {"ticker": "EBAY", "relevance_score": "0.19661", "ticker_sentiment_score": "0.134125", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.19661", "ticker_sentiment_score": "0.076913", "ticker_sentiment_label": "Neutral"}]}, {"title": "Win Streak Continues As This Sector Soars; TSLA Rivals Report", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-win-streak-continues-as-this-sector-soars-tsla-rivals-report/", "time_published": "20231107T222800", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "Win Streak Continues As This Sector Soars. TSLA Rivals Report Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/01/Stock-DogJump-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.154993, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARRY", "relevance_score": "0.091509", "ticker_sentiment_score": "-0.268354", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DDOG", "relevance_score": "0.326578", "ticker_sentiment_score": "0.145334", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPWK", "relevance_score": "0.121804", "ticker_sentiment_score": "0.150709", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDB", "relevance_score": "0.181819", "ticker_sentiment_score": "0.036338", "ticker_sentiment_label": "Neutral"}, {"ticker": "DT", "relevance_score": "0.181819", "ticker_sentiment_score": "0.007343", "ticker_sentiment_label": "Neutral"}, {"ticker": "LCID", "relevance_score": "0.061081", "ticker_sentiment_score": "-0.150566", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TSLA", "relevance_score": "0.151922", "ticker_sentiment_score": "0.127886", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOW", "relevance_score": "0.151922", "ticker_sentiment_score": "0.067405", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.211454", "ticker_sentiment_score": "0.078384", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.091509", "ticker_sentiment_score": "-0.268354", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "UPST", "relevance_score": "0.091509", "ticker_sentiment_score": "-0.268354", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "UBER", "relevance_score": "0.061081", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.061081", "ticker_sentiment_score": "0.018008", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.030563", "ticker_sentiment_score": "0.186806", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead Sciences  ( GILD )  Tops Q3 Earnings and Revenue Estimates", "url": "https://www.zacks.com/stock/news/2180365/gilead-sciences-gild-tops-q3-earnings-and-revenue-estimates", "time_published": "20231107T221502", "authors": ["Zacks Equity Research"], "summary": "Gilead (GILD) delivered earnings and revenue surprises of 19.90% and 4.08%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default44.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.169086, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ETON", "relevance_score": "0.206392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.138464", "ticker_sentiment_score": "0.095763", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences Stock Slides After Hours On Q3 Report - Here's Why - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/earnings/23/11/35659653/gilead-sciences-stock-slides-after-hours-on-q3-report-heres-why", "time_published": "20231107T213637", "authors": ["Ryan Gustafson"], "summary": "Gilead Sciences, Inc. GILD shares are volatile in Tuesday's after-hours session on the heels of the company's third-quarter earnings report. What To Know: Gilead reported quarterly earnings of $2.29 per share, which beat the analyst consensus estimate of $1.92, a 20.53% increase over earnings of ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/07/gilead.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.222839, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.449503", "ticker_sentiment_score": "0.275867", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead quarterly results beat Street estimates as profit up on lower taxes", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-quarterly-results-beat-street-estimates-profit-up-lower-taxes-2023-11-07/", "time_published": "20231107T210200", "authors": ["Deena Beasley"], "summary": "Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo Acquire Licensing Rights Nov 7 ( Reuters ) - Drugmaker Gilead Sciences ( GILD.O ) on Tuesday said third-quarter sales were little changed from a year earlier, but ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/IHTTUR6VOFPXHLBNXC4U2UUJWM.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Earnings", "relevance_score": "0.988915"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.103801, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.25168", "ticker_sentiment_score": "-0.111247", "ticker_sentiment_label": "Neutral"}]}, {"title": "BIIB: Biogen  ( BIIB )  Earnings Spotlight: Is the Biotech Stock a Buy or Sell?", "url": "https://stocknews.com/news/biib-gild-jazz-alks-biogen-biib-earnings-spotlight-is-the-biotech-stock-a-buy/", "time_published": "20231107T170210", "authors": ["StockNews.com Staff"], "summary": "BIIB: Biogen ( BIIB ) Earnings Spotlight: Is the Biotech Stock a Buy or ... ...", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/iSto_GreenStockChart_FB.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999186"}], "overall_sentiment_score": 0.093338, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.076115", "ticker_sentiment_score": "0.006126", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.076115", "ticker_sentiment_score": "0.006126", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.076115", "ticker_sentiment_score": "0.006126", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.038101", "ticker_sentiment_score": "0.101926", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.526355", "ticker_sentiment_score": "0.189417", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Positive News For Gastric Cancers - Gilead/Arcus Biosciences' Combination Cancer Therapy Shows Encouraging Clinical Activity - Arcus Biosciences  ( NYSE:RCUS ) , Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/general/biotech/23/11/35638777/positive-news-for-gastric-cancers-gileadarcus-biosciences-combination-cancer-therapy-shows-encour", "time_published": "20231107T161725", "authors": ["Vandana Singh"], "summary": "Gilead Sciences Inc GILD and Arcus Biosciences Inc RCUS announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate ( ORR ) and six-month progression-free survival ( PFS ) rate results in a preliminary analysis from Arm A1 of the EDGE-Gastric study.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/07/rcus.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.084579, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RCUS", "relevance_score": "0.401331", "ticker_sentiment_score": "0.337997", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.27432", "ticker_sentiment_score": "0.244726", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Markets Await Consumer Credit Report", "url": "https://www.zacks.com/stock/news/2180194/markets-await-consumer-credit-report", "time_published": "20231107T155200", "authors": ["Zacks Equity Research"], "summary": "Pre-market futures are trying to push out of the red this morning, having opened the early trading day decidedly down after rare winning streaks now extended to 6 days on the Dow and 7 on the Nasdaq. In fact, the Nasdaq is already trading higher in the early session, +20 points at this hour.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cc/3778.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.135919, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.148731", "ticker_sentiment_score": "0.034768", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARM", "relevance_score": "0.148731", "ticker_sentiment_score": "0.034768", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBAY", "relevance_score": "0.074692", "ticker_sentiment_score": "0.027383", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.360752", "ticker_sentiment_score": "0.189491", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Can Markets Keep the Winning Streak Intact?", "url": "https://www.zacks.com/stock/news/2180187/can-markets-keep-the-winning-streak-intact", "time_published": "20231107T153200", "authors": ["Mark Vickery"], "summary": "Uber missed on headline although business was good, D.R. Horton beat and raised, and the U.S. trade deficit got slimmer.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6b/50022.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.135889, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.146025", "ticker_sentiment_score": "0.03569", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARM", "relevance_score": "0.146025", "ticker_sentiment_score": "0.03569", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBAY", "relevance_score": "0.073321", "ticker_sentiment_score": "0.028348", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.354572", "ticker_sentiment_score": "0.187098", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "S&P 500, Nasdaq Set To Break 6-Day Rally Today? Traders Await Fed Cues, Analyst Says Seasonal Rally Has Started With Gusto - Celsius Holdings  ( NASDAQ:CELH ) , Matterport  ( NASDAQ:MTTR ) , Choice Hotels Intl  ( NYSE:CHH ) , TripAdvisor  ( NASDAQ:TRIP ) ", "url": "https://www.benzinga.com/news/earnings/23/11/35640681/s-p-500-nasdaq-set-to-break-6-day-rally-today-traders-await-fed-cues-analyst-says-seasonal-rally-ha", "time_published": "20231107T121527", "authors": ["Shanthi Rexaline"], "summary": "Sentiment appears to have dipped after a six-session winning streak. Stock futures indicate a modestly lower opening on Tuesday as small and mid-cap earnings reports gain momentum. Reaction to earnings has been mixed, adding to the prevailing uncertainty.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/stock_charts_3_10.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Financial Markets", "relevance_score": "0.998682"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.102995, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CELH", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MTTR", "relevance_score": "0.075635", "ticker_sentiment_score": "0.051467", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHH", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRIP", "relevance_score": "0.075635", "ticker_sentiment_score": "0.051467", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADTN", "relevance_score": "0.075635", "ticker_sentiment_score": "0.051467", "ticker_sentiment_label": "Neutral"}, {"ticker": "DDOG", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXPD", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GPRO", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKAM", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIVN", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNG", "relevance_score": "0.075635", "ticker_sentiment_score": "0.051467", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.03786", "ticker_sentiment_score": "0.062228", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPST", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SQ", "relevance_score": "0.03786", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AYX", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "III", "relevance_score": "0.03786", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.075635", "ticker_sentiment_score": "0.051467", "ticker_sentiment_label": "Neutral"}, {"ticker": "SANM", "relevance_score": "0.075635", "ticker_sentiment_score": "0.051467", "ticker_sentiment_label": "Neutral"}, {"ticker": "FIS", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LCID", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBAY", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HRB", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UIS", "relevance_score": "0.075635", "ticker_sentiment_score": "0.051467", "ticker_sentiment_label": "Neutral"}, {"ticker": "FNF", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAIN", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Arbutus Announces CEO, William Collier, to Retire December 31, 2023 - Arbutus Biopharma  ( NASDAQ:ABUS ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35640675/arbutus-announces-ceo-william-collier-to-retire-december-31-2023", "time_published": "20231107T121500", "authors": ["Globe Newswire"], "summary": "WARMINSTER, Pa., Nov. 07, 2023 ( GLOBE NEWSWIRE ) -- Arbutus Biopharma Corporation ABUS ( \"Arbutus\" or the \"Company\" ) , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatitis B virus ( cHBV ) infection, today ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.145277, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABUS", "relevance_score": "0.122581", "ticker_sentiment_score": "-0.002381", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.061473", "ticker_sentiment_score": "-0.018", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.030759", "ticker_sentiment_score": "-0.016534", "ticker_sentiment_label": "Neutral"}]}, {"title": "A wall of debt rolling over: Here's what's scaring Bridgewater's co-CIO", "url": "https://www.marketwatch.com/story/a-wall-of-debt-rolling-over-heres-whats-scaring-bridgewaters-co-cio-ea1e6852", "time_published": "20231107T115200", "authors": ["Barbara Kollmeyer"], "summary": "Bridgewater's co chief investment officer says investors need to start thinking about a wall of U.S. debt that's coming.", "banner_image": "https://images.mktw.net/im-882513?width=700&height=409", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Financial Markets", "relevance_score": "0.99977"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.495866"}], "overall_sentiment_score": -0.186763, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.038101", "ticker_sentiment_score": "0.121209", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRIP", "relevance_score": "0.076115", "ticker_sentiment_score": "-0.114296", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.076115", "ticker_sentiment_score": "-0.223903", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JPM", "relevance_score": "0.038101", "ticker_sentiment_score": "0.121209", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLNT", "relevance_score": "0.076115", "ticker_sentiment_score": "0.130557", "ticker_sentiment_label": "Neutral"}, {"ticker": "SANM", "relevance_score": "0.076115", "ticker_sentiment_score": "-0.114296", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.038101", "ticker_sentiment_score": "0.121209", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.076115", "ticker_sentiment_score": "0.130557", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.038101", "ticker_sentiment_score": "0.121209", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBAY", "relevance_score": "0.076115", "ticker_sentiment_score": "0.130557", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.076115", "ticker_sentiment_score": "0.130557", "ticker_sentiment_label": "Neutral"}, {"ticker": "WEWOW", "relevance_score": "0.038101", "ticker_sentiment_score": "-0.181136", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SBNY", "relevance_score": "0.038101", "ticker_sentiment_score": "0.02682", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.076115", "ticker_sentiment_score": "0.130557", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.038101", "ticker_sentiment_score": "-0.074659", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.038101", "ticker_sentiment_score": "-0.235466", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Anti-Infective Drugs Market to Hit USD 177.9 billion by 2031 | Transparency Market Research Inc.", "url": "https://www.benzinga.com/pressreleases/23/11/g35637643/anti-infective-drugs-market-to-hit-usd-177-9-billion-by-2031-transparency-market-research-inc", "time_published": "20231107T103000", "authors": ["Globe Newswire"], "summary": "Wilmington, Delaware, United States, Nov. 07, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global anti-infective drugs market is projected to flourish at a CAGR of 4.0% from 2023 to 2031. As per the report published by TMR, a valuation of US$ 117.9 billion is anticipated for ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.195618, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.043658", "ticker_sentiment_score": "-0.109878", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.043658", "ticker_sentiment_score": "-0.109878", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.043658", "ticker_sentiment_score": "-0.109878", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.043658", "ticker_sentiment_score": "-0.109878", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.043658", "ticker_sentiment_score": "0.212463", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.043658", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.043658", "ticker_sentiment_score": "-0.109878", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.043658", "ticker_sentiment_score": "-0.109878", "ticker_sentiment_label": "Neutral"}]}, {"title": "S&P 500 futures dip after six-day winning streak", "url": "https://www.marketwatch.com/story/s-p-500-futures-dip-after-six-day-winning-streak-8d539d83", "time_published": "20231107T094800", "authors": ["Jamie Chisholm"], "summary": "U.S. stock futures inched lower as traders adopted a more cautious stance following a six-day winning streak.", "banner_image": "https://images.mktw.net/im-870735/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.016873, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RIVN", "relevance_score": "0.142565", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.142565", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVN", "relevance_score": "0.142565", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.142565", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWQGF", "relevance_score": "0.07157", "ticker_sentiment_score": "-0.116718", "ticker_sentiment_label": "Neutral"}, {"ticker": "DDOG", "relevance_score": "0.142565", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "CIIE to share China's enormous market with world - PR Newswire", "url": "https://www.prnewswire.com/apac/news-releases/ciie-to-share-chinas-enormous-market-with-world-301979539.html", "time_published": "20231107T071344", "authors": [], "summary": "CIIE to share China's enormous market with world PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.409047, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MMM", "relevance_score": "0.079392", "ticker_sentiment_score": "0.06975", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.079392", "ticker_sentiment_score": "0.054775", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.039745", "ticker_sentiment_score": "0.065645", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILD: Gilead Sciences  ( GILD )  Earnings Forecast and Gameplan", "url": "https://stocknews.com/news/gild-otsky-alxn-cort-gilead-sciences-gild-earnings-forecast-and-gameplan/", "time_published": "20231106T190149", "authors": ["StockNews.com Staff"], "summary": "GILD: Gilead Sciences ( GILD ) Earnings Forecast and ...", "banner_image": "https://stocknews.com/wp-content/uploads/2017/02/gilead-logo.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999996"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.308845, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CORT", "relevance_score": "0.050679", "ticker_sentiment_score": "0.155326", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.573091", "ticker_sentiment_score": "0.390296", "ticker_sentiment_label": "Bullish"}]}, {"title": "Momentum Monday: Don't Miss the Year End Rally", "url": "https://www.zacks.com/stock/news/2179513/momentum-monday-dont-miss-the-year-end-rally", "time_published": "20231106T182000", "authors": ["Zacks Investment Research"], "summary": "Want to start the week ahead of the pack? Check out Momentum Monday to get the scoop on market leading stocks and major economic news ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default134.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.125875, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "APP", "relevance_score": "0.179121", "ticker_sentiment_score": "0.1882", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.179121", "ticker_sentiment_score": "0.1882", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OXY", "relevance_score": "0.090134", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.090134", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.090134", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DELL", "relevance_score": "0.179121", "ticker_sentiment_score": "0.1882", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,200 Today - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/23/11/35622438/if-you-invested-100-in-this-stock-20-years-ago-you-would-have-1-200-today", "time_published": "20231106T153023", "authors": ["Benzinga Insights"], "summary": "Gilead Sciences GILD has outperformed the market over the past 20 years by 5.88% on an annualized basis producing an average annual return of 13.18%. Currently, Gilead Sciences has a market capitalization of $101.86 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More", "url": "https://www.zacks.com/stock/news/2179006/biotechdrug-stocks-q3-earnings-due-nov-7-gild-prgo-vtrs-more", "time_published": "20231106T132600", "authors": ["Zacks Equity Research"], "summary": "Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/53200.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.116825, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SAGE", "relevance_score": "0.2872", "ticker_sentiment_score": "-0.170109", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GILD", "relevance_score": "0.181956", "ticker_sentiment_score": "0.048847", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOVA", "relevance_score": "0.217508", "ticker_sentiment_score": "0.079032", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.073321", "ticker_sentiment_score": "0.120064", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRGO", "relevance_score": "0.217508", "ticker_sentiment_score": "0.037845", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.252612", "ticker_sentiment_score": "0.089265", "ticker_sentiment_label": "Neutral"}]}, {"title": "Active Pharmaceutical Ingredients Market Set to Surge USD 363.68 Billion by 2032 | Precedence Research", "url": "https://www.prnewswire.com/news-releases/active-pharmaceutical-ingredients-market-set-to-surge-usd-363-68-billion-by-2032--precedence-research-301978434.html", "time_published": "20231106T113800", "authors": ["Precedence Research"], "summary": "OTAWA,ON, Nov. 6, 2023 /PRNewswire/ -- The active pharmaceutical ingredients ( API ) market size was valued at USD 204.04 billion in 2023 and likely to hit around USD 363.68 billion by 2032, growing at a CAGR of 6.1% from 2023 to 2032. An active pharmaceutical ingredient ( API ) is a drug's ...", "banner_image": "https://mma.prnewswire.com/media/2264617/Precedence_Research_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.796627"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.272037, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "0.018554", "ticker_sentiment_score": "0.078226", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.018554", "ticker_sentiment_score": "0.078226", "ticker_sentiment_label": "Neutral"}]}, {"title": "Disney and other entertainment giants report after upbeat results from peers, but investors are getting harsher on companies that don't deliver", "url": "https://www.marketwatch.com/story/disney-and-other-entertainment-giants-report-after-upbeat-results-from-peers-but-investors-are-getting-harsher-on-companies-that-dont-deliver-c7318fa7", "time_published": "20231105T153100", "authors": ["Bill Peters"], "summary": "Walt Disney Co., Warner Bros. Discovery Inc., Lions Gate Entertainment Corp. and AMC Entertainment Holdings Inc. all report results this week.", "banner_image": "https://images.mktw.net/im-881106/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": 0.004812, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSGE", "relevance_score": "0.076847", "ticker_sentiment_score": "0.047981", "ticker_sentiment_label": "Neutral"}, {"ticker": "NFLX", "relevance_score": "0.076847", "ticker_sentiment_score": "0.305284", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CNK", "relevance_score": "0.076847", "ticker_sentiment_score": "0.072289", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.076847", "ticker_sentiment_score": "0.305284", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SWI", "relevance_score": "0.076847", "ticker_sentiment_score": "-0.201914", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PARA", "relevance_score": "0.076847", "ticker_sentiment_score": "0.305284", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PLNT", "relevance_score": "0.076847", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYV", "relevance_score": "0.076847", "ticker_sentiment_score": "0.047981", "ticker_sentiment_label": "Neutral"}, {"ticker": "NYT", "relevance_score": "0.076847", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIVN", "relevance_score": "0.076847", "ticker_sentiment_score": "0.047981", "ticker_sentiment_label": "Neutral"}, {"ticker": "DASH", "relevance_score": "0.076847", "ticker_sentiment_score": "0.02848", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGF-A", "relevance_score": "0.038468", "ticker_sentiment_score": "0.186247", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MGM", "relevance_score": "0.115048", "ticker_sentiment_score": "-0.101257", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBAY", "relevance_score": "0.076847", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAVA", "relevance_score": "0.076847", "ticker_sentiment_score": "0.047981", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMC", "relevance_score": "0.115048", "ticker_sentiment_score": "0.141777", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBD", "relevance_score": "0.076847", "ticker_sentiment_score": "0.072289", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.076847", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.152983", "ticker_sentiment_score": "0.014438", "ticker_sentiment_label": "Neutral"}, {"ticker": "CART", "relevance_score": "0.076847", "ticker_sentiment_score": "0.026876", "ticker_sentiment_label": "Neutral"}, {"ticker": "TTWO", "relevance_score": "0.076847", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gene Therapy Market size to grow by USD 4.61 billion from 2022 to 2027, North America to account for 39% of market ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/gene-therapy-market-size-to-grow-by-usd-4-61-billion-from-2022-to-2027--north-america-to-account-for-39-of-market-growth--technavio-301976707.html", "time_published": "20231103T223500", "authors": [], "summary": "Gene Therapy Market size to grow by USD 4.61 billion from 2022 to 2027, North America to account for 39% of market ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.217263, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GBIO", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORTX", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSTX", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADVM", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VYGR", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADAP", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGMO", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABEO", "relevance_score": "0.148731", "ticker_sentiment_score": "0.045255", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fed Holds Rates Steady, Powell's Cautious Stance Soothes Investors, Labor Market Softens: The Week In The Markets - Apple  ( NASDAQ:AAPL ) , Advanced Micro Devices  ( NASDAQ:AMD ) ", "url": "https://www.benzinga.com/markets/equities/23/11/35601229/fed-holds-rates-steady-powells-cautious-stance-soothes-investors-labor-market-softens-the-week-i", "time_published": "20231103T200339", "authors": ["Piero Cingari"], "summary": "Markets bounced back decisively this week, shrugging off prior volatile months marked by heightened geopolitical tensions. The resurgence of risk sentiment ignited a relief rally in both equities and bonds, with investors embracing the Federal Reserve's decision to hold steady on interest rates.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/03/shutterstock_176534375.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.890401"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.99737"}], "overall_sentiment_score": 0.135775, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "OXY", "relevance_score": "0.129168", "ticker_sentiment_score": "-0.093536", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.192694", "ticker_sentiment_score": "0.209739", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "QCOM", "relevance_score": "0.129168", "ticker_sentiment_score": "0.364054", "ticker_sentiment_label": "Bullish"}, {"ticker": "NVO", "relevance_score": "0.129168", "ticker_sentiment_score": "0.185591", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BDX", "relevance_score": "0.064797", "ticker_sentiment_score": "-0.080072", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.129168", "ticker_sentiment_score": "0.364054", "ticker_sentiment_label": "Bullish"}, {"ticker": "LLY", "relevance_score": "0.129168", "ticker_sentiment_score": "0.185591", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.129168", "ticker_sentiment_score": "-0.093536", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.129168", "ticker_sentiment_score": "-0.093536", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.129168", "ticker_sentiment_score": "-0.093536", "ticker_sentiment_label": "Neutral"}]}, {"title": "Which Corporations Pay The Most Federal Income Tax?", "url": "https://www.forbes.com/sites/taxnotes/2023/11/03/which-corporations-pay-the-most-federal-income-tax/", "time_published": "20231103T143105", "authors": ["Martin Sullivan"], "summary": "Corporations report their total cash payments of income tax - federal, state, and foreign combined - but they don't identify, nor does the IRS reveal, how much federal income tax they pay. We believe, however, that we can make reasonable estimates from information reported by publicly traded ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6543f3665804d392fe20b011/0x0.jpg?format=jpg&crop=1362,766,x0,y32,safe&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.213813, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.0367", "ticker_sentiment_score": "0.036094", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.0367", "ticker_sentiment_score": "0.061273", "ticker_sentiment_label": "Neutral"}, {"ticker": "MPC", "relevance_score": "0.0367", "ticker_sentiment_score": "0.036094", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.0367", "ticker_sentiment_score": "0.061273", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.0367", "ticker_sentiment_score": "0.036094", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.0367", "ticker_sentiment_score": "0.036094", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.0367", "ticker_sentiment_score": "0.036094", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.0367", "ticker_sentiment_score": "0.036094", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.0367", "ticker_sentiment_score": "0.04961", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.0367", "ticker_sentiment_score": "0.036094", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.0367", "ticker_sentiment_score": "0.061273", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.0367", "ticker_sentiment_score": "0.04961", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.0367", "ticker_sentiment_score": "0.036094", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.0367", "ticker_sentiment_score": "0.036094", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks Flashing Renewed Technical Strength: Gilead Sciences", "url": "https://www.investors.com/ibd-data-stories/stocks-flashing-renewed-technical-strength-gilead-sciences/", "time_published": "20231103T080000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "When looking for the best stocks to buy and watch, focus on those with rising relative price strength. One stock that fits that bill is Gilead Sciences ( GILD ) , which had its Relative Strength ( RS ) Rating upgraded from 78 to 81 Friday.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.394094, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.582526", "ticker_sentiment_score": "0.368754", "ticker_sentiment_label": "Bullish"}, {"ticker": "HCM", "relevance_score": "0.31482", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "This Is What Whales Are Betting On Gilead Sciences - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/markets/options/23/11/35574505/this-is-what-whales-are-betting-on-gilead-sciences", "time_published": "20231102T192016", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bullish stance on Gilead Sciences GILD. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.224026, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.658003", "ticker_sentiment_score": "0.336161", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Earnings Preview: Illumina  ( ILMN )  Q3 Earnings Expected to Decline", "url": "https://www.zacks.com/stock/news/2177328/earnings-preview-illumina-ilmn-q3-earnings-expected-to-decline", "time_published": "20231102T140049", "authors": ["Zacks Equity Research"], "summary": "Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default343.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.121687, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ILMN", "relevance_score": "0.257442", "ticker_sentiment_score": "0.001977", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.087185", "ticker_sentiment_score": "0.038018", "ticker_sentiment_label": "Neutral"}]}, {"title": "REGN: Regeneron Pharmaceuticals  ( REGN )  Earnings Analysis -- Should Investors Brace for Impact?", "url": "https://stocknews.com/news/regn-otsky-gild-jazz-regeneron-pharmaceuticals-regn-earnings-analysis-should-investors-brace-for/", "time_published": "20231101T180255", "authors": ["StockNews.com Staff"], "summary": "REGN: Regeneron Pharmaceuticals ( REGN ) Earnings Analysis ... ...", "banner_image": "https://stocknews.com/wp-content/uploads/2021/04/shutterstock_745024336-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999612"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.214468, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.52395", "ticker_sentiment_score": "0.248758", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JAZZ", "relevance_score": "0.054114", "ticker_sentiment_score": "0.172807", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.054114", "ticker_sentiment_score": "0.172807", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead Sciences  ( GILD )  Earnings Expected to Grow: Should You Buy?", "url": "https://www.zacks.com/stock/news/2175549/gilead-sciences-gild-earnings-expected-to-grow-should-you-buy", "time_published": "20231031T140130", "authors": ["Zacks Equity Research"], "summary": "Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default169.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.126412, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.174272", "ticker_sentiment_score": "-0.025617", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.087663", "ticker_sentiment_score": "0.088507", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences Sees RS Rating Improve To 71", "url": "https://www.investors.com/ibd-data-stories/gilead-sciences-sees-rs-rating-improve-to-71/", "time_published": "20231031T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "The Relative Strength ( RS ) Rating for Gilead Sciences ( GILD ) jumped into a higher percentile Tuesday, as it got a lift from 67 to 71. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.332915, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.279015", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.141726", "ticker_sentiment_score": "0.138896", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.524949", "ticker_sentiment_score": "0.41869", "ticker_sentiment_label": "Bullish"}, {"ticker": "HCM", "relevance_score": "0.279015", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Outperforms Broader Market: What You Need to Know", "url": "https://www.zacks.com/stock/news/2174854/gilead-sciences-gild-outperforms-broader-market-what-you-need-to-know", "time_published": "20231030T215010", "authors": ["Zacks Equity Research"], "summary": "Gilead Sciences (GILD) closed at $77.88 in the latest trading session, marking a +1.64% move from the prior day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default254.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.986564"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.197824, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.463792", "ticker_sentiment_score": "0.322689", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead  ( GILD )  Gears Up to Report Q3 Earnings: What's in Store?", "url": "https://www.zacks.com/stock/news/2174771/gilead-gild-gears-up-to-report-q3-earnings-whats-in-store", "time_published": "20231030T155900", "authors": ["Zacks Equity Research"], "summary": "Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its third-quarter 2023 results.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999985"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.154909, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LGND", "relevance_score": "0.119433", "ticker_sentiment_score": "-0.002279", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACAD", "relevance_score": "0.119433", "ticker_sentiment_score": "0.096879", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.236205", "ticker_sentiment_score": "0.267495", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AMGN: Amgen  ( AMGN )  Earnings Watch: Buy or Sell?", "url": "https://stocknews.com/news/amgn-gild-jazz-alks-amgen-amgn-earnings-watch-buy-or-sell/", "time_published": "20231030T153404", "authors": ["StockNews.com Staff"], "summary": "Pharmaceutical major Amgen Inc. ( AMGN ) is scheduled to report its third-quarter earnings on October 31. In this piece, I have discussed why it could be wise to buy the stock now. Wall Street expects a year-over-year decline in earnings on higher revenues when AMGN reports results for the ...", "banner_image": "https://stocknews.com/wp-content/uploads/2017/02/amgen-logo-amgn.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.998356"}], "overall_sentiment_score": 0.183455, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.072108", "ticker_sentiment_score": "0.071115", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.072108", "ticker_sentiment_score": "0.071115", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.558244", "ticker_sentiment_score": "0.259511", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JAZZ", "relevance_score": "0.072108", "ticker_sentiment_score": "0.071115", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer's  ( PFE )  Key Drugs to Drive Q3 Earnings Amid COVID Decline?", "url": "https://www.zacks.com/stock/news/2174310/pfizers-pfe-key-drugs-to-drive-q3-earnings-amid-covid-decline", "time_published": "20231030T124900", "authors": ["Zacks Equity Research"], "summary": "Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ce/3721.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.104476, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BHVN", "relevance_score": "0.062761", "ticker_sentiment_score": "0.034004", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.247208", "ticker_sentiment_score": "0.276957", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.363388", "ticker_sentiment_score": "0.203159", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNTX", "relevance_score": "0.186738", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Non-alcoholic Steatohepatitis Market to grow by USD 11.22 billion from 2022 to 2027, North America to account for 51 ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/non-alcoholic-steatohepatitis-market-to-grow-by-usd-11-22-billion--from-2022-to-2027--north-america-to-account-for-51-of-market-growth--technavio-301969658.html", "time_published": "20231027T183000", "authors": [], "summary": "Non-alcoholic Steatohepatitis Market to grow by USD 11.22 billion from 2022 to 2027, North America to account for 51 ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.239625, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ENZ", "relevance_score": "0.068112", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GNFT", "relevance_score": "0.068112", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.068112", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVA", "relevance_score": "0.068112", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.068112", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDGL", "relevance_score": "0.068112", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.068112", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEMHF", "relevance_score": "0.068112", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICPT", "relevance_score": "0.068112", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Merck  ( MRK )  Q3 Earnings Top Estimates, COVID Drug Boosts Sales", "url": "https://www.zacks.com/stock/news/2172963/merck-mrk-q3-earnings-top-estimates-covid-drug-boosts-sales", "time_published": "20231026T151300", "authors": ["Zacks Equity Research"], "summary": "Merck (MRK) beats Q3 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/20/2483.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.997874"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.658903"}], "overall_sentiment_score": 0.106966, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SKXJF", "relevance_score": "0.132806", "ticker_sentiment_score": "0.034841", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.106423", "ticker_sentiment_score": "0.165144", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSKYF", "relevance_score": "0.132806", "ticker_sentiment_score": "0.034841", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.106423", "ticker_sentiment_score": "-0.025234", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.079921", "ticker_sentiment_score": "0.050166", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.02668", "ticker_sentiment_score": "-0.001852", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Pharma Stocks That Are Screaming Buys in October", "url": "https://www.fool.com/investing/2023/10/26/3-pharma-stocks-that-are-screaming-buys-in-october/", "time_published": "20231026T113000", "authors": ["Jim Halley"], "summary": "Each company delivers an above-average dividend and revenue growth.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}], "overall_sentiment_score": 0.109768, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "0.076115", "ticker_sentiment_score": "0.002043", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.076115", "ticker_sentiment_score": "-0.044986", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.151539", "ticker_sentiment_score": "0.035847", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.188781", "ticker_sentiment_score": "0.100446", "ticker_sentiment_label": "Neutral"}]}, {"title": "USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day", "url": "https://www.zacks.com/stock/news/2171221/usa-compression-and-disney-have-been-highlighted-as-zacks-bull-and-bear-of-the-day", "time_published": "20231025T084900", "authors": ["Zacks Equity Research"], "summary": "Chicago, IL - October 25, 2023 - Zacks Equity Research shares USA Compression Partners ( USAC Quick QuoteUSAC - ) as the Bull of the Day and Disney ( DIS Quick QuoteDIS - ) as the Bear of the Day.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/9d/53642.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Energy & Transportation", "relevance_score": "0.5"}], "overall_sentiment_score": 0.155371, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.220558", "ticker_sentiment_score": "0.315034", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.273705", "ticker_sentiment_score": "0.255919", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.193575", "ticker_sentiment_score": "0.174337", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DIS", "relevance_score": "0.111358", "ticker_sentiment_score": "0.040294", "ticker_sentiment_label": "Neutral"}, {"ticker": "USAC", "relevance_score": "0.138943", "ticker_sentiment_score": "0.079014", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences Getting Closer To Key Technical Benchmark", "url": "https://www.investors.com/ibd-data-stories/gilead-sciences-getting-closer-to-key-technical-benchmark/", "time_published": "20231025T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "Gilead Sciences ( GILD ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Wednesday, rising from 70 to 73. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.36311, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.31282", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.159569", "ticker_sentiment_score": "0.145768", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.579393", "ticker_sentiment_score": "0.549012", "ticker_sentiment_label": "Bullish"}, {"ticker": "HCM", "relevance_score": "0.31282", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Exceeds Market Returns: Some Facts to Consider", "url": "https://www.zacks.com/stock/news/2171075/gilead-sciences-gild-exceeds-market-returns-some-facts-to-consider", "time_published": "20231024T215019", "authors": ["Zacks Equity Research"], "summary": "Gilead Sciences (GILD) concluded the recent trading session at $78.15, signifying a +0.76% move from its prior day's close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default332.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.99246"}], "overall_sentiment_score": 0.219422, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.584103", "ticker_sentiment_score": "0.343208", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Biotech Stocks With Decent Dividend for a Steady Return", "url": "https://www.zacks.com/stock/news/2170733/3-biotech-stocks-with-decent-dividend-for-a-steady-return", "time_published": "20231024T131500", "authors": ["Indrajit Bandyopadhyay"], "summary": "Here we pick three medical device stocks, AbbVie (ABBV), Amgen (AMGN) and Gilead Sciences (GILD), which have a solid five-year dividend growth history.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999701"}], "overall_sentiment_score": 0.301538, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.406197", "ticker_sentiment_score": "0.344854", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.359262", "ticker_sentiment_score": "0.524882", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.451494", "ticker_sentiment_score": "0.422583", "ticker_sentiment_label": "Bullish"}]}, {"title": "Gilead Sciences  ( GILD )  Falls More Steeply Than Broader Market: What Investors Need to Know", "url": "https://www.zacks.com/stock/news/2170500/gilead-sciences-gild-falls-more-steeply-than-broader-market-what-investors-need-to-know", "time_published": "20231023T220019", "authors": ["Zacks Equity Research"], "summary": "Gilead Sciences (GILD) concluded the recent trading session at $77.56, signifying a -0.31% move from its prior day's close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default196.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.983783"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.174696, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.516073", "ticker_sentiment_score": "0.280244", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "A 27-year-old investor building a $2 million retirement portfolio in 8 years shares why he's buying a fund that's up 324% since inception and made up of cheap stocks with strong competitive advantages", "url": "https://markets.businessinsider.com/news/stocks/fund-etf-with-high-return-since-inception-investor-retirement-portfolio-2023-10", "time_published": "20231021T091702", "authors": ["Laila Maidan"], "summary": "At the turn of the year, personal finance content creator Austin Hankwitz decided to start a public challenge: amass a $2 million retirement portfolio in eight years, or up to 15 years in the event of a stock market slowdown or if he has low-income years.", "banner_image": null, "source": "Business Insider", "category_within_source": "RSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999174"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.152858, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MORN", "relevance_score": "0.223866", "ticker_sentiment_score": "0.189058", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CCZ", "relevance_score": "0.056674", "ticker_sentiment_score": "0.008", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.113062", "ticker_sentiment_score": "0.008966", "ticker_sentiment_label": "Neutral"}]}, {"title": "A 27-year-old investor building a $2 million retirement portfolio in 8 years shares why he's buying a fund that's up 324% since inception and made up of cheap stocks with strong competitive advantages", "url": "https://www.businessinsider.com/fund-etf-with-high-return-since-inception-investor-retirement-portfolio-2023-10", "time_published": "20231021T091700", "authors": ["Laila Maidan"], "summary": "Fund With 324% Return Since Inception in Investor's Retirement Portfolio - Business Insider ...", "banner_image": null, "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "www.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999174"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.152858, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MORN", "relevance_score": "0.223866", "ticker_sentiment_score": "0.189058", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CCZ", "relevance_score": "0.056674", "ticker_sentiment_score": "0.008", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.113062", "ticker_sentiment_score": "0.008966", "ticker_sentiment_label": "Neutral"}]}, {"title": "Comparative Study: Gilead Sciences And Industry Competitors In Biotechnology Industry - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/23/10/35353698/comparative-study-gilead-sciences-and-industry-competitors-in-biotechnology-industry", "time_published": "20231020T160241", "authors": ["Benzinga Insights"], "summary": "Amidst the fast-paced and highly competitive business environment of today, conducting comprehensive company analysis is essential for investors and industry enthusiasts.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.265182, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.586322", "ticker_sentiment_score": "0.321102", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Torrent lines up at least $5 billion funding to buy 33% stake in Cipla", "url": "https://www.business-standard.com/companies/news/torrent-lines-up-at-least-5-billion-funding-to-buy-33-stake-in-cipla-123102000660_1.html", "time_published": "20231020T103156", "authors": ["Bloomberg"], "summary": "Torrent Pharmaceuticals Ltd. has lined up at least $5 billion in funding as the company is seeking to buy a stake in Mumbai-listed drugmaker Cipla Ltd., according to people familiar with the matter.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-07/27/full/1690478805-3801.jpg?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.07127, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.113062", "ticker_sentiment_score": "0.050223", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILD or VRTX: Which Is the Better Value Stock Right Now?", "url": "https://www.zacks.com/stock/news/2169033/gild-or-vrtx-which-is-the-better-value-stock-right-now", "time_published": "20231019T154012", "authors": ["Zacks Equity Research"], "summary": "GILD vs. VRTX: Which Stock Is the Better Value Option?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default35.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.468652, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.606706", "ticker_sentiment_score": "0.49223", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.77735", "ticker_sentiment_score": "0.575786", "ticker_sentiment_label": "Bullish"}]}, {"title": "Pfizer Decides To Raise COVID-19 Treatment Pill Price, Defends Itself Amid Criticism for Cost Increase - Pfizer  ( NYSE:PFE ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35323628/pfizer-decides-to-raise-covid-19-treatment-pill-price-defends-itself-amid-criticism-for-cost-incr", "time_published": "20231019T124510", "authors": ["Vandana Singh"], "summary": "Pfizer Inc PFE is reportedly gearing up to price its Covid-19 drug Paxlovid at $1,390 for a five-day course, more than double what the U.S. government initially paid for it, at $529. Pfizer's decision to raise the price has garnered criticism from doctors and patient advocates who fear limited ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/19/paxlovid.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.048622, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "0.827318", "ticker_sentiment_score": "0.222289", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.266828", "ticker_sentiment_score": "-0.237603", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Vertex Pharmaceuticals, Gilead Sciences And 2 Other Stocks Insiders Are Selling - Gilead Sciences  ( NASDAQ:GILD ) , HubSpot  ( NYSE:HUBS ) ", "url": "https://www.benzinga.com/news/23/10/35326531/vertex-pharmaceuticals-gilead-sciences-and-2-other-stocks-insiders-are-selling", "time_published": "20231019T114201", "authors": ["Lisa Levin"], "summary": "The Nasdaq 100 closed lower by over 200 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/19/gilead_sciences_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.02414, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.421485", "ticker_sentiment_score": "-0.042918", "ticker_sentiment_label": "Neutral"}, {"ticker": "VMW", "relevance_score": "0.495015", "ticker_sentiment_score": "-0.050696", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.421485", "ticker_sentiment_score": "0.130694", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUBS", "relevance_score": "0.421485", "ticker_sentiment_score": "0.028882", "ticker_sentiment_label": "Neutral"}, {"ticker": "DELL", "relevance_score": "0.088472", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "SAP Announces Q3 2023 Results", "url": "https://www.prnewswire.com/news-releases/sap-announces-q3-2023-results-301961175.html", "time_published": "20231018T200500", "authors": ["SAP SE"], "summary": "in \u20ac millions, unless otherwise stated.", "banner_image": "https://mma.prnewswire.com/media/1093077/SAP_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.223597, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.02013", "ticker_sentiment_score": "0.071001", "ticker_sentiment_label": "Neutral"}, {"ticker": "CURN", "relevance_score": "0.02013", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.02013", "ticker_sentiment_score": "0.171944", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SAP", "relevance_score": "0.622815", "ticker_sentiment_score": "0.33921", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HTHIF", "relevance_score": "0.02013", "ticker_sentiment_score": "0.079945", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSTM", "relevance_score": "0.02013", "ticker_sentiment_score": "0.079945", "ticker_sentiment_label": "Neutral"}, {"ticker": "HIZOF", "relevance_score": "0.02013", "ticker_sentiment_score": "0.079945", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.02013", "ticker_sentiment_score": "0.075425", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBGSF", "relevance_score": "0.02013", "ticker_sentiment_score": "-0.236889", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Why AstraZeneca's Lung Cancer Update Also Tripped Gilead Stock", "url": "https://www.investors.com/news/technology/astrazeneca-stock-dives-pulling-gilead-with-it-on-a-disappointing-update-in-lung-cancer-treatment/", "time_published": "20231018T153500", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "AstraZeneca Stock Dives, Pulling Gilead With It, On A Disappointing ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/03/Stock-astrazenecavac-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}], "overall_sentiment_score": 0.017385, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SKXJF", "relevance_score": "0.119532", "ticker_sentiment_score": "-0.093561", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.119532", "ticker_sentiment_score": "0.008141", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.119532", "ticker_sentiment_score": "-0.093561", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.633079", "ticker_sentiment_score": "-0.111714", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pharmaceutical Pellets Market Major Driver - Increasing Prevalence Of Chronic Diseases As Per The Business Research Company's Pharmaceutical Pellets Global Market Report 2023", "url": "https://www.benzinga.com/pressreleases/23/10/g35312139/pharmaceutical-pellets-market-major-driver-increasing-prevalence-of-chronic-diseases-as-per-the-bu", "time_published": "20231018T153000", "authors": ["Globe Newswire"], "summary": "LONDON, Oct. 18, 2023 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Pharmaceutical Pellets Global Market Report 2023, the global pharmaceutical pellets market is set to undergo remarkable growth.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.231517, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.064276", "ticker_sentiment_score": "0.050309", "ticker_sentiment_label": "Neutral"}]}, {"title": "HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus  ( HBV )  therapeutic vaccine developed in collaboration with Gilead Sciences", "url": "https://www.globenewswire.com/news-release/2023/10/18/2762210/0/en/HOOKIPA-Pharma-announces-publication-of-preclinical-data-of-hepatitis-B-virus-HBV-therapeutic-vaccine-developed-in-collaboration-with-Gilead-Sciences.html", "time_published": "20231018T110100", "authors": ["HOOKIPA Pharma Inc"], "summary": "NEW YORK and VIENNA, Austria, Oct. 18, 2023 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( NASDAQ: HOOK, 'HOOKIPA' ) , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that The Journal of Infectious Diseases has published ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/62ba88bb-8adc-44c4-9fd7-3f6ca365c93d", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.061156, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HOOK", "relevance_score": "0.159834", "ticker_sentiment_score": "-0.017933", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.080323", "ticker_sentiment_score": "-0.089207", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Zacks Analyst Blog Highlights Walmart, NIKE, TJX, Gilead Sciences and Schlumberger", "url": "https://www.zacks.com/stock/news/2167708/the-zacks-analyst-blog-highlights-walmart-nike-tjx-gilead-sciences-and-schlumberger", "time_published": "20231018T105600", "authors": ["Zacks Investment Research"], "summary": "Walmart, NIKE, TJX, Gilead Sciences and Schlumberger are included in this Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/26/123.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.999346"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}], "overall_sentiment_score": 0.102477, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SLB", "relevance_score": "0.064973", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NKE", "relevance_score": "0.193207", "ticker_sentiment_score": "0.179187", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.129516", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TJX", "relevance_score": "0.193207", "ticker_sentiment_score": "0.096304", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.193207", "ticker_sentiment_score": "0.155122", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is American Century U.S. Quality Value ETF  ( VALQ )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2167684/is-american-century-us-quality-value-etf-valq-a-strong-etf-right-now", "time_published": "20231018T102006", "authors": ["Zacks Equity Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default44.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.289018, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.114682", "ticker_sentiment_score": "0.04541", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.114682", "ticker_sentiment_score": "0.04541", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.114682", "ticker_sentiment_score": "0.04541", "ticker_sentiment_label": "Neutral"}]}, {"title": "TRDA: 3 Biotech Stocks for Long-Term Value", "url": "https://stocknews.com/news/trda-mgnx-gnft-gild-3-biotech-stocks-for-long-term-value/", "time_published": "20231017T171944", "authors": ["StockNews.com Staff"], "summary": "Innovative biotech companies are making remarkable progress in creating novel medications and therapies for a diverse array of conditions, such as cancer, heart disease, and rare ailments. Encouraging trial outcomes and enhanced patient well-being are spurring the demand for continuous medical ...", "banner_image": "https://stocknews.com/wp-content/uploads/2023/01/ISt_Biotechnology.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.723405"}, {"topic": "Earnings", "relevance_score": "0.995077"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.218321, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MGNX", "relevance_score": "0.256839", "ticker_sentiment_score": "0.12055", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.086975", "ticker_sentiment_score": "0.119542", "ticker_sentiment_label": "Neutral"}, {"ticker": "GNFT", "relevance_score": "0.229149", "ticker_sentiment_score": "0.204536", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TRDA", "relevance_score": "0.311201", "ticker_sentiment_score": "0.16128", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Hepatitis-Focused Assembly Biosciences Stock Trading Over 100% Higher: Here's Why - Assembly Biosciences  ( NASDAQ:ASMB ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35286090/hepatitis-focused-assembly-biosciences-stock-trading-over-100-higher-heres-why", "time_published": "20231017T135116", "authors": ["Vandana Singh"], "summary": "Gilead Sciences Inc GILD and Assembly Biosciences Inc ASMB have entered into a 12-year partnership. Their goal is to advance the research and development of novel antiviral therapies, with an initial focus on Assembly Bio's established areas of herpesviruses, hepatitis B virus ( HBV ) and ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/17/aapharma_1.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.095827, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ASMB", "relevance_score": "0.320279", "ticker_sentiment_score": "0.164031", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.21686", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Beats Stock Market Upswing: What Investors Need to Know", "url": "https://www.zacks.com/stock/news/2166772/gilead-sciences-gild-beats-stock-market-upswing-what-investors-need-to-know", "time_published": "20231016T220020", "authors": ["Zacks Equity Research"], "summary": "Gilead Sciences (GILD) reachead $79.20 at the closing of the latest trading day, reflecting a +2% change compared to its last close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default232.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Earnings", "relevance_score": "0.983783"}], "overall_sentiment_score": 0.197045, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.573213", "ticker_sentiment_score": "0.294515", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Large Granular Lymphocyte Leukemia Market is Projected to Grow During the Study Period  ( 2019-2032 ) , Assesses DelveInsight | Key Companies - Bristol Myers Squibb, Innate Pharma, Kymera Therapeutics, EUSA Pharma, Abcuro, Dren Bio, Novotech", "url": "https://www.prnewswire.com/news-releases/large-granular-lymphocyte-leukemia-market-is-projected-to-grow-during-the-study-period-20192032-assesses-delveinsight--key-companies---bristol-myers-squibb-innate-pharma-kymera-therapeutics-eusa-pharma-abcuro-dren-bio-n-301957023.html", "time_published": "20231016T210100", "authors": ["LLP", "DelveInsight Business Research"], "summary": "Large Granular Lymphocyte Leukemia Market is Projected to Grow During the Study Period ( 2019-2032 ) , Assesses ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.069381, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IPHA", "relevance_score": "0.025845", "ticker_sentiment_score": "0.095897", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.032245", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.051663", "ticker_sentiment_score": "-0.028928", "ticker_sentiment_label": "Neutral"}, {"ticker": "LVTX", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.026539", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.026539", "ticker_sentiment_label": "Neutral"}, {"ticker": "KYMR", "relevance_score": "0.025845", "ticker_sentiment_score": "0.095897", "ticker_sentiment_label": "Neutral"}, {"ticker": "TGTX", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.026539", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.077426", "ticker_sentiment_score": "-0.029504", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONCT", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.026539", "ticker_sentiment_label": "Neutral"}, {"ticker": "APVO", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.023726", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRIX", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.026539", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.026539", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.051663", "ticker_sentiment_score": "-0.028928", "ticker_sentiment_label": "Neutral"}, {"ticker": "APRE", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.026539", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.023726", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.025845", "ticker_sentiment_score": "-0.023726", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILD: 4 Promising Biotech Stocks for Smart Investment Strategies", "url": "https://stocknews.com/news/gild-vrtx-uthr-jazz-4-promising-biotech-stocks-for-smart-investment-strategies/", "time_published": "20231016T192531", "authors": ["StockNews.com Staff"], "summary": "The biotechnology sector has thrived exceptionally over the past few years, catalyzed by continued innovations that fortify its status as a vanguard in crucial sectors like healthcare, agriculture, and the environment.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/01/shutterstock_357740228-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.333881, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.082464", "ticker_sentiment_score": "0.099953", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.12342", "ticker_sentiment_score": "0.218092", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JAZZ", "relevance_score": "0.102976", "ticker_sentiment_score": "0.164116", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UTHR", "relevance_score": "0.102976", "ticker_sentiment_score": "0.07271", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors", "url": "https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-appoints-life-science-industry-leaders-jeremy-bender-teresa-bitetti-and-david-meek-to-its-board-of-directors-301957344.html", "time_published": "20231016T115000", "authors": ["Fusion Pharmaceuticals"], "summary": "Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1196797/Fusion_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.092194, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.02047", "ticker_sentiment_label": "Neutral"}, {"ticker": "INVA", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.02047", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.044386", "ticker_sentiment_score": "0.041683", "ticker_sentiment_label": "Neutral"}, {"ticker": "STRO", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.061069", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAWN", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.061069", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUSN", "relevance_score": "0.132611", "ticker_sentiment_score": "0.06807", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.061069", "ticker_sentiment_label": "Neutral"}, {"ticker": "MREO", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.061069", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.02047", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.047896", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors", "url": "https://www.newswire.ca/news-releases/fusion-pharmaceuticals-appoints-life-science-industry-leaders-jeremy-bender-teresa-bitetti-and-david-meek-to-its-board-of-directors-816998848.html", "time_published": "20231016T115000", "authors": ["Fusion Pharmaceuticals"], "summary": "Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its ... Canada ...", "banner_image": "https://mma.prnewswire.com/media/1196797/Fusion_Logo.jpg?p=facebook", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.092194, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QURE", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.02047", "ticker_sentiment_label": "Neutral"}, {"ticker": "INVA", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.02047", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.044386", "ticker_sentiment_score": "0.041683", "ticker_sentiment_label": "Neutral"}, {"ticker": "STRO", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.061069", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAWN", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.061069", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUSN", "relevance_score": "0.132611", "ticker_sentiment_score": "0.06807", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.061069", "ticker_sentiment_label": "Neutral"}, {"ticker": "MREO", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.061069", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.02047", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.044386", "ticker_sentiment_score": "-0.047896", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Dirt Cheap High-Yield Dividend Stocks to Buy Right Now", "url": "https://www.fool.com/investing/2023/10/15/2-dirt-cheap-high-yield-dividend-stocks-to-buy/", "time_published": "20231015T140000", "authors": ["Prosper Junior Bakiny"], "summary": "These companies aren't getting the respect they deserve.", "banner_image": "https://media.ycharts.com/charts/be648908ed6570627c237517126ff40a.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.284851, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "0.522854", "ticker_sentiment_score": "0.36755", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.330286", "ticker_sentiment_score": "0.317256", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SGEN", "relevance_score": "0.056674", "ticker_sentiment_score": "0.150101", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/earnings/23/10/35248115/heres-how-much-100-invested-in-gilead-sciences-20-years-ago-would-be-worth-today", "time_published": "20231013T200020", "authors": ["Benzinga Insights"], "summary": "Gilead Sciences GILD has outperformed the market over the past 20 years by 5.07% on an annualized basis producing an average annual return of 12.39%. Currently, Gilead Sciences has a market capitalization of $96.67 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Growing Geriatric Population Fuels Ankylosing Spondylitis Market: Management of Pain and Mobility Gains Importance in Aging Demographics", "url": "https://www.prnewswire.com/news-releases/growing-geriatric-population-fuels-ankylosing-spondylitis-market-management-of-pain-and-mobility-gains-importance-in-aging-demographics-301956060.html", "time_published": "20231013T154500", "authors": ["Research and Markets"], "summary": "Growing Geriatric Population Fuels Ankylosing Spondylitis Market: Management of Pain and Mobility Gains Importance ... PR ...", "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.144187, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXDX", "relevance_score": "0.073209", "ticker_sentiment_score": "0.139168", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.073209", "ticker_sentiment_score": "0.08925", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILD: How to Enhance Your Own Strategies with POWR Ratings", "url": "https://stocknews.com/news/gild-amgn-uthr-biib-regn-how-to-enhance-your-own-strategies-with-powr-ratings/", "time_published": "20231012T162947", "authors": ["StockNews.com Staff"], "summary": "One thing Wall Street is never short of is ideas. Technical strategies, fundamental strategies, seasonal investing, and the list goes on and on and on.", "banner_image": "https://stocknews.com/wp-content/uploads/2021/06/shutterstock_530971462-1-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.998333"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999612"}], "overall_sentiment_score": 0.16666, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AWON", "relevance_score": "0.035035", "ticker_sentiment_score": "0.006888", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.139467", "ticker_sentiment_score": "0.121564", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.173832", "ticker_sentiment_score": "0.036379", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTHR", "relevance_score": "0.241512", "ticker_sentiment_score": "0.114", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.207868", "ticker_sentiment_score": "0.139319", "ticker_sentiment_label": "Neutral"}]}, {"title": "Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032", "url": "https://investingnews.com/global-car-t-cell-therapy-market-projected-to-reach-83-billion-by-2032/", "time_published": "20231012T133921", "authors": ["Investing News Network"], "summary": "FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines.", "banner_image": "https://investingnews.com/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yNTg1ODg1NS9vcmlnaW4ucG5nIiwiZXhwaXJlc19hdCI6MTcwODY4MTIxOX0.Phin9ClvosnPNpkGRdBWHz_VFepTco5fqEYZcXCsZIQ/image.png?width=210", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.976913"}], "overall_sentiment_score": 0.106971, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "INCY", "relevance_score": "0.084796", "ticker_sentiment_score": "0.028337", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.084796", "ticker_sentiment_score": "0.055474", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.105883", "ticker_sentiment_score": "0.065147", "ticker_sentiment_label": "Neutral"}, {"ticker": "RGBP", "relevance_score": "0.105883", "ticker_sentiment_score": "0.04808", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.084796", "ticker_sentiment_score": "0.054363", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.021237", "ticker_sentiment_score": "0.135143", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gene Siskel Film Center of The School of the Art Institute of Chicago Announces the Full Program for the 29th Annual Black Harvest Film Festival", "url": "https://www.benzinga.com/pressreleases/23/10/n35203301/gene-siskel-film-center-of-the-school-of-the-art-institute-of-chicago-announces-the-full-program-f", "time_published": "20231011T195100", "authors": ["PRNewswire"], "summary": "CHICAGO, Oct. 11, 2023 /PRNewswire/ -- The School of the Art Institute of Chicago's Gene Siskel Film Center is pleased to announce the complete festival program and schedule for its 29th Annual Black Harvest Film Festival.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.500203, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.040348", "ticker_sentiment_score": "0.180164", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Nurix  ( NRIX )  to Report Q3 Earnings: What's in Store?", "url": "https://www.zacks.com/stock/news/2164117/nurix-nrix-to-report-q3-earnings-whats-in-store", "time_published": "20231011T110900", "authors": ["Zacks Equity Research"], "summary": "On Nurix's (NRIX) Q3 earnings call, investors will likely focus on updates related to its pipeline candidates for hematologic malignancies and solid tumor indications.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.995869"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.071568, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.157141", "ticker_sentiment_score": "-0.004093", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.157141", "ticker_sentiment_score": "0.165995", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SGEN", "relevance_score": "0.157141", "ticker_sentiment_score": "0.029307", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRIX", "relevance_score": "0.402941", "ticker_sentiment_score": "0.090715", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.052685", "ticker_sentiment_score": "0.133612", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Invest in the VanEck Biotech ETF  ( BBH ) ?", "url": "https://www.zacks.com/stock/news/2164069/should-you-invest-in-the-vaneck-biotech-etf-bbh", "time_published": "20231011T102006", "authors": ["Zacks Equity Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default245.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.09889, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.134968", "ticker_sentiment_score": "0.071604", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.134968", "ticker_sentiment_score": "0.071604", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.134968", "ticker_sentiment_score": "0.071604", "ticker_sentiment_label": "Neutral"}]}, {"title": "Northrop Grumman  ( NYSE:NOC )  Lowered to \"Hold\" at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/northrop-grumman-nysenoc-lowered-to-hold-at-stocknews-com.html", "time_published": "20231011T084053", "authors": ["Defense World Staff"], "summary": "StockNews.com downgraded shares of Northrop Grumman ( NYSE:NOC - Free Report ) from a buy rating to a hold rating in a research note published on Tuesday. NOC has been the topic of several other reports.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/northrop-grumman-co-logo.png?v=20221021083322&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.947132"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.262255, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "C", "relevance_score": "0.098862", "ticker_sentiment_score": "0.017016", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.049526", "ticker_sentiment_score": "0.114672", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOC", "relevance_score": "0.785851", "ticker_sentiment_score": "0.444105", "ticker_sentiment_label": "Bullish"}, {"ticker": "RBCPF", "relevance_score": "0.049526", "ticker_sentiment_score": "0.015881", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.049526", "ticker_sentiment_score": "0.015881", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.049526", "ticker_sentiment_score": "0.015881", "ticker_sentiment_label": "Neutral"}]}, {"title": "F.N.B.  ( NYSE:FNB )  Upgraded to \"Hold\" at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/f-n-b-nysefnb-upgraded-to-hold-at-stocknews-com.html", "time_published": "20231011T080842", "authors": ["Defense World Staff"], "summary": "StockNews.com upgraded shares of F.N.B. ( NYSE:FNB - Free Report ) from a sell rating to a hold rating in a research note released on Tuesday. Several other equities analysts have also weighed in on the stock.", "banner_image": "https://www.marketbeat.com/logos/fnb-corp-logo.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.692272"}, {"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.235119, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BOM", "relevance_score": "0.122269", "ticker_sentiment_score": "0.194485", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JEF", "relevance_score": "0.061315", "ticker_sentiment_score": "-0.002002", "ticker_sentiment_label": "Neutral"}, {"ticker": "FNB", "relevance_score": "0.751437", "ticker_sentiment_score": "0.401221", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.061315", "ticker_sentiment_score": "0.13113", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.122269", "ticker_sentiment_score": "0.194485", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RJF", "relevance_score": "0.122269", "ticker_sentiment_score": "0.194485", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Mobileye Global  ( NASDAQ:MBLY )  Upgraded to Hold at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/mobileye-global-nasdaqmbly-upgraded-to-hold-at-stocknews-com.html", "time_published": "20231011T080842", "authors": ["Defense World Staff"], "summary": "Mobileye Global ( NASDAQ:MBLY ) Upgraded to Hold at StockNews ... Defense World ...", "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=MBLY", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.99793"}, {"topic": "Earnings", "relevance_score": "0.904684"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.214378"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.305329, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "C", "relevance_score": "0.055236", "ticker_sentiment_score": "0.036892", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.055236", "ticker_sentiment_score": "0.215", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAC", "relevance_score": "0.055236", "ticker_sentiment_score": "0.036892", "ticker_sentiment_label": "Neutral"}, {"ticker": "MBLY", "relevance_score": "0.854321", "ticker_sentiment_score": "0.499829", "ticker_sentiment_label": "Bullish"}]}, {"title": "Eltek  ( NASDAQ:ELTK )  Downgraded by StockNews.com to \"Buy\"", "url": "https://www.defenseworld.net/2023/10/11/eltek-nasdaqeltk-downgraded-by-stocknews-com-to-buy.html", "time_published": "20231011T080450", "authors": ["Defense World Staff"], "summary": "StockNews.com lowered shares of Eltek ( NASDAQ:ELTK - Free Report ) from a strong-buy rating to a buy rating in a research note released on Tuesday. NASDAQ ELTK opened at $11.35 on Tuesday. Eltek has a 12-month low of $3.57 and a 12-month high of $11.49.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/eltek-ltd-logo.png&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.983783"}], "overall_sentiment_score": 0.256941, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BOM", "relevance_score": "0.090474", "ticker_sentiment_score": "0.21464", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ELTK", "relevance_score": "0.88837", "ticker_sentiment_score": "0.432351", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.090474", "ticker_sentiment_score": "0.105801", "ticker_sentiment_label": "Neutral"}]}, {"title": "Protagonist Therapeutics  ( NASDAQ:PTGX )  Upgraded to Hold at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/protagonist-therapeutics-nasdaqptgx-upgraded-to-hold-at-stocknews-com-2.html", "time_published": "20231011T080450", "authors": ["Defense World Staff"], "summary": "Protagonist Therapeutics ( NASDAQ:PTGX ) Upgraded to Hold at ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/protagonist-therapeutics-inc-logo.png?v=20221213132207", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.206349, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PTGX", "relevance_score": "0.85054", "ticker_sentiment_score": "0.347474", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.071784", "ticker_sentiment_score": "-0.02337", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBCPF", "relevance_score": "0.142989", "ticker_sentiment_score": "0.192937", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.071784", "ticker_sentiment_score": "0.08586", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bright Horizons Family Solutions  ( NYSE:BFAM )  Upgraded to \"Hold\" by StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/bright-horizons-family-solutions-nysebfam-upgraded-to-hold-by-stocknews-com.html", "time_published": "20231011T080244", "authors": ["Defense World Staff"], "summary": "Bright Horizons Family Solutions ( NYSE:BFAM ) Upgraded to \"Hold ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/bright-horizons-family-solutions-inc-logo.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.752319"}, {"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.389575, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PRU", "relevance_score": "0.091335", "ticker_sentiment_score": "0.28467", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.045743", "ticker_sentiment_score": "0.223204", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.045743", "ticker_sentiment_score": "0.04338", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.045743", "ticker_sentiment_score": "0.04338", "ticker_sentiment_label": "Neutral"}, {"ticker": "BFAM", "relevance_score": "0.771638", "ticker_sentiment_score": "0.597339", "ticker_sentiment_label": "Bullish"}]}, {"title": "Johnson & Johnson  ( NYSE:JNJ )  Upgraded by StockNews.com to Strong-Buy", "url": "https://www.defenseworld.net/2023/10/11/johnson-johnson-nysejnj-upgraded-by-stocknews-com-to-strong-buy.html", "time_published": "20231011T080244", "authors": ["Defense World Staff"], "summary": "Johnson & Johnson ( NYSE:JNJ ) Upgraded by StockNews.com to ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/johnson--johnson-logo.png?v=20221020135923", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.846708"}, {"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.30983, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MS", "relevance_score": "0.040829", "ticker_sentiment_score": "0.093661", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.040829", "ticker_sentiment_score": "0.094895", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.717663", "ticker_sentiment_score": "0.495744", "ticker_sentiment_label": "Bullish"}]}, {"title": "Rite Aid  ( NYSE:RAD )  Now Covered by StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/rite-aid-nyserad-now-covered-by-stocknews-com.html", "time_published": "20231011T080243", "authors": ["Defense World Staff"], "summary": "StockNews.com began coverage on shares of Rite Aid ( NYSE:RAD - Get Free Report ) in a research report issued to clients and investors on Wednesday. The brokerage set a \"sell\" rating on the stock. Shares of NYSE:RAD opened at $0.74 on Wednesday. Rite Aid has a 1-year low of $0.38 and a 1-year ...", "banner_image": "https://www.marketbeat.com/logos/rite-aid-co-logo.png?v=20221216131240", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Blockchain", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.343922, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RAD", "relevance_score": "0.814929", "ticker_sentiment_score": "0.546177", "ticker_sentiment_label": "Bullish"}, {"ticker": "AWON", "relevance_score": "0.095899", "ticker_sentiment_score": "0.00106", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.095899", "ticker_sentiment_score": "0.211208", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Empire State Realty OP  ( NYSE:ESBA )  Now Covered by Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/empire-state-realty-op-nyseesba-now-covered-by-analysts-at-stocknews-com-2.html", "time_published": "20231011T080243", "authors": ["Defense World Staff"], "summary": "Empire State Realty OP ( NYSE:ESBA ) Now Covered by Analysts at ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/empire-state-realty-op-lp-logo.jpg?v=20230515112648&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.330256, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ESRT", "relevance_score": "0.089797", "ticker_sentiment_score": "0.192356", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.089797", "ticker_sentiment_score": "0.192356", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UBS", "relevance_score": "0.178459", "ticker_sentiment_score": "0.285093", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Enservco  ( NYSEAMERICAN:ENSV )  Earns Sell Rating from Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/enservco-nyseamericanensv-earns-sell-rating-from-analysts-at-stocknews-com.html", "time_published": "20231011T073041", "authors": ["Defense World Staff"], "summary": "Enservco ( NYSEAMERICAN:ENSV ) Earns Sell Rating from Analysts ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/enservco-corp-logo.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}, {"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.326864, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.088147", "ticker_sentiment_score": "0.268426", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Espey Mfg. & Electronics  ( NYSEAMERICAN:ESP )  Coverage Initiated at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/espey-mfg-electronics-nyseamericanesp-coverage-initiated-at-stocknews-com.html", "time_published": "20231011T073041", "authors": ["Defense World Staff"], "summary": "Espey Mfg. & Electronics ( NYSEAMERICAN:ESP ) Coverage ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/espey-mfg--electronics-corp-logo.jpg?v=20220214075959", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": 0.347132, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.165031", "ticker_sentiment_score": "0.281661", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.082963", "ticker_sentiment_score": "0.122723", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBCPF", "relevance_score": "0.165031", "ticker_sentiment_score": "0.281661", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "PNM Resources  ( NYSE:PNM )  Upgraded at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/pnm-resources-nysepnm-upgraded-at-stocknews-com.html", "time_published": "20231011T073041", "authors": ["Defense World Staff"], "summary": "PNM Resources ( NYSE:PNM - Get Free Report ) was upgraded by investment analysts at StockNews.com from a \"sell\" rating to a \"hold\" rating in a research note issued to investors on Wednesday.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/pnm-resources-inc-logo.gif&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Earnings", "relevance_score": "0.967321"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.314435, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FITB", "relevance_score": "0.143843", "ticker_sentiment_score": "0.285494", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "C", "relevance_score": "0.072217", "ticker_sentiment_score": "0.023113", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.072217", "ticker_sentiment_score": "0.15822", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PNM", "relevance_score": "0.91494", "ticker_sentiment_score": "0.523392", "ticker_sentiment_label": "Bullish"}]}, {"title": "Corporate Office Properties Trust  ( NYSE:OFC )  Receives New Coverage from Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/corporate-office-properties-trust-nyseofc-receives-new-coverage-from-analysts-at-stocknews-com.html", "time_published": "20231011T073041", "authors": ["Defense World Staff"], "summary": "Corporate Office Properties Trust ( NYSE:OFC ) Receives New ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/corporate-office-properties-trust-logo.png?v=20221121144007&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999922"}, {"topic": "Earnings", "relevance_score": "0.967321"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.422368, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "EVR", "relevance_score": "0.060541", "ticker_sentiment_score": "0.089028", "ticker_sentiment_label": "Neutral"}, {"ticker": "TFC", "relevance_score": "0.060541", "ticker_sentiment_score": "0.089028", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.060541", "ticker_sentiment_score": "0.219103", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.060541", "ticker_sentiment_score": "0.089028", "ticker_sentiment_label": "Neutral"}]}, {"title": "Birks Group  ( NYSEAMERICAN:BGI )  Receives New Coverage from Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/birks-group-nyseamericanbgi-receives-new-coverage-from-analysts-at-stocknews-com.html", "time_published": "20231011T073041", "authors": ["Defense World Staff"], "summary": "Birks Group ( NYSEAMERICAN:BGI ) Receives New Coverage from ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/birks-group-inc-logo.png", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.360456, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AWON", "relevance_score": "0.124164", "ticker_sentiment_score": "0.003541", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.124164", "ticker_sentiment_score": "0.278381", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAC", "relevance_score": "0.124164", "ticker_sentiment_score": "0.152419", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VIRT", "relevance_score": "0.124164", "ticker_sentiment_score": "0.152419", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:GBP", "relevance_score": "0.124164", "ticker_sentiment_score": "0.278381", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Westwood Holdings Group  ( NYSE:WHG )  Earns Buy Rating from Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/westwood-holdings-group-nysewhg-earns-buy-rating-from-analysts-at-stocknews-com.html", "time_published": "20231011T072859", "authors": ["Defense World Staff"], "summary": "Westwood Holdings Group ( NYSE:WHG ) Earns Buy Rating from ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/westwood-holdings-group-inc-logo.png?v=20211203143200", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}, {"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.318774, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.082963", "ticker_sentiment_score": "0.185506", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UBS", "relevance_score": "0.165031", "ticker_sentiment_score": "0.228426", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WHG", "relevance_score": "0.904419", "ticker_sentiment_score": "0.526769", "ticker_sentiment_label": "Bullish"}]}, {"title": "Teekay Tankers  ( NYSE:TNK )  Downgraded to \"Buy\" at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/teekay-tankers-nysetnk-downgraded-to-buy-at-stocknews-com.html", "time_published": "20231011T072859", "authors": ["Defense World Staff"], "summary": "Teekay Tankers ( NYSE:TNK - Get Free Report ) was downgraded by research analysts at StockNews.com from a \"strong-buy\" rating to a \"buy\" rating in a research note issued to investors on Wednesday.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/teekay-tankers-ltd-logo.png?v=20221202065522&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.268135, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.152983", "ticker_sentiment_score": "0.228343", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TNK", "relevance_score": "0.877268", "ticker_sentiment_score": "0.447658", "ticker_sentiment_label": "Bullish"}, {"ticker": "JEF", "relevance_score": "0.076847", "ticker_sentiment_score": "0.075853", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.076847", "ticker_sentiment_score": "0.088476", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.152983", "ticker_sentiment_score": "0.228343", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TK", "relevance_score": "0.852088", "ticker_sentiment_score": "0.443788", "ticker_sentiment_label": "Bullish"}]}, {"title": "Zovio  ( NYSE:ZVO )  Coverage Initiated at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/zovio-nysezvo-coverage-initiated-at-stocknews-com-2.html", "time_published": "20231011T072859", "authors": ["Defense World Staff"], "summary": "Analysts at StockNews.com assumed coverage on shares of Zovio ( NYSE:ZVO - Get Free Report ) in a research note issued to investors on Wednesday. The brokerage set a \"hold\" rating on the stock. Zovio has a twelve month low of $0.08 and a twelve month high of $1.79.", "banner_image": "https://www.marketbeat.com/logos/zovio-inc-logo.jpg?v=20221212132559", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.249874, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ZVOI", "relevance_score": "0.888822", "ticker_sentiment_score": "0.42313", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.209365", "ticker_sentiment_score": "0.175948", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:EUR", "relevance_score": "0.209365", "ticker_sentiment_score": "0.175948", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "StockNews.com Begins Coverage on Flexible Solutions International  ( NYSE:FSI ) ", "url": "https://www.defenseworld.net/2023/10/11/stocknews-com-begins-coverage-on-flexible-solutions-international-nysefsi-2.html", "time_published": "20231011T071643", "authors": ["Defense World Staff"], "summary": "StockNews.com Begins Coverage on Flexible Solutions ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/flexible-solutions-international-inc-logo.jpg?v=20230615060248&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": 0.430226, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.078611", "ticker_sentiment_score": "0.19911", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "StockNews.com Begins Coverage on Phoenix New Media  ( NYSE:FENG ) ", "url": "https://www.defenseworld.net/2023/10/11/stocknews-com-begins-coverage-on-phoenix-new-media-nysefeng.html", "time_published": "20231011T071643", "authors": ["Defense World Staff"], "summary": "StockNews.com Begins Coverage on Phoenix New Media ( NYSE ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/phoenix-new-media-logo.JPG", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.136764, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "FENG", "relevance_score": "0.887556", "ticker_sentiment_score": "0.237513", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "III", "relevance_score": "0.249106", "ticker_sentiment_score": "0.029076", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.126119", "ticker_sentiment_score": "0.153564", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Culp  ( NYSE:CULP )  Receives New Coverage from Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/culp-nyseculp-receives-new-coverage-from-analysts-at-stocknews-com.html", "time_published": "20231011T071642", "authors": ["Defense World Staff"], "summary": "Culp ( NYSE:CULP ) Receives New Coverage from Analysts at ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/culp-inc-logo.jpg?v=20230104132031&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.928769"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.269532, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CULP", "relevance_score": "0.151064", "ticker_sentiment_score": "0.072359", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.075874", "ticker_sentiment_score": "0.110628", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTRS", "relevance_score": "0.151064", "ticker_sentiment_score": "0.25406", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Fortis  ( NYSE:FTS )  Raised to \"Hold\" at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/fortis-nysefts-raised-to-hold-at-stocknews-com.html", "time_published": "20231011T071642", "authors": ["Defense World Staff"], "summary": "Fortis ( NYSE:FTS - Get Free Report ) was upgraded by investment analysts at StockNews.com from a \"sell\" rating to a \"hold\" rating in a research note issued to investors on Wednesday. Other research analysts have also issued reports about the stock.", "banner_image": "https://www.marketbeat.com/logos/fortis-inc-logo.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.240518, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FITB", "relevance_score": "0.072435", "ticker_sentiment_score": "0.128215", "ticker_sentiment_label": "Neutral"}, {"ticker": "PWCDF", "relevance_score": "0.072435", "ticker_sentiment_score": "0.128215", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.072435", "ticker_sentiment_score": "0.122881", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBCPF", "relevance_score": "0.072435", "ticker_sentiment_score": "0.057436", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.072435", "ticker_sentiment_score": "0.057436", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTS", "relevance_score": "0.898236", "ticker_sentiment_score": "0.410188", "ticker_sentiment_label": "Bullish"}]}, {"title": "Cedar Fair  ( NYSE:FUN )  Rating Lowered to Hold at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/cedar-fair-nysefun-rating-lowered-to-hold-at-stocknews-com.html", "time_published": "20231011T071642", "authors": ["Defense World Staff"], "summary": "Cedar Fair ( NYSE:FUN - Get Free Report ) was downgraded by equities researchers at StockNews.com from a \"buy\" rating to a \"hold\" rating in a report issued on Wednesday. Other equities analysts also recently issued research reports about the company.", "banner_image": "https://www.marketbeat.com/logos/cedar-fair-lp-logo.jpg?v=20200928120753", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.858979"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.22894, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "C", "relevance_score": "0.053153", "ticker_sentiment_score": "-0.02294", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.10607", "ticker_sentiment_score": "0.220671", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.053153", "ticker_sentiment_score": "-0.02294", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBS", "relevance_score": "0.10607", "ticker_sentiment_score": "0.220671", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SEIC", "relevance_score": "0.10607", "ticker_sentiment_score": "0.220671", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.053153", "ticker_sentiment_score": "0.175709", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GS", "relevance_score": "0.053153", "ticker_sentiment_score": "-0.02294", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.10607", "ticker_sentiment_score": "0.220671", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FUN", "relevance_score": "0.769861", "ticker_sentiment_score": "0.371496", "ticker_sentiment_label": "Bullish"}, {"ticker": "KEY", "relevance_score": "0.053153", "ticker_sentiment_score": "-0.02294", "ticker_sentiment_label": "Neutral"}]}, {"title": "Eagle Materials  ( NYSE:EXP )  Cut to \"Hold\" at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/eagle-materials-nyseexp-cut-to-hold-at-stocknews-com.html", "time_published": "20231011T071642", "authors": ["Defense World Staff"], "summary": "Eagle Materials ( NYSE:EXP - Get Free Report ) was downgraded by equities researchers at StockNews.com from a \"buy\" rating to a \"hold\" rating in a research report issued on Wednesday.", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&Symbol=EXP", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.285627, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TFC", "relevance_score": "0.042723", "ticker_sentiment_score": "0.053707", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.042723", "ticker_sentiment_score": "0.053707", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.042723", "ticker_sentiment_score": "0.146292", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXP", "relevance_score": "0.691254", "ticker_sentiment_score": "0.400546", "ticker_sentiment_label": "Bullish"}, {"ticker": "JPM", "relevance_score": "0.042723", "ticker_sentiment_score": "0.053707", "ticker_sentiment_label": "Neutral"}]}, {"title": "StockNews.com Initiates Coverage on China Pharma  ( NYSE:CPHI ) ", "url": "https://www.defenseworld.net/2023/10/11/stocknews-com-initiates-coverage-on-china-pharma-nysecphi.html", "time_published": "20231011T071642", "authors": ["Defense World Staff"], "summary": "Analysts at StockNews.com started coverage on shares of China Pharma ( NYSE:CPHI - Get Free Report ) in a note issued to investors on Wednesday. The firm set a \"hold\" rating on the stock. NYSE CPHI opened at $0.13 on Wednesday. China Pharma has a one year low of $0.11 and a one year high of ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/china-pharma-holdings-inc-logo.png?v=20230512105225&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.180113, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.144275", "ticker_sentiment_score": "0.175242", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "StockNews.com Initiates Coverage on Global Cord Blood  ( NYSE:CO ) ", "url": "https://www.defenseworld.net/2023/10/11/stocknews-com-initiates-coverage-on-global-cord-blood-nyseco.html", "time_published": "20231011T071456", "authors": ["Defense World Staff"], "summary": "Research analysts at StockNews.com started coverage on shares of Global Cord Blood ( NYSE:CO - Get Free Report ) in a research note issued to investors on Wednesday. The firm set a \"strong-buy\" rating on the medical research company's stock. Shares of CO stock opened at $1.24 on Wednesday.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/global-cord-blood-co-logo.jpg?v=20221214071832&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.275564, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.092569", "ticker_sentiment_score": "0.13364", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTRS", "relevance_score": "0.092569", "ticker_sentiment_score": "0.169389", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Brooklyn ImmunoTherapeutics  ( NYSE:BTX )  Research Coverage Started at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/brooklyn-immunotherapeutics-nysebtx-research-coverage-started-at-stocknews-com.html", "time_published": "20231011T071456", "authors": ["Defense World Staff"], "summary": "Brooklyn ImmunoTherapeutics ( NYSE:BTX ) Research Coverage ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/brooklyn-immunotherapeutics-inc-logo.png?v=20221104084421", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.318152, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ERNA", "relevance_score": "0.116348", "ticker_sentiment_score": "0.234414", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.116348", "ticker_sentiment_score": "0.234414", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Brunswick  ( NYSE:BC )  Upgraded by StockNews.com to Buy", "url": "https://www.defenseworld.net/2023/10/11/brunswick-nysebc-upgraded-by-stocknews-com-to-buy-2.html", "time_published": "20231011T071455", "authors": ["Defense World Staff"], "summary": "Brunswick ( NYSE:BC - Get Free Report ) was upgraded by StockNews.com from a \"hold\" rating to a \"buy\" rating in a research note issued on Wednesday. BC has been the subject of several other research reports.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/brunswick-co-logo.png?v=20221114205250&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Earnings", "relevance_score": "0.990786"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.234078, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BC", "relevance_score": "0.893234", "ticker_sentiment_score": "0.399296", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.064276", "ticker_sentiment_score": "0.119123", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.064276", "ticker_sentiment_score": "0.014017", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.064276", "ticker_sentiment_score": "0.014017", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bluerock Residential Growth REIT  ( NYSE:BRG )  Coverage Initiated by Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/bluerock-residential-growth-reit-nysebrg-coverage-initiated-by-analysts-at-stocknews-com.html", "time_published": "20231011T071455", "authors": ["Defense World Staff"], "summary": "Bluerock Residential Growth REIT ( NYSE:BRG ) Coverage Initiated ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/bluerock-residential-growth-reit-inc-logo.png?v=20230621054513", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.454309, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.173333", "ticker_sentiment_score": "0.211729", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:EUR", "relevance_score": "0.173333", "ticker_sentiment_score": "0.211729", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AngloGold Ashanti  ( NYSE:AU )  Coverage Initiated by Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/anglogold-ashanti-nyseau-coverage-initiated-by-analysts-at-stocknews-com.html", "time_published": "20231011T071453", "authors": ["Defense World Staff"], "summary": "AngloGold Ashanti ( NYSE:AU ) Coverage Initiated by Analysts at ... Defense World ...", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&Symbol=AU", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.310508, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "C", "relevance_score": "0.124164", "ticker_sentiment_score": "0.242468", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.062271", "ticker_sentiment_score": "0.148159", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBCPF", "relevance_score": "0.062271", "ticker_sentiment_score": "0.044003", "ticker_sentiment_label": "Neutral"}, {"ticker": "AU", "relevance_score": "0.815863", "ticker_sentiment_score": "0.500941", "ticker_sentiment_label": "Bullish"}, {"ticker": "BNS", "relevance_score": "0.062271", "ticker_sentiment_score": "0.044003", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ampio Pharmaceuticals  ( NYSE:AMPE )  Receives New Coverage from Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/ampio-pharmaceuticals-nyseampe-receives-new-coverage-from-analysts-at-stocknews-com.html", "time_published": "20231011T071452", "authors": ["Defense World Staff"], "summary": "Ampio Pharmaceuticals ( NYSE:AMPE ) Receives New Coverage ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/ampio-pharmaceuticals-inc-logo.png?v=20230901084425", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}, {"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.283143, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.166169", "ticker_sentiment_score": "0.234034", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "STT", "relevance_score": "0.166169", "ticker_sentiment_score": "0.234034", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.083541", "ticker_sentiment_score": "0.058399", "ticker_sentiment_label": "Neutral"}]}, {"title": "AutoNation  ( NYSE:AN )  Upgraded at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/autonation-nysean-upgraded-at-stocknews-com.html", "time_published": "20231011T071452", "authors": ["Defense World Staff"], "summary": "AutoNation ( NYSE:AN - Get Free Report ) was upgraded by equities research analysts at StockNews.com from a \"hold\" rating to a \"buy\" rating in a research note issued on Wednesday.", "banner_image": "https://www.marketbeat.com/logos/autonation-inc-logo.jpg?v=20221114165007", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.275042, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.046816", "ticker_sentiment_score": "0.113135", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.046816", "ticker_sentiment_score": "0.060197", "ticker_sentiment_label": "Neutral"}, {"ticker": "AN", "relevance_score": "0.735347", "ticker_sentiment_score": "0.433073", "ticker_sentiment_label": "Bullish"}, {"ticker": "MET", "relevance_score": "0.09347", "ticker_sentiment_score": "0.18145", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.046816", "ticker_sentiment_score": "0.060197", "ticker_sentiment_label": "Neutral"}, {"ticker": "RJF", "relevance_score": "0.09347", "ticker_sentiment_score": "0.18145", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "StockNews.com Begins Coverage on American Equity Investment Life  ( NYSE:AEL ) ", "url": "https://www.defenseworld.net/2023/10/11/stocknews-com-begins-coverage-on-american-equity-investment-life-nyseael.html", "time_published": "20231011T071451", "authors": ["Defense World Staff"], "summary": "StockNews.com Begins Coverage on American Equity Investment ... Defense World ...", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&Symbol=AEL", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.310034, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AEL", "relevance_score": "0.716929", "ticker_sentiment_score": "0.477955", "ticker_sentiment_label": "Bullish"}, {"ticker": "TFC", "relevance_score": "0.045054", "ticker_sentiment_score": "0.044288", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.045054", "ticker_sentiment_score": "0.144637", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBCPF", "relevance_score": "0.045054", "ticker_sentiment_score": "0.044288", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.089965", "ticker_sentiment_score": "0.189921", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Air Industries Group  ( NYSE:AIRI )  Coverage Initiated at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/air-industries-group-nyseairi-coverage-initiated-at-stocknews-com.html", "time_published": "20231011T071451", "authors": ["Defense World Staff"], "summary": "Air Industries Group ( NYSE:AIRI ) Coverage Initiated at StockNews ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/air-industries-group-logo.jpg?v=20230512104924", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Earnings", "relevance_score": "0.947132"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.171882, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.117486", "ticker_sentiment_score": "0.171327", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "WW International  ( NASDAQ:WW )  Rating Increased to Hold at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/ww-international-nasdaqww-rating-increased-to-hold-at-stocknews-com.html", "time_published": "20231011T071450", "authors": ["Defense World Staff"], "summary": "WW International ( NASDAQ:WW ) Rating Increased to Hold at ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/weight-watchers-international-inc-logo.png?v=20190927174115&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}, {"topic": "Earnings", "relevance_score": "0.857896"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.287582, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "WW", "relevance_score": "0.855104", "ticker_sentiment_score": "0.473265", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.061159", "ticker_sentiment_score": "0.182199", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MET", "relevance_score": "0.121959", "ticker_sentiment_score": "0.208007", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.061159", "ticker_sentiment_score": "0.046007", "ticker_sentiment_label": "Neutral"}]}, {"title": "United-Guardian  ( NASDAQ:UG )  Earns Buy Rating from Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/united-guardian-nasdaqug-earns-buy-rating-from-analysts-at-stocknews-com.html", "time_published": "20231011T071445", "authors": ["Defense World Staff"], "summary": "United-Guardian ( NASDAQ:UG ) Earns Buy Rating from Analysts at ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/united-guardian-inc-logo.png?v=20211203103746&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}, {"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.367166, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "UG", "relevance_score": "0.795517", "ticker_sentiment_score": "0.572927", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.072217", "ticker_sentiment_score": "0.177184", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.143843", "ticker_sentiment_score": "0.240967", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UBS", "relevance_score": "0.143843", "ticker_sentiment_score": "0.240967", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "ENGlobal  ( NASDAQ:ENG )  Receives New Coverage from Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/englobal-nasdaqeng-receives-new-coverage-from-analysts-at-stocknews-com-2.html", "time_published": "20231011T071444", "authors": ["Defense World Staff"], "summary": "ENGlobal ( NASDAQ:ENG ) Receives New Coverage from Analysts ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/englobal-co-logo.png?v=20230111170440&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Earnings", "relevance_score": "0.857896"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.341913, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "STT", "relevance_score": "0.172097", "ticker_sentiment_score": "0.286792", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ENG", "relevance_score": "0.917988", "ticker_sentiment_score": "0.560115", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.086556", "ticker_sentiment_score": "0.229488", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:EUR", "relevance_score": "0.086556", "ticker_sentiment_score": "0.229488", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "StockNews.com Begins Coverage on OpGen  ( NASDAQ:OPGN ) ", "url": "https://www.defenseworld.net/2023/10/11/stocknews-com-begins-coverage-on-opgen-nasdaqopgn.html", "time_published": "20231011T071444", "authors": ["Defense World Staff"], "summary": "Equities research analysts at StockNews.com started coverage on shares of OpGen ( NASDAQ:OPGN - Get Free Report ) in a report issued on Wednesday. The brokerage set a \"hold\" rating on the medical research company's stock.", "banner_image": "https://www.marketbeat.com/logos/opgen-inc-logo.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}, {"topic": "Earnings", "relevance_score": "0.947132"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.221176, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OPGN", "relevance_score": "0.85246", "ticker_sentiment_score": "0.371794", "ticker_sentiment_label": "Bullish"}, {"ticker": "VIRT", "relevance_score": "0.082393", "ticker_sentiment_score": "0.134305", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.082393", "ticker_sentiment_score": "0.115379", "ticker_sentiment_label": "Neutral"}]}, {"title": "Manhattan Bridge Capital  ( NASDAQ:LOAN )  Upgraded to \"Strong-Buy\" at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/manhattan-bridge-capital-nasdaqloan-upgraded-to-strong-buy-at-stocknews-com.html", "time_published": "20231011T071444", "authors": ["Defense World Staff"], "summary": "Manhattan Bridge Capital ( NASDAQ:LOAN ) Upgraded to \"Strong ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/manhattan-bridge-capital-inc-logo.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999186"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}], "overall_sentiment_score": 0.414631, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.076115", "ticker_sentiment_score": "0.124003", "ticker_sentiment_label": "Neutral"}, {"ticker": "LOAN", "relevance_score": "0.74841", "ticker_sentiment_score": "0.621459", "ticker_sentiment_label": "Bullish"}]}, {"title": "Heron Therapeutics  ( NASDAQ:HRTX )  Upgraded to Hold at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/heron-therapeutics-nasdaqhrtx-upgraded-to-hold-at-stocknews-com.html", "time_published": "20231011T071444", "authors": ["Defense World Staff"], "summary": "Heron Therapeutics ( NASDAQ:HRTX ) Upgraded to Hold at ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/heron-therapeutics-inc-logo.jpg?v=20221214151850", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.998356"}, {"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.321937, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.123844", "ticker_sentiment_score": "0.217705", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "STT", "relevance_score": "0.123844", "ticker_sentiment_score": "0.217705", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.06211", "ticker_sentiment_score": "0.170259", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.123844", "ticker_sentiment_score": "0.217705", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HRTX", "relevance_score": "0.814721", "ticker_sentiment_score": "0.485273", "ticker_sentiment_label": "Bullish"}]}, {"title": "Intuitive Surgical  ( NASDAQ:ISRG )  Downgraded to \"Hold\" at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/intuitive-surgical-nasdaqisrg-downgraded-to-hold-at-stocknews-com.html", "time_published": "20231011T071444", "authors": ["Defense World Staff"], "summary": "Intuitive Surgical ( NASDAQ:ISRG ) Downgraded to \"Hold\" at ... Defense World ...", "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=ISRG", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999998"}, {"topic": "Earnings", "relevance_score": "0.947132"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.292638, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.085936", "ticker_sentiment_score": "0.203206", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AB", "relevance_score": "0.085936", "ticker_sentiment_score": "0.203206", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "STT", "relevance_score": "0.085936", "ticker_sentiment_score": "0.203206", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.04303", "ticker_sentiment_score": "0.049999", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.04303", "ticker_sentiment_score": "0.065888", "ticker_sentiment_label": "Neutral"}, {"ticker": "JBARF", "relevance_score": "0.085936", "ticker_sentiment_score": "0.203206", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ISRG", "relevance_score": "0.719473", "ticker_sentiment_score": "0.411321", "ticker_sentiment_label": "Bullish"}]}, {"title": "ObsEva  ( NASDAQ:OBSV )  Now Covered by Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/obseva-nasdaqobsv-now-covered-by-analysts-at-stocknews-com-2.html", "time_published": "20231011T071443", "authors": ["Defense World Staff"], "summary": "ObsEva ( NASDAQ:OBSV ) Now Covered by Analysts at StockNews ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/obseva-sa-logo.png?v=20230117114420", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.336681, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OBSEF", "relevance_score": "0.829093", "ticker_sentiment_score": "0.539538", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.099066", "ticker_sentiment_score": "0.133757", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.19661", "ticker_sentiment_score": "0.322867", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VIRT", "relevance_score": "0.099066", "ticker_sentiment_score": "0.226792", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Intevac  ( NASDAQ:IVAC )  Lowered to \"Sell\" at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/intevac-nasdaqivac-lowered-to-sell-at-stocknews-com-2.html", "time_published": "20231011T071443", "authors": ["Defense World Staff"], "summary": "Intevac ( NASDAQ:IVAC - Get Free Report ) was downgraded by stock analysts at StockNews.com from a \"hold\" rating to a \"sell\" rating in a research note issued on Wednesday. Separately, Benchmark lowered shares of Intevac from a \"buy\" rating to a \"hold\" rating in a report on Wednesday, June 14th.", "banner_image": "https://www.marketbeat.com/logos/intevac-logo.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.201269, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.097062", "ticker_sentiment_score": "0.157224", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVAC", "relevance_score": "0.887117", "ticker_sentiment_score": "0.344248", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.192694", "ticker_sentiment_score": "0.165451", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.097062", "ticker_sentiment_score": "0.115624", "ticker_sentiment_label": "Neutral"}, {"ticker": "AIG", "relevance_score": "0.097062", "ticker_sentiment_score": "0.115624", "ticker_sentiment_label": "Neutral"}]}, {"title": "ContraFect  ( NASDAQ:CFRX )  Coverage Initiated at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/contrafect-nasdaqcfrx-coverage-initiated-at-stocknews-com-3.html", "time_published": "20231011T071443", "authors": ["Defense World Staff"], "summary": "Equities researchers at StockNews.com initiated coverage on shares of ContraFect ( NASDAQ:CFRX - Get Free Report ) in a research report issued on Wednesday. The brokerage set a \"sell\" rating on the biotechnology company's stock. Shares of ContraFect stock opened at $0.48 on Wednesday.", "banner_image": "https://www.marketbeat.com/logos/contrafect-corp-logo.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}, {"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.322183, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AWON", "relevance_score": "0.082963", "ticker_sentiment_score": "0.002055", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.082963", "ticker_sentiment_score": "0.127692", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.165031", "ticker_sentiment_score": "0.280379", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VIRT", "relevance_score": "0.165031", "ticker_sentiment_score": "0.280379", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CFRX", "relevance_score": "0.855251", "ticker_sentiment_score": "0.522905", "ticker_sentiment_label": "Bullish"}]}, {"title": "ProPhase Labs  ( NASDAQ:PRPH )  Lifted to Hold at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/prophase-labs-nasdaqprph-lifted-to-hold-at-stocknews-com.html", "time_published": "20231011T071443", "authors": ["Defense World Staff"], "summary": "ProPhase Labs ( NASDAQ:PRPH - Get Free Report ) was upgraded by stock analysts at StockNews.com from a \"sell\" rating to a \"hold\" rating in a research note issued to investors on Wednesday. Separately, HC Wainwright reissued a \"buy\" rating and issued a $14.00 price target on shares of ProPhase ...", "banner_image": "https://www.marketbeat.com/logos/prophase-labs-inc-logo.jpg?v=20210416125710", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.299688, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.081001", "ticker_sentiment_score": "0.186043", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RBCPF", "relevance_score": "0.16117", "ticker_sentiment_score": "0.234257", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VCTR", "relevance_score": "0.081001", "ticker_sentiment_score": "0.178592", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PRPH", "relevance_score": "0.872847", "ticker_sentiment_score": "0.493102", "ticker_sentiment_label": "Bullish"}]}, {"title": "EMCORE  ( NASDAQ:EMKR )  Coverage Initiated by Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/emcore-nasdaqemkr-coverage-initiated-by-analysts-at-stocknews-com.html", "time_published": "20231011T071443", "authors": ["Defense World Staff"], "summary": "EMCORE ( NASDAQ:EMKR ) Coverage Initiated by Analysts at ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/emcore-co-logo.png?v=20230110211442&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999967"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.282257, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SEIC", "relevance_score": "0.153961", "ticker_sentiment_score": "0.289617", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EMKR", "relevance_score": "0.825924", "ticker_sentiment_score": "0.461033", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.077343", "ticker_sentiment_score": "0.149085", "ticker_sentiment_label": "Neutral"}]}, {"title": "PFSweb  ( NASDAQ:PFSW )  Earns Hold Rating from Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/pfsweb-nasdaqpfsw-earns-hold-rating-from-analysts-at-stocknews-com.html", "time_published": "20231011T071443", "authors": ["Defense World Staff"], "summary": "PFSweb ( NASDAQ:PFSW ) Earns Hold Rating from Analysts at ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/pfsweb-inc-logo.png?v=20221222073539&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Earnings", "relevance_score": "0.917436"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.273653, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "STT", "relevance_score": "0.146025", "ticker_sentiment_score": "0.164592", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BCS", "relevance_score": "0.146025", "ticker_sentiment_score": "0.164592", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.146025", "ticker_sentiment_score": "0.164592", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BK", "relevance_score": "0.146025", "ticker_sentiment_score": "0.164592", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.073321", "ticker_sentiment_score": "0.172605", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DB", "relevance_score": "0.146025", "ticker_sentiment_score": "0.164592", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFSW", "relevance_score": "0.768428", "ticker_sentiment_score": "0.43759", "ticker_sentiment_label": "Bullish"}]}, {"title": "Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Upgraded at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/rigel-pharmaceuticals-nasdaqrigl-upgraded-at-stocknews-com.html", "time_published": "20231011T071443", "authors": ["Defense World Staff"], "summary": "Rigel Pharmaceuticals ( NASDAQ:RIGL - Get Free Report ) was upgraded by equities research analysts at StockNews.com from a \"hold\" rating to a \"buy\" rating in a note issued to investors on Wednesday.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/rigel-pharmaceuticals-inc-logo.png?v=20221216130713&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}], "overall_sentiment_score": 0.368068, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "RIGL", "relevance_score": "0.800175", "ticker_sentiment_score": "0.574667", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.068112", "ticker_sentiment_score": "0.089021", "ticker_sentiment_label": "Neutral"}]}, {"title": "Global Indemnity Group  ( NASDAQ:GBLI )  Coverage Initiated at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/global-indemnity-group-nasdaqgbli-coverage-initiated-at-stocknews-com.html", "time_published": "20231011T071443", "authors": ["Defense World Staff"], "summary": "Global Indemnity Group ( NASDAQ:GBLI ) Coverage Initiated at ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/global-indemnity-group-llc-logo.jpg?v=20221214140056", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999365"}, {"topic": "Earnings", "relevance_score": "0.928769"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.227245, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMP", "relevance_score": "0.13459", "ticker_sentiment_score": "0.220588", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GBLI", "relevance_score": "0.796338", "ticker_sentiment_score": "0.373119", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.067536", "ticker_sentiment_score": "0.001013", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gladstone Investment  ( NASDAQ:GAIN )  Upgraded at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/gladstone-investment-nasdaqgain-upgraded-at-stocknews-com.html", "time_published": "20231011T071443", "authors": ["Defense World Staff"], "summary": "Gladstone Investment ( NASDAQ:GAIN - Get Free Report ) was upgraded by analysts at StockNews.com from a \"sell\" rating to a \"hold\" rating in a research report issued to clients and investors on Wednesday. GAIN opened at $12.58 on Wednesday.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/gladstone-investment-co-logo.jpg&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.904684"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.319814, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.067158", "ticker_sentiment_score": "0.092797", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.133841", "ticker_sentiment_score": "0.265424", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GAIN", "relevance_score": "0.793786", "ticker_sentiment_score": "0.507089", "ticker_sentiment_label": "Bullish"}, {"ticker": "UBS", "relevance_score": "0.133841", "ticker_sentiment_score": "0.265424", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Allied Healthcare Products  ( NASDAQ:AHPI )  Now Covered by Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/allied-healthcare-products-nasdaqahpi-now-covered-by-analysts-at-stocknews-com.html", "time_published": "20231011T071443", "authors": ["Defense World Staff"], "summary": "Allied Healthcare Products ( NASDAQ:AHPI ) Now Covered by ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/allied-healthcare-products-inc-logo.jpg?v=20211103153637", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}], "overall_sentiment_score": 0.287234, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.116348", "ticker_sentiment_score": "0.184734", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "China Jo-Jo Drugstores  ( NASDAQ:CJJD )  Now Covered by Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/china-jo-jo-drugstores-nasdaqcjjd-now-covered-by-analysts-at-stocknews-com-2.html", "time_published": "20231011T071443", "authors": ["Defense World Staff"], "summary": "China Jo-Jo Drugstores ( NASDAQ:CJJD ) Now Covered by Analysts ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/china-jo-jo-drugstores-inc-logo.png?v=20220121113022", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.276666, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VIRT", "relevance_score": "0.227007", "ticker_sentiment_score": "0.24361", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CJJD", "relevance_score": "0.887383", "ticker_sentiment_score": "0.463387", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.114682", "ticker_sentiment_score": "0.134711", "ticker_sentiment_label": "Neutral"}]}, {"title": "StockNews.com Begins Coverage on ARCA biopharma  ( NASDAQ:ABIO ) ", "url": "https://www.defenseworld.net/2023/10/11/stocknews-com-begins-coverage-on-arca-biopharma-nasdaqabio.html", "time_published": "20231011T071442", "authors": ["Defense World Staff"], "summary": "StockNews.com Begins Coverage on ARCA biopharma ( NASDAQ ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/arca-biopharma-inc-logo.png?v=20211013111358", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.321735, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABIO", "relevance_score": "0.910945", "ticker_sentiment_score": "0.531493", "ticker_sentiment_label": "Bullish"}, {"ticker": "VIRT", "relevance_score": "0.096671", "ticker_sentiment_score": "0.167682", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.096671", "ticker_sentiment_score": "0.182865", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Athersys  ( NASDAQ:ATHX )  Coverage Initiated by Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/athersys-nasdaqathx-coverage-initiated-by-analysts-at-stocknews-com.html", "time_published": "20231011T071442", "authors": ["Defense World Staff"], "summary": "Athersys ( NASDAQ:ATHX ) Coverage Initiated by Analysts at ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/athersys-logo.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}, {"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.281939, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "STT", "relevance_score": "0.167322", "ticker_sentiment_score": "0.221667", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.084127", "ticker_sentiment_score": "0.104935", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.167322", "ticker_sentiment_score": "0.221667", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ATHX", "relevance_score": "0.830322", "ticker_sentiment_score": "0.461509", "ticker_sentiment_label": "Bullish"}, {"ticker": "VIRT", "relevance_score": "0.167322", "ticker_sentiment_score": "0.221667", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Brainstorm Cell Therapeutics  ( NASDAQ:BCLI )  Earns Hold Rating from Analysts at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/brainstorm-cell-therapeutics-nasdaqbcli-earns-hold-rating-from-analysts-at-stocknews-com.html", "time_published": "20231011T071442", "authors": ["Defense World Staff"], "summary": "Brainstorm Cell Therapeutics ( NASDAQ:BCLI ) Earns Hold Rating ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/brainstorm-cell-therapeutics-inc-logo.png?v=20230103152601", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.278358, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.16171", "ticker_sentiment_score": "0.173233", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BCLI", "relevance_score": "0.815336", "ticker_sentiment_score": "0.453179", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.081276", "ticker_sentiment_score": "0.160878", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.16171", "ticker_sentiment_score": "0.173233", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.081276", "ticker_sentiment_score": "0.160878", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AstroNova  ( NASDAQ:ALOT )  Research Coverage Started at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/astronova-nasdaqalot-research-coverage-started-at-stocknews-com.html", "time_published": "20231011T071442", "authors": ["Defense World Staff"], "summary": "AstroNova ( NASDAQ:ALOT ) Research Coverage Started at ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/astronova-inc-logo.png", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}, {"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.26991, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "STT", "relevance_score": "0.155451", "ticker_sentiment_score": "0.20609", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AWON", "relevance_score": "0.078099", "ticker_sentiment_score": "-0.027314", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.078099", "ticker_sentiment_score": "0.139058", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTRS", "relevance_score": "0.155451", "ticker_sentiment_score": "0.20609", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RBCPF", "relevance_score": "0.155451", "ticker_sentiment_score": "0.20609", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALOT", "relevance_score": "0.830107", "ticker_sentiment_score": "0.444299", "ticker_sentiment_label": "Bullish"}]}, {"title": "Aethlon Medical  ( NASDAQ:AEMD )  Coverage Initiated at StockNews.com", "url": "https://www.defenseworld.net/2023/10/11/aethlon-medical-nasdaqaemd-coverage-initiated-at-stocknews-com.html", "time_published": "20231011T071442", "authors": ["Defense World Staff"], "summary": "Aethlon Medical ( NASDAQ:AEMD ) Coverage Initiated at StockNews ... Defense World ...", "banner_image": "https://www.marketbeat.com/logos/aethlon-medical-inc-logo.png", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}], "overall_sentiment_score": 0.224822, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AEMD", "relevance_score": "0.827318", "ticker_sentiment_score": "0.373042", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.077593", "ticker_sentiment_score": "0.016798", "ticker_sentiment_label": "Neutral"}]}, {"title": "StockNews.com Initiates Coverage on Heritage-Crystal Clean  ( NASDAQ:HCCI ) ", "url": "https://www.defenseworld.net/2023/10/11/stocknews-com-initiates-coverage-on-heritage-crystal-clean-nasdaqhcci.html", "time_published": "20231011T071442", "authors": ["Defense World Staff"], "summary": "StockNews.com Initiates Coverage on Heritage-Crystal Clean ... Defense World ...", "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=HCCI", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.692272"}, {"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.260942, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HCCI", "relevance_score": "0.844813", "ticker_sentiment_score": "0.432143", "ticker_sentiment_label": "Bullish"}, {"ticker": "C", "relevance_score": "0.11894", "ticker_sentiment_score": "0.228836", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.059636", "ticker_sentiment_score": "0.047174", "ticker_sentiment_label": "Neutral"}]}, {"title": "Tango Therapeutics  ( TNGX )  Rises 20% in a Month: Here's Why", "url": "https://www.zacks.com/stock/news/2163685/tango-therapeutics-tngx-rises-20-in-a-month-heres-why", "time_published": "20231010T152800", "authors": ["Zacks Equity Research"], "summary": "The upside in Tango's (TNGX) shares can be attributed to the company's progress with its pipeline candidates. A recent acquisition offer for a biotech making similar drugs also bolstered this surge.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}], "overall_sentiment_score": 0.147038, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TNGX", "relevance_score": "0.613875", "ticker_sentiment_score": "0.191412", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRTX", "relevance_score": "0.10607", "ticker_sentiment_score": "0.187834", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.10607", "ticker_sentiment_score": "-0.112528", "ticker_sentiment_label": "Neutral"}]}, {"title": "Russell Reynolds Associates, World 50 Group To Help Accelerate Executive Diversity With Third Cohort of \"Next Generation Director\" Development Program", "url": "https://www.prnewswire.com/news-releases/russell-reynolds-associates-world-50-group-to-help-accelerate-executive-diversity-with-third-cohort-of-next-generation-director-development-program-301951425.html", "time_published": "20231010T130000", "authors": ["Russell Reynolds Associates"], "summary": "Russell Reynolds Associates, World 50 Group To Help Accelerate Executive Diversity With Third Cohort of \"Next ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1502546/Russell_Reynolds_Associates_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.37705, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "SYF", "relevance_score": "0.04161", "ticker_sentiment_score": "0.089247", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.04161", "ticker_sentiment_score": "0.089247", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.04161", "ticker_sentiment_score": "0.089247", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXP", "relevance_score": "0.04161", "ticker_sentiment_score": "0.217634", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.04161", "ticker_sentiment_score": "0.089247", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.04161", "ticker_sentiment_score": "0.089247", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATGE", "relevance_score": "0.04161", "ticker_sentiment_score": "0.217634", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BA", "relevance_score": "0.04161", "ticker_sentiment_score": "0.089247", "ticker_sentiment_label": "Neutral"}]}, {"title": "A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip", "url": "https://www.fool.com/investing/2023/10/10/a-bull-market-is-coming-1-beaten-down-growth-stock/", "time_published": "20231010T094000", "authors": ["Cory Renauer"], "summary": "Wall Street price targets suggest this stock can rocket more than 400% higher.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.031667, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CRBU", "relevance_score": "0.272788", "ticker_sentiment_score": "0.082456", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.110973", "ticker_sentiment_score": "-0.140828", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Ascends But Remains Behind Market: Some Facts to Note", "url": "https://www.zacks.com/stock/news/2162984/gilead-sciences-gild-ascends-but-remains-behind-market-some-facts-to-note", "time_published": "20231009T220020", "authors": ["Zacks Equity Research"], "summary": "In the closing of the recent trading day, Gilead Sciences (GILD) stood at $75.06, denoting a +0.43% change from the preceding trading day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default265.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.169428, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.532556", "ticker_sentiment_score": "0.273258", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Antibody Drug Conjugates Market Revenue to Hit $29.6 Billion, Globally, by 2030 - Exclusive Study by The Insight Partners", "url": "https://www.benzinga.com/pressreleases/23/10/g35143608/antibody-drug-conjugates-market-revenue-to-hit-29-6-billion-globally-by-2030-exclusive-study-by-th", "time_published": "20231009T120410", "authors": ["Globe Newswire"], "summary": "Pune, India, Oct. 09, 2023 ( GLOBE NEWSWIRE ) -- Antibody drug conjugates ( ADC ) are one of the fastest growing anticancer drugs. It is typically composed of a monoclonal antibody ( mAbs ) covalently attached to a cytotoxic drug via a chemical linker.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.138172, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ASAN", "relevance_score": "0.04406", "ticker_sentiment_score": "0.047239", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRNEQ", "relevance_score": "0.04406", "ticker_sentiment_score": "0.047239", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.04406", "ticker_sentiment_score": "0.092172", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMGN", "relevance_score": "0.174903", "ticker_sentiment_score": "0.089155", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADCT", "relevance_score": "0.301052", "ticker_sentiment_score": "0.09182", "ticker_sentiment_label": "Neutral"}, {"ticker": "PKBO", "relevance_score": "0.04406", "ticker_sentiment_score": "0.047239", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.04406", "ticker_sentiment_score": "0.092172", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGMF", "relevance_score": "0.04406", "ticker_sentiment_score": "0.092172", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.04406", "ticker_sentiment_score": "0.092172", "ticker_sentiment_label": "Neutral"}, {"ticker": "STRO", "relevance_score": "0.04406", "ticker_sentiment_score": "0.047239", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.087985", "ticker_sentiment_score": "0.057624", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.04406", "ticker_sentiment_score": "0.047239", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.04406", "ticker_sentiment_score": "0.047239", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.04406", "ticker_sentiment_score": "0.092172", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.04406", "ticker_sentiment_score": "0.047239", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.04406", "ticker_sentiment_score": "0.092172", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/earnings/23/10/35114040/heres-how-much-100-invested-in-gilead-sciences-20-years-ago-would-be-worth-today", "time_published": "20231005T173050", "authors": ["Benzinga Insights"], "summary": "Gilead Sciences GILD has outperformed the market over the past 20 years by 4.82% on an annualized basis producing an average annual return of 12.02%. Currently, Gilead Sciences has a market capitalization of $93.13 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Strides Pharma Science trades marginally lower despite USFDA nod", "url": "https://www.moneycontrol.com/news/business/stocks/strides-pharma-science-trades-marginally-lower-despite-usfda-nod-11478241.html", "time_published": "20231005T041148", "authors": [], "summary": "The company has received approval for Efavirenz ( 600mg ) , Emtricitabine ( 200mg ) , Tenofovir Disproxil Fumurate ( 300mg ) , ( EET ) tablets from the United States Food Drug Administration ( USFDA ) .", "banner_image": "https://images.moneycontrol.com/static-mcnews/2023/10/engineering_new.jpg?impolicy=website&width=168&height=118", "source": "Money Control", "category_within_source": "Buzzing Stocks", "source_domain": "www.moneycontrol.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.221437, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.172097", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "CTSH: Supercharge Your October Portfolio With These 3 Promising Tech Stocks", "url": "https://stocknews.com/news/ctsh-it-hckt-supercharge-your-october-portfolio-with-these-3-promising-tech-stocks/", "time_published": "20231004T134309", "authors": ["StockNews.com Staff"], "summary": "CTSH: Supercharge Your October Portfolio With These 3 Promising ... ...", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/shutterstock_1990825910-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.803643"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.278875, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HESG", "relevance_score": "0.063509", "ticker_sentiment_score": "0.094052", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISSC", "relevance_score": "0.03178", "ticker_sentiment_score": "0.163637", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CTSH", "relevance_score": "0.367412", "ticker_sentiment_score": "0.340219", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.095138", "ticker_sentiment_score": "0.150134", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IT", "relevance_score": "0.03178", "ticker_sentiment_score": "0.134446", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCKT", "relevance_score": "0.188928", "ticker_sentiment_score": "0.358619", "ticker_sentiment_label": "Bullish"}]}, {"title": "Lilly Announces Leadership Transitions", "url": "https://markets.businessinsider.com/news/stocks/lilly-announces-leadership-transitions-1032677321", "time_published": "20231004T104500", "authors": ["markets.businessinsider.com"], "summary": "INDIANAPOLIS, Oct. 4, 2023 /PRNewswire/ -- Eli Lilly and Company ( NYSE: LLY ) today announced changes to its executive leadership team. Mike Mason, executive vice president and president of Lilly Diabetes and Obesity, will retire from Lilly at the end of 2023 after 34 years with the company.", "banner_image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg", "source": "Business Insider", "category_within_source": "RSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.145632, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.600823", "ticker_sentiment_score": "0.193581", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CURN", "relevance_score": "0.028023", "ticker_sentiment_score": "0.005719", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.028023", "ticker_sentiment_score": "0.160467", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.028023", "ticker_sentiment_score": "-0.049462", "ticker_sentiment_label": "Neutral"}]}, {"title": "Lilly Announces Leadership Transitions", "url": "https://www.prnewswire.com/news-releases/lilly-announces-leadership-transitions-301946467.html", "time_published": "20231004T104500", "authors": ["Eli Lilly and Company"], "summary": "INDIANAPOLIS, Oct. 4, 2023 /PRNewswire/ -- Eli Lilly and Company ( NYSE: LLY ) today announced changes to its executive leadership team. Mike Mason, executive vice president and president of Lilly Diabetes and Obesity, will retire from Lilly at the end of 2023 after 34 years with the company.", "banner_image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.152655, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.5948", "ticker_sentiment_score": "0.192587", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CURN", "relevance_score": "0.027667", "ticker_sentiment_score": "0.00571", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.027667", "ticker_sentiment_score": "0.159271", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.027667", "ticker_sentiment_score": "-0.049386", "ticker_sentiment_label": "Neutral"}]}, {"title": "Breast Cancer Therapeutics Market to Hit $63.96 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners", "url": "https://www.benzinga.com/pressreleases/23/10/g35082720/breast-cancer-therapeutics-market-to-hit-63-96-billion-globally-by-2030-exclusive-report-by-the-in", "time_published": "20231004T095703", "authors": ["Globe Newswire"], "summary": "Pune, India, Oct. 04, 2023 ( GLOBE NEWSWIRE ) -- Breast cancer is one of the most common types of cancer and has a sizable market for therapies. According to the Centers for Disease Control and Prevention, in 2020, in the US, 239,612 new cases of breast cancer were reported among women, of which ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.334725, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "NVS", "relevance_score": "0.036643", "ticker_sentiment_score": "-0.119027", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.036643", "ticker_sentiment_score": "-0.119027", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.036643", "ticker_sentiment_score": "-0.119027", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.036643", "ticker_sentiment_score": "-0.119027", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.073209", "ticker_sentiment_score": "-0.060171", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.036643", "ticker_sentiment_score": "-0.119027", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGN: Top 3 Biotech Stocks Leading the Way This October", "url": "https://stocknews.com/news/amgn-gild-jazz-top-3-biotech-stocks-leading-the-way-this-october/", "time_published": "20231003T164408", "authors": ["StockNews.com Staff"], "summary": "The biotech industry is thriving, driven by innovation and stable demand, positioning it for sustained growth. Despite macroeconomic challenges, this positive outlook is supported by an aging population and the demand for quality treatments for both rare and common diseases.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/Biotech-Lg_FB.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.256922, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.308742", "ticker_sentiment_score": "0.115153", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.121404", "ticker_sentiment_score": "0.150495", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.169335", "ticker_sentiment_score": "0.147264", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Stock Sinks As Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2158894/gilead-sciences-gild-stock-sinks-as-market-gains-what-you-should-know", "time_published": "20231002T220018", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Gilead Sciences (GILD) closed at $74.10, marking a -1.12% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default211.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.150126, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.538782", "ticker_sentiment_score": "0.270872", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Message from Renovaro Biosciences CEO, The Hon. Mark Dybul, MD", "url": "https://www.globenewswire.com/news-release/2023/10/02/2753011/0/en/Message-from-Renovaro-Biosciences-CEO-The-Hon-Mark-Dybul-MD.html", "time_published": "20231002T160500", "authors": ["Renovaro Biosciences Inc."], "summary": "AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/25c79e82-0148-4a7e-beb5-e0c67d2e108f", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.938793"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.22126, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.051184", "ticker_sentiment_score": "-0.041993", "ticker_sentiment_label": "Neutral"}, {"ticker": "RENB", "relevance_score": "0.068209", "ticker_sentiment_score": "0.208806", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.017072", "ticker_sentiment_score": "0.107168", "ticker_sentiment_label": "Neutral"}]}, {"title": "AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine - Renovaro Biosciences  ( NASDAQ:RENB ) ", "url": "https://www.benzinga.com/pressreleases/23/10/g35031585/ai-company-gedicube-and-renovaro-biosciences-sign-definitive-agreement-to-combine", "time_published": "20231002T132500", "authors": ["Globe Newswire"], "summary": "LOS ANGELES, Oct. 02, 2023 ( GLOBE NEWSWIRE ) -- Renovaro Biosciences Inc. RENB", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Mergers", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.967645"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.230291, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.034984", "ticker_sentiment_score": "-0.030371", "ticker_sentiment_label": "Neutral"}, {"ticker": "RENB", "relevance_score": "0.0699", "ticker_sentiment_score": "0.252817", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.017496", "ticker_sentiment_score": "0.104397", "ticker_sentiment_label": "Neutral"}]}, {"title": "AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine", "url": "https://www.globenewswire.com/news-release/2023/10/02/2752845/0/en/AI-Company-GEDiCube-and-Renovaro-Biosciences-Sign-Definitive-Agreement-to-Combine.html", "time_published": "20231002T132500", "authors": ["Renovaro Biosciences Inc."], "summary": "Message from Renovaro Biosciences CEO, The Hon. Mark Dybul, MD ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/25c79e82-0148-4a7e-beb5-e0c67d2e108f", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.938793"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.22126, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.051184", "ticker_sentiment_score": "-0.041993", "ticker_sentiment_label": "Neutral"}, {"ticker": "RENB", "relevance_score": "0.068209", "ticker_sentiment_score": "0.208806", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.017072", "ticker_sentiment_score": "0.107168", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Magnificent Dividend Stocks to Buy in October", "url": "https://www.fool.com/investing/2023/09/30/3-magnificent-dividend-stocks-to-buy-in-october/", "time_published": "20230930T105500", "authors": ["Keith Speights", "David Jagielski", "and Prosper Junior Bakiny"], "summary": "These stocks come with great dividends and more.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}, {"topic": "Earnings", "relevance_score": "0.976913"}], "overall_sentiment_score": 0.244586, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.350564", "ticker_sentiment_score": "0.204761", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.179788", "ticker_sentiment_score": "0.03029", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.266828", "ticker_sentiment_score": "0.205411", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2157520/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now", "time_published": "20230929T102005", "authors": ["Zacks Equity Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default17.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999953"}], "overall_sentiment_score": 0.239238, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.061631", "ticker_sentiment_score": "0.074005", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.122894", "ticker_sentiment_score": "0.068464", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.122894", "ticker_sentiment_score": "0.068464", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.122894", "ticker_sentiment_score": "0.068464", "ticker_sentiment_label": "Neutral"}]}, {"title": "Two Trial Halts In A Row - Gilead Sciences Stops Late Stage COVID-19 Study - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/general/biotech/23/09/34982869/two-trial-halts-in-a-row-gilead-sciences-stops-late-stage-covid-19-study", "time_published": "20230928T173528", "authors": ["Vandana Singh"], "summary": "Gilead Sciences Inc GILD said it has stopped patient enrollment in BIRCH ( Study GS-US-611-6273 ) , a Phase 3 study evaluating the efficacy and safety of obeldesivir compared with placebo in non-hospitalized participants who are at high risk for developing severe COVID-19.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/28/gild.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.029371, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.479683", "ticker_sentiment_score": "0.069836", "ticker_sentiment_label": "Neutral"}]}, {"title": "Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields - Gilead Sciences  ( NASDAQ:GILD ) , Pfizer  ( NYSE:PFE ) ", "url": "https://www.benzinga.com/news/23/09/34947896/wall-streets-most-accurate-analysts-say-hold-these-3-health-care-stocks-with-over-4-dividend-yields", "time_published": "20230927T130332", "authors": ["Lisa Levin"], "summary": "During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/27/image_1.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.100294, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.103778", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.103778", "ticker_sentiment_score": "-0.068615", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.205807", "ticker_sentiment_score": "-0.056764", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.103778", "ticker_sentiment_score": "0.079384", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGIOF", "relevance_score": "0.103778", "ticker_sentiment_score": "0.079384", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.103778", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Gains As Market Dips: What You Should Know", "url": "https://www.zacks.com/stock/news/2155735/gilead-sciences-gild-gains-as-market-dips-what-you-should-know", "time_published": "20230926T220019", "authors": ["Zacks Equity Research"], "summary": "Gilead Sciences (GILD) closed the most recent trading day at $75.53, moving +0.94% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default334.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.983783"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.129218, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.670305", "ticker_sentiment_score": "0.243891", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Miami man pleads guilty to selling adulterated, misbranded HIV drugs across U.S.", "url": "https://www.cnbc.com/2023/09/26/miami-man-pleads-guilty-to-selling-misbranded-hiv-drugs.html", "time_published": "20230926T193139", "authors": ["Spencer Kimball"], "summary": "The misbranded HIV drugs, which included Truvada and Biktarvy, were distributed to pharmacies across the U.S. and dispensed to unsuspecting patients.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107306794-1695744630618-gettyimages-1690204409-US-NEWS-MIAMI-MAN-DISTRIBUTED-OVER-16-1-MI.jpeg?v=1695757605&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.289658, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.130926", "ticker_sentiment_score": "-0.020614", "ticker_sentiment_label": "Neutral"}]}, {"title": "CAR T-cell Therapy for Multiple Myeloma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key Companies - Cartesian, Arcellx, Novartis, Bristol-Myers Squibb, CARsgen, Poseida, Juno, CRISPR, bluebird bio", "url": "https://www.prnewswire.com/news-releases/car-t-cell-therapy-for-multiple-myeloma-market-to-observe-stunning-growth-by-2032-evaluates-delveinsight--key-companies---cartesian-arcellx-novartis-bristol-myers-squibb-carsgen-poseida-juno-crispr-bluebird-bio-301937157.html", "time_published": "20230925T210100", "authors": ["LLP", "DelveInsight Business Research"], "summary": "CAR T-cell Therapy for Multiple Myeloma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.0762, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SRNEQ", "relevance_score": "0.037504", "ticker_sentiment_score": "0.019103", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.05623", "ticker_sentiment_score": "0.056937", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.018757", "ticker_sentiment_score": "0.026387", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLYYF", "relevance_score": "0.018757", "ticker_sentiment_score": "0.057813", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.037504", "ticker_sentiment_score": "0.028556", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVBXF", "relevance_score": "0.018757", "ticker_sentiment_score": "0.012868", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWTX", "relevance_score": "0.018757", "ticker_sentiment_score": "0.024665", "ticker_sentiment_label": "Neutral"}, {"ticker": "DTIL", "relevance_score": "0.018757", "ticker_sentiment_score": "0.012868", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRTHF", "relevance_score": "0.130723", "ticker_sentiment_score": "0.064024", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRBU", "relevance_score": "0.018757", "ticker_sentiment_score": "0.057813", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCCC", "relevance_score": "0.018757", "ticker_sentiment_score": "0.026387", "ticker_sentiment_label": "Neutral"}, {"ticker": "MBIO", "relevance_score": "0.018757", "ticker_sentiment_score": "0.012868", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSTX", "relevance_score": "0.037504", "ticker_sentiment_score": "0.05738", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.018757", "ticker_sentiment_score": "0.026387", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASPHF", "relevance_score": "0.018757", "ticker_sentiment_score": "0.024665", "ticker_sentiment_label": "Neutral"}, {"ticker": "SANA", "relevance_score": "0.018757", "ticker_sentiment_score": "0.024665", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALNY", "relevance_score": "0.018757", "ticker_sentiment_score": "0.012868", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.037504", "ticker_sentiment_score": "0.029512", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLCM", "relevance_score": "0.018757", "ticker_sentiment_score": "0.012868", "ticker_sentiment_label": "Neutral"}, {"ticker": "CASI", "relevance_score": "0.018757", "ticker_sentiment_score": "0.012868", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITOS", "relevance_score": "0.018757", "ticker_sentiment_score": "0.024665", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.130723", "ticker_sentiment_score": "0.049466", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLLS", "relevance_score": "0.037504", "ticker_sentiment_score": "0.05738", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACLX", "relevance_score": "0.09358", "ticker_sentiment_score": "0.057751", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALLO", "relevance_score": "0.05623", "ticker_sentiment_score": "0.045942", "ticker_sentiment_label": "Neutral"}, {"ticker": "JWCTF", "relevance_score": "0.018757", "ticker_sentiment_score": "0.012868", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.018757", "ticker_sentiment_score": "0.024665", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.018757", "ticker_sentiment_score": "0.012868", "ticker_sentiment_label": "Neutral"}, {"ticker": "SZIHF", "relevance_score": "0.037504", "ticker_sentiment_score": "0.014356", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATRA", "relevance_score": "0.018757", "ticker_sentiment_score": "0.012868", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.037504", "ticker_sentiment_score": "0.029512", "ticker_sentiment_label": "Neutral"}]}, {"title": "AstraZeneca's  ( AZN )  Dato-DXd Meets Goal in Breast Cancer Study", "url": "https://www.zacks.com/stock/news/2154945/astrazenecas-azn-dato-dxd-meets-goal-in-breast-cancer-study", "time_published": "20230925T150500", "authors": ["Zacks Equity Research"], "summary": "AstraZeneca (AZN) announces positive results from the late-stage study evaluating its antibody-drug conjugate, Dato-DXd, in pre-treated patients with HR+/HER2- metastatic breast cancer.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e5/1416.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928139"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.063404, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CORT", "relevance_score": "0.158173", "ticker_sentiment_score": "0.12322", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVAX", "relevance_score": "0.158173", "ticker_sentiment_score": "0.092984", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.158173", "ticker_sentiment_score": "-0.140101", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.105836", "ticker_sentiment_score": "0.217231", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSKYF", "relevance_score": "0.158173", "ticker_sentiment_score": "-0.140101", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.49407", "ticker_sentiment_score": "-0.181821", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "THE BLACK WOMEN'S AGENDA, INC. HOSTS 46TH ANNUAL SYMPOSIUM TOWN HALL & AWARDS LUNCHEON - PR Newswire", "url": "https://www.prnewswire.com/news-releases/the-black-womens-agenda-inc-hosts-46th-annual-symposium-town-hall--awards-luncheon-301936600.html", "time_published": "20230922T202700", "authors": [], "summary": "THE BLACK WOMEN'S AGENDA, INC. HOSTS 46TH ANNUAL SYMPOSIUM TOWN HALL & AWARDS LUNCHEON PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.212721, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.075161", "ticker_sentiment_score": "0.096641", "ticker_sentiment_label": "Neutral"}]}, {"title": "Chronic Lower Back Pain Market to Showcase Tremendous Growth by 2032, Predicts DelveInsight | Key Companies to Look Out - Eli Lilly, Camurus, Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG", "url": "https://www.prnewswire.com/news-releases/chronic-lower-back-pain-market-to-showcase-tremendous-growth-by-2032-predicts-delveinsight--key-companies-to-look-out---eli-lilly-camurus-braeburn-inc-scilex-holding-mesoblast-limited-anges-mg-301934365.html", "time_published": "20230921T210100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "Chronic Lower Back Pain Market to Showcase Tremendous Growth by 2032, Predicts DelveInsight | Key Companies to ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.337142, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "MESO", "relevance_score": "0.068177", "ticker_sentiment_score": "-0.133049", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSNUF", "relevance_score": "0.02275", "ticker_sentiment_score": "0.014186", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNBWY", "relevance_score": "0.02275", "ticker_sentiment_score": "0.014186", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKESF", "relevance_score": "0.02275", "ticker_sentiment_score": "0.014186", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUJIF", "relevance_score": "0.02275", "ticker_sentiment_score": "0.014186", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCLX", "relevance_score": "0.02275", "ticker_sentiment_score": "-0.104786", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.02275", "ticker_sentiment_score": "0.014186", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.02275", "ticker_sentiment_score": "0.014186", "ticker_sentiment_label": "Neutral"}, {"ticker": "KYKOF", "relevance_score": "0.02275", "ticker_sentiment_score": "0.014186", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.02275", "ticker_sentiment_score": "0.014186", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.02275", "ticker_sentiment_score": "0.014186", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVBXF", "relevance_score": "0.02275", "ticker_sentiment_score": "0.014186", "ticker_sentiment_label": "Neutral"}]}, {"title": "CAAN AND GILEAD SCIENCES CANADA IGNITE HOPE WITH NEW INDIGENOUS HEALTH GRANT - Canada NewsWire", "url": "https://www.newswire.ca/news-releases/caan-and-gilead-sciences-canada-ignite-hope-with-new-indigenous-health-grant-800507084.html", "time_published": "20230921T200000", "authors": [], "summary": "CAAN AND GILEAD SCIENCES CANADA IGNITE HOPE WITH NEW INDIGENOUS HEALTH GRANT Canada ...", "banner_image": null, "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.31706, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.302346", "ticker_sentiment_score": "0.401423", "ticker_sentiment_label": "Bullish"}]}, {"title": "How Is The Market Feeling About Gilead Sciences? - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/short-sellers/23/09/34803110/how-is-the-market-feeling-about-gilead-sciences", "time_published": "20230921T181531", "authors": ["Benzinga Insights"], "summary": "Gilead Sciences's GILD short percent of float has fallen 6.82% since its last report. The company recently reported that it has 18.25 million shares sold short, which is 1.64% of all regular shares that are available for trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.239316, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.221819", "ticker_sentiment_score": "0.083071", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Bargain Stocks to Buy in a Market That's Priced for Perfection", "url": "https://www.fool.com/investing/2023/09/21/3-bargain-stocks-to-buy-in-a-market-thats-priced-f/", "time_published": "20230921T175400", "authors": ["David Jagielski", "and Prosper Junior Bakiny", "Keith Speights"], "summary": "Many stocks have nosebleed valuations. But not these.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.658903"}], "overall_sentiment_score": 0.222675, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.40348", "ticker_sentiment_score": "0.199045", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.40348", "ticker_sentiment_score": "0.291742", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SGEN", "relevance_score": "0.046907", "ticker_sentiment_score": "0.024022", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.362065", "ticker_sentiment_score": "0.068748", "ticker_sentiment_label": "Neutral"}]}, {"title": "Big pharma can't get enough of one class of cancer drugs", "url": "https://www.economist.com/business/2023/09/21/big-pharma-cant-get-enough-of-one-class-of-cancer-drugs", "time_published": "20230921T125146", "authors": ["The Economist"], "summary": "A spate of dealmaking suggests high expectations for antibody-drug conjugates ...", "banner_image": "https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20230923_WBC663.png", "source": "The Economist", "category_within_source": "Business", "source_domain": "www.economist.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.048564, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.27432", "ticker_sentiment_score": "0.06449", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRIX", "relevance_score": "0.0699", "ticker_sentiment_score": "-0.026247", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.0699", "ticker_sentiment_score": "0.034814", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.0699", "ticker_sentiment_score": "0.157028", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SGEN", "relevance_score": "0.0699", "ticker_sentiment_score": "-0.026247", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.0699", "ticker_sentiment_score": "0.034814", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.0699", "ticker_sentiment_score": "-0.026247", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.0699", "ticker_sentiment_score": "0.099427", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.0699", "ticker_sentiment_score": "0.099427", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice President, head of business development", "url": "https://www.benzinga.com/pressreleases/23/09/g34789158/bluejay-therapeutics-expands-management-team-and-hired-christopher-holterhoff-as-senior-vice-presi", "time_published": "20230921T115500", "authors": ["Globe Newswire"], "summary": "SAN MATEO, Calif., Sept. 21, 2023 ( GLOBE NEWSWIRE ) -- Bluejay Therapeutics, Inc. a private clinical stage biopharmaceutical company focused on viral and liver diseases, today announced the appointment of Christopher Holterhoff as Senior Vice President, Head of Business Development.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.229839, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FOLD", "relevance_score": "0.03853", "ticker_sentiment_score": "0.106315", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.076971", "ticker_sentiment_score": "0.032651", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.03853", "ticker_sentiment_score": "0.153119", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CDMO", "relevance_score": "0.03853", "ticker_sentiment_score": "0.0127", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBRX", "relevance_score": "0.03853", "ticker_sentiment_score": "0.0127", "ticker_sentiment_label": "Neutral"}, {"ticker": "SQZ", "relevance_score": "0.03853", "ticker_sentiment_score": "0.153119", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead Sciences Unusual Options Activity - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/markets/options/23/09/34772999/gilead-sciences-unusual-options-activity", "time_published": "20230920T201548", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bullish stance on Gilead Sciences. Looking at options history for Gilead Sciences GILD we detected 10 strange trades. If we consider the specifics of each trade, it is accurate to state that 60% of the investors opened trades with ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.858979"}], "overall_sentiment_score": 0.164594, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.743681", "ticker_sentiment_score": "0.405647", "ticker_sentiment_label": "Bullish"}]}, {"title": "Gilead's  ( GILD )  Veklury Gets CHMP Nod in Damaged Liver Patients", "url": "https://www.zacks.com/stock/news/2152969/gileads-gild-veklury-gets-chmp-nod-in-damaged-liver-patients", "time_published": "20230920T115100", "authors": ["Zacks Equity Research"], "summary": "Gilead's (GILD) Veklury gets a positive CHMP opinion, recommending the use of the drug to treat people with COVID-19 with mild to severe hepatic impairment.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/2227.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.983605"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.053363, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BTTX", "relevance_score": "0.252463", "ticker_sentiment_score": "-0.007763", "ticker_sentiment_label": "Neutral"}, {"ticker": "CORT", "relevance_score": "0.153145", "ticker_sentiment_score": "0.092381", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVAX", "relevance_score": "0.153145", "ticker_sentiment_score": "0.059857", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.203215", "ticker_sentiment_score": "0.083354", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?", "url": "https://www.zacks.com/stock/news/2152870/should-you-invest-in-the-ishares-biotechnology-etf-ibb", "time_published": "20230920T102005", "authors": ["Zacks Equity Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default165.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.18723, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.069294", "ticker_sentiment_score": "0.034094", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.138066", "ticker_sentiment_score": "0.072464", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.138066", "ticker_sentiment_score": "0.072464", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.138066", "ticker_sentiment_score": "0.072464", "ticker_sentiment_label": "Neutral"}]}, {"title": "1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know", "url": "https://www.fool.com/investing/2023/09/19/1-huge-risk-that-gene-editing-stock-investors-desp/", "time_published": "20230919T113500", "authors": ["Alex Carchidi"], "summary": "Good medicines aren't always good business.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}], "overall_sentiment_score": 0.068269, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BLUE", "relevance_score": "0.204936", "ticker_sentiment_score": "-0.124206", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.103331", "ticker_sentiment_score": "-0.272132", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NTLA", "relevance_score": "0.103331", "ticker_sentiment_score": "-0.272132", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Gilead Sciences  ( GILD )  Stock Sinks As Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2152175/gilead-sciences-gild-stock-sinks-as-market-gains-what-you-should-know", "time_published": "20230918T220018", "authors": ["Zacks Equity Research"], "summary": "Gilead Sciences (GILD) closed the most recent trading day at $75.62, moving -0.07% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default18.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.986564"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.142764, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.531019", "ticker_sentiment_score": "0.24678", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "$100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/earnings/23/09/34700117/100-invested-in-gilead-sciences-20-years-ago-would-be-worth-this-much-today", "time_published": "20230918T183032", "authors": ["Benzinga Insights"], "summary": "Gilead Sciences GILD has outperformed the market over the past 20 years by 4.95% on an annualized basis producing an average annual return of 12.68%. Currently, Gilead Sciences has a market capitalization of $94.47 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "GILD: Bionano Genomics  ( BNGO )  vs. Gilead Sciences  ( GILD ) : Buy, Hold or Sell these Biotech Stocks?", "url": "https://stocknews.com/news/gild-bngo-mrk-bionano-genomics-bngo-vs-gilead-sciences-gild-buy-hold-or/", "time_published": "20230918T155309", "authors": ["StockNews.com Staff"], "summary": "GILD: Bionano Genomics ( BNGO ) vs. Gilead Sciences ( GILD ) : Buy ... ...", "banner_image": "https://stocknews.com/wp-content/uploads/2021/01/VS.-3-1-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}, {"topic": "Earnings", "relevance_score": "0.999612"}], "overall_sentiment_score": 0.161632, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BNGO", "relevance_score": "0.402501", "ticker_sentiment_score": "0.252776", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.557513", "ticker_sentiment_score": "0.263808", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Black Diamond Therapeutics Announces CEO Transition - Black Diamond Therapeutic  ( NASDAQ:BDTX ) , G1 Therapeutics  ( NASDAQ:GTHX ) ", "url": "https://www.benzinga.com/pressreleases/23/09/g34682997/black-diamond-therapeutics-announces-ceo-transition", "time_published": "20230918T110000", "authors": ["Globe Newswire"], "summary": "Current Chairman of the Board and industry veteran Mark Velleca appointed CEO CAMBRIDGE, Mass. and NEW YORK, Sept. 18, 2023 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.227457, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BDTX", "relevance_score": "0.342487", "ticker_sentiment_score": "0.35462", "ticker_sentiment_label": "Bullish"}, {"ticker": "BDIMF", "relevance_score": "0.445569", "ticker_sentiment_score": "0.405311", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.058903", "ticker_sentiment_score": "-0.061986", "ticker_sentiment_label": "Neutral"}, {"ticker": "GTHX", "relevance_score": "0.117486", "ticker_sentiment_score": "0.120169", "ticker_sentiment_label": "Neutral"}]}, {"title": "Breast Cancer Monoclonal Antibodies Market to grow by USD 15 billion from 2022 to 2027, North America to account ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/breast-cancer-monoclonal-antibodies-market-to-grow-by-usd-15-billion-from-2022-to-2027-north-america-to-account-for-42-of-market-growth---technavio-301929309.html", "time_published": "20230918T091500", "authors": [], "summary": "Breast Cancer Monoclonal Antibodies Market to grow by USD 15 billion from 2022 to 2027, North America to account ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.019617, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MGNX", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLDX", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBYI", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.08609", "ticker_sentiment_score": "-0.093515", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Large Molecule Injectable Drugs Market to grow by USD 191.45 billion from 2022-2027 | North America to account for ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/large-molecule-injectable-drugs-market-to-grow-by-usd-191-45-billion-from-2022-2027--north-america-to-account-for-45-of-market-growth---technavio-301929312.html", "time_published": "20230918T083500", "authors": [], "summary": "Large Molecule Injectable Drugs Market to grow by USD 191.45 billion from 2022-2027 | North America to account for ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.157274, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAX", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer - Pliant Therapeutics  ( NASDAQ:PLRX ) ", "url": "https://www.benzinga.com/pressreleases/23/09/g34612138/pliant-therapeutics-appoints-minnie-kuo-as-chief-development-officer", "time_published": "20230915T120000", "authors": ["Globe Newswire"], "summary": "SOUTH SAN FRANCISCO, Calif., Sept. 15, 2023 ( GLOBE NEWSWIRE ) -- Pliant Therapeutics, Inc. PLRX, a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the appointment of Ms. Minnie Kuo as Chief Development ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}], "overall_sentiment_score": 0.197509, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.048621", "ticker_sentiment_score": "0.050766", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.048621", "ticker_sentiment_score": "0.050766", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.048621", "ticker_sentiment_score": "-0.037608", "ticker_sentiment_label": "Neutral"}, {"ticker": "VIR", "relevance_score": "0.048621", "ticker_sentiment_score": "-0.037608", "ticker_sentiment_label": "Neutral"}, {"ticker": "NKTR", "relevance_score": "0.048621", "ticker_sentiment_score": "-0.037608", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLRX", "relevance_score": "0.145145", "ticker_sentiment_score": "0.073352", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates", "url": "https://www.zacks.com/stock/news/2148988/biotech-stock-roundup-mrnas-pipeline-news-rckt-bcyc-rally-on-study-updates", "time_published": "20230914T141200", "authors": ["Zacks Equity Research"], "summary": "Pipeline and regulatory updates from Moderna (MRNA) and Rocket Pharmaceuticals (RCKT) are in focus in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.052524, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.057628", "ticker_sentiment_score": "-0.016084", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCYC", "relevance_score": "0.057628", "ticker_sentiment_score": "0.077171", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.227538", "ticker_sentiment_score": "0.056455", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCKT", "relevance_score": "0.114956", "ticker_sentiment_score": "0.10906", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.057628", "ticker_sentiment_score": "0.117973", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cipla founding family's stake sale in jeopardy over $13 bn valuation target", "url": "https://www.business-standard.com/companies/news/cipla-founding-family-s-stake-sale-in-jeopardy-over-13-bn-valuation-target-123091400368_1.html", "time_published": "20230914T070814", "authors": ["Bloomberg"], "summary": "The sale of a stake in Cipla Ltd. is in jeopardy as potential buyers have balked at the Rs 1.09 trillion ( $13.1 billion ) valuation members of the founding family are targeting for the Indian firm in a deal, according to people familiar with the matter.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-07/27/full/1690478805-3801.jpg?im=FitAndFill=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.047234, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GS", "relevance_score": "0.089797", "ticker_sentiment_score": "-0.077618", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.089797", "ticker_sentiment_score": "0.049613", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Stock Moves -0.31%: What You Should Know", "url": "https://www.zacks.com/stock/news/2148041/gilead-sciences-gild-stock-moves--031-what-you-should-know", "time_published": "20230912T215017", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Gilead Sciences (GILD) closed at $76.80, marking a -0.31% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default247.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.138785, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.649828", "ticker_sentiment_score": "0.163752", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Time for Gilead Sciences-Heavy ETFs?", "url": "https://www.zacks.com/stock/news/2147978/time-for-gilead-sciences-heavy-etfs", "time_published": "20230912T180000", "authors": ["Sanghamitra Saha"], "summary": "Bank of America expects the Gilead Sciences to jump about 30%, as quoted on CNBC.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c9/2325.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980716"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.170581, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BAC", "relevance_score": "0.086556", "ticker_sentiment_score": "-0.02288", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.172097", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.255641", "ticker_sentiment_score": "-0.01583", "ticker_sentiment_label": "Neutral"}]}, {"title": "CARGO Therapeutics Announces Appointment of Michael Ports, PhD, as Chief Scientific Officer", "url": "https://www.benzinga.com/pressreleases/23/09/g34487555/cargo-therapeutics-announces-appointment-of-michael-ports-phd-as-chief-scientific-officer", "time_published": "20230912T130551", "authors": ["Globe Newswire"], "summary": "- Scientific leader with multi-company cell therapy drug development experience spanning early discovery initiatives through late-stage development -", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.117385, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BMY", "relevance_score": "0.051999", "ticker_sentiment_score": "0.058896", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.051999", "ticker_sentiment_score": "0.058896", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead's Breast Cancer Drug Shows Promise When Combined With Merck's Treatment - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/general/biotech/23/09/34447206/gileads-breast-cancer-drug-shows-promise-when-combined-with-mercks-treatment", "time_published": "20230911T164507", "authors": ["Vandana Singh"], "summary": "Gilead Sciences Inc GILD revealed early data from its open-label, Phase 2 EVOKE-02 study evaluating Trodelvy. The study saw a combination with Merck & Co Inc's MRK Keytruda ( pembrolizumab ) with or without platinum agents in patients with previously untreated advanced or metastatic non-small ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/11/aapharma_4.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.092634, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.357293", "ticker_sentiment_score": "0.183117", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Nurix  ( NRIX )  Stock Increases 9% in a Month: Here's Why", "url": "https://www.zacks.com/stock/news/2147375/nurix-nrix-stock-increases-9-in-a-month-heres-why", "time_published": "20230911T161000", "authors": ["Zacks Equity Research"], "summary": "The upside in Nurix's (NRIX) shares can be attributed to the company's recently signed collaboration with Seagen (SGEN) to develop a new class of medicines for cancer.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.057827, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.185781", "ticker_sentiment_score": "0.177066", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SGEN", "relevance_score": "0.611103", "ticker_sentiment_score": "0.078526", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.245959", "ticker_sentiment_score": "0.231238", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NRIX", "relevance_score": "0.245959", "ticker_sentiment_score": "0.162226", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.062434", "ticker_sentiment_score": "0.122052", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead's  ( GILD )  Trodelvy Combo Shows Promise in NSCLC Study", "url": "https://www.zacks.com/stock/news/2147280/gileads-gild-trodelvy-combo-shows-promise-in-nsclc-study", "time_published": "20230911T152000", "authors": ["Zacks Investment Research"], "summary": "Gilead's (GILD) breast cancer drug Trodelvy, in combination with Keytruda, shows positive data in a phase II lung cancer study.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c9/2325.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.009701, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DVAX", "relevance_score": "0.112269", "ticker_sentiment_score": "0.063809", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.167709", "ticker_sentiment_score": "0.140327", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.112269", "ticker_sentiment_score": "-0.154782", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "S&P 500 closes up slightly ahead of US inflation data", "url": "https://www.moneycontrol.com/news/business/markets/sp-500-closes-up-slightly-ahead-of-us-inflation-data-11337721.html", "time_published": "20230909T031933", "authors": [], "summary": "The Dow Jones Industrial Average rose 75.86 points, or 0.22%, to 34,576.59, the SP 500 gained 6.35 points, or 0.14%, to 4,457.49 and the Nasdaq Composite added 12.69 points, or 0.09%, to 13,761.53.", "banner_image": "https://images.moneycontrol.com/static-mcnews/2020/08/wall-street-1.jpg?impolicy=website&width=168&height=118", "source": "Money Control", "category_within_source": "Markets", "source_domain": "www.moneycontrol.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}], "overall_sentiment_score": -0.024452, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GME", "relevance_score": "0.055751", "ticker_sentiment_score": "0.094876", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.055751", "ticker_sentiment_score": "0.321008", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Oral Antiviral Market Report 2023: Demand for Novel Therapeutics Boosts Opportunities", "url": "https://www.prnewswire.com/news-releases/oral-antiviral-market-report-2023-demand-for-novel-therapeutics-boosts-opportunities-301921979.html", "time_published": "20230909T011500", "authors": ["Research and Markets"], "summary": "DUBLIN, Sept. 8, 2023 /PRNewswire/ -- The \"Oral Antiviral Market by Indication, Drug Class, Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031\" report has been added to ResearchAndMarkets.com's offering.", "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.158869, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.085022", "ticker_sentiment_score": "0.079948", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.085022", "ticker_sentiment_score": "0.079948", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.085022", "ticker_sentiment_score": "0.079948", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.085022", "ticker_sentiment_score": "0.079948", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.085022", "ticker_sentiment_score": "0.079948", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMRX", "relevance_score": "0.085022", "ticker_sentiment_score": "0.079948", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.085022", "ticker_sentiment_score": "0.079948", "ticker_sentiment_label": "Neutral"}]}, {"title": "How To Earn $500 A Month From Gilead Sciences Stock - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/09/34366120/how-to-earn-500-a-month-from-gilead-sciences-stock", "time_published": "20230908T183154", "authors": ["AJ Fabino"], "summary": "Shares of Gilead Sciences, Inc GILD are trading higher during Friday's trading session, bolstered by the Bank of America Securities bullish outlook on the stock. Bank of America's nod of confidence drew attention to the underappreciated growth avenues within Gilead Sciences' core HIV segment and ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/08/shutterstock_131746163.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}], "overall_sentiment_score": 0.235111, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BAC", "relevance_score": "0.262522", "ticker_sentiment_score": "0.465135", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.820009", "ticker_sentiment_score": "0.564662", "ticker_sentiment_label": "Bullish"}]}, {"title": "Why Vir Biotechnology  ( VIR )  Shares Are Falling Today - Vir Biotechnology  ( NASDAQ:VIR ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/09/34363871/infectious-disease-player-vir-biotech-has-limited-near-term-upside-analyst-downgrad", "time_published": "20230908T181500", "authors": ["Vandana Singh"], "summary": "BofA Securities has downgraded Vir Biotechnology Inc VIR to Neutral from Buy with a price target of $14, down from $23.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/08/vir.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.021822, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VIR", "relevance_score": "0.614086", "ticker_sentiment_score": "0.063907", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.271274", "ticker_sentiment_score": "-0.13787", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Unexpected Reason Gilead Notched Its Biggest Single-Day Move In A Month", "url": "https://www.investors.com/news/technology/gild-stock-nabs-biggest-single-day-move-in-a-month-here-is-why/", "time_published": "20230908T164200", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "GILD Stock Nabs Biggest Single-Day Move In A Month. Here's Why Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-Gilead-07-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.996023"}], "overall_sentiment_score": 0.05558, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BAC", "relevance_score": "0.077094", "ticker_sentiment_score": "-0.039416", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.077094", "ticker_sentiment_score": "-0.186819", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GILD", "relevance_score": "0.50186", "ticker_sentiment_score": "0.214434", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stocks making the biggest moves midday: Kroger, DocuSign, Planet Labs, First Solar and more", "url": "https://www.cnbc.com/2023/09/08/stocks-making-the-biggest-moves-midday-kroger-docusign-planet-labs-first-solar-and-more.html", "time_published": "20230908T155802", "authors": ["Brian Evans"], "summary": "These are the stocks posting the largest moves in midday trading.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107134962-16657637862022-10-14t154810z_696473791_rc221x974gen_rtrmadp_0_albertsons-m-a-kroger.jpeg?v=1694188682&w=1920&h=1080", "source": "CNBC", "category_within_source": "Market Insider", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.988915"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.190538, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FSLR", "relevance_score": "0.277958", "ticker_sentiment_score": "0.535929", "ticker_sentiment_label": "Bullish"}, {"ticker": "BAC", "relevance_score": "0.09439", "ticker_sentiment_score": "0.085317", "ticker_sentiment_label": "Neutral"}, {"ticker": "RH", "relevance_score": "0.09439", "ticker_sentiment_score": "-0.024642", "ticker_sentiment_label": "Neutral"}, {"ticker": "HPP", "relevance_score": "0.09439", "ticker_sentiment_score": "0.006364", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.09439", "ticker_sentiment_score": "0.085317", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDMO", "relevance_score": "0.09439", "ticker_sentiment_score": "0.114638", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOCU", "relevance_score": "0.187463", "ticker_sentiment_score": "0.239706", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Could A Gilead Sciences' Next-Generation Asset Be The Key To Bullish Analyst Upgrade? - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/09/34362892/gilead-sciences-shares-trade-higher-after-bullish-analyst-upgrades-stock", "time_published": "20230908T152826", "authors": ["AJ Fabino"], "summary": "Shares of Gilead Sciences, Inc. GILD are trading higher into Friday's trading session after Bank of America Securities upgraded the stock, highlighting an underappreciated growth potential in its core HIV business and emerging hematology/oncology franchises.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/08/lab.cdc-wceotvmk2vy-unsplash.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.400626, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "BAC", "relevance_score": "0.263942", "ticker_sentiment_score": "0.316785", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.936251", "ticker_sentiment_score": "0.657953", "ticker_sentiment_label": "Bullish"}]}, {"title": "Adobe To Rally Over 12%? Here Are 10 Other Analyst Forecasts For Friday - Adobe  ( NASDAQ:ADBE ) , ABM Indus  ( NYSE:ABM ) ", "url": "https://www.benzinga.com/news/23/09/34360130/adobe-to-rally-over-12-here-are-10-other-analyst-forecasts-for-friday", "time_published": "20230908T122411", "authors": ["Lisa Levin"], "summary": "B of A Securities cut the price target for DigitalOcean Holdings, Inc. DOCN from $47 to $25. B of A Securities analyst Wamsi Mohan downgraded the stock from Buy to Underperform. DigitalOcean shares fell 6% to $24.98 in pre-market trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/08/adobe_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.085916, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "C", "relevance_score": "0.186738", "ticker_sentiment_score": "0.143336", "ticker_sentiment_label": "Neutral"}, {"ticker": "DLKGF", "relevance_score": "0.186738", "ticker_sentiment_score": "0.143336", "ticker_sentiment_label": "Neutral"}, {"ticker": "GIII", "relevance_score": "0.276909", "ticker_sentiment_score": "-0.052597", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRZE", "relevance_score": "0.276909", "ticker_sentiment_score": "0.31153", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DKL", "relevance_score": "0.276909", "ticker_sentiment_score": "0.194271", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBI", "relevance_score": "0.276909", "ticker_sentiment_score": "0.071644", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPRB", "relevance_score": "0.276909", "ticker_sentiment_score": "0.577615", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABM", "relevance_score": "0.276909", "ticker_sentiment_score": "-0.156033", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BCS", "relevance_score": "0.186738", "ticker_sentiment_score": "-0.098047", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOCN", "relevance_score": "0.276909", "ticker_sentiment_score": "-0.178604", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ADBE", "relevance_score": "0.276909", "ticker_sentiment_score": "0.128808", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLVT", "relevance_score": "0.276909", "ticker_sentiment_score": "-0.133336", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.276909", "ticker_sentiment_score": "0.142114", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks making the biggest moves before the bell: Kroger, DocuSign, Snowflake, Adobe and more", "url": "https://www.cnbc.com/2023/09/08/premarket-movers-kroger-docusign-snowflake-adobe-and-more.html", "time_published": "20230908T121834", "authors": ["Alex Harring"], "summary": "These are the stocks posting the largest moves in premarket trading.", "banner_image": "https://image.cnbcfm.com/api/v1/image/106984230-1638546523988-gettyimages-1232071132-DOCUSIGN_APP.jpeg?v=1694175514&w=1920&h=1080", "source": "CNBC", "category_within_source": "Market Insider", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.996718"}], "overall_sentiment_score": 0.16783, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FSLR", "relevance_score": "0.07913", "ticker_sentiment_score": "0.25502", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.07913", "ticker_sentiment_score": "0.041067", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.07913", "ticker_sentiment_score": "0.041067", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOCU", "relevance_score": "0.157483", "ticker_sentiment_score": "0.159655", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RH", "relevance_score": "0.07913", "ticker_sentiment_score": "0.046005", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Dips More Than Broader Markets: What You Should Know", "url": "https://www.zacks.com/stock/news/2146319/gilead-sciences-gild-dips-more-than-broader-markets-what-you-should-know", "time_published": "20230907T220017", "authors": ["Zacks Equity Research"], "summary": "Gilead Sciences (GILD) closed at $73.94 in the latest trading session, marking a -0.4% move from the prior day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default307.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.170688, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.601928", "ticker_sentiment_score": "0.238828", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "$1000 Invested In This Stock 20 Years Ago Would Be Worth $9,000 Today - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/earnings/23/09/34326865/1000-invested-in-this-stock-20-years-ago-would-be-worth-9-000-today", "time_published": "20230907T163040", "authors": ["Benzinga Insights"], "summary": "Gilead Sciences GILD has outperformed the market over the past 20 years by 4.42% on an annualized basis producing an average annual return of 11.97%. Currently, Gilead Sciences has a market capitalization of $92.51 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "GILD: 3 Biotech Stocks with Breakout Growth Potential", "url": "https://stocknews.com/news/gild-sgioy-thtx-3-biotech-stocks-with-breakout-growth-potential/", "time_published": "20230907T144843", "authors": ["StockNews.com Staff"], "summary": "Innovative technology is propelling the biotech sector to new heights. Therefore, I present quality biotech stocks Theratechnologies Inc. ( THTX ) , Shionogi & Co., Ltd. ( SGIOY ) , and Gilead Sciences, Inc. ( GILD ) , which show solid signs of breakout growth potential.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/Biotech-Lg_FB.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.231881, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.243498", "ticker_sentiment_score": "0.127085", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGIOF", "relevance_score": "0.030918", "ticker_sentiment_score": "0.187683", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "THTX", "relevance_score": "0.153666", "ticker_sentiment_score": "0.191359", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why One Drug Company Held Back a Better Drug", "url": "https://www.nytimes.com/2023/09/07/podcasts/the-daily/gilead-hiv-drug.html", "time_published": "20230907T100012", "authors": ["Dan Powell", "Liz O. Baylen", "Alyssa Moxley", "Rowan Niemisto", "Marion Lozano", "Elisheba Ittoop", "Paige Cowett", "Sabrina Tavernise", "Eric Krupke", "Will Reid"], "summary": "Edited by Liz O. Baylen and Paige Cowett Original music by Rowan Niemisto, Dan Powell, Elisheba Ittoop and Marion Lozano For decades, drugmakers have argued that patents are critical to bringing new drugs to the market.", "banner_image": "https://static01.nyt.com/images/2023/02/09/reader-center/author-rebecca-robbins/author-rebecca-robbins-square320.png", "source": "New York Times", "category_within_source": "GoogleRSS", "source_domain": "www.nytimes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.099656, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NYT", "relevance_score": "0.09439", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.09439", "ticker_sentiment_score": "0.018497", "ticker_sentiment_label": "Neutral"}]}, {"title": "Triple-Negative Breast Cancer Market to Accelerate Substantially During the Forecast Period  ( 2023-2032 ) , Examines DelveInsight | Key Companies to Watch - Roche, AbbVie, AstraZeneca, BeiGene, GlaxoSmithKline, Genentech, Eli Lilly, Novartis", "url": "https://www.prnewswire.com/news-releases/triple-negative-breast-cancer-market-to-accelerate-substantially-during-the-forecast-period-20232032-examines-delveinsight--key-companies-to-watch---roche-abbvie-astrazeneca-beigene-glaxosmithkline-genentech-eli-lilly--301918858.html", "time_published": "20230906T210100", "authors": ["LLP", "DelveInsight Business Research"], "summary": "Triple-Negative Breast Cancer Market to Accelerate Substantially During the Forecast Period ( 2023-2032 ) , Examines ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}], "overall_sentiment_score": -0.032041, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VINC", "relevance_score": "0.022494", "ticker_sentiment_score": "0.023078", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTMX", "relevance_score": "0.022494", "ticker_sentiment_score": "0.023078", "ticker_sentiment_label": "Neutral"}, {"ticker": "PGEN", "relevance_score": "0.022494", "ticker_sentiment_score": "0.023078", "ticker_sentiment_label": "Neutral"}, {"ticker": "CELC", "relevance_score": "0.022494", "ticker_sentiment_score": "-0.053504", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.022494", "ticker_sentiment_score": "0.023078", "ticker_sentiment_label": "Neutral"}, {"ticker": "INFI", "relevance_score": "0.06741", "ticker_sentiment_score": "0.006065", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUSN", "relevance_score": "0.022494", "ticker_sentiment_score": "-0.053504", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.022494", "ticker_sentiment_score": "0.023078", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.022494", "ticker_sentiment_score": "-0.053504", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.022494", "ticker_sentiment_score": "0.023078", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKESF", "relevance_score": "0.022494", "ticker_sentiment_score": "-0.053504", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLS", "relevance_score": "0.022494", "ticker_sentiment_score": "0.023078", "ticker_sentiment_label": "Neutral"}, {"ticker": "GTHX", "relevance_score": "0.06741", "ticker_sentiment_score": "-0.109639", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.022494", "ticker_sentiment_score": "0.023078", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLDX", "relevance_score": "0.022494", "ticker_sentiment_score": "0.023078", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.022494", "ticker_sentiment_score": "0.023078", "ticker_sentiment_label": "Neutral"}, {"ticker": "JBPHF", "relevance_score": "0.022494", "ticker_sentiment_score": "0.023078", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMMP", "relevance_score": "0.022494", "ticker_sentiment_score": "-0.053504", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCUS", "relevance_score": "0.022494", "ticker_sentiment_score": "0.023078", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.022494", "ticker_sentiment_score": "0.023078", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNA", "relevance_score": "0.022494", "ticker_sentiment_score": "0.023078", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.022494", "ticker_sentiment_score": "0.023078", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOVA", "relevance_score": "0.022494", "ticker_sentiment_score": "-0.053504", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.04497", "ticker_sentiment_score": "0.005975", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.022494", "ticker_sentiment_score": "0.023078", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.022494", "ticker_sentiment_score": "0.023078", "ticker_sentiment_label": "Neutral"}, {"ticker": "NGIO", "relevance_score": "0.022494", "ticker_sentiment_score": "-0.053504", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCAB", "relevance_score": "0.022494", "ticker_sentiment_score": "0.023078", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBRX", "relevance_score": "0.022494", "ticker_sentiment_score": "-0.053504", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLVSQ", "relevance_score": "0.022494", "ticker_sentiment_score": "0.023078", "ticker_sentiment_label": "Neutral"}]}, {"title": " ( GILD )  - Analyzing Gilead Sciences's Short Interest - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/short-sellers/23/09/34238663/gild-analyzing-gilead-sciencess-short-interest", "time_published": "20230905T143021", "authors": ["Benzinga Insights"], "summary": "Gilead Sciences's GILD short percent of float has risen 4.14% since its last report. The company recently reported that it has 19.63 million shares sold short, which is 1.76% of all regular shares that are available for trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.267332, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.221819", "ticker_sentiment_score": "0.155473", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead's Nomination of a Bispecific Research Program - Macrogenics  ( NASDAQ:MGNX ) , Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/pressreleases/23/09/g34228797/macrogenics-announces-achievement-of-15-million-milestone-related-to-gileads-nomination-of-a-bispe", "time_published": "20230905T110000", "authors": ["Globe Newswire"], "summary": "ROCKVILLE, MD, Sept. 05, 2023 ( GLOBE NEWSWIRE ) -- MacroGenics, Inc. MGNX, a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that its partner, Gilead Sciences, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.108854, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MGNX", "relevance_score": "0.58705", "ticker_sentiment_score": "0.159252", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.093108", "ticker_sentiment_score": "0.079693", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 No-Brainer Dividend Stocks to Buy in September", "url": "https://www.fool.com/investing/2023/09/02/3-no-brainer-dividend-stocks-to-buy-in-september/", "time_published": "20230902T105500", "authors": ["and Prosper Junior Bakiny", "David Jagielski", "Keith Speights"], "summary": "Income investors should really like these biopharma stocks with juicy dividends.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F745806%2Fsocial-security-benefits-application-retirement-income-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.858979"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999922"}], "overall_sentiment_score": 0.262353, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.363683", "ticker_sentiment_score": "0.409901", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.166455", "ticker_sentiment_score": "-0.008488", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.436691", "ticker_sentiment_score": "0.299708", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead Sciences  ( GILD )  Outpaces Stock Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2143965/gilead-sciences-gild-outpaces-stock-market-gains-what-you-should-know", "time_published": "20230901T215012", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Gilead Sciences (GILD) closed at $76.65, marking a +0.22% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default170.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.195486, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.668563", "ticker_sentiment_score": "0.35468", "ticker_sentiment_label": "Bullish"}]}, {"title": "CTSH: Top 3 Tech Stocks You Would Regret Not Buying in September", "url": "https://stocknews.com/news/ctsh-tdc-hckt-gild-now-top-3-tech-stocks-you-would-regret-not-buying-in/", "time_published": "20230901T161037", "authors": ["StockNews.com Staff"], "summary": "Cloud migrations and digitization trends across industries fuel the tech industry's growth. Given the industry's steady prospects, investors could consider quality tech stocks Cognizant Technology Solutions Corporation ( CTSH ) , Teradata Corporation ( TDC ) , and The Hackett Group, Inc. ( HCKT ) ...", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/TechStock_FBOpt.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.623304"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.266794, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HESG", "relevance_score": "0.06001", "ticker_sentiment_score": "0.094", "ticker_sentiment_label": "Neutral"}, {"ticker": "TDC", "relevance_score": "0.17868", "ticker_sentiment_score": "0.197644", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCKT", "relevance_score": "0.207826", "ticker_sentiment_score": "0.309759", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NOW", "relevance_score": "0.030026", "ticker_sentiment_score": "0.060127", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTSH", "relevance_score": "0.375395", "ticker_sentiment_score": "0.243594", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AWON", "relevance_score": "0.030026", "ticker_sentiment_score": "0.060127", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.089909", "ticker_sentiment_score": "0.075541", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cognizant  ( CTSH )  Up 1.6% Since Last Earnings Report: Can It Continue?", "url": "https://www.zacks.com/stock/news/2143797/cognizant-ctsh-up-16-since-last-earnings-report-can-it-continue", "time_published": "20230901T153139", "authors": ["Zacks Equity Research"], "summary": "Cognizant (CTSH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default43.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Earnings", "relevance_score": "0.997874"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.153842, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HESG", "relevance_score": "0.053449", "ticker_sentiment_score": "0.236013", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSFT", "relevance_score": "0.053449", "ticker_sentiment_score": "0.138022", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.106659", "ticker_sentiment_score": "0.001126", "ticker_sentiment_label": "Neutral"}, {"ticker": "TYL", "relevance_score": "0.106659", "ticker_sentiment_score": "0.038857", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARAY", "relevance_score": "0.053449", "ticker_sentiment_score": "0.138022", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOW", "relevance_score": "0.080099", "ticker_sentiment_score": "0.070643", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTSH", "relevance_score": "0.02674", "ticker_sentiment_score": "0.059047", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.053449", "ticker_sentiment_score": "0.107915", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORKLF", "relevance_score": "0.02674", "ticker_sentiment_score": "0.019557", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILD: 3 Best Biotech Stocks for Growth in September", "url": "https://stocknews.com/news/gild-jazz-alks-teva-bbh-3-best-biotech-stocks-for-growth-in-september/", "time_published": "20230830T170635", "authors": ["StockNews.com Staff"], "summary": "Despite the macroeconomic challenges, the biotech industry is primed for long-term growth. An aging population and the need for quality treatments for rare and common diseases underpins this positive outlook.", "banner_image": "https://stocknews.com/wp-content/uploads/2021/08/shutterstock_94464889-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.226354, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALKS", "relevance_score": "0.308246", "ticker_sentiment_score": "0.252889", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JAZZ", "relevance_score": "0.105141", "ticker_sentiment_score": "0.175311", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.2589", "ticker_sentiment_score": "0.152917", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Nearing Retirement? These Stocks Will Pay You For Life", "url": "https://www.fool.com/investing/2023/08/29/nearing-retirement-these-stocks-will-pay-you-for/", "time_published": "20230829T134500", "authors": ["Prosper Junior Bakiny"], "summary": "These companies are passive income machines.", "banner_image": "https://media.ycharts.com/charts/9ea7f751c8fdbfdda46d0e0f1c545e4b.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.962106"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.94762"}], "overall_sentiment_score": 0.306406, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.442767", "ticker_sentiment_score": "0.315135", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.051999", "ticker_sentiment_score": "0.069013", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.304428", "ticker_sentiment_score": "0.279454", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "A-Alpha Bio Nets $22.4M For Groundbreaking Protein Interaction Predictions", "url": "https://www.benzinga.com/news/23/08/34055486/a-alpha-bio-nets-22-4m-for-groundbreaking-protein-interaction-predictions", "time_published": "20230826T120011", "authors": ["Chris Bibey"], "summary": "What do you get when you combine a revolutionary healthcare startup with artificial intelligence ( AI ) technology? In the case of A-Alpha Bio, the answer is simple: a $22.4 million funding round and a bright future.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Surgeon,Operating,Surgery,Using,Vr,Goggles,At,Hospital,Operation,Theater.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.211401, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BMY", "relevance_score": "0.092569", "ticker_sentiment_score": "-0.040468", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.092569", "ticker_sentiment_score": "-0.040468", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILD: 3 Biotech Stocks to Buy This Month and Beyond", "url": "https://stocknews.com/news/gild-jazz-alks-3-biotech-stocks-to-buy-this-month-and-beyond/", "time_published": "20230825T174915", "authors": ["StockNews.com Staff"], "summary": "Biotech companies are making significant strides in developing new drugs and treatments for various diseases, including cancer, cardiovascular disease, and rare diseases. Positive clinical trial results and improved patient outcomes are driving the need for ongoing medical care and treatment.", "banner_image": "https://stocknews.com/wp-content/uploads/2023/01/ISt_Biotechnology.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.278165, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALKS", "relevance_score": "0.216087", "ticker_sentiment_score": "0.161238", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JAZZ", "relevance_score": "0.173645", "ticker_sentiment_score": "0.055629", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.173645", "ticker_sentiment_score": "0.016451", "ticker_sentiment_label": "Neutral"}]}, {"title": "MRNA: Is Now the Time to Buy Into Moderna, Inc.  ( MRNA ) ?", "url": "https://stocknews.com/news/mrna-alks-gild-otsky-is-now-the-time-to-buy-into-moderna-inc-mrna/", "time_published": "20230825T164132", "authors": ["StockNews.com Staff"], "summary": "COVID-19-related hospitalizations are once again on the rise due to the onslaught of new subvariants. Vaccine-maker Moderna, Inc. ( MRNA ) announced that an initial study shows that its updated vaccine is effective against the EG.5 ( Eris ) and FL 1.5.1 ( Fornax ) subvariants.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/03/shutterstock_745024336-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.105101, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.597862", "ticker_sentiment_score": "0.078067", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.051386", "ticker_sentiment_score": "0.166452", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.051386", "ticker_sentiment_score": "0.166452", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead  ( GILD )  Gets FDA Nod for Veklury for Hepatic Impairment", "url": "https://www.zacks.com/stock/news/2140945/gilead-gild-gets-fda-nod-for-veklury-for-hepatic-impairment", "time_published": "20230825T154800", "authors": ["Zacks Equity Research"], "summary": "Gilead's (GILD) anti-viral treatment Veklury gets FDA approval for the treatment of COVID-19 in patients with mild, moderate or severe hepatic impairment.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/388.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.082372, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DVAX", "relevance_score": "0.169676", "ticker_sentiment_score": "0.035144", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.113597", "ticker_sentiment_score": "0.125294", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPRO", "relevance_score": "0.169676", "ticker_sentiment_score": "0.073812", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.113597", "ticker_sentiment_score": "0.183938", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics", "url": "https://www.zacks.com/stock/news/2140807/the-zacks-analyst-blog-highlights-regeneron-pharmaceuticals-gilead-sciences-novavax-apellis-pharmaceuticals-and-fulcrum-therapeutics", "time_published": "20230825T131600", "authors": ["Zacks Equity Research"], "summary": "Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics are part of the Zacks top Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c9/2325.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.148916, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.10087", "ticker_sentiment_score": "0.038774", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.10087", "ticker_sentiment_score": "0.054348", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.200134", "ticker_sentiment_score": "0.040362", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.067347", "ticker_sentiment_score": "0.030389", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.10087", "ticker_sentiment_score": "0.059516", "ticker_sentiment_label": "Neutral"}, {"ticker": "FULC", "relevance_score": "0.10087", "ticker_sentiment_score": "0.062715", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stock buybacks spur wealth inequality and stifle innovation. Should they be banned?", "url": "https://www.marketwatch.com/story/stock-buybacks-spur-wealth-inequality-and-stifle-innovation-but-should-they-be-banned-13e963c0", "time_published": "20230824T215600", "authors": ["Ciara Linnane"], "summary": "Stock buybacks have become a major source of wealth inequality and have stifled innovation in the U.S., according to this academic.", "banner_image": "https://images.mktw.net/im-841345?width=700&height=554", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.999998"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.769861"}], "overall_sentiment_score": 0.178846, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.140076", "ticker_sentiment_score": "0.170483", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CSCO", "relevance_score": "0.105295", "ticker_sentiment_score": "0.07433", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.07031", "ticker_sentiment_score": "0.146063", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.105295", "ticker_sentiment_score": "0.087187", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORCL", "relevance_score": "0.07031", "ticker_sentiment_score": "0.106509", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.105295", "ticker_sentiment_score": "0.087187", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.105295", "ticker_sentiment_score": "-0.05102", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.07031", "ticker_sentiment_score": "0.106509", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSNLF", "relevance_score": "0.07031", "ticker_sentiment_score": "0.165721", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "QCOM", "relevance_score": "0.07031", "ticker_sentiment_score": "0.106509", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.07031", "ticker_sentiment_score": "0.106509", "ticker_sentiment_label": "Neutral"}, {"ticker": "PG", "relevance_score": "0.105295", "ticker_sentiment_score": "0.157777", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "XOM", "relevance_score": "0.07031", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.07031", "ticker_sentiment_score": "0.080602", "ticker_sentiment_label": "Neutral"}, {"ticker": "HD", "relevance_score": "0.105295", "ticker_sentiment_score": "0.181737", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GE", "relevance_score": "0.07031", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.07031", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.105295", "ticker_sentiment_score": "0.181737", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biotech Stocks Rally After Roche's  ( RHHBY )  Accidental Data Leak", "url": "https://www.zacks.com/stock/news/2140458/biotech-stocks-rally-after-roches-rhhby-accidental-data-leak", "time_published": "20230824T153000", "authors": ["Zacks Equity Research"], "summary": "Shares of several companies developing anti-TIGIT therapies rise after Roche (RHHBY) accidentally leaks encouraging late-stage study data.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.076493, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ITOS", "relevance_score": "0.327366", "ticker_sentiment_score": "0.060921", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCUS", "relevance_score": "0.327366", "ticker_sentiment_score": "0.075314", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.084127", "ticker_sentiment_score": "0.042916", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More", "url": "https://www.zacks.com/stock/news/2140318/biotech-stock-roundup-regn-up-on-approval-apls-nvax-gain-on-updates-more", "time_published": "20230824T141500", "authors": ["Zacks Equity Research"], "summary": "Regulatory updates from Regeneron (REGN) and Apellis (APLS) are in focus in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/88/898.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.153817, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.071463", "ticker_sentiment_score": "0.075322", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.071463", "ticker_sentiment_score": "0.112486", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.17741", "ticker_sentiment_score": "0.058468", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.071463", "ticker_sentiment_score": "0.030591", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.071463", "ticker_sentiment_score": "0.143951", "ticker_sentiment_label": "Neutral"}, {"ticker": "FULC", "relevance_score": "0.071463", "ticker_sentiment_score": "0.136884", "ticker_sentiment_label": "Neutral"}]}, {"title": "Roche  ( RHHBY )  Up on Upbeat Data From Combo Drug Cancer Study", "url": "https://www.zacks.com/stock/news/2140250/roche-rhhby-up-on-upbeat-data-from-combo-drug-cancer-study", "time_published": "20230824T130200", "authors": ["Zacks Equity Research"], "summary": "Roche's (RHHBY) stock jumps 4.3% on Wednesday after the company inadvertently publishes encouraging second interim analysis data from its combination drug study to treat cancer.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d7/2114.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.10078, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ITOS", "relevance_score": "0.178459", "ticker_sentiment_score": "0.029953", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCUS", "relevance_score": "0.119532", "ticker_sentiment_score": "0.130863", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.059935", "ticker_sentiment_score": "-0.047035", "ticker_sentiment_label": "Neutral"}]}, {"title": "PM360 Announces 2023 Trailblazer Award Finalists", "url": "https://www.prnewswire.com/news-releases/pm360-announces-2023-trailblazer-award-finalists-301907769.html", "time_published": "20230824T130000", "authors": ["PM360"], "summary": "Top Companies, Marketers, CEOs, Products, and Initiatives to be Honored During Gala on October 3rd NEW YORK, Aug. 24, 2023 /PRNewswire/ -- PM360 has announced the finalists for its 15th annual Trailblazer Awards.", "banner_image": "https://mma.prnewswire.com/media/545940/PM360_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.284744, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GDRX", "relevance_score": "0.027747", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPRX", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.04161", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.027747", "ticker_sentiment_score": "0.27629", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SUPN", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYNH", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TARS", "relevance_score": "0.027747", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDNA", "relevance_score": "0.013876", "ticker_sentiment_score": "-0.066083", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.013876", "ticker_sentiment_score": "-0.24502", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.04161", "ticker_sentiment_score": "0.075016", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTHR", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVCR", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLGC", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.027747", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.04161", "ticker_sentiment_score": "0.080752", "ticker_sentiment_label": "Neutral"}, {"ticker": "TVTX", "relevance_score": "0.027747", "ticker_sentiment_score": "0.23749", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCRB", "relevance_score": "0.027747", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MAYNF", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALNY", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "APLS", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.027747", "ticker_sentiment_score": "-0.073367", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLCO", "relevance_score": "0.013876", "ticker_sentiment_score": "0.273432", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DVAX", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.027747", "ticker_sentiment_score": "-0.071498", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.027747", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.083107", "ticker_sentiment_score": "-0.072498", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSUMF", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHRS", "relevance_score": "0.04161", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.013876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.05546", "ticker_sentiment_score": "0.086858", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.013876", "ticker_sentiment_score": "0.202947", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TXMD", "relevance_score": "0.013876", "ticker_sentiment_score": "0.349415", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NSRGF", "relevance_score": "0.027747", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.013876", "ticker_sentiment_score": "-0.187445", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Indexes end sharply higher; AI chip maker Nvidia jumps again after the bell", "url": "https://www.moneycontrol.com/news/business/markets/indexes-end-sharply-higher-ai-chip-maker-nvidia-jumps-again-after-the-bell-11247481.html", "time_published": "20230824T003952", "authors": [], "summary": "Shares of Nvidia, which reported results after the closing bell, jumped 9%, extending a gain of 3.2% during the regular session.", "banner_image": "https://images.moneycontrol.com/static-mcnews/2020/04/wall-street_1.jpg?impolicy=website&width=168&height=118", "source": "Money Control", "category_within_source": "Markets", "source_domain": "www.moneycontrol.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.189893, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.081552", "ticker_sentiment_score": "0.081497", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.317869", "ticker_sentiment_score": "0.523631", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.081552", "ticker_sentiment_score": "0.043283", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.081552", "ticker_sentiment_score": "0.286052", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:EUR", "relevance_score": "0.162255", "ticker_sentiment_score": "-0.028997", "ticker_sentiment_label": "Neutral"}]}, {"title": "Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update - Roche Holding  ( OTC:RHHBF ) , Roche Holding  ( OTC:RHHVF ) , Roche Holding  ( OTC:RHHBY ) ", "url": "https://www.benzinga.com/general/biotech/23/08/34010167/who-are-other-players-gaining-from-roches-accidental-lung-cancer-data-update", "time_published": "20230823T190515", "authors": ["Vandana Singh"], "summary": "Earlier today, Roche Holdings AG RHHBY announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus Tecentriq ( atezolizumab ) versus Tecentriq alone as an initial ( first-line ) treatment for ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/23/roche_0.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": -0.009712, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RCUS", "relevance_score": "0.375251", "ticker_sentiment_score": "0.057271", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.485711", "ticker_sentiment_score": "0.17879", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.375251", "ticker_sentiment_score": "0.357725", "ticker_sentiment_label": "Bullish"}, {"ticker": "ITOS", "relevance_score": "0.375251", "ticker_sentiment_score": "0.057271", "ticker_sentiment_label": "Neutral"}]}, {"title": "How Roche's Accidental Update Lifted An Entire Group Of Stocks", "url": "https://www.investors.com/news/technology/roche-stock-surges-on-accidental-lung-cancer-update-boosting-iteos-and-arcus/", "time_published": "20230823T132400", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Roche Stock Surges On Accidental Lung Cancer Update. Boosting ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/Stock-Roche-02-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}], "overall_sentiment_score": 0.097116, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RCUS", "relevance_score": "0.305058", "ticker_sentiment_score": "0.253362", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.305058", "ticker_sentiment_score": "0.451642", "ticker_sentiment_label": "Bullish"}, {"ticker": "MDT", "relevance_score": "0.155451", "ticker_sentiment_score": "0.094963", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.155451", "ticker_sentiment_score": "-0.496733", "ticker_sentiment_label": "Bearish"}, {"ticker": "ITOS", "relevance_score": "0.305058", "ticker_sentiment_score": "0.253362", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Looking for the Next Big Biopharma Stock? These 4 Letters Are 1 Big Clue Where to Find It", "url": "https://www.fool.com/investing/2023/08/23/looking-next-big-biopharma-stock-nash-novo/", "time_published": "20230823T093100", "authors": ["Alex Carchidi"], "summary": "NASH is a surprisingly common ailment, and the first treatments are on the way.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.119908, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VKTX", "relevance_score": "0.09186", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.046006", "ticker_sentiment_score": "0.039626", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.137409", "ticker_sentiment_score": "0.13244", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.09186", "ticker_sentiment_score": "0.089734", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDGL", "relevance_score": "0.09186", "ticker_sentiment_score": "0.006517", "ticker_sentiment_label": "Neutral"}, {"ticker": "TERN", "relevance_score": "0.09186", "ticker_sentiment_score": "0.089734", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.046006", "ticker_sentiment_score": "0.039626", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead's  ( GILD )  Leukemia Study Progress Put on Clinical Hold", "url": "https://www.zacks.com/stock/news/2139160/gileads-gild-leukemia-study-progress-put-on-clinical-hold", "time_published": "20230822T154700", "authors": ["Zacks Equity Research"], "summary": "Gilead (GILD) faces a setback as the FDA puts a partial clinical hold on enrolling new patients in studies evaluating magrolimab for treating AML in the United States.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default301.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.182661, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.169676", "ticker_sentiment_score": "0.139977", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVAX", "relevance_score": "0.169676", "ticker_sentiment_score": "0.035144", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.113597", "ticker_sentiment_score": "0.174783", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SPRO", "relevance_score": "0.169676", "ticker_sentiment_score": "0.073812", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Pauses Gilead's Investigational Magrolimab Study In Blood Cancer Patients - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/general/biotech/23/08/33964646/fda-pauses-gileads-investigational-magrolimab-study-in-blood-cancer-patients", "time_published": "20230821T154630", "authors": ["Vandana Singh"], "summary": "FDA has placed a partial clinical hold on Gilead Sciences Inc GILD initiation of new patients in U.S. studies evaluating magrolimab to treat acute myeloid leukemia ( AML ) . The FDA action follows the previously announced discontinuation of Phase 3 ENHANCE study of magrolimab in higher-risk ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/21/aapharma_3.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.370546, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.488777", "ticker_sentiment_score": "0.554837", "ticker_sentiment_label": "Bullish"}]}, {"title": "US FDA puts Gilead Sciences blood cancer drug studies on hold", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-puts-gilead-sciences-blood-cancer-drug-studies-hold-2023-08-21/", "time_published": "20230821T125526", "authors": ["Reuters"], "summary": "The logo of Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo/File Photo Acquire Licensing Rights", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/ABIV5OHS3FOONCLVUTPIG425MQ.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.100453, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.421485", "ticker_sentiment_score": "-0.274929", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "HIV Drugs Market size to grow by USD 10.47 biilion from 2022 to 2027 | Expanding access to HIV treatment is a major ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/hiv-drugs-market-size-to-grow-by-usd-10-47-biilion-from-2022-to-2027--expanding-access-to-hiv-treatment-is-a-major-trend--technavio-301905076.html", "time_published": "20230821T113000", "authors": [], "summary": "HIV Drugs Market size to grow by USD 10.47 biilion from 2022 to 2027 | Expanding access to HIV treatment is a major ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.016891, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "APNHF", "relevance_score": "0.064973", "ticker_sentiment_score": "0.102266", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.064973", "ticker_sentiment_score": "0.102266", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.064973", "ticker_sentiment_score": "0.102266", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.064973", "ticker_sentiment_score": "0.102266", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.064973", "ticker_sentiment_score": "0.102266", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.064973", "ticker_sentiment_score": "0.102266", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.064973", "ticker_sentiment_score": "0.102266", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Under-the-Radar Biotech Stocks to Buy in 2023", "url": "https://www.fool.com/investing/2023/08/19/3-under-the-radar-biotech-stocks-to-buy-in-2023/", "time_published": "20230819T114000", "authors": ["Jim Halley"], "summary": "All three biotech companies focus on oncology therapies.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F744322%2Fsocial-security-benefits-application-retirement-income-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999174"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.048551, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MGNX", "relevance_score": "0.286082", "ticker_sentiment_score": "0.084344", "ticker_sentiment_label": "Neutral"}, {"ticker": "DCPH", "relevance_score": "0.097259", "ticker_sentiment_score": "0.033908", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.04872", "ticker_sentiment_score": "0.126979", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZLAB", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.274181", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GILD", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.274181", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRTX", "relevance_score": "0.097259", "ticker_sentiment_score": "0.033908", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.097259", "ticker_sentiment_score": "0.013139", "ticker_sentiment_label": "Neutral"}]}, {"title": "CTSH: Top 3 Tech Stocks in the A-Rated Industry on Wall Street", "url": "https://stocknews.com/news/ctsh-it-hckt-gild-now-top-3-tech-stocks-in-the-a-rated-industry-on-wall/", "time_published": "20230817T184029", "authors": ["StockNews.com Staff"], "summary": "The U.S. tech industry is one of the most dynamic and innovative in the world. Companies in this space constantly develop new products and services and disrupt traditional industries. Despite facing multiple macroeconomic headwinds over the past two years, the sector is poised to rake in ...", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/TechStock_FBOpt.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.29929, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HESG", "relevance_score": "0.05333", "ticker_sentiment_score": "0.108682", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.079921", "ticker_sentiment_score": "0.157166", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NGRRF", "relevance_score": "0.02668", "ticker_sentiment_score": "0.166962", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCKT", "relevance_score": "0.106423", "ticker_sentiment_score": "0.152513", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NOW", "relevance_score": "0.05333", "ticker_sentiment_score": "0.168001", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CTSH", "relevance_score": "0.311829", "ticker_sentiment_score": "0.238919", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.05333", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IT", "relevance_score": "0.02668", "ticker_sentiment_score": "0.025186", "ticker_sentiment_label": "Neutral"}]}, {"title": "Autolus Therapeutics' Obe-Cel's Shows Compelling Safety Over Gilead's Drug For Acute Lymphoblastic Leukemia - Autolus Therapeutics  ( NASDAQ:AUTL ) ", "url": "https://www.benzinga.com/general/biotech/23/08/33898135/autolus-therapeutics-obe-cels-shows-compelling-safety-over-gileads-drug-for-acute-lymphoblastic-l", "time_published": "20230817T172214", "authors": ["Vandana Singh"], "summary": "Truist has raised the price target for Autolus Therapeutics PLC AUTL from $6 to $9 with a Buy rating on Obe-cel's prospects. The analyst Asthika Goonewardene sees Obe-cel as poised to be a new standard of care and the preferred CAR-T in adults with acute lymphoblastic leukemia ( ALL ) over ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/17/autl.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.428658, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AUTL", "relevance_score": "0.416844", "ticker_sentiment_score": "0.32399", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.285526", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More", "url": "https://www.zacks.com/stock/news/2137533/biotech-stock-roundup-glto-plunges-on-setback-blue-offers-updates-more", "time_published": "20230817T125800", "authors": ["Zacks Equity Research"], "summary": "Regulatory updates from Galecto (GLTO) and Sonnet BioTherapeutics Holdings (SONN) are in focus in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ba/1149.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.016686, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GLTO", "relevance_score": "0.317722", "ticker_sentiment_score": "-0.092504", "ticker_sentiment_label": "Neutral"}, {"ticker": "SONN", "relevance_score": "0.093108", "ticker_sentiment_score": "0.122477", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.093108", "ticker_sentiment_score": "-0.132014", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.093108", "ticker_sentiment_score": "-0.108881", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.139265", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Up 126% in 3 Days, Is Tango Therapeutics a Buy Right Now?", "url": "https://www.fool.com/investing/2023/08/17/up-126-in-3-days-is-tango-therapeutics-a-buy-right/", "time_published": "20230817T090500", "authors": ["Alex Carchidi"], "summary": "Remember that past performance doesn't predict future returns.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F744039%2Fsmart-investment-bank-analyst-on-wall-street.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}], "overall_sentiment_score": 0.039171, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TNGX", "relevance_score": "0.244723", "ticker_sentiment_score": "0.051698", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.06211", "ticker_sentiment_score": "0.091165", "ticker_sentiment_label": "Neutral"}]}, {"title": "Two brands suspend advertising on X after their ads appeared next to pro-Nazi content | Business", "url": "https://edition.cnn.com/2023/08/16/tech/x-ads-pro-nazi-account-brand-safety/index.html", "time_published": "20230816T233900", "authors": ["Brian Fung", "Clare Duffy"], "summary": "Two brands suspend advertising on X after their ads appeared next to pro-Nazi content CNN International ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230810111515-linda-yaccarino-1019-file-restricted.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Economy", "source_domain": "edition.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.088744, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.237668", "ticker_sentiment_score": "-0.060516", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.04823", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Two brands suspend advertising on X after their ads appeared next to pro-Nazi content | Business", "url": "https://www.cnn.com/2023/08/16/tech/x-ads-pro-nazi-account-brand-safety/index.html", "time_published": "20230816T233900", "authors": ["Clare Duffy", "Brian Fung"], "summary": "Two brands suspend advertising on X after their ads appeared next to pro-Nazi content ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230810111515-linda-yaccarino-1019-file-restricted.jpg?c=16x9&q=h_144,w_256,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.088744, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.237668", "ticker_sentiment_score": "-0.060516", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.04823", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead  ( GILD ) , Tentarix To Develop Cancer, Inflammation Therapies", "url": "https://www.zacks.com/stock/news/2137191/gilead-gild-tentarix-to-develop-cancer-inflammation-therapies", "time_published": "20230816T172100", "authors": ["Zacks Equity Research"], "summary": "Gilead (GILD) enters into a deal with Tentarix Biotherapeutics to discover and develop novel therapies for cancer and inflammation.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.069547, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.254973", "ticker_sentiment_score": "0.119955", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVAX", "relevance_score": "0.254973", "ticker_sentiment_score": "0.046093", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.192694", "ticker_sentiment_score": "0.014766", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPRO", "relevance_score": "0.254973", "ticker_sentiment_score": "0.093202", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead ties up with Tentarix for cancer, inflammatory disease therapies", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-ties-up-with-tentarix-cancer-inflammatory-disease-therapies-2023-08-15/", "time_published": "20230815T124900", "authors": ["Reuters"], "summary": "The logo of Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo Aug 15 ( Reuters ) - Gilead Sciences ( GILD.O ) said on Tuesday it had entered into an agreement with privately held Tentarix Biotherapeutics to develop ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/UWJ5WZILKVI6PCB5AMT2MRAJPU.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.033441, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.690822", "ticker_sentiment_score": "-0.296079", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Biotechnology Market to Worth Around USD 3,995.22 Billion by 2032", "url": "https://www.benzinga.com/pressreleases/23/08/g33835844/biotechnology-market-to-worth-around-usd-3-995-22-billion-by-2032", "time_published": "20230814T150000", "authors": ["Globe Newswire"], "summary": "Ottawa, Aug. 14, 2023 ( GLOBE NEWSWIRE ) -- The global biotechnology market size accounted for USD 1,224.31 billion in 2022, a study published by Towards Healthcare a sister firm of Precedence Research.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.318732, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.013202", "ticker_sentiment_score": "0.172021", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.013202", "ticker_sentiment_score": "0.172021", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CASBF", "relevance_score": "0.013202", "ticker_sentiment_score": "0.050568", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.013202", "ticker_sentiment_score": "0.172021", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMXHF", "relevance_score": "0.013202", "ticker_sentiment_score": "0.172021", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.013202", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WLDS", "relevance_score": "0.026401", "ticker_sentiment_score": "0.128473", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.013202", "ticker_sentiment_score": "0.172021", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCSG", "relevance_score": "0.013202", "ticker_sentiment_score": "0.226716", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.013202", "ticker_sentiment_score": "0.172021", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.013202", "ticker_sentiment_score": "0.172021", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is Vir Biotechnology Stock a Buy?", "url": "https://www.fool.com/investing/2023/08/11/is-vir-biotechnology-stock-a-buy/", "time_published": "20230811T141500", "authors": ["Prosper Junior Bakiny"], "summary": "The biotech is out to prove that it isn't just a \"pandemic stock.\" ...", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F743014%2Fbuffett6-tmf.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.955357"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.060686, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VIR", "relevance_score": "0.246582", "ticker_sentiment_score": "0.073346", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.062597", "ticker_sentiment_score": "0.137077", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Invest in the VanEck Biotech ETF  ( BBH ) ?", "url": "https://www.zacks.com/stock/news/2135485/should-you-invest-in-the-vaneck-biotech-etf-bbh", "time_published": "20230811T102008", "authors": ["Zacks Equity Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default168.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.184085, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.13459", "ticker_sentiment_score": "0.071501", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.13459", "ticker_sentiment_score": "0.071501", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.13459", "ticker_sentiment_score": "0.071501", "ticker_sentiment_label": "Neutral"}]}, {"title": "How Is The Market Feeling About Gilead Sciences? - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/short-sellers/23/08/33709999/how-is-the-market-feeling-about-gilead-sciences", "time_published": "20230810T141526", "authors": ["Benzinga Insights"], "summary": "Gilead Sciences's GILD short percent of float has risen 6.96% since its last report. The company recently reported that it has 18.84 million shares sold short, which is 1.69% of all regular shares that are available for trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.267332, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.221819", "ticker_sentiment_score": "0.155473", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights", "url": "https://www.globenewswire.com/news-release/2023/08/10/2722508/0/en/HOOKIPA-Pharma-Reports-Second-Quarter-2023-Financial-Results-and-Recent-Business-Highlights.html", "time_published": "20230810T110100", "authors": ["HOOKIPA Pharma Inc"], "summary": "NEW YORK and VIENNA, Austria, Aug. 10, 2023 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( NASDAQ: HOOK, 'HOOKIPA' ) , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the second quarter ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/62ba88bb-8adc-44c4-9fd7-3f6ca365c93d", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.992549"}, {"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.576289"}], "overall_sentiment_score": 0.142158, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HOOK", "relevance_score": "0.107881", "ticker_sentiment_score": "0.077807", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.02164", "ticker_sentiment_score": "0.075115", "ticker_sentiment_label": "Neutral"}]}, {"title": "Entrada Therapeutics Appoints Gina Chapman to its Board of Directors - Entrada Therapeutics  ( NASDAQ:TRDA ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g33701692/entrada-therapeutics-appoints-gina-chapman-to-its-board-of-directors", "time_published": "20230810T110000", "authors": ["Globe Newswire"], "summary": "BOSTON, Aug. 10, 2023 ( GLOBE NEWSWIRE ) -- Entrada Therapeutics, Inc. TRDA, a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle ( EEV\u2122 ) -therapeutics as a new class of medicines, today announced the appointment of Gina ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.207433, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TRDA", "relevance_score": "0.262522", "ticker_sentiment_score": "0.244972", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.066784", "ticker_sentiment_score": "0.026221", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stocks To Watch: Track The Latest News On Pharmaceutical Stocks And Drug Companies", "url": "https://www.investors.com/news/technology/biotech-and-pharma-industry-and-stock-news-merk-bristol-myers-amgn-gilead/", "time_published": "20230809T120600", "authors": ["IBD STAFF", "Investor's Business Daily"], "summary": "One minute Dow Jones industrial average component Merck ( MRK ) might be doing battle with fellow drugmaker Bristol Myers Squibb ( BMY ) over drugs that can ward off cancer. The next, biotech giants like Amgen ( AMGN ) and Sanofi ( SNY ) are tussling in court over the fate of ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/05/Stock-TargetDollarSign-02-adobe-300x170.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.083353, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.366061", "ticker_sentiment_score": "0.043641", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVCR", "relevance_score": "0.366061", "ticker_sentiment_score": "-0.381253", "ticker_sentiment_label": "Bearish"}, {"ticker": "AMGN", "relevance_score": "0.366061", "ticker_sentiment_score": "0.043641", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.366061", "ticker_sentiment_score": "-0.549433", "ticker_sentiment_label": "Bearish"}, {"ticker": "SNY", "relevance_score": "0.366061", "ticker_sentiment_score": "0.043641", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILD: 2 Biotech Stocks You Should Buy While You Can, 1 That Investors Are Avoiding", "url": "https://stocknews.com/news/gild-jazz-bngo-2-biotech-stocks-you-should-buy-while-you-can-1/", "time_published": "20230808T155836", "authors": ["StockNews.com Staff"], "summary": "Despite the slowdown over the past year, the biotech sector is well-positioned for long-term growth due to increasing demand for agro-based products, personalized healthcare, and synthetic biology solutions. Additionally, government initiatives and growing healthcare needs reinforce its promising ...", "banner_image": "https://stocknews.com/wp-content/uploads/2023/01/ISt_Biotechnology.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.210456, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JAZZ", "relevance_score": "0.106857", "ticker_sentiment_score": "0.156156", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNGO", "relevance_score": "0.106857", "ticker_sentiment_score": "0.160026", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.211806", "ticker_sentiment_score": "0.104154", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 High-Yield Dividend Stocks to Buy on the Dip", "url": "https://www.fool.com/investing/2023/08/08/2-high-yield-dividend-stocks-to-buy-on-the-dip/", "time_published": "20230808T092600", "authors": ["Prosper Junior Bakiny"], "summary": "The market may have been a bit too harsh on these stocks.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F742650%2Fa-frustrated-investor-with-their-head-resting-in-their-arms-at-their-desk-in-front-of-stock-charts-on-computer-monitors.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Earnings", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.248207, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "0.346278", "ticker_sentiment_score": "0.33192", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.462648", "ticker_sentiment_score": "0.287065", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SGEN", "relevance_score": "0.044718", "ticker_sentiment_score": "0.107442", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction", "url": "https://www.globenewswire.com/news-release/2023/08/07/2719566/0/en/Ikena-Oncology-Acquires-Pionyr-Immunotherapeutics-in-All-Stock-Transaction.html", "time_published": "20230807T110000", "authors": ["Inc.", "Ikena Oncology"], "summary": "Ikena receives approximately $43 million in net cash at closing ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/f9619b5e-e798-4b96-bcb1-161635962b69", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.192087, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BMY", "relevance_score": "0.028798", "ticker_sentiment_score": "0.053363", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.086245", "ticker_sentiment_score": "0.082227", "ticker_sentiment_label": "Neutral"}, {"ticker": "IKNA", "relevance_score": "0.086245", "ticker_sentiment_score": "0.008401", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction - Ikena Oncology  ( NASDAQ:IKNA ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g33596881/ikena-oncology-acquires-pionyr-immunotherapeutics-in-all-stock-transaction", "time_published": "20230807T110000", "authors": ["Globe Newswire"], "summary": "Ikena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena's targeted oncology pipeline BOSTON and SOUTH SAN FRANCISCO, Calif., Aug. 07, 2023 ( GLOBE NEWSWIRE ) -- Ikena Oncology, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Mergers", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.224132, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BMY", "relevance_score": "0.038843", "ticker_sentiment_score": "0.054649", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.116161", "ticker_sentiment_score": "0.088994", "ticker_sentiment_label": "Neutral"}, {"ticker": "IKNA", "relevance_score": "0.116161", "ticker_sentiment_score": "0.008075", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Stock Jumps On Strong Q2 Performance Despite Lower Profit Outlook Amid Litigation - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/general/biotech/23/08/33576008/gilead-stock-jumps-on-strong-q2-performance-despite-lower-profit-outlook-amid-litigation", "time_published": "20230804T175542", "authors": ["Vandana Singh"], "summary": "Gilead Sciences Inc's GILD Q2 FY23 sales increased 6% Y/Y to $6.60 billion, above the consensus of $6.43 billion, primarily driven by increased sales in HIV and Oncology, partially offset by lower Veklury ( remdesivir ) sales.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/04/gilead.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.143871, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.511256", "ticker_sentiment_score": "0.24333", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead's  ( GILD )  Q2 Earnings Miss, Revenues Beat on Oncology", "url": "https://www.zacks.com/stock/news/2132850/gileads-gild-q2-earnings-miss-revenues-beat-on-oncology", "time_published": "20230804T170000", "authors": ["Zacks Equity Research"], "summary": "Gilead's (GILD) Q2 earnings miss on litigation charges while revenues beat on strong oncology and HIV franchise.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c9/2325.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.998287"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.10382, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DVAX", "relevance_score": "0.167904", "ticker_sentiment_score": "0.032042", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.209004", "ticker_sentiment_score": "-0.012346", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.209004", "ticker_sentiment_score": "0.099077", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.084423", "ticker_sentiment_score": "0.178796", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Market Rally Under Pressure As Yields Soar: Weekly Review", "url": "https://www.investors.com/news/market-rally-under-pressure-as-yields-soar-amazon-elf-caterpillar-are-earnings-winners/", "time_published": "20230804T145100", "authors": ["IBD STAFF", "Investor's Business Daily"], "summary": "The stock market rally came under pressure amid surging Treasury yields, fueled by a U.S. credit-rating downgrade as well, swelling Treasury issuance and improving U.S. economic growth. But yields pared gains following a mixed jobs report. Apple ( AAPL ) and Amazon ( AMZN ) capped a huge week of ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/A1MAIN-bullsbears-100220-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.022066, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "XPEV", "relevance_score": "0.081111", "ticker_sentiment_score": "0.080527", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.081111", "ticker_sentiment_score": "0.007297", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.081111", "ticker_sentiment_score": "0.105986", "ticker_sentiment_label": "Neutral"}, {"ticker": "LSCC", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.068563", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXAS", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.016541", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEX", "relevance_score": "0.04872", "ticker_sentiment_score": "0.015992", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.064929", "ticker_sentiment_score": "-0.066696", "ticker_sentiment_label": "Neutral"}, {"ticker": "DT", "relevance_score": "0.081111", "ticker_sentiment_score": "0.166261", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DV", "relevance_score": "0.081111", "ticker_sentiment_score": "0.108704", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.064929", "ticker_sentiment_score": "0.132381", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOCN", "relevance_score": "0.064929", "ticker_sentiment_score": "-0.040515", "ticker_sentiment_label": "Neutral"}, {"ticker": "MTSI", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.068563", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAYC", "relevance_score": "0.032491", "ticker_sentiment_score": "0.136337", "ticker_sentiment_label": "Neutral"}, {"ticker": "HWM", "relevance_score": "0.032491", "ticker_sentiment_score": "0.266242", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DKNG", "relevance_score": "0.032491", "ticker_sentiment_score": "0.206139", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MELI", "relevance_score": "0.064929", "ticker_sentiment_score": "0.090092", "ticker_sentiment_label": "Neutral"}, {"ticker": "POWI", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.068563", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.081111", "ticker_sentiment_score": "-0.030628", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACLS", "relevance_score": "0.032491", "ticker_sentiment_score": "0.13877", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.064929", "ticker_sentiment_score": "0.066645", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUBS", "relevance_score": "0.081111", "ticker_sentiment_score": "0.023152", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYNA", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.068563", "ticker_sentiment_label": "Neutral"}, {"ticker": "MAR", "relevance_score": "0.064929", "ticker_sentiment_score": "-0.066696", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXG", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.235891", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "EXPE", "relevance_score": "0.064929", "ticker_sentiment_score": "-0.066696", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNBR", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.198779", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ALGM", "relevance_score": "0.064929", "ticker_sentiment_score": "-0.012104", "ticker_sentiment_label": "Neutral"}, {"ticker": "QLYS", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.108", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.010001", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXTR", "relevance_score": "0.064929", "ticker_sentiment_score": "0.08922", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRUS", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.068563", "ticker_sentiment_label": "Neutral"}, {"ticker": "NCLH", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.065997", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.068563", "ticker_sentiment_label": "Neutral"}, {"ticker": "BKNG", "relevance_score": "0.064929", "ticker_sentiment_score": "-0.066696", "ticker_sentiment_label": "Neutral"}, {"ticker": "TPX", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.203852", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SQ", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.118638", "ticker_sentiment_label": "Neutral"}, {"ticker": "ON", "relevance_score": "0.016249", "ticker_sentiment_score": "-0.062612", "ticker_sentiment_label": "Neutral"}, {"ticker": "PYPL", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.121934", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.016249", "ticker_sentiment_score": "0.067967", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNST", "relevance_score": "0.032491", "ticker_sentiment_score": "0.023975", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.016999", "ticker_sentiment_label": "Neutral"}, {"ticker": "SITM", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.068563", "ticker_sentiment_label": "Neutral"}, {"ticker": "RMBS", "relevance_score": "0.064929", "ticker_sentiment_score": "-0.012104", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMDX", "relevance_score": "0.064929", "ticker_sentiment_score": "-0.237782", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NIO", "relevance_score": "0.081111", "ticker_sentiment_score": "0.080527", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEWR", "relevance_score": "0.032491", "ticker_sentiment_score": "0.170055", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GNRC", "relevance_score": "0.032491", "ticker_sentiment_score": "0.136337", "ticker_sentiment_label": "Neutral"}, {"ticker": "IDXX", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.23063", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GILD", "relevance_score": "0.032491", "ticker_sentiment_score": "-0.016541", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.04872", "ticker_sentiment_score": "-0.016999", "ticker_sentiment_label": "Neutral"}, {"ticker": "LI", "relevance_score": "0.064929", "ticker_sentiment_score": "0.078464", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.097259", "ticker_sentiment_score": "0.119103", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Pulmonary Embolism Therapeutics Market size to grow at a CAGR of 9.52% from 2022 to 2027|The advancement ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/the-pulmonary-embolism-therapeutics-market-size-to-grow-at-a-cagr-of-9-52-from-2022-to-2027the-advancement-in-the-healthcare-and-medical-sector-is-a-major-trend-technavio-301892623.html", "time_published": "20230804T093000", "authors": [], "summary": "The Pulmonary Embolism Therapeutics Market size to grow at a CAGR of 9.52% from 2022 to 2027|The advancement ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.05773, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BAYZF", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "NARI", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Q2 2023 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2023/08/04/gilead-sciences-gild-q2-2023-earnings-call-transcr/", "time_published": "20230804T040029", "authors": ["Motley Fool Transcribing"], "summary": "GILD earnings call for the period ending June 30, 2023.", "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.413559"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.258403, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.01938", "ticker_sentiment_score": "0.139284", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.004845", "ticker_sentiment_score": "0.152914", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAC", "relevance_score": "0.004845", "ticker_sentiment_score": "0.12995", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.004845", "ticker_sentiment_score": "0.152914", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.004845", "ticker_sentiment_score": "0.152914", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.004845", "ticker_sentiment_score": "0.152914", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NHPEF", "relevance_score": "0.004845", "ticker_sentiment_score": "-0.010635", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.004845", "ticker_sentiment_score": "0.086423", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.004845", "ticker_sentiment_score": "0.152914", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead Sciences  ( GILD )  Q2 Earnings Lag Estimates", "url": "https://www.zacks.com/stock/news/2132287/gilead-sciences-gild-q2-earnings-lag-estimates", "time_published": "20230803T214513", "authors": ["Zacks Equity Research"], "summary": "Gilead (GILD) delivered earnings and revenue surprises of -16.25% and 2.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default246.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.152895, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "XENE", "relevance_score": "0.206392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.138464", "ticker_sentiment_score": "0.117364", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead quarterly profit falls on COVID sales drop, legal settlement charge", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-quarterly-profit-falls-covid-sales-drop-legal-settlement-charge-2023-08-03/", "time_published": "20230803T211200", "authors": ["Michael Erman"], "summary": "[1/2] Gilead Sciences is seen during the outbreak of the coronavirus disease ( COVID-19 ) , in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/7AEOT4MZSVO4NIKU2ST6AKIZGI.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Earnings", "relevance_score": "0.980716"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.02873, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.195025", "ticker_sentiment_score": "-0.018094", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures: Amazon, Apple Lead Earnings Late", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-apple-amazon-lead-earnings-movers-late-jobs-report-on-tap/", "time_published": "20230803T210900", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "Dow Jones Futures: Apple, Amazon Lead Earnings Movers Late. Jobs Report On Tap Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/09/Stock-applestoreentrance-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.998311"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.060409, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.173541", "ticker_sentiment_score": "0.119001", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.257744", "ticker_sentiment_score": "-0.059213", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXG", "relevance_score": "0.116207", "ticker_sentiment_score": "-0.167471", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MNST", "relevance_score": "0.087291", "ticker_sentiment_score": "-0.26012", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PGNY", "relevance_score": "0.087291", "ticker_sentiment_score": "0.185046", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EXPE", "relevance_score": "0.058259", "ticker_sentiment_score": "-0.171055", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "H", "relevance_score": "0.058259", "ticker_sentiment_score": "-0.171055", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TMDX", "relevance_score": "0.14497", "ticker_sentiment_score": "-0.031434", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.087291", "ticker_sentiment_score": "-0.197907", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CLX", "relevance_score": "0.058259", "ticker_sentiment_score": "-0.040218", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.116207", "ticker_sentiment_score": "0.113592", "ticker_sentiment_label": "Neutral"}, {"ticker": "MELI", "relevance_score": "0.087291", "ticker_sentiment_score": "-0.041467", "ticker_sentiment_label": "Neutral"}, {"ticker": "APPN", "relevance_score": "0.087291", "ticker_sentiment_score": "0.203788", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.029149", "ticker_sentiment_score": "0.216902", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FTNT", "relevance_score": "0.173541", "ticker_sentiment_score": "-0.191926", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "OLED", "relevance_score": "0.087291", "ticker_sentiment_score": "0.185046", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBX", "relevance_score": "0.087291", "ticker_sentiment_score": "0.203788", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.087291", "ticker_sentiment_score": "0.205872", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HUBS", "relevance_score": "0.058259", "ticker_sentiment_score": "-0.040218", "ticker_sentiment_label": "Neutral"}, {"ticker": "NET", "relevance_score": "0.087291", "ticker_sentiment_score": "0.203788", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BKNG", "relevance_score": "0.116207", "ticker_sentiment_score": "0.223456", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.285193", "ticker_sentiment_score": "0.259269", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SQ", "relevance_score": "0.14497", "ticker_sentiment_score": "-0.14445", "ticker_sentiment_label": "Neutral"}]}, {"title": "Will An Earnings Miss Cloud Gilead's Massive Cancer Drug Growth?", "url": "https://www.investors.com/news/technology/gild-stock-gilead-earnings-q2-2023/", "time_published": "20230803T202300", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Two out of three of Gilead Sciences' ( GILD ) cancer drugs topped Wall Street's second-quarter sales expectations Thursday. But GILD stock was hamstrung on an earnings miss. Sales of Trodelvy, Yescarta and Tecartus - Gilead's cancer medicines - surged a combined 38% to $728 million.", "banner_image": "https://www.investors.com/wp-content/uploads/2020/06/Stock-gilead-07-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.947132"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.007249, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.484191", "ticker_sentiment_score": "-0.170809", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Gilead's profit lags consensus but sales beat, sending stock up after hours", "url": "https://www.marketwatch.com/story/gileads-stock-slides-2-after-q2-profit-lags-consensus-and-as-company-lowers-guidance-529efb68", "time_published": "20230803T201500", "authors": ["Ciara Linnane"], "summary": "Gilead's quarterly revenue topped estimates and it tweaked guidance.", "banner_image": "https://images.mktw.net/im-829529/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.009594, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RXDX", "relevance_score": "0.118647", "ticker_sentiment_score": "-0.150184", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GILD", "relevance_score": "0.234684", "ticker_sentiment_score": "0.157746", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Cognizant  ( CTSH )  Q2 Earnings Beat Estimates, Revenues Down Y/Y", "url": "https://www.zacks.com/stock/news/2132168/cognizant-ctsh-q2-earnings-beat-estimates-revenues-down-yy", "time_published": "20230803T165400", "authors": ["Zacks Equity Research"], "summary": "Cognizant's (CTSH) second-quarter 2023 results benefit from strong Health Sciences revenues and acquisitions amid a challenging macro environment.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/35/34812.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Earnings", "relevance_score": "0.905476"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.147061, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HESG", "relevance_score": "0.064797", "ticker_sentiment_score": "0.217231", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSFT", "relevance_score": "0.097062", "ticker_sentiment_score": "0.123693", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.129168", "ticker_sentiment_score": "0.001217", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARAY", "relevance_score": "0.064797", "ticker_sentiment_score": "0.115657", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOW", "relevance_score": "0.097062", "ticker_sentiment_score": "0.061664", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTSH", "relevance_score": "0.129168", "ticker_sentiment_score": "0.053648", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.064797", "ticker_sentiment_score": "0.091207", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORKLF", "relevance_score": "0.032425", "ticker_sentiment_score": "0.014206", "ticker_sentiment_label": "Neutral"}]}, {"title": "US Oil Inventories Drop By Most On Record - Apple  ( NASDAQ:AAPL ) , Ambev  ( NYSE:ABEV ) ", "url": "https://www.benzinga.com/economics/macro-economic-events/23/08/33551926/us-oil-inventories-drop-by-most-on-record", "time_published": "20230803T145637", "authors": ["GRIT Capital"], "summary": "Billionaire hedge fund manager Bill Ackman is making a bold move! He's shorting 30-year Treasury bills using options, and he predicts yields could skyrocket to 5.5% 'soon'. His strategy is a hedge against the impact of long-term rates on stocks in \"a world with persistent 3% inflation.\"", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/03/maxim-hopman-fixlqxahcfk-unsplash_1.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.980716"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.839681"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.080458", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "APD", "relevance_score": "0.080458", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.080458", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BX", "relevance_score": "0.04028", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.04028", "ticker_sentiment_score": "-0.389927", "ticker_sentiment_label": "Bearish"}, {"ticker": "MNST", "relevance_score": "0.080458", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNQ", "relevance_score": "0.080458", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.080458", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAL", "relevance_score": "0.04028", "ticker_sentiment_score": "0.101989", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.080458", "ticker_sentiment_score": "0.064027", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.04028", "ticker_sentiment_score": "0.101989", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:EUR", "relevance_score": "0.04028", "ticker_sentiment_score": "-0.13649", "ticker_sentiment_label": "Neutral"}]}, {"title": "US Stock Futures Dip As Apple, Amazon Earnings Loom: Analyst Warns Of 'Perfectly Normal' 5% Pullback This Month - Cars.com  ( NYSE:CARS ) , DraftKings  ( NASDAQ:DKNG ) , PayPal Holdings  ( NASDAQ:PYPL ) , Cheesecake Factory  ( NASDAQ:CAKE ) , Expedia Group  ( NASDAQ:EXPE ) , Hyatt Hotels  ( NYSE:H ) , Kellogg  ( NYSE:K ) , Amgen  ( NASDAQ:AMGN ) , DoorDash  ( NYSE:DASH ) , Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , Occidental Petroleum  ( NYSE:OXY ) , Etsy  ( NASDAQ:ETSY ) , Qualcomm  ( NASDAQ:QCOM ) , Warner Bros. Discovery  ( NASDAQ:WBD ) , EVgo  ( NASDAQ:EVGO ) , Atlassian  ( NASDAQ:TEAM ) , Gilead Sciences  ( NASDAQ:GILD ) , Hasbro  ( NASDAQ:HAS ) , Bausch Health Companies  ( NYSE:BHC ) , Moderna  ( NASDAQ:MRNA ) , Qorvo  ( NASDAQ:QRVO ) , Regeneron Pharmaceuticals  ( NASDAQ:REGN ) , SPDR S&P 500  ( ARCA:SPY ) , Amazon.com  ( NASDAQ:AMZN ) ", "url": "https://www.benzinga.com/markets/equities/23/08/33543176/us-stock-futures-dip-as-apple-amazon-earnings-loom-analyst-warns-of-perfectly-normal-5-pullback-", "time_published": "20230803T105308", "authors": ["Shanthi Rexaline"], "summary": "As Fitch's U.S. ratings downgrade overhang persists and earnings new flow turns negative, stock futures are pulling back yet again on Thursday. Traders may find caution a virtue as a few profile tech names, including Apple, Inc. AAPL, are scheduled to report their quarterly results.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/WallStreet.NYSE_2.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.98396"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": -0.048216, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PYPL", "relevance_score": "0.106541", "ticker_sentiment_score": "-0.191391", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AAPL", "relevance_score": "0.159218", "ticker_sentiment_score": "0.035669", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAKE", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.05339", "ticker_sentiment_score": "0.063035", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DASH", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ETSY", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EVGO", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEAM", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QRVO", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors", "url": "https://www.prnewswire.com/news-releases/kyverna-therapeutics-extends-series-b-financing-round-to-145-million-and-brings-in-new-investors-301891039.html", "time_published": "20230803T090000", "authors": ["Kyverna Therapeutics"], "summary": "Proceeds to support clinical development of novel fully human anti-CD19 CAR T-cell therapies for autoimmune diseases", "banner_image": "https://mma.prnewswire.com/media/1065240/Kyverna_Therapeutics_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.076573, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NHPEF", "relevance_score": "0.050044", "ticker_sentiment_score": "0.033989", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.050044", "ticker_sentiment_score": "-0.037797", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Popular Miracle 'Off-Label' Weight Loss Drug for Diabetes Is Paralyzing Stomachs: 'This Medicine Made My Life Hell.'", "url": "https://www.benzinga.com/news/23/08/33527068/the-popular-miracle-off-label-weight-loss-drug-for-diabetes-is-paralyzing-stomachs-this-medicine-mad", "time_published": "20230802T170116", "authors": ["Jeannine Mancini"], "summary": "A July 25 CNN report shed light on severe gastroparesis, also known as stomach paralysis, experienced by some patients after taking Ozempic and Wegovy, medications known to result in weight loss in type 2 diabetes patients.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Doctor,Measuring,Obese,Man,Waist,Body,Fat.,Obesity,And,Weight_8.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.116345, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.109956", "ticker_sentiment_score": "-0.111995", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.109956", "ticker_sentiment_score": "0.119408", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.055109", "ticker_sentiment_score": "0.143861", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.055109", "ticker_sentiment_score": "0.143861", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.109956", "ticker_sentiment_score": "-0.009064", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILD: 3 Biotech Stocks to Buy for August", "url": "https://stocknews.com/news/gild-regn-uthr-3-biotech-stocks-to-buy-for-august/", "time_published": "20230802T124337", "authors": ["StockNews.com Staff"], "summary": "The biotechnology industry has emerged at the forefront as a vital industry harboring potential for innovation, economic development, and enhanced healthcare deliverables.", "banner_image": "https://stocknews.com/wp-content/uploads/2021/07/shutterstock_357740228-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999998"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.225061, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.162255", "ticker_sentiment_score": "0.11428", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTHR", "relevance_score": "0.162255", "ticker_sentiment_score": "-0.02238", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.292657", "ticker_sentiment_score": "0.140016", "ticker_sentiment_label": "Neutral"}]}, {"title": "$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/earnings/23/07/33477554/1000-invested-in-gilead-sciences-20-years-ago-would-be-worth-this-much-today", "time_published": "20230731T190037", "authors": ["Benzinga Insights"], "summary": "Gilead Sciences GILD has outperformed the market over the past 20 years by 4.04% on an annualized basis producing an average annual return of 12.04%. Currently, Gilead Sciences has a market capitalization of $94.96 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Robert W. Baird Remains a Hold on Gilead Sciences  ( GILD ) ", "url": "https://markets.businessinsider.com/news/stocks/robert-w-baird-remains-a-hold-on-gilead-sciences-gild-1032494585", "time_published": "20230731T094515", "authors": ["Tipranks"], "summary": "Robert W. Baird Remains a Hold on Gilead Sciences (GILD) - Markets Insider ...", "banner_image": "https://markets.businessinsider.com/Images/FacebookIcon.jpg", "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.067803, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.651499", "ticker_sentiment_score": "-0.043652", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.148731", "ticker_sentiment_score": "0.056613", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.148731", "ticker_sentiment_score": "0.135159", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.148731", "ticker_sentiment_score": "0.135159", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Stocks Retirees Should Absolutely Love", "url": "https://www.fool.com/investing/2023/07/29/3-stocks-retirees-should-absolutely-love/", "time_published": "20230729T101400", "authors": ["Keith Speights", "David Jagielski", "and Prosper Junior Bakiny"], "summary": "These stocks offer solid income plus more.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}], "overall_sentiment_score": 0.324334, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "0.342093", "ticker_sentiment_score": "0.290083", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.21803", "ticker_sentiment_score": "0.215939", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.175221", "ticker_sentiment_score": "0.195826", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead  ( GILD )  Gears Up to Report Q2 Earnings: What's in Store?", "url": "https://www.zacks.com/stock/news/2129602/gilead-gild-gears-up-to-report-q2-earnings-whats-in-store", "time_published": "20230728T162900", "authors": ["Zacks Equity Research"], "summary": "Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its second-quarter 2023 results.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default178.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999985"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.08877, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ACAD", "relevance_score": "0.1437", "ticker_sentiment_score": "-0.002513", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.282777", "ticker_sentiment_score": "0.297312", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SRPT", "relevance_score": "0.096091", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.1437", "ticker_sentiment_score": "0.07408", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILEAD LAUNCHES GLOBAL ALL4LIVER GRANT PROGRAM TO HELP ACHIEVE THE WORLD HEALTH ORGANIZATION'S GOAL OF VIRAL HEPATITIS ELIMINATION BY 2030", "url": "https://www.prnewswire.com/apac/news-releases/gilead-launches-global-all4liver-grant-program-to-help-achieve-the-world-health-organizations-goal-of-viral-hepatitis-elimination-by-2030-301885938.html", "time_published": "20230728T040000", "authors": ["Inc.", "Gilead Sciences"], "summary": "GILEAD LAUNCHES GLOBAL ALL4LIVER GRANT PROGRAM TO HELP ACHIEVE THE WORLD HEALTH ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1775570/Gilead_Sciences_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.350019, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.341699", "ticker_sentiment_score": "0.354796", "ticker_sentiment_label": "Bullish"}]}, {"title": "Gilead Sciences  ( GILD )  Dips More Than Broader Markets: What You Should Know", "url": "https://www.zacks.com/stock/news/2128274/gilead-sciences-gild-dips-more-than-broader-markets-what-you-should-know", "time_published": "20230726T215019", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Gilead Sciences (GILD) closed at $77.19, marking a -0.05% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default208.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.161791, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.488777", "ticker_sentiment_score": "0.17379", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biotech Stock Roundup: BIIB, GSK's Q2 Earnings, KOD Faces Setback & More", "url": "https://www.zacks.com/stock/news/2128013/biotech-stock-roundup-biib-gsks-q2-earnings-kod-faces-setback-more", "time_published": "20230726T140800", "authors": ["Zacks Equity Research"], "summary": "Earnings updates from Biogen (BIIB) and GSK (GSK) are in focus in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.9973"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.151902, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "INCY", "relevance_score": "0.038969", "ticker_sentiment_score": "0.014869", "ticker_sentiment_label": "Neutral"}, {"ticker": "KOD", "relevance_score": "0.116536", "ticker_sentiment_score": "0.112892", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.077845", "ticker_sentiment_score": "0.122632", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.193001", "ticker_sentiment_score": "0.117207", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.116536", "ticker_sentiment_score": "0.027736", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should SPDR Russell 1000 Yield Focus ETF  ( ONEY )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2127494/should-spdr-russell-1000-yield-focus-etf-oney-be-on-your-investing-radar", "time_published": "20230726T102007", "authors": ["Zacks Equity Research"], "summary": "Style Box ETF report for ONEY ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default336.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.255842, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HPQ", "relevance_score": "0.12013", "ticker_sentiment_score": "0.067797", "ticker_sentiment_label": "Neutral"}, {"ticker": "STT", "relevance_score": "0.060236", "ticker_sentiment_score": "0.108002", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.12013", "ticker_sentiment_score": "0.067797", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSX", "relevance_score": "0.12013", "ticker_sentiment_score": "0.067797", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Stock Sinks As Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2127347/gilead-sciences-gild-stock-sinks-as-market-gains-what-you-should-know", "time_published": "20230725T220019", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Gilead Sciences (GILD) closed at $77.23, marking a -0.55% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default84.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.223171, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.666827", "ticker_sentiment_score": "0.376657", "ticker_sentiment_label": "Bullish"}]}, {"title": "Cognizant signs $800-mn deal with Gilead Sciences", "url": "https://www.financialexpress.com/industry/cognizant-signs-800-mn-deal-with-gilead-sciences/3185238/", "time_published": "20230724T233000", "authors": ["Sameer Ranjan Bakshi"], "summary": "In keeping with the recent trend of software majors bagging big deals, Cognizant on Monday said it is expanding its IT service partnership with Gilead Sciences for a total expected value of $800 million over the next five years.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/07/1-332.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.15239, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HESG", "relevance_score": "0.124809", "ticker_sentiment_score": "0.158152", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INFY", "relevance_score": "0.362505", "ticker_sentiment_score": "0.142366", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.124809", "ticker_sentiment_score": "0.078175", "ticker_sentiment_label": "Neutral"}, {"ticker": "WIT", "relevance_score": "0.124809", "ticker_sentiment_score": "0.059876", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNSKF", "relevance_score": "0.124809", "ticker_sentiment_score": "0.118685", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Top ETFs to Buy Right Now", "url": "https://www.fool.com/investing/2023/07/24/3-top-etfs-to-buy-right-now/", "time_published": "20230724T214500", "authors": ["George Budwell"], "summary": "These three exchange-traded funds could be winning plays for patient investors.", "banner_image": "https://media.ycharts.com/charts/10c809fadfdf2cfdadbb0f05f36f42c8.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.857896"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.280327, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.07423", "ticker_sentiment_score": "0.069923", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.07423", "ticker_sentiment_score": "0.235814", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.07423", "ticker_sentiment_score": "0.069923", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.07423", "ticker_sentiment_score": "0.235814", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.07423", "ticker_sentiment_score": "0.235814", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EXAS", "relevance_score": "0.07423", "ticker_sentiment_score": "0.235814", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.07423", "ticker_sentiment_score": "0.039438", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.07423", "ticker_sentiment_score": "0.039438", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.07423", "ticker_sentiment_score": "0.039438", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.07423", "ticker_sentiment_score": "0.039438", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks making the biggest moves midday: AMC Entertainment, Mattel, Chevron, Spotify and more", "url": "https://www.cnbc.com/2023/07/24/stocks-making-the-biggest-moves-midday-amc-mat-cvx-spot.html", "time_published": "20230724T170023", "authors": ["Tanaya Macheel"], "summary": "These are the stocks posting the largest moves in midday trading.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107270624-16891860642023-07-12t181656z_1498558957_rc2t12aywftd_rtrmadp_0_netflix-results.jpeg?v=1690194348", "source": "CNBC", "category_within_source": "Market Insider", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.999981"}], "overall_sentiment_score": 0.200788, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DMPZF", "relevance_score": "0.117486", "ticker_sentiment_score": "0.090542", "ticker_sentiment_label": "Neutral"}, {"ticker": "MAT", "relevance_score": "0.058903", "ticker_sentiment_score": "0.242049", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KNX", "relevance_score": "0.058903", "ticker_sentiment_score": "0.161001", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "APE", "relevance_score": "0.058903", "ticker_sentiment_score": "-0.041162", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMAX", "relevance_score": "0.175433", "ticker_sentiment_score": "0.130766", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.058903", "ticker_sentiment_score": "-0.081065", "ticker_sentiment_label": "Neutral"}, {"ticker": "SIRI", "relevance_score": "0.058903", "ticker_sentiment_score": "0.22203", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ISRG", "relevance_score": "0.117486", "ticker_sentiment_score": "0.029906", "ticker_sentiment_label": "Neutral"}, {"ticker": "DPZ", "relevance_score": "0.117486", "ticker_sentiment_score": "0.090542", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead  ( GILD )  Ends Myelodysplastic Syndromes Study on Magrolimab", "url": "https://www.zacks.com/stock/news/2126211/gilead-gild-ends-myelodysplastic-syndromes-study-on-magrolimab", "time_published": "20230724T144400", "authors": ["Zacks Equity Research"], "summary": "Gilead Sciences, Inc. (GILD) discontinues phase III ENHANCE study, evaluating the potential of magrolimab as a treatment for higher-risk myelodysplastic syndromes, due to futility based on a planned analysis.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/2227.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.140973, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.171688", "ticker_sentiment_score": "0.051216", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANIX", "relevance_score": "0.227538", "ticker_sentiment_score": "0.070133", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.114956", "ticker_sentiment_score": "0.123622", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.282234", "ticker_sentiment_score": "0.162533", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Are Gilead Sciences  ( GILD )  Stock Trading Lower Today - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/general/biotech/23/07/33341414/trial-setback-for-gilead-sciences-shuts-late-stage-magrolimabazacitidine-combo-study-in-type-of-b", "time_published": "20230724T123632", "authors": ["Vandana Singh"], "summary": "Gilead Sciences Inc GILD decided to discontinue the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes ( MDS ) due to futility based on a planned analysis. The Phase 3 study evaluated the combination of magrolimab plus azacitidine as first-line treatments for higher-risk ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/24/gild.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.221397, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.412298", "ticker_sentiment_score": "0.226142", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Bank of America, Bank of New York Mellon And 2 Other Stocks Insiders Are Selling - Bank of America  ( NYSE:BAC ) , Bank of New York Mellon  ( NYSE:BK ) ", "url": "https://www.benzinga.com/news/23/07/33343121/bank-of-america-bank-of-new-york-mellon-and-2-other-stocks-insiders-are-selling", "time_published": "20230724T120806", "authors": ["Lisa Levin"], "summary": "The Nasdaq 100 closed slightly higher on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.126181, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BK", "relevance_score": "0.31482", "ticker_sentiment_score": "0.062262", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.31482", "ticker_sentiment_score": "0.043153", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.387674", "ticker_sentiment_score": "0.266058", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNH", "relevance_score": "0.387674", "ticker_sentiment_score": "0.2624", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Cognizant and Gilead Extend Partnership with Five-Year Service Agreement Estimated at $800 Million", "url": "https://www.prnewswire.com/news-releases/cognizant-and-gilead-extend-partnership-with-five-year-service-agreement-estimated-at-800-million-301883522.html", "time_published": "20230724T120000", "authors": ["Cognizant Technology Solutions"], "summary": "Cognizant will manage Gilead's global IT infrastructure while leading digital transformation initiatives designed to enhance overall client experience and enable faster time to market for Gilead products.", "banner_image": "https://mma.prnewswire.com/media/1794711/Cognizant_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.304149, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.113956", "ticker_sentiment_score": "0.106617", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2125862/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now", "time_published": "20230724T102008", "authors": ["Zacks Equity Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default147.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999953"}], "overall_sentiment_score": 0.282717, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.061159", "ticker_sentiment_score": "0.109012", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.121959", "ticker_sentiment_score": "0.061385", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.121959", "ticker_sentiment_score": "0.061385", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.121959", "ticker_sentiment_score": "0.061385", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMC shares surge after judge rejects APE conversion plan, Tesla stock slips on downgrade and other stocks on the move", "url": "https://www.marketwatch.com/story/amc-shares-surge-after-judge-rejects-ape-conversion-plan-tesla-stock-slips-on-downgrade-and-other-stocks-on-the-move-a6ac8ccd", "time_published": "20230724T090400", "authors": ["MarketWatch"], "summary": "Here are some of the biggest movers of the day: AMC Entertainment, Tesla and Gilead Sciences.", "banner_image": "https://images.mktw.net/im-822406/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.028816, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MAT", "relevance_score": "0.411176", "ticker_sentiment_score": "0.458422", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.411176", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.411176", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "APE", "relevance_score": "0.720339", "ticker_sentiment_score": "-0.429656", "ticker_sentiment_label": "Bearish"}]}, {"title": "Drugmakers Are 'Throwing the Kitchen Sink' to Halt Medicare Price Negotiations", "url": "https://www.nytimes.com/2023/07/23/us/politics/medicare-drug-price-negotiations-lawsuits.html", "time_published": "20230723T070017", "authors": ["Sheryl Gay Stolberg", "Rebecca Robbins"], "summary": "The government will soon announce the first 10 medications that will be subject to price negotiations with Medicare under a new law. Drugmakers are fighting the measure in court.", "banner_image": "https://static01.nyt.com/images/2023/07/17/multimedia/00dc-drugprices-01-tlkq/00dc-drugprices-01-tlkq-articleLarge.jpg?quality=75&auto=webp&disable=upscale", "source": "New York Times", "category_within_source": "Business", "source_domain": "www.nytimes.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.045938, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALPMF", "relevance_score": "0.024053", "ticker_sentiment_score": "-0.025632", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.024053", "ticker_sentiment_score": "-0.040908", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.024053", "ticker_sentiment_score": "-0.025632", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.024053", "ticker_sentiment_score": "-0.025632", "ticker_sentiment_label": "Neutral"}]}, {"title": "How a Drug Maker Profited by Slow-Walking a Promising H.I.V. Therapy", "url": "https://www.nytimes.com/2023/07/22/business/gilead-hiv-drug-tenofovir.html", "time_published": "20230722T090028", "authors": ["Rebecca Robbins", "Sheryl Gay Stolberg"], "summary": "Gilead delayed a new version of a drug, allowing it to extend the patent life of a blockbuster line of medications, internal documents show.", "banner_image": "https://static01.nyt.com/images/2023/07/06/multimedia/00Gilead-HIV-Swisher-vpzw/00Gilead-HIV-Swisher-vpzw-articleLarge.jpg?quality=75&auto=webp&disable=upscale", "source": "New York Times", "category_within_source": "Business", "source_domain": "www.nytimes.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.0935, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.025299", "ticker_sentiment_score": "-0.121025", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead scraps late-stage trial of blood cancer treatment", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-stops-late-stage-trial-blood-cancer-treatment-2023-07-21/", "time_published": "20230721T213400", "authors": ["Reuters"], "summary": "July 21 ( Reuters ) - Gilead Sciences Inc ( GILD.O ) said on Friday it was stopping a late-stage trial of its blood cancer combination treatment following an analysis that showed it would not be effective.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/CQQRVCVK4BIYFNSCV4MUXC23AM.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.253612, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.355588", "ticker_sentiment_score": "-0.540177", "ticker_sentiment_label": "Bearish"}]}, {"title": "Stock Market Struggles To Stay Ahead; Dow Tries For A 10-Day Winning Streak", "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-struggles-to-stay-ahead-dow-keeps-rally-going-auto-parts-stock-breaks-out/", "time_published": "20230721T174600", "authors": ["Investor's Business Daily", "KIMBERLEY KOENIG"], "summary": "Stock Market Struggles To Stay Ahead. Dow Tries For A 10-Day Winning Streak Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/01/Stock-AutoDetailBlowUp-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.99999"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.993856"}], "overall_sentiment_score": 0.237111, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MDLZ", "relevance_score": "0.144708", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVGO", "relevance_score": "0.144708", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.144708", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADI", "relevance_score": "0.144708", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXP", "relevance_score": "0.144708", "ticker_sentiment_score": "-0.311136", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ALV", "relevance_score": "0.144708", "ticker_sentiment_score": "0.236723", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.144708", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.072655", "ticker_sentiment_score": "0.046862", "ticker_sentiment_label": "Neutral"}, {"ticker": "BKNG", "relevance_score": "0.144708", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Fades; Trump-Backed DWAC Surges As Cathie Wood Swoops On Battered Chip Leader", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-rises-trump-backed-dwac-surges-as-cathie-wood-swoops-down-on-battered-chip-leader/", "time_published": "20230721T145700", "authors": ["Investor's Business Daily", "VIDYA RAMAKRISHNAN"], "summary": "Dow Jones Fades. Trump-Backed DWAC Surges As Cathie Wood Swoops On Battered Chip Leader Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/01/Stock-nasdaq-0122-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.999355"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.857896"}], "overall_sentiment_score": -0.113814, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MDLZ", "relevance_score": "0.145583", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.21686", "ticker_sentiment_score": "-0.054212", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADI", "relevance_score": "0.145583", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLB", "relevance_score": "0.145583", "ticker_sentiment_score": "-0.258745", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MDB", "relevance_score": "0.145583", "ticker_sentiment_score": "0.143522", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALV", "relevance_score": "0.145583", "ticker_sentiment_score": "-0.103407", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADP", "relevance_score": "0.145583", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AN", "relevance_score": "0.073098", "ticker_sentiment_score": "-0.083585", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.21686", "ticker_sentiment_score": "-0.054212", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.145583", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.145583", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXP", "relevance_score": "0.145583", "ticker_sentiment_score": "-0.098649", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.145583", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUBS", "relevance_score": "0.145583", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BKNG", "relevance_score": "0.145583", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.145583", "ticker_sentiment_score": "-0.258745", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HRI", "relevance_score": "0.145583", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Got $1,000? Buying Caribou Biosciences Stock Right Now Could Be a Brilliant Move in 5 Years", "url": "https://www.fool.com/investing/2023/07/21/got-1000-buying-caribou-biosciences-stock-could/", "time_published": "20230721T140000", "authors": ["Alex Carchidi"], "summary": "It's still early going, but this small biotech shows great promise.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": 0.01951, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CRBU", "relevance_score": "0.158519", "ticker_sentiment_score": "0.030149", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.053153", "ticker_sentiment_score": "-0.058994", "ticker_sentiment_label": "Neutral"}]}, {"title": "Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/pressreleases/23/07/g33307586/center-for-disease-analysis-foundation-announces-receipt-of-an-8-million-grant-from-gilead-science", "time_published": "20230720T160000", "authors": ["Globe Newswire"], "summary": "LAFAYETTE, Colo., July 20, 2023 ( GLOBE NEWSWIRE ) -- The Center for Disease Analysis Foundation ( CDA Foundation ) announced today that it received an $8 million grant from Gilead Sciences GILD as part of Gilead's Relink grant program.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.002494, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.215894", "ticker_sentiment_score": "0.101132", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Growth Stocks That Could Rocket 81% to 233% Higher, According to Wall Street", "url": "https://www.fool.com/investing/2023/07/20/3-growth-stocks-that-could-rocket-to-higher-accord/", "time_published": "20230720T153500", "authors": ["Cory Renauer"], "summary": "The investment bank analysts who follow these stocks think they could deliver enormous gains in the not-so-distant future.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F740095%2Fanalyst-on-wall-street-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.159793, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALHC", "relevance_score": "0.175009", "ticker_sentiment_score": "0.124145", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.058759", "ticker_sentiment_score": "0.056558", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRBU", "relevance_score": "0.1172", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.058759", "ticker_sentiment_score": "0.164001", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNH", "relevance_score": "0.058759", "ticker_sentiment_score": "0.217417", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Shares of Vir Biotechnology Are Plunging Thursday", "url": "https://www.fool.com/investing/2023/07/20/why-shares-of-vir-biotechnology-are-plunging-thurs/", "time_published": "20230720T153100", "authors": ["Jim Halley"], "summary": "The company had disappointing trial news for one of its lead therapies.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F740180%2Fa-person-on-the-couch-keying-credit-card-information-into-a-laptop.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.77141"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.102112, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.135347", "ticker_sentiment_score": "-0.216391", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GILD", "relevance_score": "0.135347", "ticker_sentiment_score": "-0.216391", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BRIBF", "relevance_score": "0.135347", "ticker_sentiment_score": "-0.216391", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "VIR", "relevance_score": "0.767202", "ticker_sentiment_score": "-0.269145", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Pfizer, Gilead, GSK to capture 62% of $150 billion infectious diseases market | The Financial Express", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/pfizer-gilead-gsk-to-capture-62-of-150-billion-infectious-diseases-market/3178455/", "time_published": "20230720T043000", "authors": [], "summary": "Pfizer, Gilead, GSK to capture 62% of $150 billion infectious diseases market The Financial Express ...", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/07/painkillers-g0651a5da2_1920.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.342637, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GLDAF", "relevance_score": "0.258351", "ticker_sentiment_score": "0.131195", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.258351", "ticker_sentiment_score": "0.389872", "ticker_sentiment_label": "Bullish"}, {"ticker": "GSK", "relevance_score": "0.258351", "ticker_sentiment_score": "0.3295", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.339745", "ticker_sentiment_score": "0.264231", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead Sciences  ( GILD )  Outpaces Stock Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2124129/gilead-sciences-gild-outpaces-stock-market-gains-what-you-should-know", "time_published": "20230719T220019", "authors": ["Zacks Investment Research"], "summary": "Gilead Sciences (GILD) closed the most recent trading day at $78.96, moving +0.95% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default223.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.179069, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.631282", "ticker_sentiment_score": "0.246566", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Peering Into Gilead Sciences's Recent Short Interest - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/short-sellers/23/07/33289199/peering-into-gilead-sciencess-recent-short-interest", "time_published": "20230719T164526", "authors": ["Benzinga Insights"], "summary": "Gilead Sciences's GILD short percent of float has risen 6.16% since its last report. The company recently reported that it has 17.34 million shares sold short, which is 1.55% of all regular shares that are available for trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.267332, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.221819", "ticker_sentiment_score": "0.155473", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Healthcare Stocks to Buy and Hold for the Next 10 Years", "url": "https://www.fool.com/investing/2023/07/19/3-healthcare-stocks-to-buy-and-hold-for-the-next/", "time_published": "20230719T121500", "authors": ["Prosper Junior Bakiny"], "summary": "It helps to offer products everyone needs.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F740156%2Fbob_iger.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.338782, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.308891", "ticker_sentiment_score": "0.358895", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.259451", "ticker_sentiment_score": "0.263973", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.308891", "ticker_sentiment_score": "0.270539", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?", "url": "https://www.zacks.com/stock/news/2123401/should-you-invest-in-the-ishares-biotechnology-etf-ibb", "time_published": "20230719T102007", "authors": ["Zacks Investment Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default167.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.164146, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.068896", "ticker_sentiment_score": "0.034085", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.137278", "ticker_sentiment_score": "0.072244", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.137278", "ticker_sentiment_score": "0.072244", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.137278", "ticker_sentiment_score": "0.072244", "ticker_sentiment_label": "Neutral"}]}, {"title": "SARS-CoV-2 Is Not Done Yet - Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19? - Merck & Co  ( NYSE:MRK ) , Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/general/biotech/23/07/33264588/sars-cov-2-is-not-done-yet-could-this-new-drug-in-clinical-trials-be-the-safest-option-for-treati", "time_published": "20230718T120740", "authors": ["David Willey"], "summary": "SARS-CoV-2 is not done yet - Although it is not grabbing as many headlines, the number of deaths arestill greater than even a pandemic influenza year at last count.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/18/screenshot_2023-07-18_at_5.32.41_pm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.244561, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APG", "relevance_score": "0.05339", "ticker_sentiment_score": "0.170729", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.106541", "ticker_sentiment_score": "0.042105", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.106541", "ticker_sentiment_score": "0.05881", "ticker_sentiment_label": "Neutral"}]}, {"title": "ACELYRIN, INC. Appoints Ken Lock as Chief Commercial Officer", "url": "https://www.globenewswire.com/news-release/2023/07/18/2706277/0/en/ACELYRIN-INC-Appoints-Ken-Lock-as-Chief-Commercial-Officer.html", "time_published": "20230718T110000", "authors": ["Inc.", "Acelyrin"], "summary": "Accomplished global leader brings 20 years of immunology sales and marketing expertise.", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.266431, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARQT", "relevance_score": "0.048919", "ticker_sentiment_score": "0.090139", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.048919", "ticker_sentiment_score": "0.090139", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLRN", "relevance_score": "0.538389", "ticker_sentiment_score": "0.38475", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.048919", "ticker_sentiment_score": "0.090139", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is SPDR Russell 1000 Yield Focus ETF  ( ONEY )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2122580/is-spdr-russell-1000-yield-focus-etf-oney-a-strong-etf-right-now", "time_published": "20230718T102006", "authors": ["Zacks Investment Research"], "summary": "Smart Beta ETF report for ONEY ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default241.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.321847, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HPQ", "relevance_score": "0.114137", "ticker_sentiment_score": "0.060868", "ticker_sentiment_label": "Neutral"}, {"ticker": "STT", "relevance_score": "0.057215", "ticker_sentiment_score": "0.134969", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.114137", "ticker_sentiment_score": "0.060868", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSX", "relevance_score": "0.114137", "ticker_sentiment_score": "0.060868", "ticker_sentiment_label": "Neutral"}]}, {"title": "Price Over Earnings Overview: Gilead Sciences - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/23/07/33255587/price-over-earnings-overview-gilead-sciences", "time_published": "20230717T200018", "authors": ["Benzinga Insights"], "summary": "In the current market session, Gilead Sciences Inc. GILD share price is at $77.52, after a 0.42% spike. Moreover, over the past month, the stock fell by 0.25%, but in the past year, spiked by 24.78%.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": -0.079997, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.421485", "ticker_sentiment_score": "-0.062358", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead's  ( GILD )  Veklury Gets FDA Nod for Label Expansion", "url": "https://www.zacks.com/stock/news/2122308/gileads-gild-veklury-gets-fda-nod-for-label-expansion", "time_published": "20230717T154000", "authors": ["Zacks Investment Research"], "summary": "Gilead's (GILD) antiviral treatment Veklury (remdesivir) has now been approved for the treatment of COVID-19 patients with severe renal impairment, including those on dialysis.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c9/2325.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.075143, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALKS", "relevance_score": "0.290607", "ticker_sentiment_score": "0.178714", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LGND", "relevance_score": "0.290607", "ticker_sentiment_score": "0.122779", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.147818", "ticker_sentiment_score": "0.110645", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should IQ Chaikin U.S. Large Cap ETF  ( CLRG )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2121855/should-iq-chaikin-us-large-cap-etf-clrg-be-on-your-investing-radar", "time_published": "20230717T102006", "authors": ["Zacks Investment Research"], "summary": "Style Box ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default54.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.170992, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LVS", "relevance_score": "0.124486", "ticker_sentiment_score": "0.068857", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.124486", "ticker_sentiment_score": "0.068857", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.124486", "ticker_sentiment_score": "0.068857", "ticker_sentiment_label": "Neutral"}]}, {"title": "These 2 Numbers Should Scare Every Biogen Shareholder", "url": "https://www.fool.com/investing/2023/07/16/numbers-should-scare-every-biogen-shareholder/", "time_published": "20230716T111500", "authors": ["Alex Carchidi"], "summary": "There are a couple of pieces of evidence that Biogen's long-term strategy isn't working.", "banner_image": "https://media.ycharts.com/charts/9b620ff8aa5bd98c2bdaba7734389acc.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.043812, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.056275", "ticker_sentiment_score": "-0.044013", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.056275", "ticker_sentiment_score": "-0.044013", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.056275", "ticker_sentiment_score": "-0.044013", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.222327", "ticker_sentiment_score": "0.152752", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "FDA Approves Gilead's Remdesivir For COVID-19 Treatment Patients With Severe Renal Impairment - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/general/biotech/23/07/33232032/fda-approves-gileads-remdesivir-for-covid-19-treatment-patients-with-severe-renal-impairment", "time_published": "20230714T152357", "authors": ["Vandana Singh"], "summary": "The FDA approved Gilead Sciences Inc's GILD supplemental new drug application for using Veklury ( remdesivir ) in COVID-19 patients with severe renal impairment, including those on dialysis.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/14/remdesivir.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.031397, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.433523", "ticker_sentiment_score": "0.153506", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead Sciences  ( GILD )  Gains But Lags Market: What You Should Know", "url": "https://www.zacks.com/stock/news/2120956/gilead-sciences-gild-gains-but-lags-market-what-you-should-know", "time_published": "20230713T220020", "authors": ["Zacks Investment Research"], "summary": "In the latest trading session, Gilead Sciences (GILD) closed at $76.71, marking a +0.43% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default2.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.182458, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.479683", "ticker_sentiment_score": "0.316727", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stocks Run With Big Earnings, Nasdaq Rebalance Due", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-stocks-run-with-big-earnings-nasdaq-100-rebalance-due/", "time_published": "20230713T204000", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Dow Jones futures tilted lower after hours, along with S&P 500 futures and Nasdaq futures. JPMorgan Chase headlines big earnings Friday. Tech growth plays led another solid session for the stock market rally, with Treasury yields and the dollar continuing to slide.", "banner_image": "https://www.investors.com/wp-content/uploads/2018/07/stock-bull-charge-02-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.714479"}], "overall_sentiment_score": 0.163032, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.099168", "ticker_sentiment_score": "-0.032745", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.148273", "ticker_sentiment_score": "0.040072", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDLZ", "relevance_score": "0.04968", "ticker_sentiment_score": "0.278397", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.07446", "ticker_sentiment_score": "0.102565", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.172624", "ticker_sentiment_score": "0.027269", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.12378", "ticker_sentiment_score": "0.082327", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.12378", "ticker_sentiment_score": "0.052377", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.07446", "ticker_sentiment_score": "-0.031226", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNOW", "relevance_score": "0.099168", "ticker_sentiment_score": "0.054809", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADI", "relevance_score": "0.04968", "ticker_sentiment_score": "0.278397", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.12378", "ticker_sentiment_score": "-0.056044", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.024852", "ticker_sentiment_score": "0.263562", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ADP", "relevance_score": "0.04968", "ticker_sentiment_score": "0.278397", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNH", "relevance_score": "0.12378", "ticker_sentiment_score": "0.027071", "ticker_sentiment_label": "Neutral"}, {"ticker": "AEHR", "relevance_score": "0.099168", "ticker_sentiment_score": "0.005472", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.148273", "ticker_sentiment_score": "0.028787", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.19681", "ticker_sentiment_score": "0.095225", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.04968", "ticker_sentiment_score": "0.278397", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.099168", "ticker_sentiment_score": "0.048015", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.04968", "ticker_sentiment_score": "0.278397", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BKNG", "relevance_score": "0.04968", "ticker_sentiment_score": "0.278397", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ISRG", "relevance_score": "0.04968", "ticker_sentiment_score": "0.278397", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.07446", "ticker_sentiment_score": "0.040683", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.04968", "ticker_sentiment_score": "0.080084", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.024852", "ticker_sentiment_score": "-0.071168", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Hidden Winner Of Nasdaq's \"Great Rebalancing\"", "url": "https://moneymorning.com/investing/the-hidden-winner-of-nasdaqs-great-rebalancing/", "time_published": "20230713T191302", "authors": ["Chris Johnson", "alexkagin", "Shah Gilani", "Alex Kagin"], "summary": "One of the most notable trends in the stock market this year has been the meteoric rise of mega-cap tech. These companies have outperformed all other sectors of the equity market, and their dominance has become increasingly concentrated. Currently, the seven largest companies account for over 54% ...", "banner_image": "https://moneymorning.com/wp-content/blogs.dir/1/files/2023/06/bp-report-01.png", "source": "Money Morning", "category_within_source": "GoogleRSS", "source_domain": "moneymorning.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.905476"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.217229, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ENPH", "relevance_score": "0.16117", "ticker_sentiment_score": "0.181986", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDLZ", "relevance_score": "0.16117", "ticker_sentiment_score": "0.425203", "ticker_sentiment_label": "Bullish"}, {"ticker": "AAPL", "relevance_score": "0.239698", "ticker_sentiment_score": "0.031604", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADI", "relevance_score": "0.16117", "ticker_sentiment_score": "0.425203", "ticker_sentiment_label": "Bullish"}, {"ticker": "SIRI", "relevance_score": "0.16117", "ticker_sentiment_score": "0.181986", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ADP", "relevance_score": "0.16117", "ticker_sentiment_score": "0.425203", "ticker_sentiment_label": "Bullish"}, {"ticker": "MSFT", "relevance_score": "0.16117", "ticker_sentiment_score": "0.054892", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZM", "relevance_score": "0.16117", "ticker_sentiment_score": "0.181986", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SBUX", "relevance_score": "0.16117", "ticker_sentiment_score": "0.425203", "ticker_sentiment_label": "Bullish"}, {"ticker": "WFC", "relevance_score": "0.081001", "ticker_sentiment_score": "0.332231", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.16117", "ticker_sentiment_score": "0.425203", "ticker_sentiment_label": "Bullish"}, {"ticker": "BKNG", "relevance_score": "0.16117", "ticker_sentiment_score": "0.425203", "ticker_sentiment_label": "Bullish"}, {"ticker": "ISRG", "relevance_score": "0.16117", "ticker_sentiment_score": "0.425203", "ticker_sentiment_label": "Bullish"}]}, {"title": "Biotech Stocks To Watch: Track The Latest News On Pharmaceutical Stocks And Drug Companies", "url": "https://www.investors.com/news/technology/biotech-and-pharma-industry-and-stock-news-merk-bristol-myers-amgn-gilead/", "time_published": "20230713T120600", "authors": ["IBD STAFF", "Investor's Business Daily"], "summary": "One minute Dow Jones industrial average component Merck ( MRK ) might be doing battle with fellow drugmaker Bristol Myers Squibb ( BMY ) over drugs that can ward off cancer. The next, biotech giants like Amgen ( AMGN ) and Sanofi ( SNY ) are tussling in court over the fate of ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/05/JUMP-moderna-050820-newscom-300x169.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.083353, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.366061", "ticker_sentiment_score": "0.043641", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVCR", "relevance_score": "0.366061", "ticker_sentiment_score": "-0.381253", "ticker_sentiment_label": "Bearish"}, {"ticker": "AMGN", "relevance_score": "0.366061", "ticker_sentiment_score": "0.043641", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.366061", "ticker_sentiment_score": "-0.549433", "ticker_sentiment_label": "Bearish"}, {"ticker": "SNY", "relevance_score": "0.366061", "ticker_sentiment_score": "0.043641", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Now the Right Time to Embrace Biotech ETFs?", "url": "https://www.zacks.com/stock/news/2120021/is-now-the-right-time-to-embrace-biotech-etfs", "time_published": "20230712T150900", "authors": ["Zacks Investment Research"], "summary": "Look if it's the right time to invest in biotech ETFs to help diversify your portfolio.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/2266.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.986413"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Earnings", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.182418, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.124164", "ticker_sentiment_score": "0.04872", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.124164", "ticker_sentiment_score": "0.04872", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.124164", "ticker_sentiment_score": "0.04872", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.041538", "ticker_sentiment_score": "-0.027545", "ticker_sentiment_label": "Neutral"}]}, {"title": "ETFs in Focus as Nasdaq 100 Undergoes Rejiggering", "url": "https://www.zacks.com/stock/news/2119996/etfs-in-focus-as-nasdaq-100-undergoes-rejiggering", "time_published": "20230712T144200", "authors": ["Zacks Investment Research"], "summary": "The Nasdaq 100 is set to undergo a special rebalance on Jul 24 to address overconcentration issues posed by a handful of technology stocks on the index by redistributing the weights.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/0c/833.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.999894"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.234634, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.100308", "ticker_sentiment_score": "0.103204", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDLZ", "relevance_score": "0.050254", "ticker_sentiment_score": "0.047906", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.100308", "ticker_sentiment_score": "0.172861", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.149966", "ticker_sentiment_score": "0.123868", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.149966", "ticker_sentiment_score": "0.123868", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADI", "relevance_score": "0.050254", "ticker_sentiment_score": "0.047906", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.050254", "ticker_sentiment_score": "0.161254", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVZ", "relevance_score": "0.340915", "ticker_sentiment_score": "0.24557", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ADP", "relevance_score": "0.050254", "ticker_sentiment_score": "0.047906", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.149966", "ticker_sentiment_score": "0.123868", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.149966", "ticker_sentiment_score": "0.123868", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.050254", "ticker_sentiment_score": "0.047906", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.050254", "ticker_sentiment_score": "0.047906", "ticker_sentiment_label": "Neutral"}, {"ticker": "BKNG", "relevance_score": "0.050254", "ticker_sentiment_score": "0.047906", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.050254", "ticker_sentiment_score": "0.047906", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.149966", "ticker_sentiment_score": "0.123868", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is IQ Chaikin U.S. Large Cap ETF  ( CLRG )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2119624/is-iq-chaikin-us-large-cap-etf-clrg-a-strong-etf-right-now", "time_published": "20230712T102005", "authors": ["Zacks Investment Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default338.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999998"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.239607, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LVS", "relevance_score": "0.116631", "ticker_sentiment_score": "0.061379", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.116631", "ticker_sentiment_score": "0.061379", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.116631", "ticker_sentiment_score": "0.061379", "ticker_sentiment_label": "Neutral"}]}, {"title": "Explainer: What is Nasdaq's special rebalancing and its impact?", "url": "https://www.reuters.com/markets/us/what-is-nasdaqs-special-rebalancing-its-impact-2023-07-11/", "time_published": "20230711T172100", "authors": ["Sruthi Shankar", "Medha Singh"], "summary": "July 11 ( Reuters ) - A \"special rebalance\" of the Nasdaq 100 index ( .NDX ) will take place later this month as exchange operator Nasdaq ( NDAQ.O ) looks to reduce the concentration of heavyweight companies that account for nearly half of the index's weight.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/RQOQAIWD5JIR7OD2Z7OHFMW33E.jpg", "source": "Reuters", "category_within_source": "Markets", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.928769"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.147234, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MDLZ", "relevance_score": "0.063425", "ticker_sentiment_score": "0.099056", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.063425", "ticker_sentiment_score": "0.086041", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.249744", "ticker_sentiment_score": "0.139977", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADI", "relevance_score": "0.063425", "ticker_sentiment_score": "0.099056", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.063425", "ticker_sentiment_score": "0.091047", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADP", "relevance_score": "0.063425", "ticker_sentiment_score": "0.099056", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.30928", "ticker_sentiment_score": "0.073968", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.249744", "ticker_sentiment_score": "0.139977", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.063425", "ticker_sentiment_score": "0.099056", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.12645", "ticker_sentiment_score": "0.112402", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.063425", "ticker_sentiment_score": "0.099056", "ticker_sentiment_label": "Neutral"}, {"ticker": "BKNG", "relevance_score": "0.063425", "ticker_sentiment_score": "0.099056", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.063425", "ticker_sentiment_score": "0.099056", "ticker_sentiment_label": "Neutral"}]}, {"title": "Mega-cap tech stocks have gotten so big that the Nasdaq 100 is about to undergo a 'special rebalance' to address overconcentration", "url": "https://markets.businessinsider.com/news/stocks/mega-cap-tech-stocks-nasdaq-100-forcing-special-rebalance-winners-2023-7", "time_published": "20230711T143100", "authors": ["Matthew Fox"], "summary": "Mega-cap tech stocks are so big that the Nasdaq 100 is forcing a shake-up - Markets Insider ...", "banner_image": "https://i.insider.com/64620f7711971c00188f4844?width=1200&format=jpeg", "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.164702, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.340915", "ticker_sentiment_score": "0.042236", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDLZ", "relevance_score": "0.087824", "ticker_sentiment_score": "0.17276", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.087824", "ticker_sentiment_score": "0.065924", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.087824", "ticker_sentiment_score": "0.065924", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.087824", "ticker_sentiment_score": "0.065924", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.087824", "ticker_sentiment_score": "0.17276", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.174587", "ticker_sentiment_score": "0.103482", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADI", "relevance_score": "0.087824", "ticker_sentiment_score": "0.17276", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.087824", "ticker_sentiment_score": "0.17276", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ADP", "relevance_score": "0.087824", "ticker_sentiment_score": "0.17276", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BKNG", "relevance_score": "0.087824", "ticker_sentiment_score": "0.17276", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ISRG", "relevance_score": "0.087824", "ticker_sentiment_score": "0.17276", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials - What Other Viruses Could This COVID Treatment Target? - Merck & Co  ( NYSE:MRK ) , Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/general/biotech/23/07/33166416/novel-nanomedicine-platform-with-pipeline-of-antivirals-goes-to-human-trials-what-other-viruses-c", "time_published": "20230710T131314", "authors": ["David Willey"], "summary": "NanoViricides NNVC has begun trials for its new drug candidate, NV-CoV-2 - an exciting development for the biotech company, as it starts its first human trials with drug sponsor Karveer Meditech Pvt. Ltd. India, the company's licensee and co-developer in India.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/10/screenshot_2023-07-10_at_6.42.30_pm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.153653, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "0.099271", "ticker_sentiment_score": "-0.045466", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.099271", "ticker_sentiment_score": "-0.045466", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Johnson & Johnson Stock a Buy Now?", "url": "https://www.fool.com/investing/2023/07/09/is-johnson-johnson-stock-a-buy-now/", "time_published": "20230709T114500", "authors": ["Prosper Junior Bakiny"], "summary": "Some businesses never go out of style.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F738271%2Fhands-behind-head.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.684621"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.278455, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "0.059488", "ticker_sentiment_score": "0.083997", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.059488", "ticker_sentiment_score": "0.077996", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.059488", "ticker_sentiment_score": "0.077996", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.118647", "ticker_sentiment_score": "0.187733", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "US Stocks Dip After Mixed Jobs Data", "url": "https://www.barrons.com/news/us-stocks-dip-after-mixed-jobs-data-da0d5c5b", "time_published": "20230707T203544", "authors": ["AFP - Agence France Presse"], "summary": "Wall Street stocks dipped Friday following data that showed slower hiring in the United States but which was seen as keeping the Federal Reserve on track to raise interest rates.", "banner_image": "https://asset.barrons.com/barrons/images/afp-metadata-default.jpg", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.034599, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "COST", "relevance_score": "0.18967", "ticker_sentiment_score": "0.053266", "ticker_sentiment_label": "Neutral"}, {"ticker": "LPLA", "relevance_score": "0.18967", "ticker_sentiment_score": "0.053266", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.18967", "ticker_sentiment_score": "0.053266", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.18967", "ticker_sentiment_score": "0.053266", "ticker_sentiment_label": "Neutral"}]}, {"title": "$1 Billion Deal For Moderna To Expand Product Pipeline In China - Gilead Sciences  ( NASDAQ:GILD ) , Moderna  ( NASDAQ:MRNA ) , Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33145546/1-billion-deal-for-moderna-to-expand-product-pipeline-in-china", "time_published": "20230707T124517", "authors": ["MarketBeat"], "summary": "The defensive stocks sector has been underperforming most - if not all - of the remaining cyclical sectors in the U.S. economy. These preferences come from underlying dynamics in the money markets and where investors think we are in the business cycle.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/07/moderna_logo.svg_.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": -0.012008, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.402941", "ticker_sentiment_score": "-0.088447", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.157141", "ticker_sentiment_score": "-0.041704", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.157141", "ticker_sentiment_score": "-0.041704", "ticker_sentiment_label": "Neutral"}]}, {"title": "Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer", "url": "https://www.globenewswire.com/news-release/2023/07/05/2699908/0/en/Lyell-Immunopharma-Appoints-Matthew-Lang-as-Chief-Business-Officer.html", "time_published": "20230705T200500", "authors": ["Lyell Immunopharma", "Inc"], "summary": "SOUTH SAN FRANCISCO, Calif., July 05, 2023 ( GLOBE NEWSWIRE ) -- Lyell Immunopharma, Inc. ( Nasdaq: LYEL ) , a clinical\u2011stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that Matthew Lang, J.D. has joined the ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/fa4a7bb1-f8ea-45e7-ba51-37077689a4fb", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.255609, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.066598", "ticker_sentiment_score": "0.065286", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYEL", "relevance_score": "0.132733", "ticker_sentiment_score": "0.117455", "ticker_sentiment_label": "Neutral"}]}, {"title": "NanoViricides Inc.  ( NYSE American: NNVC )  Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment - Nanoviricides  ( AMEX:NNVC ) ", "url": "https://www.benzinga.com/general/biotech/23/07/33113617/nanoviricides-inc-nyse-american-nnvc-begins-long-awaited-clinical-trials-for-its-anti-viral-nanom", "time_published": "20230705T115051", "authors": ["David Willey"], "summary": "NanoViricides NNVC is a drug development company working on a novel nanomedical treatment. It recently updated the world on the status of its long-awaited and now active trials into its lead drug candidate, NV-CoV-2.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/05/screenshot_2023-07-05_at_5.18.51_pm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.048487, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "0.137671", "ticker_sentiment_score": "0.027658", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.137671", "ticker_sentiment_score": "0.027658", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILEAD SCIENCES AND IAS - THE INTERNATIONAL AIDS SOCIETY - HONOUR HEALTHCARE PROVIDERS GLOBALLY WHO CHAMPION STIGMA-FREE HIV SERVICES", "url": "https://www.prnewswire.com/apac/news-releases/gilead-sciences-and-ias--the-international-aids-society---honour-healthcare-providers-globally-who-champion-stigma-free-hiv-services-301869864.html", "time_published": "20230705T030000", "authors": ["Gilead Sciences", "Inc."], "summary": "GILEAD SCIENCES AND IAS - THE INTERNATIONAL AIDS SOCIETY - HONOUR HEALTHCARE PROVIDERS ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1775570/Gilead_Sciences_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.263896, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.199365", "ticker_sentiment_score": "0.15493", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead Sciences  ( GILD )  Stock Sinks As Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2116263/gilead-sciences-gild-stock-sinks-as-market-gains-what-you-should-know", "time_published": "20230703T220018", "authors": ["Zacks Investment Research"], "summary": "Gilead Sciences (GILD) closed at $76.72 in the latest trading session, marking a -0.46% move from the prior day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default105.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.18651, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.6809", "ticker_sentiment_score": "0.327844", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight", "url": "https://www.prnewswire.com/news-releases/bispecific-antibody-clinical-trial-pipeline-appears-robust-with-250-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-301868673.html", "time_published": "20230703T210100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.15175, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MGNX", "relevance_score": "0.081483", "ticker_sentiment_score": "0.144952", "ticker_sentiment_label": "Neutral"}, {"ticker": "TBPH", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.005463", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRIS", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.004464", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.020404", "ticker_sentiment_score": "0.115855", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADCT", "relevance_score": "0.040795", "ticker_sentiment_score": "0.06675", "ticker_sentiment_label": "Neutral"}, {"ticker": "XNCR", "relevance_score": "0.020404", "ticker_sentiment_score": "0.003677", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.005463", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGEN", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.004464", "ticker_sentiment_label": "Neutral"}, {"ticker": "ELDN", "relevance_score": "0.020404", "ticker_sentiment_score": "0.115855", "ticker_sentiment_label": "Neutral"}, {"ticker": "CGEN", "relevance_score": "0.020404", "ticker_sentiment_score": "0.078882", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.020404", "ticker_sentiment_score": "0.130751", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKESF", "relevance_score": "0.081483", "ticker_sentiment_score": "0.105903", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.004464", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABUS", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.004464", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.040795", "ticker_sentiment_score": "0.032589", "ticker_sentiment_label": "Neutral"}, {"ticker": "IGMS", "relevance_score": "0.061159", "ticker_sentiment_score": "0.058024", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMMT", "relevance_score": "0.020404", "ticker_sentiment_score": "0.167562", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RCUS", "relevance_score": "0.020404", "ticker_sentiment_score": "0.078882", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCON", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.004464", "ticker_sentiment_label": "Neutral"}, {"ticker": "IRON", "relevance_score": "0.020404", "ticker_sentiment_score": "0.115855", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.005463", "ticker_sentiment_label": "Neutral"}, {"ticker": "MREO", "relevance_score": "0.020404", "ticker_sentiment_score": "0.078882", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITOS", "relevance_score": "0.020404", "ticker_sentiment_score": "0.078882", "ticker_sentiment_label": "Neutral"}, {"ticker": "APLM", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.004464", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMER", "relevance_score": "0.040795", "ticker_sentiment_score": "0.126795", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.020404", "ticker_sentiment_score": "0.078882", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASCLF", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.004464", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.020404", "ticker_sentiment_score": "0.115855", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.005463", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.020404", "ticker_sentiment_score": "0.202125", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PHIO", "relevance_score": "0.020404", "ticker_sentiment_score": "0.078882", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.081483", "ticker_sentiment_score": "0.048837", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACRS", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.005463", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLPG", "relevance_score": "0.020404", "ticker_sentiment_score": "-0.005463", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.040795", "ticker_sentiment_score": "0.143852", "ticker_sentiment_label": "Neutral"}]}, {"title": "Over $59M Bet On This Communication Services Stock? Check Out These 3 Stocks Insiders Are Buying - Asana  ( NYSE:ASAN ) , MediaAlpha  ( NYSE:MAX ) ", "url": "https://www.benzinga.com/trading-ideas/long-ideas/23/07/33096454/over-59m-bet-on-this-communication-services-stock-check-out-these-3-stocks-insiders-are-", "time_published": "20230703T132321", "authors": ["Lisa Levin"], "summary": "Although US stocks closed higher on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/03/image37.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.275344, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ASAN", "relevance_score": "0.529185", "ticker_sentiment_score": "0.573686", "ticker_sentiment_label": "Bullish"}, {"ticker": "RCUS", "relevance_score": "0.436009", "ticker_sentiment_score": "0.014782", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.114682", "ticker_sentiment_score": "0.159386", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MAX", "relevance_score": "0.529185", "ticker_sentiment_score": "0.130464", "ticker_sentiment_label": "Neutral"}]}, {"title": "This Is What Whales Are Betting On Gilead Sciences - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/markets/options/23/06/33079869/this-is-what-whales-are-betting-on-gilead-sciences", "time_published": "20230630T150150", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bearish stance on Gilead Sciences. Looking at options history for Gilead Sciences GILD we detected 13 strange trades. If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.151219, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.682689", "ticker_sentiment_score": "0.056304", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 American Mutual Funds Worth Buying for Long-Term Investing", "url": "https://www.zacks.com/stock/news/2115217/3-american-mutual-funds-worth-buying-for-long-term-investing", "time_published": "20230630T112200", "authors": ["Zacks Investment Research"], "summary": "Given the prevailing market conditions, it would be wise for investors to consider allocating their investments to renowned American mutual funds such as RMFEX, WSHFX and FIFAX.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/a8/346.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999956"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.388725, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.093653", "ticker_sentiment_score": "0.053186", "ticker_sentiment_label": "Neutral"}, {"ticker": "AFG", "relevance_score": "0.046907", "ticker_sentiment_score": "0.116633", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVGO", "relevance_score": "0.046907", "ticker_sentiment_score": "0.05216", "ticker_sentiment_label": "Neutral"}, {"ticker": "RTX", "relevance_score": "0.046907", "ticker_sentiment_score": "0.048209", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.046907", "ticker_sentiment_score": "0.048209", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.046907", "ticker_sentiment_score": "0.049196", "ticker_sentiment_label": "Neutral"}, {"ticker": "PM", "relevance_score": "0.046907", "ticker_sentiment_score": "0.049196", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.046907", "ticker_sentiment_score": "0.049196", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.046907", "ticker_sentiment_score": "0.05216", "ticker_sentiment_label": "Neutral"}]}, {"title": "Looking Into Gilead Sciences's Recent Short Interest - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/short-sellers/23/06/33067299/looking-into-gilead-sciencess-recent-short-interest", "time_published": "20230629T201543", "authors": ["Benzinga Insights"], "summary": "Gilead Sciences's GILD short percent of float has fallen 9.32% since its last report. The company recently reported that it has 16.32 million shares sold short, which is 1.46% of all regular shares that are available for trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.239316, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.221819", "ticker_sentiment_score": "0.083071", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences' Debt Overview - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/23/06/33065015/gilead-sciences-debt-overview", "time_published": "20230629T180206", "authors": ["Benzinga Insights"], "summary": "Over the past three months, shares of Gilead Sciences Inc. GILD decreased by 7.28%. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its financials.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": -0.13004, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.277958", "ticker_sentiment_score": "-0.021616", "ticker_sentiment_label": "Neutral"}]}, {"title": "Hepatitis C cure is not reaching overwhelming majority of patients due to financial barriers", "url": "https://www.cnbc.com/2023/06/29/hepatitis-c-cure-isnt-reaching-patients-due-to-cost-cdc-says.html", "time_published": "20230629T174737", "authors": ["Spencer Kimball"], "summary": "Hepatitis C is often referred to as the silent killer because the initial infection has few to no symptoms.", "banner_image": "https://image.cnbcfm.com/api/v1/image/101448696-151050768.jpg?v=1688060857&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.10607, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.05833", "ticker_sentiment_score": "-0.023275", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.116348", "ticker_sentiment_score": "0.006929", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.05833", "ticker_sentiment_score": "0.049974", "ticker_sentiment_label": "Neutral"}]}, {"title": "$11M Bet On This Healthcare Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying - AlloVir  ( NASDAQ:ALVR ) , Augusta Gold  ( OTC:AUGG ) ", "url": "https://www.benzinga.com/trading-ideas/long-ideas/23/06/33055165/11m-bet-on-this-healthcare-stock-check-out-these-3-penny-stocks-insiders-are-aggressivel", "time_published": "20230629T101525", "authors": ["Lisa Levin"], "summary": "The Dow Jones closed lower on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/29/image46.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}], "overall_sentiment_score": 0.344088, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HLLY", "relevance_score": "0.560594", "ticker_sentiment_score": "0.322887", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALVR", "relevance_score": "0.560594", "ticker_sentiment_score": "0.38208", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.122894", "ticker_sentiment_score": "0.187089", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ICNB", "relevance_score": "0.122894", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Medical Stocks to Consider Buying in June", "url": "https://www.zacks.com/stock/news/2114516/2-medical-stocks-to-consider-buying-in-june", "time_published": "20230629T000800", "authors": ["Zacks Investment Research"], "summary": "With solid top and bottom-line growth on the horizon for HealthEquity (HQY) and iRadimed (IRMD), they are starting to look like viable investments for 2023 and beyond.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/40/4066.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.917436"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.294465, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HQY", "relevance_score": "0.362065", "ticker_sentiment_score": "0.515934", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.275867", "ticker_sentiment_score": "-0.120834", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.275867", "ticker_sentiment_score": "-0.120834", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ominous Death Cross Forms On Gilead Sciences's Chart - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/markets/23/06/33044412/ominous-death-cross-forms-on-gilead-sciencess-chart", "time_published": "20230628T144805", "authors": ["Benzinga Insights"], "summary": "If history is any guide, there may be trouble ahead for shares of Gilead Sciences GILD. A so-called \"death cross\" has formed on its chart and, not surprisingly, this could be bearish for the stock. What To Know: Many traders use moving average crossover systems to make their decisions.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_2.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.016834, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.561184", "ticker_sentiment_score": "-0.458171", "ticker_sentiment_label": "Bearish"}]}, {"title": "BNGO: Should You Watch Bionano Genomics  ( BNGO )  this Week?", "url": "https://stocknews.com/news/bngo-alks-gild-biib-should-you-watch-bionano-genomics-bngo-this-week/", "time_published": "20230627T162238", "authors": [], "summary": "Genomic testing equipment manufacturer Bionano Genomics, Inc. ( BNGO ) is gaining traction with its third-generation optical mapping solution, Saphyr, which offers advanced capabilities crucial for genome research.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/shutterstock_757996678-1-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}], "overall_sentiment_score": 0.158957, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BNGO", "relevance_score": "0.68781", "ticker_sentiment_score": "0.303132", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.084722", "ticker_sentiment_score": "0.207885", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALKS", "relevance_score": "0.084722", "ticker_sentiment_score": "0.207885", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.084722", "ticker_sentiment_score": "0.207885", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "GILD: 3 Biotech Stocks With Some Major Value in Them", "url": "https://stocknews.com/news/gild-biib-alks-rcus-dnli-3-biotech-stocks-with-some-major-value-in-them/", "time_published": "20230627T121456", "authors": [], "summary": "The biotech sector assumes a crucial role in propelling the advancement of healthcare by spearheading the creation of innovative therapies and technologies aimed at addressing unmet medical requirements.", "banner_image": "https://stocknews.com/wp-content/uploads/2023/01/ISt_Biotechnology.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999922"}], "overall_sentiment_score": 0.1752, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RCUS", "relevance_score": "0.058903", "ticker_sentiment_score": "-0.070128", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.288214", "ticker_sentiment_score": "-0.032922", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.260498", "ticker_sentiment_score": "0.178042", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.232439", "ticker_sentiment_score": "0.087244", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.058903", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "BJ's Wholesale Club, Verint Systems And 2 Other Stocks Insiders Are Selling - BJ's Wholesale Club  ( NYSE:BJ ) , Arcus Biosciences  ( NYSE:RCUS ) ", "url": "https://www.benzinga.com/news/23/06/33020762/bjs-wholesale-club-verint-systems-and-2-other-stocks-insiders-are-selling", "time_published": "20230627T115828", "authors": ["Lisa Levin"], "summary": "The S&P 500 closed lower on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/27/bjs_wholesale_-_logo_copy.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.181119, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BJ", "relevance_score": "0.461283", "ticker_sentiment_score": "0.143512", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCUS", "relevance_score": "0.461283", "ticker_sentiment_score": "-0.202151", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "VRNT", "relevance_score": "0.461283", "ticker_sentiment_score": "0.663618", "ticker_sentiment_label": "Bullish"}, {"ticker": "WRBY", "relevance_score": "0.461283", "ticker_sentiment_score": "0.500004", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.097854", "ticker_sentiment_score": "-0.212307", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Gilead Sciences  ( GILD )  Dips More Than Broader Markets: What You Should Know", "url": "https://www.zacks.com/stock/news/2113303/gilead-sciences-gild-dips-more-than-broader-markets-what-you-should-know", "time_published": "20230626T220021", "authors": ["Zacks Investment Research"], "summary": "Gilead Sciences (GILD) closed the most recent trading day at $76.56, moving -1.17% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default90.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.191433, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.532556", "ticker_sentiment_score": "0.224336", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Antibody-drug Conjugates Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain", "url": "https://www.prnewswire.com/news-releases/antibody-drug-conjugates-clinical-trial-pipeline-experiences-momentum-delveinsight-estimates-a-diverse-pipeline-comprising-180-companies-working-in-the-domain-301862784.html", "time_published": "20230626T210100", "authors": ["LLP", "DelveInsight Business Research"], "summary": "Antibody-drug Conjugates Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.062676, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MGNX", "relevance_score": "0.041791", "ticker_sentiment_score": "0.070986", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASAN", "relevance_score": "0.041791", "ticker_sentiment_score": "0.038751", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRNEQ", "relevance_score": "0.062651", "ticker_sentiment_score": "0.023001", "ticker_sentiment_label": "Neutral"}, {"ticker": "GMAB", "relevance_score": "0.020903", "ticker_sentiment_score": "0.064977", "ticker_sentiment_label": "Neutral"}, {"ticker": "IGMS", "relevance_score": "0.020903", "ticker_sentiment_score": "0.063178", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.020903", "ticker_sentiment_score": "0.116206", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMGN", "relevance_score": "0.145521", "ticker_sentiment_score": "0.031689", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.041791", "ticker_sentiment_score": "0.034859", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADCT", "relevance_score": "0.266604", "ticker_sentiment_score": "0.085501", "ticker_sentiment_label": "Neutral"}, {"ticker": "IRON", "relevance_score": "0.020903", "ticker_sentiment_score": "0.116206", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.020903", "ticker_sentiment_score": "0.064977", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.041791", "ticker_sentiment_score": "0.034859", "ticker_sentiment_label": "Neutral"}, {"ticker": "PKBO", "relevance_score": "0.041791", "ticker_sentiment_score": "0.038751", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMER", "relevance_score": "0.041791", "ticker_sentiment_score": "0.127136", "ticker_sentiment_label": "Neutral"}, {"ticker": "ELDN", "relevance_score": "0.020903", "ticker_sentiment_score": "0.116206", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.062651", "ticker_sentiment_score": "0.067013", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKESF", "relevance_score": "0.020903", "ticker_sentiment_score": "0.063178", "ticker_sentiment_label": "Neutral"}, {"ticker": "STRO", "relevance_score": "0.062651", "ticker_sentiment_score": "0.023001", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.041791", "ticker_sentiment_score": "0.034859", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.104228", "ticker_sentiment_score": "0.00218", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.083468", "ticker_sentiment_score": "0.037756", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.083468", "ticker_sentiment_score": "-0.023781", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead  ( GILD )  Breast Cancer Drug Gets Positive CHMP Opinion", "url": "https://www.zacks.com/stock/news/2113218/gilead-gild-breast-cancer-drug-gets-positive-chmp-opinion", "time_published": "20230626T164800", "authors": ["Zacks Investment Research"], "summary": "Gilead's breast cancer drug Trodelvy gets positive CHMP opinion for a second indication in Europe.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c9/2325.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.002459, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.173333", "ticker_sentiment_score": "0.08918", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGND", "relevance_score": "0.215702", "ticker_sentiment_score": "0.084843", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.087185", "ticker_sentiment_score": "-0.017889", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Low-Priced Stocks That Could Make You Richer", "url": "https://www.fool.com/investing/2023/06/26/2-low-priced-stocks-that-could-make-you-richer/", "time_published": "20230626T141500", "authors": ["George Budwell"], "summary": "These two low-priced healthcare stocks could skyrocket within the next 12 months.", "banner_image": "https://media.ycharts.com/charts/dc3bcde4da57b1e2e3e5948764230ce8.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.218681, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AGEN", "relevance_score": "0.350564", "ticker_sentiment_score": "0.129383", "ticker_sentiment_label": "Neutral"}, {"ticker": "VKTX", "relevance_score": "0.051774", "ticker_sentiment_score": "0.198561", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INCY", "relevance_score": "0.051774", "ticker_sentiment_score": "0.066592", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.051774", "ticker_sentiment_score": "0.066592", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACRS", "relevance_score": "0.154455", "ticker_sentiment_score": "0.048157", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXSM", "relevance_score": "0.051774", "ticker_sentiment_score": "0.198561", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.051774", "ticker_sentiment_score": "0.066592", "ticker_sentiment_label": "Neutral"}]}, {"title": "Our early-adopters index examines how corporate America is deploying AI", "url": "https://www.economist.com/business/2023/06/25/our-early-adopters-index-examines-how-corporate-america-is-deploying-ai", "time_published": "20230625T184927", "authors": [], "summary": "T are having a bumper year. Despite a recent wobble, the share price of the Big Five-Alphabet, Amazon, Apple, Meta and Microsoft-has jumped by 60% since January, when measured in an equally weighted basket ( see chart 1 ) . The price of shares in one big chipmaker, Nvidia, has tripled and in ...", "banner_image": "https://www.economist.com/img/b/1280/826/90/media-assets/image/20230701_WBC620.png", "source": "The Economist", "category_within_source": "BusinessGoogleRSS", "source_domain": "www.economist.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.795202"}], "overall_sentiment_score": 0.181672, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.044676", "ticker_sentiment_score": "0.105334", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRMNF", "relevance_score": "0.022347", "ticker_sentiment_score": "0.166032", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.06697", "ticker_sentiment_score": "0.024111", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.022347", "ticker_sentiment_score": "0.089748", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLDAF", "relevance_score": "0.022347", "ticker_sentiment_score": "0.089748", "ticker_sentiment_label": "Neutral"}, {"ticker": "NKE", "relevance_score": "0.022347", "ticker_sentiment_score": "0.109735", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALGN", "relevance_score": "0.022347", "ticker_sentiment_score": "0.068325", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.06697", "ticker_sentiment_score": "0.083306", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSNLF", "relevance_score": "0.044676", "ticker_sentiment_score": "-0.061453", "ticker_sentiment_label": "Neutral"}, {"ticker": "STT", "relevance_score": "0.022347", "ticker_sentiment_score": "0.177931", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.022347", "ticker_sentiment_score": "0.068325", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.044676", "ticker_sentiment_score": "0.12563", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.022347", "ticker_sentiment_score": "0.025899", "ticker_sentiment_label": "Neutral"}, {"ticker": "PG", "relevance_score": "0.022347", "ticker_sentiment_score": "0.109735", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.022347", "ticker_sentiment_score": "0.068325", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.022347", "ticker_sentiment_score": "0.068325", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.022347", "ticker_sentiment_score": "0.177931", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Big Pharma Vs. Washington-An Opportunity To Buy Bristol Myers", "url": "https://www.forbes.com/sites/johnbuckingham/2023/06/23/big-pharma-vs-washington-an-opportunity-to-buy-bristol-myers/", "time_published": "20230623T222712", "authors": ["John Buckingham"], "summary": "After all, news broke on Friday that Bristol Myers Squibb has sued Uncle Sam over a Medicare price renegotiation program in the Inflation Reduction Act (IRA) that was ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6495f73568965ad5158daaa0/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "Money", "source_domain": "www.forbes.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Earnings", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.043288, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.043738", "ticker_sentiment_score": "0.032788", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.043738", "ticker_sentiment_score": "0.032788", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.087344", "ticker_sentiment_score": "0.014494", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.257895", "ticker_sentiment_score": "-0.060428", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.043738", "ticker_sentiment_score": "0.032788", "ticker_sentiment_label": "Neutral"}]}, {"title": "Mirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director", "url": "https://www.prnewswire.com/news-releases/mirati-therapeutics-appoints-industry-veteran-carol-gallagher-pharmd-as-new-independent-director-301861168.html", "time_published": "20230623T200000", "authors": ["Inc.", "Mirati Therapeutics"], "summary": "SAN DIEGO, June 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.\u00ae ( NASDAQ: MRTX ) , a commercial stage biotechnology company, today announced its Board of Directors has appointed a new independent director, Dr. Carol Gallagher.", "banner_image": "https://mma.prnewswire.com/media/341355/Mirati_Tx_v2_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.120987, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.054483", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.054483", "ticker_sentiment_score": "0.016926", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATRA", "relevance_score": "0.054483", "ticker_sentiment_score": "0.016926", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.267413", "ticker_sentiment_score": "0.178695", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.054483", "ticker_sentiment_score": "0.016926", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.054483", "ticker_sentiment_score": "0.016926", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Announces Positive HDV Treatment Data", "url": "https://www.zacks.com/stock/news/2112576/gilead-sciences-gild-announces-positive-hdv-treatment-data", "time_published": "20230623T165800", "authors": ["Zacks Investment Research"], "summary": "Gilead Sciences, Inc. (GILD) announces data on Hepcludex that reinforces the potential of bulevirtide as an effective and well-tolerated treatment for chronic HDV after 96 weeks.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default298.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.088903, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LGND", "relevance_score": "0.315628", "ticker_sentiment_score": "0.11534", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.129168", "ticker_sentiment_score": "-0.138049", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead's Chronic Hepatitis Delta Infection Treatment Shows Sustained Efficacy, Safety Profile At Two Years - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/general/biotech/23/06/32984439/gileads-chronic-hepatitis-delta-infection-treatment-shows-sustained-efficacy-safety-profile-at-tw", "time_published": "20230623T143816", "authors": ["Vandana Singh"], "summary": "Gilead Sciences Inc GILD announced Week 96 results from the MYR301 Phase 3 clinical trial evaluating bulevirtide for chronic hepatitis delta ( HDV ) infection. Bulevirtide is the only approved treatment for HDV in Europe and is not approved in the U.S.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/23/gild.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.119774, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.479683", "ticker_sentiment_score": "-0.20884", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "GILD: 3 Biotech Stocks Every Investor Wants", "url": "https://stocknews.com/news/gild-biib-alks-3-biotech-stocks-every-investor-wants/", "time_published": "20230621T161943", "authors": [], "summary": "The biotech sector is expanding due to innovations and robust demand. Furthermore, the biotech sector enjoys inelastic demand for its products and services and is relatively stable in the face of economic uncertainty.", "banner_image": "https://stocknews.com/wp-content/uploads/2023/01/ISt_Biotechnology.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.996023"}], "overall_sentiment_score": 0.208038, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALKS", "relevance_score": "0.368773", "ticker_sentiment_score": "0.19747", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.152258", "ticker_sentiment_score": "0.083183", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.299022", "ticker_sentiment_score": "0.27677", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Arcellx  ( RCLX )  Down on Hold for Lead Program CART-ddBCMA", "url": "https://www.zacks.com/stock/news/2111331/arcellx-rclx-down-on-hold-for-lead-program-cart-ddbcma", "time_published": "20230621T143800", "authors": ["Zacks Investment Research"], "summary": "Arcellx's (ACLX) study on lead program CART-ddBCMA for treating adult patients with relapsed or refractory multiple myeloma has been put on hold by the FDA. The company's shares decline on the same.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default71.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.207385, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.746902", "ticker_sentiment_score": "0.303396", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SHGI", "relevance_score": "0.075874", "ticker_sentiment_score": "0.068235", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGND", "relevance_score": "0.366061", "ticker_sentiment_score": "0.178739", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.151064", "ticker_sentiment_score": "0.168445", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2 Biotech Stocks You Can Buy and Hold for the Next Decade", "url": "https://www.fool.com/investing/2023/06/21/2-biotech-stocks-you-can-buy-and-hold-for-the-next/", "time_published": "20230621T122200", "authors": ["Jim Halley"], "summary": "Gilead and Regeneron Pharmaceuticals both had triple-digit percentage growth over the past decade.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F736572%2Fgrowth-4.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999975"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.195269, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.08609", "ticker_sentiment_score": "0.130467", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.08609", "ticker_sentiment_score": "0.130467", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.08609", "ticker_sentiment_score": "0.077705", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Dips More Than Broader Markets: What You Should Know", "url": "https://www.zacks.com/stock/news/2110861/gilead-sciences-gild-dips-more-than-broader-markets-what-you-should-know", "time_published": "20230620T220022", "authors": ["Zacks Investment Research"], "summary": "Gilead Sciences (GILD) closed the most recent trading day at $77.71, moving -1.46% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default58.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.177402, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.48724", "ticker_sentiment_score": "0.152852", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The 'Perfect Storm' That Led To A Patient Death And Arcellx's Dive", "url": "https://www.investors.com/news/technology/aclx-stock-plunges-after-perfect-storm-leads-to-patient-death-in-cancer-drug-study/", "time_published": "20230620T143800", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "ACLX Stock Plunges After 'Perfect Storm' Leads To Patient Death In ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/stock-BioTech-04-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99793"}], "overall_sentiment_score": 0.143293, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.801457", "ticker_sentiment_score": "0.162111", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.136113", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LEGN", "relevance_score": "0.136113", "ticker_sentiment_score": "0.088358", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.136113", "ticker_sentiment_score": "0.088358", "ticker_sentiment_label": "Neutral"}]}, {"title": "Arcellx's Lead Product Candidate Hit By FDA Clinical Hold For Multiple Myeloma, Stock Falls - Arcellx  ( NASDAQ:ACLX ) ", "url": "https://www.benzinga.com/general/biotech/23/06/32918224/arcellxs-lead-product-candidate-hit-by-fda-clinical-hold-for-multiple-myeloma-stock-falls", "time_published": "20230620T121918", "authors": ["Vandana Singh"], "summary": "The FDA has put a clinical hold on Arcellx Inc's ACLX iMMagine-1 Phase 2 clinical program for CART-ddBCMA investigational new drug for relapsed or refractory multiple myeloma. Arcellx's lead product candidate, CART-ddBCMA, has been granted Fast Track, Orphan Drug, and Regenerative Medicine ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/20/aclx.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.158096, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.760593", "ticker_sentiment_score": "0.157571", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSVT", "relevance_score": "0.305058", "ticker_sentiment_score": "0.178441", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.305058", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Veralox Names Jonathan Mow as Chief Executive Officer as the Company Advances Development of First-in-Class Therapies for Immune-Mediated Diseases in Conjunction with Financing", "url": "https://www.benzinga.com/pressreleases/23/06/g32918968/veralox-names-jonathan-mow-as-chief-executive-officer-as-the-company-advances-development-of-first", "time_published": "20230620T110000", "authors": ["Globe Newswire"], "summary": "-- New Financing of $24 Million Fully Funds the Phase 2 Clinical Program for Lead Candidate VLX-1005 -- Company Prepares to Evaluate VLX-1005 in Heparin-Induced Thrombocytopenia ( HIT )", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.212744, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.066784", "ticker_sentiment_score": "-0.058092", "ticker_sentiment_label": "Neutral"}, {"ticker": "PHASQ", "relevance_score": "0.066784", "ticker_sentiment_score": "0.108237", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.1331", "ticker_sentiment_score": "-0.068716", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.066784", "ticker_sentiment_score": "0.035173", "ticker_sentiment_label": "Neutral"}]}, {"title": "Big Pharma Vs. Washington - An Opportunity To Buy Merck & Co.  ( MRK ) ", "url": "https://www.forbes.com/sites/johnbuckingham/2023/06/19/big-pharma-vs-washingtonan-opportunity-to-buy-merck--co-mrk/", "time_published": "20230619T233434", "authors": ["John Buckingham"], "summary": "Warren Buffett states, \"Uncertainty is the friend of the buyer of long-term values,\" and Washington represents a big question mark these days for the pharma sector.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6490a7c2a0a8c8b02d8daaa0/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Money", "source_domain": "www.forbes.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Earnings", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.053346, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.051886", "ticker_sentiment_score": "0.033", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.103554", "ticker_sentiment_score": "0.006637", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.051886", "ticker_sentiment_score": "0.033", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.051886", "ticker_sentiment_score": "-0.232646", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.051886", "ticker_sentiment_score": "0.033", "ticker_sentiment_label": "Neutral"}]}, {"title": "Anti-Ageing Drugs Market to Amass Notable Gains by 2029 Says Brandessence Market Research", "url": "https://www.prnewswire.com/news-releases/anti-ageing-drugs-market-to-amass-notable-gains-by-2029-says-brandessence-market-research-301851923.html", "time_published": "20230615T140100", "authors": ["Brandessence Market Research and Consulting Private Limited"], "summary": "LONDON, June 15, 2023 /PRNewswire/ -- The body undergoes numerous changes as people age. They eventually start showing signs of ageing and become susceptible to numerous diseases.", "banner_image": "https://mma.prnewswire.com/media/1392316/BEMR_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.280994, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.023933", "ticker_sentiment_score": "0.100746", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.023933", "ticker_sentiment_score": "0.100746", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.023933", "ticker_sentiment_score": "0.100746", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRLCF", "relevance_score": "0.023933", "ticker_sentiment_score": "0.093007", "ticker_sentiment_label": "Neutral"}, {"ticker": "RVNC", "relevance_score": "0.023933", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.023933", "ticker_sentiment_score": "0.093007", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Antitrust Loophole That Keeps Generic Drugs Off the Market", "url": "https://www.theatlantic.com/ideas/archive/2023/06/pharmaceutical-generic-drugs-pay-for-delay/674410/", "time_published": "20230615T110000", "authors": ["Sandeep Vaheesan"], "summary": "Pay for Delay: Big Pharma's Most Maddening Business Tactic The Atlantic ...", "banner_image": "https://cdn.theatlantic.com/thumbor/vbn7RhgUi5Q7cVL86smpLmQDCUU=/0x0:2500x1406/960x540/media/img/mt/2023/06/pharma/original.jpg", "source": "The Atlantic", "category_within_source": "n/a", "source_domain": "www.theatlantic.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.019676, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.024801", "ticker_sentiment_score": "-0.023173", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biomarkers Market to Grow Significantly by 2029- Brandessence Market Research", "url": "https://www.prnewswire.com/news-releases/biomarkers-market-to-grow-significantly-by-2029--brandessence-market-research-301851886.html", "time_published": "20230615T104000", "authors": ["Brandessence Market Research and Consulting Private Limited"], "summary": "LONDON, June 15, 2023 /PRNewswire/ -- Biomarkers are referred to as a type of measurable biological indicators or characteristics found in body tissues or fluids like blood.", "banner_image": "https://mma.prnewswire.com/media/1392316/BEMR_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.254892, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ILMN", "relevance_score": "0.023861", "ticker_sentiment_score": "-0.056634", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.023861", "ticker_sentiment_score": "0.224063", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.023861", "ticker_sentiment_score": "0.109009", "ticker_sentiment_label": "Neutral"}, {"ticker": "QGEN", "relevance_score": "0.023861", "ticker_sentiment_score": "0.224063", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.023861", "ticker_sentiment_score": "0.109009", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.023861", "ticker_sentiment_score": "0.109009", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.023861", "ticker_sentiment_score": "0.109009", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Outpaces Stock Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2107888/gilead-sciences-gild-outpaces-stock-market-gains-what-you-should-know", "time_published": "20230613T220022", "authors": ["Zacks Investment Research"], "summary": "Gilead Sciences (GILD) closed the most recent trading day at $78.45, moving +0.76% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default326.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.193843, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.481177", "ticker_sentiment_score": "0.340516", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Dallas Southern Pride Announces the 2023 Juneteenth Unity Weekend Celebration, June 16-18", "url": "https://www.benzinga.com/pressreleases/23/06/n32834051/dallas-southern-pride-announces-the-2023-juneteenth-unity-weekend-celebration-june-16-18", "time_published": "20230613T125548", "authors": ["PRNewswire"], "summary": "More than 10K people expected to attend star-studded event that will feature some of the biggest names in hip-hop and entertainment. DALLAS, June 13, 2023 /PRNewswire/ -- Dallas Southern Pride will host its highly anticipated annual Juneteenth Unity Weekend Celebration, June 16-18, 2023.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.540366, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.082111", "ticker_sentiment_score": "0.229532", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Cancer Biologics Market Set to Surpass USD 185.0 Bn by 2031 Driven by Increasing Cancer Prevalence and Biotechnology Innovations, Reveals TMR Study", "url": "https://www.benzinga.com/pressreleases/23/06/g32831132/cancer-biologics-market-set-to-surpass-usd-185-0-bn-by-2031-driven-by-increasing-cancer-prevalence", "time_published": "20230613T103000", "authors": ["Globe Newswire"], "summary": "Wilmington, Delaware, United States, June 13, 2023 ( GLOBE NEWSWIRE ) -- The global cancer biologics market was valued at US$ 94.5 Bn in 2022. It is projected to expand at a CAGR of 7.7% from 2023 to 2031.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": -0.017463, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BMY", "relevance_score": "0.043264", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.043264", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RSSS", "relevance_score": "0.043264", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Arvinas, Inc.  ( ARVN )  Moves 17.5% Higher: Will This Strength Last?", "url": "https://www.zacks.com/stock/news/2107394/arvinas-inc-arvn-moves-175-higher-will-this-strength-last", "time_published": "20230613T085100", "authors": ["Zacks Investment Research"], "summary": "Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default344.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.143787, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "0.09402", "ticker_sentiment_score": "0.005336", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARVN", "relevance_score": "0.591634", "ticker_sentiment_score": "0.160471", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.276909", "ticker_sentiment_score": "-0.098204", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILD: 2 Game-Changing Biotech Stocks, 1 to Sell Now", "url": "https://stocknews.com/news/gild-regn-ttnp-rcus-2-game-changing-biotech-stocks-1-to-sell-now/", "time_published": "20230612T152355", "authors": [], "summary": "Progress in the personalized medicines sector and the adoption of new avenues for biotechnology applications are boosting the biotech industry. However, concerns such as economic slowdowns and geopolitical risks might hamper its growth.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/Biotech-Lg_FB.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999995"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.150451, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RCUS", "relevance_score": "0.105759", "ticker_sentiment_score": "-0.078982", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.342329", "ticker_sentiment_score": "0.236632", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.243585", "ticker_sentiment_score": "0.16252", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TTNP", "relevance_score": "0.209668", "ticker_sentiment_score": "0.110697", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biogen rises as FDA panel backs Alzheimer's drug, easing safety concerns", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-rises-fda-panel-backs-alzheimers-drug-easing-safety-concerns-2023-06-12/", "time_published": "20230612T102614", "authors": ["Reuters"], "summary": "Biogen rises as FDA panel backs Alzheimer's drug, easing safety ... ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/OI4G2TQGONMKZKDRKMQZ4ANLIQ.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.253448, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.155451", "ticker_sentiment_score": "0.00944", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.155451", "ticker_sentiment_score": "0.201333", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.305058", "ticker_sentiment_score": "0.30554", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.155451", "ticker_sentiment_score": "0.00944", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Top Biotech Stocks to Buy in June", "url": "https://www.fool.com/investing/2023/06/09/2-top-biotech-stocks-to-buy-in-june/", "time_published": "20230609T141500", "authors": ["Jim Halley"], "summary": "Both companies have solid therapy franchises and continue to expand their horizons.", "banner_image": "https://media.ycharts.com/charts/2f6fdb2bcfab02a3b6cc6ea87b53620e.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.98396"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.938793"}], "overall_sentiment_score": 0.206466, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.145437", "ticker_sentiment_score": "0.113764", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.145437", "ticker_sentiment_score": "0.227388", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead Sciences Shows Rising Relative Strength; Still Shy Of Key Threshold", "url": "https://www.investors.com/ibd-data-stories/gilead-sciences-shows-rising-relative-strength-still-shy-of-key-threshold/", "time_published": "20230609T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Gilead Sciences Shows Rising Relative Strength. Still Shy Of Key ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.416553, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ARCT", "relevance_score": "0.285526", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSA", "relevance_score": "0.285526", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.639616", "ticker_sentiment_score": "0.641536", "ticker_sentiment_label": "Bullish"}]}, {"title": "GILD: Buy, Hold or Sell? Gilead Sciences Inc.  ( GILD )  and Moderna Inc.  ( MRNA ) ", "url": "https://stocknews.com/news/gild-mrna-buy-hold-or-sell-gilead-sciences-inc-gild-and-moderna/", "time_published": "20230608T154512", "authors": [], "summary": "GILD: Buy, Hold or Sell? Gilead Sciences Inc. ( GILD ) and Moderna ... ...", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/shutterstock_1924266296-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.986714"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.168945, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.244354", "ticker_sentiment_score": "0.276288", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.381463", "ticker_sentiment_score": "0.205174", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead Sciences  ( GILD )  Stock Moves -0.16%: What You Should Know", "url": "https://www.zacks.com/stock/news/2105402/gilead-sciences-gild-stock-moves--016-what-you-should-know", "time_published": "20230607T215011", "authors": ["Zacks Investment Research"], "summary": "Gilead Sciences (GILD) closed the most recent trading day at $76.08, moving -0.16% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default295.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.147872, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.610329", "ticker_sentiment_score": "0.203207", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/earnings/23/06/32739292/heres-how-much-1000-invested-in-gilead-sciences-20-years-ago-would-be-worth-today", "time_published": "20230606T143033", "authors": ["Benzinga Insights"], "summary": "Gilead Sciences GILD has outperformed the market over the past 20 years by 5.38% on an annualized basis producing an average annual return of 12.94%. Currently, Gilead Sciences has a market capitalization of $95.57 billion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Gilead  ( GILD ) , Arcus Announce Results From Mid-Stage NSCLC Study", "url": "https://www.zacks.com/stock/news/2104052/gilead-gild-arcus-announce-results-from-mid-stage-nsclc-study", "time_published": "20230605T185900", "authors": ["Zacks Investment Research"], "summary": "Gilead (GILD) and Arcus announce data from the interim analysis of the mid-stage ARC-7 study on domvanalimab in the NSCLC study.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default70.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.143955, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.048523", "ticker_sentiment_score": "0.056309", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCUS", "relevance_score": "0.096866", "ticker_sentiment_score": "-0.085809", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGND", "relevance_score": "0.23907", "ticker_sentiment_score": "0.045258", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.096866", "ticker_sentiment_score": "-0.085809", "ticker_sentiment_label": "Neutral"}]}, {"title": "ASCO News Comes Fast And Furious: ImmunoGen, Day One Surge", "url": "https://www.investors.com/news/technology/imgn-stock-why-this-perfectly-rated-biotech-just-soared-again/", "time_published": "20230605T144900", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "IMGN Stock: Why This Perfectly Rated Biotech Just Soared, Again Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/IT03_ImmunoGen_060523news.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999956"}], "overall_sentiment_score": 0.087458, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RCUS", "relevance_score": "0.139265", "ticker_sentiment_score": "-0.065717", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.139265", "ticker_sentiment_score": "-0.065717", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAWN", "relevance_score": "0.339046", "ticker_sentiment_score": "0.310261", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.139265", "ticker_sentiment_score": "-0.065717", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONBI", "relevance_score": "0.0699", "ticker_sentiment_score": "0.0562", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.0699", "ticker_sentiment_score": "-0.055632", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sir Elton John Joins Forces with Donatella Versace and Other Notable Philanthropists to Announce $125 Million Rocket Fund to End AIDS For All", "url": "https://www.benzinga.com/pressreleases/23/06/n32715769/sir-elton-john-joins-forces-with-donatella-versace-and-other-notable-philanthropists-to-announce-1", "time_published": "20230605T133000", "authors": ["PRNewswire"], "summary": "Stars lead the charge on social media to let their 'Inner Elton' out and take a stand for equality by encouraging everyone to be their true selves", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.133801, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.04076", "ticker_sentiment_score": "0.124807", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Dividend Stocks You Can Buy Without Any Hesitation", "url": "https://www.fool.com/investing/2023/06/03/3-dividend-stocks-you-can-buy-without-hesitation/", "time_published": "20230603T101400", "authors": ["David Jagielski", "and Prosper Junior Bakiny", "Keith Speights"], "summary": "The choices are easy with these stocks.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F734485%2Fbull-market-2.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.992549"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}], "overall_sentiment_score": 0.401944, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "0.305328", "ticker_sentiment_score": "0.397549", "ticker_sentiment_label": "Bullish"}, {"ticker": "BMY", "relevance_score": "0.263467", "ticker_sentiment_score": "0.479562", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.386211", "ticker_sentiment_score": "0.370954", "ticker_sentiment_label": "Bullish"}]}, {"title": "Why The Biotech Buying Bonanza Will Likely Continue", "url": "https://www.investors.com/news/technology/biotech-stocks-are-in-blistering-ma-climate-ftc-could-change-that/", "time_published": "20230602T171700", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Biotech Stocks Are In A 'Blistering' M&A Climate. The FTC Could ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/wJumpB060523.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.94762"}, {"topic": "Earnings", "relevance_score": "0.962106"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.993781"}], "overall_sentiment_score": 0.055036, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.031529", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.031529", "ticker_sentiment_score": "0.163574", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLU", "relevance_score": "0.031529", "ticker_sentiment_score": "-0.045458", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROIV", "relevance_score": "0.031529", "ticker_sentiment_score": "0.161618", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.110028", "ticker_sentiment_score": "-0.017979", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.172097", "ticker_sentiment_score": "0.001427", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARWR", "relevance_score": "0.031529", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IRWD", "relevance_score": "0.031529", "ticker_sentiment_score": "0.117903", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTC", "relevance_score": "0.015767", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.031529", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.031529", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.063008", "ticker_sentiment_score": "0.016034", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCCC", "relevance_score": "0.031529", "ticker_sentiment_score": "-0.058796", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.047278", "ticker_sentiment_score": "0.036401", "ticker_sentiment_label": "Neutral"}, {"ticker": "RPRX", "relevance_score": "0.031529", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.047278", "ticker_sentiment_score": "-0.146624", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALNY", "relevance_score": "0.031529", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "APLS", "relevance_score": "0.031529", "ticker_sentiment_score": "0.066264", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISEE", "relevance_score": "0.031529", "ticker_sentiment_score": "-0.045458", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.015767", "ticker_sentiment_score": "0.089075", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.078714", "ticker_sentiment_score": "-0.025629", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.031529", "ticker_sentiment_score": "0.012717", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.031529", "ticker_sentiment_score": "-0.047297", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARVN", "relevance_score": "0.031529", "ticker_sentiment_score": "-0.058796", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCO", "relevance_score": "0.031529", "ticker_sentiment_score": "0.032413", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.031529", "ticker_sentiment_score": "0.089095", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.015767", "ticker_sentiment_score": "0.110607", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.031529", "ticker_sentiment_score": "0.012628", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXDX", "relevance_score": "0.031529", "ticker_sentiment_score": "0.022789", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.031529", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "BNGO: Is Now the Time to Buy Bionano Genomics  ( BNGO ) ?", "url": "https://stocknews.com/news/bngo-alks-biib-gild-is-now-the-time-to-buy-bionano-genomics-bngo/", "time_published": "20230601T175605", "authors": [], "summary": "Bionano Genomics, Inc. ( BNGO ) is a genome analysis software provider that enables genomics labs to analyze and interpret data across a range of platforms. The company's revenue saw a significant jump in the recent past, increasing at CAGRs of 46.4% and 25.3% over the past three and five years, ...", "banner_image": "https://stocknews.com/wp-content/uploads/2022/01/shutterstock_1551788306-3-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.107846, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BNGO", "relevance_score": "0.784632", "ticker_sentiment_score": "0.186392", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.140485", "ticker_sentiment_score": "0.219421", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALKS", "relevance_score": "0.140485", "ticker_sentiment_score": "0.219421", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.140485", "ticker_sentiment_score": "0.219421", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2 Large Cap Biotech Stocks To Watch Right Now", "url": "https://stockmarket.com/featured/2-large-cap-biotech-stocks-to-watch-right-now-2023-05-31", "time_published": "20230531T202915", "authors": ["Brandon Michael"], "summary": "The biotechnology sector is a rapidly evolving and highly exciting area of the market. The sector focuses on the use of living organisms to make products or run processes. This sector is at the forefront of scientific advancement.", "banner_image": "https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2023/05/AMGN-stock.jpg", "source": "StockMarket.com", "category_within_source": "n/a", "source_domain": "stockmarket.com", "topics": [{"topic": "Earnings", "relevance_score": "0.997874"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}], "overall_sentiment_score": 0.244748, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.319933", "ticker_sentiment_score": "0.27745", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.24289", "ticker_sentiment_score": "0.026505", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Invest in the VanEck Biotech ETF  ( BBH ) ?", "url": "https://www.zacks.com/stock/news/2101737/should-you-invest-in-the-vaneck-biotech-etf-bbh", "time_published": "20230531T102006", "authors": ["Zacks Investment Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default142.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.1363, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.134968", "ticker_sentiment_score": "0.071604", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.134968", "ticker_sentiment_score": "0.071604", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.134968", "ticker_sentiment_score": "0.071604", "ticker_sentiment_label": "Neutral"}]}, {"title": "Drugmakers Released a Ton of New Cancer Treatment Data. The Biggest Developments.", "url": "https://www.barrons.com/articles/pfizer-merck-effector-cancer-treatment-data-a1cfbbd8", "time_published": "20230526T154200", "authors": ["Josh Nathan-Kazis"], "summary": "Pfizer, Merck, eFFECTOR and Other Drugmakers Released New Cancer Treatment Data ...", "banner_image": "https://images.barrons.com/im-789674?width=639&height=426", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.048548, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "0.296761", "ticker_sentiment_score": "-0.135269", "ticker_sentiment_label": "Neutral"}, {"ticker": "EFTR", "relevance_score": "0.151064", "ticker_sentiment_score": "-0.070452", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.151064", "ticker_sentiment_score": "-0.059666", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer's  ( PFE )  COVID-19 Oral Treatment Gets FDA Nod in Adults", "url": "https://www.zacks.com/stock/news/2100448/pfizers-pfe-covid-19-oral-treatment-gets-fda-nod-in-adults", "time_published": "20230526T150800", "authors": ["Zacks Investment Research"], "summary": "Per the FDA, Pfizer's (PFE) Paxlovid is the first oral antiviral pill approved in the United States to treat COVID-19 in adults. The drug was granted emergency use authorization by the FDA in 2021.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.060242, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALLO", "relevance_score": "0.38489", "ticker_sentiment_score": "0.08861", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.442522", "ticker_sentiment_score": "0.029569", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.1331", "ticker_sentiment_score": "0.124314", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead's  ( GILD )  Veklury Gets Positive CHMP View for Extended Use", "url": "https://www.zacks.com/stock/news/2100280/gileads-gild-veklury-gets-positive-chmp-view-for-extended-use", "time_published": "20230526T143000", "authors": ["Zacks Investment Research"], "summary": "Gilead (GILD) obtains positive opinion for the use of Veklury in COVID-19 patients with severe renal impairment, including those on dialysis, from the European Medicines Agency's CHMP.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c9/2325.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.029171, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALLO", "relevance_score": "0.286864", "ticker_sentiment_score": "0.044917", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADMA", "relevance_score": "0.286864", "ticker_sentiment_score": "0.177037", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AKRO", "relevance_score": "0.286864", "ticker_sentiment_score": "0.088731", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.231332", "ticker_sentiment_score": "0.032137", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Roche's 'Meaningful' Results Sent Another Biotech Flying", "url": "https://www.investors.com/news/technology/rcus-stock-roars-higher-on-roche-meaningful-results-in-a-new-cancer-class/", "time_published": "20230526T142700", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "RCUS Stock Roars Higher On Roche's 'Meaningful' Results In A ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/03/stock-pharmaceutical-5-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999822"}], "overall_sentiment_score": -0.036842, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ITOS", "relevance_score": "0.137278", "ticker_sentiment_score": "0.234974", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RCUS", "relevance_score": "0.510838", "ticker_sentiment_score": "0.029746", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.137278", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "CIO Leadership: How Pending SEC Cyber Regulations Will Impact CXOs and the Board Will Power the Discussion at the 2023 New York CISO & Technology Executive Leadership Summit on June 15", "url": "https://www.benzinga.com/pressreleases/23/05/g32578469/cio-leadership-how-pending-sec-cyber-regulations-will-impact-cxos-and-the-board-will-power-the-dis", "time_published": "20230525T153919", "authors": ["Globe Newswire"], "summary": "WESTPORT, Conn., May 25, 2023 ( GLOBE NEWSWIRE ) -- HMG Strategy, the World's #1 digital platform for enabling technology executives to reimagine the enterprise and reshape the business world, is excited to be hosting its 2023 New York CISO & Technology Executive Leadership Summit at The Harvard ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.158239, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PYPL", "relevance_score": "0.028254", "ticker_sentiment_score": "0.156542", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SCGLF", "relevance_score": "0.028254", "ticker_sentiment_score": "-0.313852", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MDLZ", "relevance_score": "0.028254", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPWK", "relevance_score": "0.056474", "ticker_sentiment_score": "0.047006", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNG", "relevance_score": "0.056474", "ticker_sentiment_score": "0.047006", "ticker_sentiment_label": "Neutral"}, {"ticker": "DRKTF", "relevance_score": "0.056474", "ticker_sentiment_score": "0.047006", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTAP", "relevance_score": "0.028254", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "S", "relevance_score": "0.084622", "ticker_sentiment_score": "0.046614", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTNX", "relevance_score": "0.056474", "ticker_sentiment_score": "0.047006", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.084622", "ticker_sentiment_score": "0.046614", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZUO", "relevance_score": "0.028254", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZS", "relevance_score": "0.056474", "ticker_sentiment_score": "0.047006", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.028254", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBGSF", "relevance_score": "0.028254", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.028254", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PANW", "relevance_score": "0.056474", "ticker_sentiment_score": "0.047006", "ticker_sentiment_label": "Neutral"}]}, {"title": "Adverum Biotechnologies Announces New Executive Leadership Roles", "url": "https://www.globenewswire.com/news-release/2023/05/25/2675941/32452/en/Adverum-Biotechnologies-Announces-New-Executive-Leadership-Roles.html", "time_published": "20230525T103000", "authors": ["Inc.", "Adverum Biotechnologies"], "summary": "- Richard Beckman, M.D., chief medical officer, transitions to senior medical advisor ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/aaad6041-1171-4391-8d0f-65f10a3830cd", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.125208, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ADVM", "relevance_score": "0.212814", "ticker_sentiment_score": "0.150702", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.02692", "ticker_sentiment_score": "0.043135", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.02692", "ticker_sentiment_score": "0.043135", "ticker_sentiment_label": "Neutral"}]}, {"title": "Adverum Biotechnologies Announces New Executive Leadership Roles - Adverum Biotechnologies  ( NASDAQ:ADVM ) ", "url": "https://www.benzinga.com/pressreleases/23/05/g32569208/adverum-biotechnologies-announces-new-executive-leadership-roles", "time_published": "20230525T103000", "authors": ["Globe Newswire"], "summary": "- Richard Beckman, M.D., chief medical officer, transitions to senior medical advisor - - Star Seyedkazemi, Pharm.D., chief development officer, expands her responsibilities to lead Adverum's clinical development, medical affairs and pharmacovigilance teams -", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.124735, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ADVM", "relevance_score": "0.177709", "ticker_sentiment_score": "0.130266", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.025596", "ticker_sentiment_score": "0.04281", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.025596", "ticker_sentiment_score": "0.04281", "ticker_sentiment_label": "Neutral"}]}, {"title": "CytoDyn Announces President Takes Medical Leave of Absence - CytoDyn  ( OTC:CYDY ) ", "url": "https://www.benzinga.com/pressreleases/23/05/g32563519/cytodyn-announces-president-takes-medical-leave-of-absence", "time_published": "20230524T210507", "authors": ["Globe Newswire"], "summary": "Antonio Migliarese assumes interim President roleDr. Melissa Palmer appointed interim Chief Medical OfficerDr. Salah Kivlighn joins CytoDyn as clinical and strategic advisor VANCOUVER, Washington, May 24, 2023 ( GLOBE NEWSWIRE ) -- CytoDyn Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.230876, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IPHA", "relevance_score": "0.031696", "ticker_sentiment_score": "0.038658", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.031696", "ticker_sentiment_score": "0.038658", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.063341", "ticker_sentiment_score": "0.108133", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.031696", "ticker_sentiment_score": "0.031881", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.031696", "ticker_sentiment_score": "0.031881", "ticker_sentiment_label": "Neutral"}]}, {"title": "CytoDyn Announces President Takes Medical Leave of Absence", "url": "https://www.globenewswire.com/news-release/2023/05/24/2675727/19782/en/CytoDyn-Announces-President-Takes-Medical-Leave-of-Absence.html", "time_published": "20230524T210500", "authors": ["CytoDyn Inc."], "summary": "Antonio Migliarese assumes interim President roleDr. Melissa Palmer appointed interim Chief Medical OfficerDr. Salah Kivlighn joins CytoDyn as clinical and strategic advisor ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/41cd1342-b084-40b8-8ef3-c69f4bf02d3b", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.241479, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IPHA", "relevance_score": "0.022925", "ticker_sentiment_score": "0.036874", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.022925", "ticker_sentiment_score": "0.036874", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.04583", "ticker_sentiment_score": "0.10978", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.022925", "ticker_sentiment_score": "0.031241", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.022925", "ticker_sentiment_score": "0.031241", "ticker_sentiment_label": "Neutral"}]}, {"title": "TRIBECA FESTIVAL ANNOUNCES 2023 TRIBECA X SPEAKER LINEUP; OFFICIAL SELECTIONS FOR TRIBECA X AWARD", "url": "https://www.benzinga.com/pressreleases/23/05/n32559246/tribeca-festival-announces-2023-tribeca-x-speaker-lineup-official-selections-for-tribeca-x-award", "time_published": "20230524T180000", "authors": ["PRNewswire"], "summary": "KEYNOTE CONVERSATIONS WITH DIANE VON FURSTENBERG; GE'S LINDA BOFF AND GENERAL MOTORS' ALAN WEXLER TUBI'S MARK ROTBLAT IN CONVERSATION WITH VAYNERMEDIA'S GARY VAYNERCHUK. AL ROKER IN CONVERSATION WITH JOHN DEERE'S MARA DOWNING. GRINDR'S GEORGE ARISON IN CONVERSATION WITH GILEAD SCIENCES' ALEX ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.342731, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GRND", "relevance_score": "0.071677", "ticker_sentiment_score": "0.071731", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.071677", "ticker_sentiment_score": "0.166213", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.035875", "ticker_sentiment_score": "0.09852", "ticker_sentiment_label": "Neutral"}, {"ticker": "UAL", "relevance_score": "0.035875", "ticker_sentiment_score": "0.167334", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VZ", "relevance_score": "0.035875", "ticker_sentiment_score": "0.177951", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EXFY", "relevance_score": "0.035875", "ticker_sentiment_score": "0.167334", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GM", "relevance_score": "0.071677", "ticker_sentiment_score": "0.047378", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.035875", "ticker_sentiment_score": "0.177951", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DEO", "relevance_score": "0.035875", "ticker_sentiment_score": "0.167334", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNEJF", "relevance_score": "0.071677", "ticker_sentiment_score": "0.18543", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NCMI", "relevance_score": "0.035875", "ticker_sentiment_score": "0.167334", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NOW", "relevance_score": "0.035875", "ticker_sentiment_score": "0.167334", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PCRFF", "relevance_score": "0.035875", "ticker_sentiment_score": "0.177951", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TEAM", "relevance_score": "0.035875", "ticker_sentiment_score": "0.177951", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.071677", "ticker_sentiment_score": "0.03337", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.035875", "ticker_sentiment_score": "0.050927", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should SPDR Russell 1000 Yield Focus ETF  ( ONEY )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2098829/should-spdr-russell-1000-yield-focus-etf-oney-be-on-your-investing-radar", "time_published": "20230524T102007", "authors": ["Zacks Investment Research"], "summary": "Style Box ETF report for ONEY ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default275.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.240586, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HPQ", "relevance_score": "0.12013", "ticker_sentiment_score": "0.067797", "ticker_sentiment_label": "Neutral"}, {"ticker": "STT", "relevance_score": "0.060236", "ticker_sentiment_score": "0.108002", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.12013", "ticker_sentiment_score": "0.067797", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSX", "relevance_score": "0.12013", "ticker_sentiment_score": "0.067797", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2098310/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now", "time_published": "20230523T102008", "authors": ["Zacks Investment Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default322.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999892"}], "overall_sentiment_score": 0.272138, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.061949", "ticker_sentiment_score": "0.11403", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.123526", "ticker_sentiment_score": "0.068619", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.123526", "ticker_sentiment_score": "0.068619", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.123526", "ticker_sentiment_score": "0.068619", "ticker_sentiment_label": "Neutral"}]}, {"title": "Global Biotechnology Market Size & Share to Surpass $2772.7 Billion by 2030 | Vantage Market Research", "url": "https://www.benzinga.com/pressreleases/23/05/g32509392/global-biotechnology-market-size-share-to-surpass-2772-7-billion-by-2030-vantage-market-research", "time_published": "20230522T142122", "authors": ["Globe Newswire"], "summary": "WASHINGTON, May 22, 2023 ( GLOBE NEWSWIRE ) -- The Global Biotechnology Market is valued at USD 1094.6 Billion in 2022 and is projected to reach a value of USD 2772.7 Billion by 2030 at a CAGR ( Compound Annual Growth Rate ) of 14.2% over the forecast period 2023-2030.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.929393"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.281375, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.025008", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.025008", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.025008", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.025008", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.025008", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.025008", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.025008", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:NANO", "relevance_score": "0.074926", "ticker_sentiment_score": "0.133041", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Relatively Safe Stocks to Buy if a Recession Is on the Way", "url": "https://www.fool.com/investing/2023/05/20/3-relatively-safe-stocks-to-buy-if-a-recession-is/", "time_published": "20230520T101400", "authors": ["Keith Speights", "David Jagielski", "and Prosper Junior Bakiny"], "summary": "If the economy falters, these stocks should hold up better than most.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F733076%2Fbull-market-1.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Earnings", "relevance_score": "0.99676"}], "overall_sentiment_score": 0.109648, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "0.043499", "ticker_sentiment_score": "-0.093027", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.337427", "ticker_sentiment_score": "0.131217", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.043499", "ticker_sentiment_score": "-0.012978", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.214937", "ticker_sentiment_score": "0.045511", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.214937", "ticker_sentiment_score": "-0.11223", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why CymaBay Therapeutics Stock Nose-Dived This Week", "url": "https://www.fool.com/investing/2023/05/19/why-cymabay-therapeutics-stock-nose-dived-this-wee/", "time_published": "20230519T215916", "authors": ["Eric Volkman"], "summary": "Investors did not warmly greet the latest news from the biotech.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F732639%2Fbuffett17-tmf.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.087742, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CBAY", "relevance_score": "0.277433", "ticker_sentiment_score": "-0.188433", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SPGI", "relevance_score": "0.140896", "ticker_sentiment_score": "-0.115353", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.140896", "ticker_sentiment_score": "0.064497", "ticker_sentiment_label": "Neutral"}, {"ticker": "KKPCF", "relevance_score": "0.140896", "ticker_sentiment_score": "0.198501", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Eupraxia Pharmaceuticals Announces Appointment of Dr. Mark Kowalski as Chief Medical Officer", "url": "https://www.newswire.ca/news-releases/eupraxia-pharmaceuticals-announces-appointment-of-dr-mark-kowalski-as-chief-medical-officer-872724205.html", "time_published": "20230518T110000", "authors": ["Eupraxia Pharmaceuticals Inc."], "summary": "Eupraxia Pharmaceuticals Announces Appointment of Dr. Mark ... Canada ...", "banner_image": "", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.128855, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABUS", "relevance_score": "0.028456", "ticker_sentiment_score": "-0.081384", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.028456", "ticker_sentiment_score": "-0.092164", "ticker_sentiment_label": "Neutral"}, {"ticker": "EPRXF", "relevance_score": "0.085223", "ticker_sentiment_score": "0.177002", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GSK", "relevance_score": "0.028456", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Visionary Leadership: Going Beyond Protection to Make Security a Competitive Advantage Will Fuel the Discussion at the 2023 Silicon Valley CISO & Technology Executive Leadership Summit on June 1", "url": "https://www.benzinga.com/pressreleases/23/05/g32447563/visionary-leadership-going-beyond-protection-to-make-security-a-competitive-advantage-will-fuel-th", "time_published": "20230517T150259", "authors": ["Globe Newswire"], "summary": "WESTPORT, Conn., May 17, 2023 ( GLOBE NEWSWIRE ) -- HMG Strategy, the World's #1 digital platform for enabling technology executives to reimagine the enterprise and reshape the business world, is excited to be hosting its 2023 Silicon Valley CISO & Technology Executive Leadership Summit at the ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}], "overall_sentiment_score": 0.158276, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PYPL", "relevance_score": "0.021274", "ticker_sentiment_score": "0.151218", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SCGLF", "relevance_score": "0.021274", "ticker_sentiment_score": "-0.306614", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MDLZ", "relevance_score": "0.021274", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.042534", "ticker_sentiment_score": "-0.195034", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "UPWK", "relevance_score": "0.063763", "ticker_sentiment_score": "0.060228", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNG", "relevance_score": "0.063763", "ticker_sentiment_score": "0.060228", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRBG", "relevance_score": "0.021274", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DRKTF", "relevance_score": "0.063763", "ticker_sentiment_score": "0.060228", "ticker_sentiment_label": "Neutral"}, {"ticker": "LINC", "relevance_score": "0.021274", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTAP", "relevance_score": "0.021274", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WH", "relevance_score": "0.042534", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "S", "relevance_score": "0.063763", "ticker_sentiment_score": "0.060228", "ticker_sentiment_label": "Neutral"}, {"ticker": "DGX", "relevance_score": "0.021274", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTNX", "relevance_score": "0.063763", "ticker_sentiment_score": "0.060228", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.084947", "ticker_sentiment_score": "0.060192", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZUO", "relevance_score": "0.021274", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZS", "relevance_score": "0.063763", "ticker_sentiment_score": "0.060228", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNGA", "relevance_score": "0.021274", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.021274", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBGSF", "relevance_score": "0.021274", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.021274", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PANW", "relevance_score": "0.063763", "ticker_sentiment_score": "0.060228", "ticker_sentiment_label": "Neutral"}]}, {"title": "A Look Into Gilead Sciences' Debt - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/23/05/32426480/a-look-into-gilead-sciences-debt", "time_published": "20230516T154646", "authors": ["Benzinga Insights"], "summary": "Shares of Gilead Sciences Inc. GILD decreased by 7.18% in the past three months. Before having a look at the importance of debt, let's look at how much debt Gilead Sciences has.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": -0.099386, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.295867", "ticker_sentiment_score": "-0.020668", "ticker_sentiment_label": "Neutral"}]}, {"title": "Abortion pill case heads back to federal appeals court: What's at stake", "url": "https://www.marketwatch.com/story/abortion-pill-case-heads-back-to-federal-appeals-court-whats-at-stake-b3155343", "time_published": "20230516T152300", "authors": ["Eleanor Laise"], "summary": "Case threatens to \"wreak havoc\" on drug development and approval, drugmakers say ...", "banner_image": "https://images.mktw.net/im-782621/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.026692, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "0.098456", "ticker_sentiment_score": "-0.118628", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.098456", "ticker_sentiment_score": "-0.118628", "ticker_sentiment_label": "Neutral"}]}, {"title": "Arcus  ( RCUS )  & Gilead Re-Collaborate for Inflammatory Diseases", "url": "https://www.zacks.com/stock/news/2095860/arcus-rcus-gilead-re-collaborate-for-inflammatory-diseases", "time_published": "20230516T133100", "authors": ["Zacks Investment Research"], "summary": "Arcus (RCUS) surges as it expands its previous research collaboration with partner Gilead, to focus on developing therapies for inflammatory diseases.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b0/290.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.076117, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALLO", "relevance_score": "0.28387", "ticker_sentiment_score": "0.107932", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCUS", "relevance_score": "0.414559", "ticker_sentiment_score": "0.108194", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.28387", "ticker_sentiment_score": "0.091311", "ticker_sentiment_label": "Neutral"}, {"ticker": "OCUP", "relevance_score": "0.28387", "ticker_sentiment_score": "0.066509", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences To Rally Around 28%? Here Are 10 Other Analyst Forecasts For Tuesday - Clene  ( NASDAQ:CLNN ) , Absolute Software  ( NASDAQ:ABST ) ", "url": "https://www.benzinga.com/news/23/05/32419925/gilead-sciences-to-rally-around-28-here-are-10-other-analyst-forecasts-for-tuesday", "time_published": "20230516T122450", "authors": ["Lisa Levin"], "summary": "Morgan Stanley raised the price target for DraftKings Inc. DKNG from $23 to $25. Morgan Stanley analyst Stephen Grambling maintained an Overweight rating. DraftKings shares fell 0.2% to close at $23.49 on Monday. Keefe, Bruyette & Woods boosted the price target for Selective Insurance Group, Inc.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/16/gilead_sciences_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999499"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.179309, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.279015", "ticker_sentiment_score": "-0.200645", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LNC", "relevance_score": "0.279015", "ticker_sentiment_score": "0.006323", "ticker_sentiment_label": "Neutral"}, {"ticker": "XPVVV", "relevance_score": "0.094762", "ticker_sentiment_score": "0.182995", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.188193", "ticker_sentiment_score": "-0.148161", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCA", "relevance_score": "0.279015", "ticker_sentiment_score": "0.113467", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.188193", "ticker_sentiment_score": "0.262322", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MOS", "relevance_score": "0.279015", "ticker_sentiment_score": "-0.188836", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WMG", "relevance_score": "0.279015", "ticker_sentiment_score": "0.267368", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CLNN", "relevance_score": "0.279015", "ticker_sentiment_score": "0.020945", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.279015", "ticker_sentiment_score": "0.487841", "ticker_sentiment_label": "Bullish"}, {"ticker": "TOST", "relevance_score": "0.279015", "ticker_sentiment_score": "0.147045", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABST", "relevance_score": "0.279015", "ticker_sentiment_score": "0.182342", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SIGI", "relevance_score": "0.279015", "ticker_sentiment_score": "0.348905", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Allogeneic Cell Therapy Market is expected to hit USD 1.72 Bn by 2029 at a CAGR of 24.5 percent - says Maximize Market Research", "url": "https://www.benzinga.com/pressreleases/23/05/g32418357/the-allogeneic-cell-therapy-market-is-expected-to-hit-usd-1-72-bn-by-2029-at-a-cagr-of-24-5-percen", "time_published": "20230516T113316", "authors": ["Globe Newswire"], "summary": "Pune, May 16, 2023 ( GLOBE NEWSWIRE ) -- A global healthcare research and business-consulting firm, Maximize Market Research, has published a market intelligence report on the \"Allogeneic Cell Therapy Market\".", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.293343, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GMDA", "relevance_score": "0.020509", "ticker_sentiment_score": "0.408049", "ticker_sentiment_label": "Bullish"}, {"ticker": "BLUE", "relevance_score": "0.041004", "ticker_sentiment_score": "0.292904", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NKTX", "relevance_score": "0.020509", "ticker_sentiment_score": "0.408049", "ticker_sentiment_label": "Bullish"}, {"ticker": "TCRR", "relevance_score": "0.020509", "ticker_sentiment_score": "0.408049", "ticker_sentiment_label": "Bullish"}, {"ticker": "ADAP", "relevance_score": "0.041004", "ticker_sentiment_score": "0.292904", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALLO", "relevance_score": "0.0819", "ticker_sentiment_score": "0.227938", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MESO", "relevance_score": "0.020509", "ticker_sentiment_score": "0.408049", "ticker_sentiment_label": "Bullish"}, {"ticker": "SGMO", "relevance_score": "0.020509", "ticker_sentiment_score": "0.408049", "ticker_sentiment_label": "Bullish"}, {"ticker": "DTIL", "relevance_score": "0.020509", "ticker_sentiment_score": "0.408049", "ticker_sentiment_label": "Bullish"}, {"ticker": "IOVA", "relevance_score": "0.041004", "ticker_sentiment_score": "0.424556", "ticker_sentiment_label": "Bullish"}, {"ticker": "CRTHF", "relevance_score": "0.041004", "ticker_sentiment_score": "0.292904", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MXCT", "relevance_score": "0.020509", "ticker_sentiment_score": "0.408049", "ticker_sentiment_label": "Bullish"}, {"ticker": "TCBP", "relevance_score": "0.020509", "ticker_sentiment_score": "0.408049", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.020509", "ticker_sentiment_score": "0.408049", "ticker_sentiment_label": "Bullish"}, {"ticker": "MBIO", "relevance_score": "0.020509", "ticker_sentiment_score": "0.408049", "ticker_sentiment_label": "Bullish"}]}, {"title": "Aspergillosis Treatment Market is to reach USD 3569.72 Mn by 2029 at a growth rate of 5.4 percent over the forecast period", "url": "https://www.benzinga.com/pressreleases/23/05/g32416515/aspergillosis-treatment-market-is-to-reach-usd-3569-72-mn-by-2029-at-a-growth-rate-of-5-4-percent-", "time_published": "20230516T101655", "authors": ["Globe Newswire"], "summary": "Pune, May 16, 2023 ( GLOBE NEWSWIRE ) -- Maximize Market Research, a global Healthcare market research firm has published a competitive intelligence and market research report on the \"Aspergillosis Treatment Market\". The Aspergillosis Treatment Market size was valued at USD 2470.30 Mn in 2022.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999355"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.294185, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BAYZF", "relevance_score": "0.031159", "ticker_sentiment_score": "0.133497", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.031159", "ticker_sentiment_score": "0.133497", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.031159", "ticker_sentiment_score": "0.133497", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.031159", "ticker_sentiment_score": "0.133497", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.031159", "ticker_sentiment_score": "0.133497", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.031159", "ticker_sentiment_score": "0.133497", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.031159", "ticker_sentiment_score": "0.133497", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.031159", "ticker_sentiment_score": "0.133497", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.031159", "ticker_sentiment_score": "0.133497", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.031159", "ticker_sentiment_score": "0.133497", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.031159", "ticker_sentiment_score": "0.133497", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.031159", "ticker_sentiment_score": "0.133497", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.031159", "ticker_sentiment_score": "0.133497", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.031159", "ticker_sentiment_score": "0.133497", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation", "url": "https://investingnews.com/gilead-sciences-and-arcus-biosciences-expand-partnership-to-include-research-programs-in-inflammation/", "time_published": "20230515T125512", "authors": [], "summary": "Gilead to Have Early Option to Exclusively License Drug Candidates Against up to Four Targets for Inflammatory Diseases -", "banner_image": "https://investingnews.com/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yNTg1ODg1NS9vcmlnaW4ucG5nIiwiZXhwaXJlc19hdCI6MTcwODY4MTIxOX0.Phin9ClvosnPNpkGRdBWHz_VFepTco5fqEYZcXCsZIQ/image.png?width=210", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.796627"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.576289"}], "overall_sentiment_score": 0.04366, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RCUS", "relevance_score": "0.144448", "ticker_sentiment_score": "-0.027054", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.144448", "ticker_sentiment_score": "0.067664", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?", "url": "https://www.zacks.com/stock/news/2095065/should-you-invest-in-the-ishares-biotechnology-etf-ibb", "time_published": "20230515T102009", "authors": ["Zacks Investment Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default205.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.191498, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.069094", "ticker_sentiment_score": "0.03409", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.137671", "ticker_sentiment_score": "0.072354", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.137671", "ticker_sentiment_score": "0.072354", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.137671", "ticker_sentiment_score": "0.072354", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should IQ Chaikin U.S. Large Cap ETF  ( CLRG )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2095060/should-iq-chaikin-us-large-cap-etf-clrg-be-on-your-investing-radar", "time_published": "20230515T102009", "authors": ["Zacks Investment Research"], "summary": "Style Box ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default193.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.184305, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LVS", "relevance_score": "0.125789", "ticker_sentiment_score": "0.069184", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.125789", "ticker_sentiment_score": "0.069184", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.125789", "ticker_sentiment_score": "0.069184", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is SPDR Russell 1000 Yield Focus ETF  ( ONEY )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2095071/is-spdr-russell-1000-yield-focus-etf-oney-a-strong-etf-right-now", "time_published": "20230515T102008", "authors": ["Zacks Investment Research"], "summary": "Smart Beta ETF report for ONEY ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default47.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.283547, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HPQ", "relevance_score": "0.114956", "ticker_sentiment_score": "0.061034", "ticker_sentiment_label": "Neutral"}, {"ticker": "STT", "relevance_score": "0.057628", "ticker_sentiment_score": "0.090962", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.114956", "ticker_sentiment_score": "0.061034", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSX", "relevance_score": "0.114956", "ticker_sentiment_score": "0.061034", "ticker_sentiment_label": "Neutral"}]}, {"title": "Looking Into Gilead Sciences's Recent Short Interest - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/short-sellers/23/05/32369915/looking-into-gilead-sciencess-recent-short-interest", "time_published": "20230512T174528", "authors": ["Benzinga Insights"], "summary": "Gilead Sciences's GILD short percent of float has risen 8.73% since its last report. The company recently reported that it has 15.25 million shares sold short, which is 1.37% of all regular shares that are available for trading.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.267332, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.221819", "ticker_sentiment_score": "0.155473", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "CAGR of 5.6%, Red Biotechnology Market Expected to Surpass USD 609.6 Billion by 2031 - Exclusive Study by TMR", "url": "https://www.benzinga.com/pressreleases/23/05/g32362861/cagr-of-5-6-red-biotechnology-market-expected-to-surpass-usd-609-6-billion-by-2031-exclusive-study", "time_published": "20230512T123000", "authors": ["Globe Newswire"], "summary": "Wilmington, Delaware, United States, May 12, 2023 ( GLOBE NEWSWIRE ) -- The global red biotechnology market size stood at USD 357.2 Bn in 2021 and is anticipated to surpass value of USD 609.6 Bn by 2031. The global industry is anticipated to expand at a CAGR of 5.6% between 2022 and 2031.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.282507, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.044551", "ticker_sentiment_score": "-0.157838", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "REGN", "relevance_score": "0.044551", "ticker_sentiment_score": "-0.157838", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BMY", "relevance_score": "0.044551", "ticker_sentiment_score": "-0.157838", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TAK", "relevance_score": "0.044551", "ticker_sentiment_score": "-0.157838", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Is IQ Chaikin U.S. Large Cap ETF  ( CLRG )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2094534/is-iq-chaikin-us-large-cap-etf-clrg-a-strong-etf-right-now", "time_published": "20230512T102005", "authors": ["Zacks Investment Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default213.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999919"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.235422, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LVS", "relevance_score": "0.113329", "ticker_sentiment_score": "0.066247", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.113329", "ticker_sentiment_score": "0.066247", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.113329", "ticker_sentiment_score": "0.066247", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences Stock: Bear vs. Bull", "url": "https://www.fool.com/investing/2023/05/12/gilead-sciences-stock-bear-vs-bull/", "time_published": "20230512T093000", "authors": ["Adria Cimino"], "summary": "The S&P 500 has outperformed Gilead over the past five years.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F731390%2Fbuffett8-tmf.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.992549"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.213282, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.115509", "ticker_sentiment_score": "0.082309", "ticker_sentiment_label": "Neutral"}]}, {"title": "HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights", "url": "https://www.globenewswire.com/news-release/2023/05/11/2666554/0/en/HOOKIPA-Pharma-Reports-First-Quarter-2023-Financial-Results-and-Recent-Business-Highlights.html", "time_published": "20230511T110100", "authors": ["HOOKIPA Pharma Inc"], "summary": "NEW YORK and VIENNA, May 11, 2023 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( NASDAQ: HOOK, 'HOOKIPA' ) , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the first quarter of 2023.", "banner_image": "https://ml.globenewswire.com/Resource/Download/62ba88bb-8adc-44c4-9fd7-3f6ca365c93d", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.052659, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HOOK", "relevance_score": "0.123526", "ticker_sentiment_score": "0.018777", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.030998", "ticker_sentiment_score": "0.038253", "ticker_sentiment_label": "Neutral"}]}, {"title": "CIO Leadership: HMG Strategy to Recognize Visionary Leaders at Upcoming Executive Leadership Summits in Silicon Valley, Florida, New Jersey and New York", "url": "https://www.benzinga.com/pressreleases/23/05/g32321548/cio-leadership-hmg-strategy-to-recognize-visionary-leaders-at-upcoming-executive-leadership-summit", "time_published": "20230510T163536", "authors": ["Globe Newswire"], "summary": "WESTPORT, Conn., May 10, 2023 ( GLOBE NEWSWIRE ) -- HMG Strategy, the World's #1 digital platform for enabling business technology executives to reimagine the enterprise and reshape the business world, is excited to be recognizing distinguished executives for their visionary leadership at four ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}], "overall_sentiment_score": 0.18732, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PYPL", "relevance_score": "0.016205", "ticker_sentiment_score": "0.146756", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCGLF", "relevance_score": "0.016205", "ticker_sentiment_score": "-0.300352", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MDLZ", "relevance_score": "0.016205", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.016205", "ticker_sentiment_score": "-0.140266", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPWK", "relevance_score": "0.064753", "ticker_sentiment_score": "0.056256", "ticker_sentiment_label": "Neutral"}, {"ticker": "CL", "relevance_score": "0.016205", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNG", "relevance_score": "0.080892", "ticker_sentiment_score": "0.065849", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRBG", "relevance_score": "0.016205", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DRKTF", "relevance_score": "0.064753", "ticker_sentiment_score": "0.056256", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROK", "relevance_score": "0.016205", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LINC", "relevance_score": "0.032403", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTAP", "relevance_score": "0.016205", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WH", "relevance_score": "0.032403", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "S", "relevance_score": "0.048588", "ticker_sentiment_score": "0.061838", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTNX", "relevance_score": "0.064753", "ticker_sentiment_score": "0.056256", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.080892", "ticker_sentiment_score": "0.057602", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZUO", "relevance_score": "0.016205", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UL", "relevance_score": "0.016205", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZS", "relevance_score": "0.064753", "ticker_sentiment_score": "0.056256", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNGA", "relevance_score": "0.016205", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.016205", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBGSF", "relevance_score": "0.016205", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.016205", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PANW", "relevance_score": "0.064753", "ticker_sentiment_score": "0.056256", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech ETFs Pop on M&A Resurgence", "url": "https://www.zacks.com/stock/news/2093665/biotech-etfs-pop-on-ma-resurgence", "time_published": "20230510T163300", "authors": ["Zacks Investment Research"], "summary": "2023 could be a year of heightened biotech dealmaking activity ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default321.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.682689"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.310843"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.084975, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.199859", "ticker_sentiment_score": "0.13748", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLU", "relevance_score": "0.199859", "ticker_sentiment_score": "0.244943", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.199859", "ticker_sentiment_score": "0.13748", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.295867", "ticker_sentiment_score": "-0.325294", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "IVZ", "relevance_score": "0.100729", "ticker_sentiment_score": "0.010937", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXDX", "relevance_score": "0.199859", "ticker_sentiment_score": "0.244943", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.199859", "ticker_sentiment_score": "0.13748", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.295867", "ticker_sentiment_score": "-0.173328", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Gilead Emphasizes Unique Ways To Hire Top Talent", "url": "https://investingnews.com/gilead-emphasizes-unique-ways-to-hire-top-talent/", "time_published": "20230510T125309", "authors": [], "summary": "When Jamari Brooks was looking for a new job last fall, he knew he wanted his future employer to have a few key qualities. As he perused pharmaceutical companies' job postings, he kept a look out for diversity in leadership, the potential for personal career growth and a commitment to helping ...", "banner_image": "https://investingnews.com/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yNTg1ODg1NS9vcmlnaW4ucG5nIiwiZXhwaXJlc19hdCI6MTcwODY4MTIxOX0.Phin9ClvosnPNpkGRdBWHz_VFepTco5fqEYZcXCsZIQ/image.png?width=210", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.304094, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.102013", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Your Wednesday Briefing", "url": "https://www.nytimes.com/2023/05/10/briefing/trump-civil-case-liable.html", "time_published": "20230510T050001", "authors": [], "summary": "A Manhattan jury found Donald Trump liable for sexually abusing and defaming the former magazine writer E. Jean Carroll and awarded her $5 million in damages. More than a dozen women have accused the former president of sexual misconduct over the years, but this is the only allegation to be ...", "banner_image": "https://static01.nyt.com/images/2023/05/09/multimedia/10ambriefing-europe-nl-trump/10ambriefing-europe-nl-trump-articleLarge.jpg?quality=75&auto=webp&disable=upscale", "source": "New York Times", "category_within_source": "GoogleRSS", "source_domain": "www.nytimes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.044178, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.02671", "ticker_sentiment_score": "0.037909", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences prevails in US government lawsuit over HIV drug patents", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-sciences-prevails-us-government-lawsuit-over-hiv-drug-patents-2023-05-09/", "time_published": "20230509T164819", "authors": ["Blake Brittain"], "summary": "Gilead Sciences prevails in US government lawsuit over HIV drug ... ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/RQRQYXZFU5I7DCLACJITHT5VHM.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.173839, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.099066", "ticker_sentiment_score": "-0.06513", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences didn't violate government patents on HIV prevention treatment, jury finds", "url": "https://www.cnbc.com/2023/05/09/gilead-did-not-violate-patents-hiv-prevention-drug.html", "time_published": "20230509T164329", "authors": ["Spencer Kimball"], "summary": "The U.S. government had sued Gilead in 2019 arguing that the company was profiting off CDC patents.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107188826-16754420682023-02-03t155622z_1796503087_rc2q3z99gxf6_rtrmadp_0_gilead-sciences-fda-cancer.jpeg?v=1683650609&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.067143, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.214937", "ticker_sentiment_score": "-0.211727", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "U.S. Loses Key Case on Rights to H.I.V.-Prevention Drugs", "url": "https://www.nytimes.com/2023/05/09/business/prep-hiv-aids-gilead.html", "time_published": "20230509T162455", "authors": [], "summary": "A federal jury in Delaware on Tuesday found that the federal government did not have an ownership claim to lucrative drugs to prevent H.I.V. that are sold by the pharmaceutical company Gilead Sciences.", "banner_image": "https://static01.nyt.com/images/2023/05/09/multimedia/09gilead-hiv-bkhw/09gilead-hiv-bkhw-articleLarge.jpg?quality=75&auto=webp&disable=upscale", "source": "New York Times", "category_within_source": "GoogleRSS", "source_domain": "www.nytimes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.065699, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.056943", "ticker_sentiment_score": "0.11995", "ticker_sentiment_label": "Neutral"}]}, {"title": "U.S. Loses Key Case on Rights to H.I.V.-Prevention Drugs", "url": "https://www.nytimes.com/2023/05/09/business/prep-hiv-aids-gilead.html", "time_published": "20230509T162455", "authors": [], "summary": "A federal jury in Delaware on Tuesday found that the federal government did not have an ownership claim to lucrative drugs to prevent H.I.V. that are sold by the pharmaceutical company Gilead Sciences.", "banner_image": "https://static01.nyt.com/images/2023/05/09/multimedia/09gilead-hiv-bkhw/09gilead-hiv-bkhw-articleLarge.jpg?quality=75&auto=webp&disable=upscale", "source": "New York Times", "category_within_source": "GoogleRSS", "source_domain": "www.nytimes.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.074747, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.035189", "ticker_sentiment_score": "0.114777", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera", "url": "https://investingnews.com/gilead-strengthens-early-pipeline-in-oncology-and-inflammation-through-the-acquisition-of-xinthera/", "time_published": "20230509T132211", "authors": [], "summary": "Acquisition of XinThera Provides Gilead with Precision Small Molecules Focused on PARP1 and MK2 Inhibitors - Gilead Sciences, Inc. ( Nasdaq: GILD ) today announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San Diego.", "banner_image": "https://investingnews.com/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yNTg1ODg1NS9vcmlnaW4ucG5nIiwiZXhwaXJlc19hdCI6MTcwODY4MTIxOX0.Phin9ClvosnPNpkGRdBWHz_VFepTco5fqEYZcXCsZIQ/image.png?width=210", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}, {"topic": "Earnings", "relevance_score": "0.796627"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.021961, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.218817", "ticker_sentiment_score": "0.058356", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:VND", "relevance_score": "0.044304", "ticker_sentiment_score": "-0.0377", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ahmad Goree Named New Leader of Dallas Southern Pride", "url": "https://www.prnewswire.com/news-releases/ahmad-goree-named-new-leader-of-dallas-southern-pride-301818351.html", "time_published": "20230508T151100", "authors": ["Dallas Southern Pride"], "summary": "More than 10K people expected to attend the 2023 Juneteenth Unity Weekend Celebration event June 15-20 in Dallas", "banner_image": "https://mma.prnewswire.com/media/2071844/DSP_JUST_RELEASED_HOST_HOTEL_RESERVATIONS_FLYER.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.506866, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.048919", "ticker_sentiment_score": "0.403679", "ticker_sentiment_label": "Bullish"}]}, {"title": "Ahmad Goree Named New Leader of Dallas Southern Pride", "url": "https://www.benzinga.com/pressreleases/23/05/n32267196/ahmad-goree-named-new-leader-of-dallas-southern-pride", "time_published": "20230508T151100", "authors": ["PRNewswire"], "summary": "More than 10K people expected to attend the 2023 Juneteenth Unity Weekend Celebration event June 15-20 in Dallas", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.495693, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.046907", "ticker_sentiment_score": "0.403304", "ticker_sentiment_label": "Bullish"}]}, {"title": "Rates Have Risen: Here Are 5 Stocks With Little Debt", "url": "https://www.forbes.com/sites/johndorfman/2023/05/08/moderna-teradyne-rates-risen-here-are-5-stocks-with-little-debt/", "time_published": "20230508T150940", "authors": ["John Dorfman"], "summary": "Interest rates are about five percentage points higher than they were a year ago. For stock pickers, that means that debt once again matters. Here are five stocks that fit the bill.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64588b882199bcf1029c02fa/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Money", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.967321"}], "overall_sentiment_score": 0.082308, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TER", "relevance_score": "0.114409", "ticker_sentiment_score": "-0.054622", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.057352", "ticker_sentiment_score": "-0.136597", "ticker_sentiment_label": "Neutral"}, {"ticker": "IPI", "relevance_score": "0.057352", "ticker_sentiment_score": "-0.136597", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.170878", "ticker_sentiment_score": "0.18673", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CFR", "relevance_score": "0.114409", "ticker_sentiment_score": "0.007041", "ticker_sentiment_label": "Neutral"}, {"ticker": "IIIN", "relevance_score": "0.114409", "ticker_sentiment_score": "0.053718", "ticker_sentiment_label": "Neutral"}]}, {"title": "American Express, Gilead Sciences And This US Oil Giant On CNBC's 'Final Trades' - Chevron  ( NYSE:CVX ) , American Express  ( NYSE:AXP ) ", "url": "https://www.benzinga.com/trading-ideas/long-ideas/23/05/32258109/american-express-gilead-sciences-and-this-us-oil-giant-on-cnbcs-final-trades", "time_published": "20230508T121654", "authors": ["Priya Nigam"], "summary": "On CNBC's \"Halftime Report Final Trades,\" Rob Sechan of New Edge Capital Group said Gilead Sciences, Inc. GILD is a very defensive, steady growth play. \"It is cheap, cheap, cheap,\" he added.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/08/bull-g80539cf5f_1920.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.77141"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.087266, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVX", "relevance_score": "0.538389", "ticker_sentiment_score": "0.113798", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXP", "relevance_score": "0.538389", "ticker_sentiment_score": "0.372653", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.538389", "ticker_sentiment_score": "0.238776", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "This Incredible Growth Stock Has All the Hallmarks of a Prototypical Warren Buffett Stock", "url": "https://www.fool.com/investing/2023/05/06/this-incredible-growth-stock-has-all-the-hallmarks/", "time_published": "20230506T170000", "authors": ["George Budwell"], "summary": "Vertex Pharmaceuticals faces limited competition in its core area of expertise, has a top-shelf CEO, and is building out a profoundly valuable pipeline of next-generation assets.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F731188%2Fcastle-moat.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.230762, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.089965", "ticker_sentiment_score": "0.171585", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.089965", "ticker_sentiment_score": "0.009879", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.045054", "ticker_sentiment_score": "0.009005", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.045054", "ticker_sentiment_score": "0.320356", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.089965", "ticker_sentiment_score": "0.063792", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Magnificent Dividend Stocks to Buy Before the Next Recession", "url": "https://www.fool.com/investing/2023/05/05/2-magnificent-dividend-stocks-to-buy-before-next/", "time_published": "20230505T134500", "authors": ["Prosper Junior Bakiny"], "summary": "The healthcare sector is a good place to find recession-proof stocks.", "banner_image": "https://media.ycharts.com/charts/c6c06687434d40c534e3cde623ea1a27.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.092594, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.318309", "ticker_sentiment_score": "0.274021", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.442082", "ticker_sentiment_score": "0.15084", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "CHMP Adopts Positive Opinion Recommending Hepcludex\u00ae for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus", "url": "https://investingnews.com/chmp-adopts-positive-opinion-recommending-hepcludex-r-for-full-marketing-authorization-for-the-treatment-of-hepatitis-delta-virus/", "time_published": "20230504T115250", "authors": [], "summary": "Gilead Sciences, Inc. ( Nasdaq: GILD ) today announced that the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has adopted a positive opinion for Hepcludex \u00ae ( bulevirtide ) for the treatment of adults with chronic HDV and compensated liver ...", "banner_image": "https://investingnews.com/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yNTg1ODg1NS9vcmlnaW4ucG5nIiwiZXhwaXJlc19hdCI6MTcwODY4MTIxOX0.Phin9ClvosnPNpkGRdBWHz_VFepTco5fqEYZcXCsZIQ/image.png?width=210", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.174311, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.366061", "ticker_sentiment_score": "0.289601", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead Sciences Stock Has Only Done This in 1 of the Past 7 Years", "url": "https://www.fool.com/investing/2023/05/04/gilead-sciences-stock-has-only-done-this-in-1-of-t/", "time_published": "20230504T115000", "authors": ["David Jagielski"], "summary": "Should you buy Gilead Sciences stock despite its poor track record?", "banner_image": "https://media.ycharts.com/charts/5996a432d0d56fa2f3b939bc437cfee0.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.918141"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": 0.217483, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.479258", "ticker_sentiment_score": "0.393674", "ticker_sentiment_label": "Bullish"}]}, {"title": "Insmed Reports First Quarter 2023 Financial Results and Provides Business Update", "url": "https://www.prnewswire.com/news-releases/insmed-reports-first-quarter-2023-financial-results-and-provides-business-update-301815538.html", "time_published": "20230504T113000", "authors": ["Insmed Incorporated"], "summary": "Insmed Reports First Quarter 2023 Financial Results and Provides ... PR ...", "banner_image": "https://mma.prnewswire.com/media/801462/Insmed_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.98396"}, {"topic": "Earnings", "relevance_score": "0.993856"}], "overall_sentiment_score": 0.019354, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.008868", "ticker_sentiment_score": "0.06747", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.008868", "ticker_sentiment_score": "0.016659", "ticker_sentiment_label": "Neutral"}, {"ticker": "INSM", "relevance_score": "0.218896", "ticker_sentiment_score": "0.044774", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.008868", "ticker_sentiment_score": "0.06747", "ticker_sentiment_label": "Neutral"}]}, {"title": "CIO Leadership: HMG Strategy to Recognize Visionary Leaders at the 2023 Silicon Valley CISO & Technology Executive Leadership Summit on May 11", "url": "https://www.benzinga.com/pressreleases/23/05/g32194108/cio-leadership-hmg-strategy-to-recognize-visionary-leaders-at-the-2023-silicon-valley-ciso-technol", "time_published": "20230503T173951", "authors": ["Globe Newswire"], "summary": "WESTPORT, Conn., May 03, 2023 ( GLOBE NEWSWIRE ) -- HMG Strategy, the World's #1 digital platform for enabling technology executives to reimagine the enterprise and reshape the business world, is thrilled to be recognizing four exemplary global business technology leaders for their visionary ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.218481, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "C", "relevance_score": "0.020903", "ticker_sentiment_score": "-0.144294", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPWK", "relevance_score": "0.062651", "ticker_sentiment_score": "0.061186", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNG", "relevance_score": "0.083468", "ticker_sentiment_score": "0.074523", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.020903", "ticker_sentiment_score": "0.28321", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRBG", "relevance_score": "0.020903", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DRKTF", "relevance_score": "0.062651", "ticker_sentiment_score": "0.061186", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROK", "relevance_score": "0.020903", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LINC", "relevance_score": "0.020903", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTAP", "relevance_score": "0.020903", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WH", "relevance_score": "0.041791", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "S", "relevance_score": "0.041791", "ticker_sentiment_score": "0.069166", "ticker_sentiment_label": "Neutral"}, {"ticker": "DGX", "relevance_score": "0.020903", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTNX", "relevance_score": "0.062651", "ticker_sentiment_score": "0.061186", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.083468", "ticker_sentiment_score": "0.061044", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZUO", "relevance_score": "0.020903", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UL", "relevance_score": "0.020903", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZS", "relevance_score": "0.062651", "ticker_sentiment_score": "0.061186", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNGA", "relevance_score": "0.020903", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.020903", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBGSF", "relevance_score": "0.020903", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.020903", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PANW", "relevance_score": "0.062651", "ticker_sentiment_score": "0.061186", "ticker_sentiment_label": "Neutral"}]}, {"title": "Advanced Therapy Medicinal Products Market to Reach USD 24 Billion by 2032, Driven by Rising Prevalence of Chronic Diseases and Individualized Treatment Demand", "url": "https://markets.businessinsider.com/news/stocks/advanced-therapy-medicinal-products-market-to-reach-usd-24-billion-by-2032-driven-by-rising-prevalence-of-chronic-diseases-and-individualized-treatment-demand-1032286877", "time_published": "20230503T142437", "authors": [], "summary": "Advanced Therapy Medicinal Products ( ATMPs ) Market By Product Type ( Gene Therapies, Cell Therapies, Tissue-Engineered Product ) , By End-use ( Hospitals, Clinics, Research Institutes, Others ) , By Region Forecast To 2032", "banner_image": "https://markets.businessinsider.com/Images/FacebookIcon.jpg", "source": "Business Insider", "category_within_source": "RSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.208147, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SGMO", "relevance_score": "0.042196", "ticker_sentiment_score": "0.151075", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ORTX", "relevance_score": "0.042196", "ticker_sentiment_score": "0.151075", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DTIL", "relevance_score": "0.042196", "ticker_sentiment_score": "0.151075", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.208644", "ticker_sentiment_score": "0.159918", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.042196", "ticker_sentiment_score": "0.151075", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's 1 Magnificent Reason to Buy Vertex Pharmaceuticals Stock", "url": "https://www.fool.com/investing/2023/05/03/heres-1-magnificent-reason-to-buy-vertex-pharmaceu/", "time_published": "20230503T141500", "authors": ["Prosper Junior Bakiny"], "summary": "The bull case for the cystic fibrosis treatment maker is as strong as ever.", "banner_image": "https://media.ycharts.com/charts/59975357492f0a198a020bb6ae979b88.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.198171, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.2842", "ticker_sentiment_score": "0.430235", "ticker_sentiment_label": "Bullish"}, {"ticker": "KRYS", "relevance_score": "0.058047", "ticker_sentiment_score": "0.239017", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.2842", "ticker_sentiment_score": "-0.048239", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.058047", "ticker_sentiment_score": "0.115984", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLPG", "relevance_score": "0.058047", "ticker_sentiment_score": "-0.048968", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.058047", "ticker_sentiment_score": "0.115984", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts", "url": "https://investingnews.com/gilead-remains-steadfast-in-support-for-hepatitis-c-elimination-efforts/", "time_published": "20230503T114845", "authors": [], "summary": "The recent national conversation on hepatitis C ( HCV ) is an encouraging step towards viral hepatitis elimination in the U.S. With its long history of leadership in viral hepatitis, Gilead continues to support efforts that focus on HCV elimination.", "banner_image": "https://investingnews.com/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yNTg1ODg1NS9vcmlnaW4ucG5nIiwiZXhwaXJlc19hdCI6MTcwODY4MTIxOX0.Phin9ClvosnPNpkGRdBWHz_VFepTco5fqEYZcXCsZIQ/image.png?width=210", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.217848, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.2842", "ticker_sentiment_score": "0.162446", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Fed could deliver the final rate hike of a historically aggressive cycle today. Here's what to know.", "url": "https://www.businessinsider.com/fed-rate-hike-explained-policy-central-bank-may-cycle-markets-2023-5", "time_published": "20230503T101000", "authors": ["Phil Rosen"], "summary": "Fed Rate Hike Explained: Historically Aggressive Cycle Could End ... - Business Insider ...", "banner_image": null, "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "www.businessinsider.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.98396"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.028701, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SPGI", "relevance_score": "0.041251", "ticker_sentiment_score": "0.03868", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHGG", "relevance_score": "0.041251", "ticker_sentiment_score": "0.041583", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEP", "relevance_score": "0.041251", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.041251", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.041251", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.041251", "ticker_sentiment_score": "0.086022", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences battles U.S. government in court over HIV prevention patent", "url": "https://www.cnbc.com/2023/05/02/gilead-government-trial-hiv-prevention-drug.html", "time_published": "20230502T184658", "authors": ["Spencer Kimball"], "summary": "The U.S. claims Gilead's drugs Truvada and Descovy infringe on CDC patents.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107234190-1683049933852-gettyimages-1235965784-porzycki-companie211018_npov4.jpeg?v=1683053218&w=1920&h=1080", "source": "CNBC", "category_within_source": "Business", "source_domain": "www.cnbc.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.212607, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "0.102013", "ticker_sentiment_score": "-0.098913", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.102013", "ticker_sentiment_score": "-0.158588", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More", "url": "https://www.zacks.com/stock/news/2088427/biotechdrug-stocks-q1-earnings-due-may-3-uthr-pcrx-more", "time_published": "20230502T173200", "authors": ["Zacks Investment Research"], "summary": "Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default6.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.077073, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CORT", "relevance_score": "0.222022", "ticker_sentiment_score": "0.053562", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMRN", "relevance_score": "0.306963", "ticker_sentiment_score": "-0.075464", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.04497", "ticker_sentiment_score": "-0.053922", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.222022", "ticker_sentiment_score": "0.053562", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.04497", "ticker_sentiment_score": "-0.053922", "ticker_sentiment_label": "Neutral"}, {"ticker": "PCRX", "relevance_score": "0.222022", "ticker_sentiment_score": "0.053562", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTHR", "relevance_score": "0.264897", "ticker_sentiment_score": "0.140167", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.04497", "ticker_sentiment_score": "-0.053922", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johnson & Johnson Ignites CAR-T Ambitions With Licensing Pact With Cellular Biomedicine - Johnson & Johnson  ( NYSE:JNJ ) ", "url": "https://www.benzinga.com/general/biotech/23/05/32165424/johnson-johnson-ignites-car-t-ambitions-with-licensing-pact-with-cellular-biomedicine", "time_published": "20230502T161429", "authors": ["Vandana Singh"], "summary": "Johnson & Johnson's JNJ pharma unit Janssen entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc to develop, manufacture and commercialize next-generation chimeric antigen receptor ( CAR ) T-cell therapies for B-cell malignancies.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/02/jnj.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.139258, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.303175", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.56415", "ticker_sentiment_score": "0.057639", "ticker_sentiment_label": "Neutral"}, {"ticker": "LEGN", "relevance_score": "0.303175", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead vs. CDC: The $1B Showdown Over HIV Drug Profits - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/general/biotech/23/05/32160672/gilead-vs-cdc-the-1b-showdown-over-hiv-drug-profits", "time_published": "20230502T160845", "authors": ["Vandana Singh"], "summary": "Gilead Sciences Inc GILD is reportedly looking to fight claims that it owes the U.S. government a share of over $1 billion in profits from its HIV-treatment drug Truvada that could help prevent the disease. It generated sales of $147 million in 2022 compared to $371 million a year ago.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/02/gilead.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.140848, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.436009", "ticker_sentiment_score": "0.341901", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead, US square off in billion-dollar HIV drug patent trial", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-us-square-off-billion-dollar-hiv-drug-patent-trial-2023-05-02/", "time_published": "20230502T090300", "authors": ["Blake Brittain"], "summary": "May 2 ( Reuters ) - Gilead Sciences Inc ( GILD.O ) is headed to trial in Delaware federal court this week to fight claims that it owes the U.S. government a share of multibillion-dollar profits from its HIV-prevention drug regimen.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/EKL6ADZ6UZPP5MIAVME7A6DNVY.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.197938, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.101154", "ticker_sentiment_score": "0.071245", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Q1 2023 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2023/04/28/gilead-sciences-gild-q1-2023-earnings-call-transcr/", "time_published": "20230428T193403", "authors": ["Motley Fool Transcribing"], "summary": "GILD earnings call for the period ending March 31, 2023.", "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999186"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.266143"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.265797, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.029441", "ticker_sentiment_score": "0.114894", "ticker_sentiment_label": "Neutral"}, {"ticker": "EVR", "relevance_score": "0.004207", "ticker_sentiment_score": "0.181912", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAC", "relevance_score": "0.004207", "ticker_sentiment_score": "0.181912", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.004207", "ticker_sentiment_score": "0.181912", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.004207", "ticker_sentiment_score": "0.181912", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.004207", "ticker_sentiment_score": "0.181912", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.004207", "ticker_sentiment_score": "0.084776", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.008413", "ticker_sentiment_score": "0.015659", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Q1 2023 Earnings Call Transcript", "url": "https://moneymorning.com/investing/gilead-sciences-gild-q1-2023-earnings-call-transcript/", "time_published": "20230428T193403", "authors": ["Fool.com", "fool.com"], "summary": "Hello, everyone, and welcome to the first quarter 2023 Gilead Sciences earnings conference call. My name is Nadia, and I'll be coordinating the call today. [Operator instructions] I will now hand over to your host, Jacquie Ross, vice president, investor relations, to begin. Jacquie, please go ...", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Fmisc-assets%2Ffool-transcripts-logo.png&w=700", "source": "Money Morning", "category_within_source": "GoogleRSS", "source_domain": "moneymorning.com", "topics": [{"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.189961, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.256538", "ticker_sentiment_score": "0.391413", "ticker_sentiment_label": "Bullish"}]}, {"title": "Gilead's  ( GILD )  Q1 Earnings Miss, Veklury Sales Plunge", "url": "https://www.zacks.com/stock/news/2087119/gileads-gild-q1-earnings-miss-veklury-sales-plunge", "time_published": "20230428T170700", "authors": ["Zacks Investment Research"], "summary": "Gilead's (GILD) Q1 earnings and sales miss estimates due to lower Veklury sales.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/2227.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976671"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.053518, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.173958", "ticker_sentiment_score": "-0.007492", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.087503", "ticker_sentiment_score": "0.203152", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.173958", "ticker_sentiment_score": "0.072055", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.173958", "ticker_sentiment_score": "0.067845", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Gilead Sciences  ( GILD )  Stock Is Falling Today - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/general/biotech/23/04/32080628/why-gilead-sciences-stock-is-falling-today", "time_published": "20230428T142903", "authors": ["Vandana Singh"], "summary": "Gilead Sciences Inc GILD reported Q1 FY23 sales decreased 4% Y/Y to $6.35 billion, slightly above the consensus of $6.33 billion, due to lower Veklury ( remdesivir ) sales, partially offset by increased sales in HIV and Oncology.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/28/gilead.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.684621"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.111127, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.514619", "ticker_sentiment_score": "0.125269", "ticker_sentiment_label": "Neutral"}]}, {"title": "Government Drug Price Curbs Could Sound A Death Knell For Industry", "url": "https://www.investors.com/news/technology/biotech-stocks-brace-for-the-worst-as-government-drug-price-negotiations-loom/", "time_published": "20230428T120000", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Biotech Stocks Brace For The Worst As Government Drug Price ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/09/Stock-humira-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}, {"topic": "Earnings", "relevance_score": "0.684621"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.024097, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.040668", "ticker_sentiment_score": "-0.11222", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.027118", "ticker_sentiment_score": "0.044929", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.027118", "ticker_sentiment_score": "-0.055277", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.027118", "ticker_sentiment_score": "-0.076847", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.08123", "ticker_sentiment_score": "-0.011317", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.027118", "ticker_sentiment_score": "0.044929", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.027118", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.013561", "ticker_sentiment_score": "0.077066", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.027118", "ticker_sentiment_score": "-0.076847", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLVT", "relevance_score": "0.027118", "ticker_sentiment_score": "0.05187", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.067727", "ticker_sentiment_score": "-0.061364", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCO", "relevance_score": "0.027118", "ticker_sentiment_score": "0.0266", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.027118", "ticker_sentiment_score": "0.052088", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.040668", "ticker_sentiment_score": "-0.064288", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.067727", "ticker_sentiment_score": "0.005039", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.027118", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.054205", "ticker_sentiment_score": "-0.077946", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Q1 Earnings and Revenues Lag Estimates", "url": "https://www.zacks.com/stock/news/2086455/gilead-sciences-gild-q1-earnings-and-revenues-lag-estimates", "time_published": "20230427T214515", "authors": ["Zacks Investment Research"], "summary": "Gilead (GILD) delivered earnings and revenue surprises of -15.95% and 0.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default235.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.141694, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "EYPT", "relevance_score": "0.205225", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.137671", "ticker_sentiment_score": "0.11699", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures: Amazon Erases Gains On Cloud Fears; These Techs Dive", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-amazon-continues-earnings-surge-for-tech-titans-but-cloudflare-snap-plunge/", "time_published": "20230427T213200", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "Futures: Amazon Jumps On Earnings, But These Techs Plunge Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/07/stock-bull-charge-02-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.096773, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AYX", "relevance_score": "0.046184", "ticker_sentiment_score": "-0.156323", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ENPH", "relevance_score": "0.046184", "ticker_sentiment_score": "0.067013", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.023102", "ticker_sentiment_score": "0.217449", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.092213", "ticker_sentiment_score": "0.039533", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.069227", "ticker_sentiment_score": "0.198088", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CVX", "relevance_score": "0.069227", "ticker_sentiment_score": "0.079631", "ticker_sentiment_label": "Neutral"}, {"ticker": "CROX", "relevance_score": "0.115121", "ticker_sentiment_score": "0.019396", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.023102", "ticker_sentiment_score": "0.042606", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.046184", "ticker_sentiment_score": "-0.156323", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MSFT", "relevance_score": "0.137934", "ticker_sentiment_score": "0.186854", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FSLR", "relevance_score": "0.137934", "ticker_sentiment_score": "0.003946", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.046184", "ticker_sentiment_score": "-0.156323", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PI", "relevance_score": "0.046184", "ticker_sentiment_score": "-0.102237", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.046184", "ticker_sentiment_score": "-0.156323", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PINS", "relevance_score": "0.046184", "ticker_sentiment_score": "-0.156323", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NET", "relevance_score": "0.137934", "ticker_sentiment_score": "-0.109802", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.227859", "ticker_sentiment_score": "0.093466", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.183198", "ticker_sentiment_score": "-0.001522", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks making the biggest moves after hours: Amazon, Intel, Snap, Pinterest and more", "url": "https://www.cnbc.com/2023/04/27/stocks-making-the-biggest-moves-after-hours-amazon-intel-snap-pinterest-and-more.html", "time_published": "20230427T211938", "authors": ["Sarah Min"], "summary": "These are the stocks posting the largest moves in extended trading.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107229035-1682051609980-gettyimages-1136867731-hennessy-amazonsn190412_npreP.jpeg?v=1682630378&w=1920&h=1080", "source": "CNBC", "category_within_source": "Market Insider", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.021964, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TMUS", "relevance_score": "0.135729", "ticker_sentiment_score": "-0.138851", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDLZ", "relevance_score": "0.135729", "ticker_sentiment_score": "0.22395", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FSLR", "relevance_score": "0.068112", "ticker_sentiment_score": "-0.023175", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.068112", "ticker_sentiment_score": "-0.09095", "ticker_sentiment_label": "Neutral"}, {"ticker": "PINS", "relevance_score": "0.135729", "ticker_sentiment_score": "0.096915", "ticker_sentiment_label": "Neutral"}, {"ticker": "LHX", "relevance_score": "0.135729", "ticker_sentiment_score": "0.017327", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAM", "relevance_score": "0.135729", "ticker_sentiment_score": "-0.043639", "ticker_sentiment_label": "Neutral"}, {"ticker": "FICO", "relevance_score": "0.202366", "ticker_sentiment_score": "-0.04563", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead shares fall after mixed results, as weaker COVID-19 drug remand weighs", "url": "https://www.marketwatch.com/story/gilead-shares-fall-after-mixed-results-as-weaker-covid-19-drug-remand-weighs-353bd3f4", "time_published": "20230427T211800", "authors": ["Bill Peters"], "summary": "Gilead Sciences Inc. on Thursday cut one of its profit forecasts and reported first-quarter profit that missed expectations.", "banner_image": "https://images.mktw.net/im-771567/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.015088, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.47672", "ticker_sentiment_score": "-0.220754", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Gilead Sciences Announces First Quarter 2023 Financial Results - Investing News Network", "url": "https://investingnews.com/gilead-sciences-announces-first-quarter-2023-financial-results/", "time_published": "20230427T205331", "authors": [], "summary": "Gilead Sciences Announces First Quarter 2023 Financial Results Investing News Network ...", "banner_image": null, "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.94762"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.316726"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.159095, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.016598", "ticker_sentiment_score": "0.033226", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.082848", "ticker_sentiment_score": "0.034946", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Posts Bullish Cancer Drug Sales, But Profit Questions Linger", "url": "https://www.investors.com/news/technology/gild-stock-gilead-earnings-amgen-stock-amgen-earnings-q1-2023/", "time_published": "20230427T201700", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "GILD Stock: Cancer Treatments Surge, But Profit Questions Linger Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-Gilead-07-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}], "overall_sentiment_score": -0.026446, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.398781", "ticker_sentiment_score": "-0.230628", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GILD", "relevance_score": "0.469457", "ticker_sentiment_score": "-0.124062", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead profit misses Wall Street expectations as COVID drug sales decline", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-profit-misses-wall-street-expectations-covid-drug-sales-decline-2023-04-27/", "time_published": "20230427T201000", "authors": ["Reuters"], "summary": "Gilead profit misses Wall Street expectations as COVID drug sales ... ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/EKL6ADZ6UZPP5MIAVME7A6DNVY.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.012225, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.204072", "ticker_sentiment_score": "-0.043191", "ticker_sentiment_label": "Neutral"}]}, {"title": "REGN: A Prescription for Success: Check Out This Strong Pharmaceutical Stock This Week", "url": "https://stocknews.com/news/regn-biib-gild-vnda-a-prescription-for-success-check-out-this-strong-pharmaceutical-stock/", "time_published": "20230427T155446", "authors": [], "summary": "REGN: A Prescription for Success: Check Out This Strong ... ...", "banner_image": "https://stocknews.com/wp-content/uploads/2023/01/ISt_Biotechnology.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972756"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.263793, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.150592", "ticker_sentiment_score": "0.228145", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.552443", "ticker_sentiment_score": "0.362894", "ticker_sentiment_label": "Bullish"}, {"ticker": "VNDA", "relevance_score": "0.150592", "ticker_sentiment_score": "0.228145", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.150592", "ticker_sentiment_score": "0.228145", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "P/E Ratio Insights for Gilead Sciences - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/23/04/32049564/pe-ratio-insights-for-gilead-sciences", "time_published": "20230427T150046", "authors": ["Benzinga Insights"], "summary": "In the current market session, Gilead Sciences Inc. GILD stock price is at $82.75, after a 1.18% decrease. However, over the past month, the company's stock increased by 1.60%, and in the past year, by 39.45%.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_8011.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": -0.04018, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.428632", "ticker_sentiment_score": "0.068711", "ticker_sentiment_label": "Neutral"}]}, {"title": "Debt Limit Bill Heads To Senate To Be Rejected - AbbVie  ( NYSE:ABBV ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/economics/macro-economic-events/23/04/32046950/debt-limit-bill-heads-to-senate-to-be-rejected", "time_published": "20230427T133302", "authors": ["GRIT Capital"], "summary": "House passed a bill to increase debt \"ceiling\" by $1.5 TRILLION. Almost zero chance it passes through Senate. In 230 years, America has never defaulted on its debt aside from Nixon, FDR, Lincoln. Speaker Kevin McCarthy passed his debt limit bill through the House yesterday\u2026barely.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/27/joshua-sukoff-5ddyhjk_kmu-unsplash.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.905476"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.036792, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "FRC", "relevance_score": "0.041394", "ticker_sentiment_score": "0.120475", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.041394", "ticker_sentiment_score": "0.122059", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATVI", "relevance_score": "0.123738", "ticker_sentiment_score": "-0.335588", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GLCNF", "relevance_score": "0.041394", "ticker_sentiment_score": "0.163692", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VOD", "relevance_score": "0.041394", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.082677", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSN", "relevance_score": "0.041394", "ticker_sentiment_score": "-0.219539", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BA", "relevance_score": "0.082677", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCKRF", "relevance_score": "0.082677", "ticker_sentiment_score": "0.227709", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.123738", "ticker_sentiment_score": "0.125961", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:UNI", "relevance_score": "0.041394", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "What Does Gilead Sciences' Debt Look Like? - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/23/04/32046283/what-does-gilead-sciences-debt-look-like", "time_published": "20230427T131623", "authors": ["Benzinga Insights"], "summary": "Over the past three months, shares of Gilead Sciences Inc. GILD moved lower by 0.44%. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its financials.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": -0.080246, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.273807", "ticker_sentiment_score": "-0.085346", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alarming Rates of HIV and AIDS among Houston's Blacks and Hispanics Bring National AIDS Memorial Quilt to the City", "url": "https://www.benzinga.com/pressreleases/23/04/g32045937/alarming-rates-of-hiv-and-aids-among-houstons-blacks-and-hispanics-bring-national-aids-memorial-qu", "time_published": "20230427T130433", "authors": ["Globe Newswire"], "summary": "HOUSTON, April 27, 2023 ( GLOBE NEWSWIRE ) -- The statistics tell the story, and there's a serious HIV crisis in Houston and even more specifically among Blacks and Hispanics. That's why the National AIDS Memorial Quilt is making a stop in Houston May 3-7.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.112989, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BAC", "relevance_score": "0.049732", "ticker_sentiment_score": "0.050483", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.049732", "ticker_sentiment_score": "0.050483", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.099271", "ticker_sentiment_score": "0.044402", "ticker_sentiment_label": "Neutral"}]}, {"title": "Morning Bid: Fresh spur from Meta and Europe's banks", "url": "https://www.reuters.com/markets/europe/global-markets-view-usa-2023-04-27/", "time_published": "20230427T100538", "authors": ["Reuters"], "summary": "A look at the day ahead in U.S. and global markets from Mike Dolan The Big Tech earnings season is going some way to justifying the striking outperformance of its mega cap shares this year, with Meta Platforms the latest to impress overnight and Amazon ( AMZN.O ) advancing ahead of its readout on ...", "banner_image": "https://graphics.reuters.com/META-RESULTS/zdpxdkkzqpx/chart_eikon.jpg", "source": "Reuters", "category_within_source": "Markets", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": -0.02688, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.048919", "ticker_sentiment_score": "0.001008", "ticker_sentiment_label": "Neutral"}, {"ticker": "CINF", "relevance_score": "0.048919", "ticker_sentiment_score": "0.035546", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDLZ", "relevance_score": "0.048919", "ticker_sentiment_score": "0.035546", "ticker_sentiment_label": "Neutral"}, {"ticker": "DPZ", "relevance_score": "0.048919", "ticker_sentiment_score": "0.035546", "ticker_sentiment_label": "Neutral"}, {"ticker": "MA", "relevance_score": "0.048919", "ticker_sentiment_score": "0.035546", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDP", "relevance_score": "0.048919", "ticker_sentiment_score": "0.035546", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.048919", "ticker_sentiment_score": "0.035546", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPS", "relevance_score": "0.048919", "ticker_sentiment_score": "-0.176897", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PINS", "relevance_score": "0.048919", "ticker_sentiment_score": "0.035546", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOG", "relevance_score": "0.048919", "ticker_sentiment_score": "0.035546", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.048919", "ticker_sentiment_score": "0.205034", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MO", "relevance_score": "0.048919", "ticker_sentiment_score": "0.035546", "ticker_sentiment_label": "Neutral"}, {"ticker": "WY", "relevance_score": "0.048919", "ticker_sentiment_score": "0.035546", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOC", "relevance_score": "0.048919", "ticker_sentiment_score": "0.035546", "ticker_sentiment_label": "Neutral"}, {"ticker": "EMN", "relevance_score": "0.048919", "ticker_sentiment_score": "0.035546", "ticker_sentiment_label": "Neutral"}, {"ticker": "USCS", "relevance_score": "0.048919", "ticker_sentiment_score": "0.035546", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.048919", "ticker_sentiment_score": "0.035546", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAL", "relevance_score": "0.048919", "ticker_sentiment_score": "0.035546", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.048919", "ticker_sentiment_score": "0.035546", "ticker_sentiment_label": "Neutral"}, {"ticker": "DMPZF", "relevance_score": "0.048919", "ticker_sentiment_score": "0.035546", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.048919", "ticker_sentiment_score": "0.16586", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NEM", "relevance_score": "0.048919", "ticker_sentiment_score": "0.035546", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATVI", "relevance_score": "0.097655", "ticker_sentiment_score": "-0.024582", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCZ", "relevance_score": "0.048919", "ticker_sentiment_score": "0.035546", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.048919", "ticker_sentiment_score": "0.035546", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAS", "relevance_score": "0.048919", "ticker_sentiment_score": "0.035546", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRSN", "relevance_score": "0.048919", "ticker_sentiment_score": "0.035546", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.048919", "ticker_sentiment_score": "-0.165035", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Better Buy: Pfizer vs. Gilead", "url": "https://moneymorning.com/investing/better-buy-pfizer-vs-gilead/", "time_published": "20230427T093000", "authors": ["Fool.com", "fool.com"], "summary": "You may not immediately think of growth when you think of big-pharma companies. Smaller biotech players often steal the show when they introduce a first product or report positive clinical-trial news. But bigger, more established companies actually can bring you a fair share of growth -- and ...", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fmedia.ycharts.com%2Fcharts%2F8a82b35b63247e9d63b5aa0e17ef7f79.png&w=700", "source": "Money Morning", "category_within_source": "GoogleRSS", "source_domain": "moneymorning.com", "topics": [{"topic": "Earnings", "relevance_score": "0.316726"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.234392, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TRMNF", "relevance_score": "0.080728", "ticker_sentiment_score": "0.180925", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.582526", "ticker_sentiment_score": "0.256661", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.160633", "ticker_sentiment_score": "0.076379", "ticker_sentiment_label": "Neutral"}]}, {"title": "Better Buy: Pfizer vs. Gilead", "url": "https://www.fool.com/investing/2023/04/27/better-buy-pfizer-vs-gilead/", "time_published": "20230427T093000", "authors": ["Adria Cimino"], "summary": "Pfizer and Gilead look cheap right now.", "banner_image": "https://media.ycharts.com/charts/8a82b35b63247e9d63b5aa0e17ef7f79.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999355"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.302214, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HPNN", "relevance_score": "0.051886", "ticker_sentiment_score": "0.313827", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TRMNF", "relevance_score": "0.051886", "ticker_sentiment_score": "0.175", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.103554", "ticker_sentiment_score": "0.062779", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.565145", "ticker_sentiment_score": "0.26186", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "$100 Invested In This Stock 20 Years Ago Would Be Worth $1,400 Today - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/earnings/23/04/32025028/100-invested-in-this-stock-20-years-ago-would-be-worth-1-400-today", "time_published": "20230426T213205", "authors": ["Benzinga Insights"], "summary": "Gilead Sciences GILD has outperformed the market over the past 20 years by 6.62% on an annualized basis producing an average annual return of 14.24%. Currently, Gilead Sciences has a market capitalization of $104.58 billion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More", "url": "https://www.zacks.com/stock/news/2084870/drugbiotech-stocks-q1-earnings-due-apr-27-lly-abbv-more", "time_published": "20230426T132800", "authors": ["Zacks Investment Research"], "summary": "Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.193386, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.263942", "ticker_sentiment_score": "0.031445", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.263942", "ticker_sentiment_score": "0.127168", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.263942", "ticker_sentiment_score": "0.095222", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.038407", "ticker_sentiment_score": "0.106241", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.227361", "ticker_sentiment_score": "0.046608", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.038407", "ticker_sentiment_score": "0.106241", "ticker_sentiment_label": "Neutral"}]}, {"title": "CIO Leadership: HMG Strategy to Recognize Visionary Leaders at the 2023 Florida CIO Executive Leadership Summit on May 11", "url": "https://www.benzinga.com/pressreleases/23/04/g31997215/cio-leadership-hmg-strategy-to-recognize-visionary-leaders-at-the-2023-florida-cio-executive-leade", "time_published": "20230425T190803", "authors": ["Globe Newswire"], "summary": "WESTPORT, Conn., April 25, 2023 ( GLOBE NEWSWIRE ) -- HMG Strategy, the World's #1 digital platform for enabling technology executives to reimagine the enterprise and reshape the business world, is excited to be recognizing four exemplary global business technology leaders for their visionary ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.202525, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "C", "relevance_score": "0.02214", "ticker_sentiment_score": "-0.145289", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPWK", "relevance_score": "0.066352", "ticker_sentiment_score": "0.061388", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNG", "relevance_score": "0.066352", "ticker_sentiment_score": "0.061388", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.02214", "ticker_sentiment_score": "0.284602", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DRKTF", "relevance_score": "0.066352", "ticker_sentiment_score": "0.061388", "ticker_sentiment_label": "Neutral"}, {"ticker": "TNET", "relevance_score": "0.02214", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROK", "relevance_score": "0.02214", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LINC", "relevance_score": "0.02214", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTAP", "relevance_score": "0.02214", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WH", "relevance_score": "0.044263", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "S", "relevance_score": "0.044263", "ticker_sentiment_score": "0.069475", "ticker_sentiment_label": "Neutral"}, {"ticker": "DGX", "relevance_score": "0.02214", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTNX", "relevance_score": "0.066352", "ticker_sentiment_score": "0.061388", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.08839", "ticker_sentiment_score": "0.062815", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZUO", "relevance_score": "0.02214", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UL", "relevance_score": "0.02214", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZS", "relevance_score": "0.066352", "ticker_sentiment_score": "0.061388", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNGA", "relevance_score": "0.02214", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.02214", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBGSF", "relevance_score": "0.02214", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PANW", "relevance_score": "0.066352", "ticker_sentiment_score": "0.061388", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Biotech Stocks To Watch Today", "url": "https://stockmarket.com/featured/3-biotech-stocks-to-watch-today-2023-04-25", "time_published": "20230425T170000", "authors": ["Brett David"], "summary": "The biotechnology sector is a highly innovative and dynamic industry that is constantly evolving. Biotech companies develop and produce drugs, therapies, and other products that are designed to improve health outcomes for patients.", "banner_image": "https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2023/04/REGN-stock.jpg", "source": "StockMarket.com", "category_within_source": "n/a", "source_domain": "stockmarket.com", "topics": [{"topic": "Earnings", "relevance_score": "0.917436"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999997"}], "overall_sentiment_score": 0.138483, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.338119", "ticker_sentiment_score": "-0.038845", "ticker_sentiment_label": "Neutral"}]}, {"title": "Incyte  ( INCY )  Earnings Expected to Grow: What to Know Ahead of Next Week's Release", "url": "https://www.zacks.com/stock/news/2084210/incyte-incy-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release", "time_published": "20230425T140127", "authors": ["Zacks Investment Research"], "summary": "Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default325.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.17234, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "INCY", "relevance_score": "0.261117", "ticker_sentiment_score": "0.216037", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.088472", "ticker_sentiment_score": "0.038117", "ticker_sentiment_label": "Neutral"}]}, {"title": "This Supercharged Dividend King Stock Might Soon Run Out of Steam", "url": "https://www.fool.com/investing/2023/04/25/this-supercharged-dividend-king-stock-may-soon-run/", "time_published": "20230425T134500", "authors": ["George Budwell"], "summary": "Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F729290%2Fnegative-growth-trend.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.77141"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.122113, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.076358", "ticker_sentiment_score": "0.13366", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.038223", "ticker_sentiment_score": "0.056664", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.038223", "ticker_sentiment_score": "0.001966", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.434763", "ticker_sentiment_score": "0.12606", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.038223", "ticker_sentiment_score": "0.001966", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXDX", "relevance_score": "0.076358", "ticker_sentiment_score": "0.023564", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.038223", "ticker_sentiment_score": "0.056664", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.038223", "ticker_sentiment_score": "0.056664", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.038223", "ticker_sentiment_score": "0.056664", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Excellent Dividend Stocks to Buy for Less Than $100", "url": "https://www.fool.com/investing/2023/04/25/2-excellent-dividend-stocks-to-buy-for-less-than-1/", "time_published": "20230425T114500", "authors": ["Prosper Junior Bakiny"], "summary": "Both companies are steals at current levels.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F728900%2Fwarren-buffett-brka-brkb-berkshire-hathaway-motley-fool2.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.929393"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.94762"}], "overall_sentiment_score": 0.248028, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "0.217834", "ticker_sentiment_score": "0.213638", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.631144", "ticker_sentiment_score": "0.518169", "ticker_sentiment_label": "Bullish"}, {"ticker": "SGEN", "relevance_score": "0.055109", "ticker_sentiment_score": "0.11203", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences Releases Inaugural ESG Impact Report", "url": "https://investingnews.com/gilead-sciences-releases-inaugural-esg-impact-report/", "time_published": "20230424T215340", "authors": [], "summary": "Gilead Sciences recently released its inaugural Environmental, Social and Governance ( ESG ) Impact Report. This is an evolution of our traditional Year in Review, and uses the ESG framework to highlight the successes and achievements of the prior year", "banner_image": "https://orders.newsfilecorp.com/files/8151/92368_1922e1f3a4068ba4_logo.jpg", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.356026, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.84035", "ticker_sentiment_score": "0.55457", "ticker_sentiment_label": "Bullish"}]}, {"title": "Big Tech Earnings & Economic Numbers: 3 Ways to Survive the Week Ahead", "url": "https://www.zacks.com/commentary/2083214/big-tech-earnings-economic-numbers-3-ways-to-survive-the-week-ahead", "time_published": "20230424T112700", "authors": ["Zacks Investment Research"], "summary": "Many of the FANG stocks are slated to report earnings this week. Today, we will lay out how investors can best navigate the action packed week ahead.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/427.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.858979"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.990678"}], "overall_sentiment_score": 0.058616, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.155451", "ticker_sentiment_score": "0.001308", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.155451", "ticker_sentiment_score": "0.001308", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.155451", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBD", "relevance_score": "0.078099", "ticker_sentiment_score": "-0.085183", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.155451", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PINS", "relevance_score": "0.155451", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.155451", "ticker_sentiment_score": "0.001308", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.155451", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Will HIV and Oncology Propel Gilead's  ( GILD )  Q1 Earnings?", "url": "https://www.zacks.com/stock/news/2082974/will-hiv-and-oncology-propel-gileads-gild-q1-earnings", "time_published": "20230421T165500", "authors": ["Zacks Investment Research"], "summary": "Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its first-quarter 2023 results.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default199.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999965"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.112432, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.267315", "ticker_sentiment_score": "0.203694", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.135602", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.135602", "ticker_sentiment_score": "0.060969", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.135602", "ticker_sentiment_score": "-0.002433", "ticker_sentiment_label": "Neutral"}]}, {"title": "B - Berkshire Hathaway Inc. Common Stock  ( NYSE:BRK/A ) , Berkshire Hathaway Inc. New Common Stock  ( NYSE:BRK/B ) ", "url": "https://www.benzinga.com/trading-ideas/long-ideas/23/04/31929561/berkshire-hathaway-gilead-sciences-vertex-pharmaceuticals-and-a-break-out-casino-stock-f", "time_published": "20230421T115932", "authors": ["Priya Nigam"], "summary": "On CNBC's \"Halftime Report Final Trades,\" Bryn Talkington of Requisite Capital Management named Gilead Sciences, Inc. GILD, which has 7% free cash flow yield and a 3.6% dividend yield. \"I think it will continue to be a good name to own this year,\" she added.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/21/trader2.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.272893, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LVS", "relevance_score": "0.305058", "ticker_sentiment_score": "0.68325", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.443626", "ticker_sentiment_score": "0.593413", "ticker_sentiment_label": "Bullish"}, {"ticker": "WYNN", "relevance_score": "0.443626", "ticker_sentiment_score": "0.279576", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.673107", "ticker_sentiment_score": "0.332993", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.155451", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.305058", "ticker_sentiment_score": "0.374276", "ticker_sentiment_label": "Bullish"}]}, {"title": "CIO Leadership: HMG Strategy to Recognize Visionary Leaders at the 2023 New Jersey CIO Executive Leadership Summit on May 18", "url": "https://www.benzinga.com/pressreleases/23/04/g31919657/cio-leadership-hmg-strategy-to-recognize-visionary-leaders-at-the-2023-new-jersey-cio-executive-le", "time_published": "20230420T162044", "authors": ["Globe Newswire"], "summary": "WESTPORT, Conn., April 20, 2023 ( GLOBE NEWSWIRE ) -- HMG Strategy, the World's #1 digital platform for enabling technology executives to reimagine the enterprise and reshape the business world, is excited to be recognizing four exemplary global business technology leaders for their visionary ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.211785, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "C", "relevance_score": "0.044222", "ticker_sentiment_score": "0.210213", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UPWK", "relevance_score": "0.066291", "ticker_sentiment_score": "0.063416", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNG", "relevance_score": "0.066291", "ticker_sentiment_score": "0.063416", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.02212", "ticker_sentiment_score": "0.284579", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DRKTF", "relevance_score": "0.066291", "ticker_sentiment_score": "0.063416", "ticker_sentiment_label": "Neutral"}, {"ticker": "TNET", "relevance_score": "0.02212", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROK", "relevance_score": "0.02212", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LINC", "relevance_score": "0.02212", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTAP", "relevance_score": "0.02212", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WH", "relevance_score": "0.044222", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "S", "relevance_score": "0.044222", "ticker_sentiment_score": "0.072484", "ticker_sentiment_label": "Neutral"}, {"ticker": "DGX", "relevance_score": "0.02212", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTNX", "relevance_score": "0.066291", "ticker_sentiment_score": "0.063416", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.088309", "ticker_sentiment_score": "0.063892", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZUO", "relevance_score": "0.02212", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UL", "relevance_score": "0.02212", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZS", "relevance_score": "0.066291", "ticker_sentiment_score": "0.063416", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNGA", "relevance_score": "0.02212", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.02212", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBGSF", "relevance_score": "0.02212", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PANW", "relevance_score": "0.066291", "ticker_sentiment_score": "0.063416", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release", "url": "https://www.zacks.com/stock/news/2082075/gilead-sciences-gild-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q1-release", "time_published": "20230420T140314", "authors": ["Zacks Investment Research"], "summary": "Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default88.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.177777, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.102013", "ticker_sentiment_score": "-0.001099", "ticker_sentiment_label": "Neutral"}]}, {"title": "Get Income On Gilead Stock, Or Buy It At A Discount With This Option Trade", "url": "https://www.investors.com/research/options/get-income-on-gilead-stock-or-buy-it-at-a-discount-with-this-option-trade/", "time_published": "20230420T140000", "authors": ["Investor's Business Daily", "GAVIN McMASTER"], "summary": "Get Income On Gilead Stock, Or Buy It At A Discount With This ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/10/stock-gilead-03-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": -0.014587, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.136499", "ticker_sentiment_score": "-0.17248", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Will Gilead  ( GILD )  Beat Estimates Again in Its Next Earnings Report?", "url": "https://www.zacks.com/stock/news/2081494/will-gilead-gild-beat-estimates-again-in-its-next-earnings-report", "time_published": "20230419T161013", "authors": ["Zacks Investment Research"], "summary": "Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default145.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99989"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.33125, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.176502", "ticker_sentiment_score": "0.153808", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead Sciences: Breaking Down Barriers To Access in HIV and Beyond: A Perspective", "url": "https://investingnews.com/gilead-sciences-breaking-down-barriers-to-access-in-hiv-and-beyond-a-perspective/", "time_published": "20230419T132030", "authors": [], "summary": "When I came to Gilead in 2019, I did so in part because of the revolutionary way this company thinks about bringing therapies to those who could benefit. Health equity and access are more than goals or ambitions - they're woven into the fabric of who we are and what we do.", "banner_image": "https://investingnews.com/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yNTg1ODg1NS9vcmlnaW4ucG5nIiwiZXhwaXJlc19hdCI6MTcwODY4MTIxOX0.Phin9ClvosnPNpkGRdBWHz_VFepTco5fqEYZcXCsZIQ/image.png?width=210", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.343235, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.137671", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Outpaces Stock Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2080758/gilead-sciences-gild-outpaces-stock-market-gains-what-you-should-know", "time_published": "20230418T220019", "authors": ["Zacks Investment Research"], "summary": "In the latest trading session, Gilead Sciences (GILD) closed at $83.78, marking a +0.18% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default37.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.179679, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.588876", "ticker_sentiment_score": "0.193727", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "PCSA: Why Insiders Are Aggressively Buying This Under $1 Stock", "url": "https://stocknews.com/news/pcsa-gild-otsky-alxn-why-insiders-are-aggressively-buying-this-under-1-stock/", "time_published": "20230418T190914", "authors": [], "summary": "Insider buying activity for Processa Pharmaceuticals, Inc. ( PCSA ) indicates confidence in the company's growth prospects. Insiders have been net buyers of 5.4% shares of the company over the past six months.", "banner_image": "https://stocknews.com/wp-content/uploads/2023/01/ISt_Biotechnology.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.193744, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PCSA", "relevance_score": "0.784902", "ticker_sentiment_score": "0.323802", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.195814", "ticker_sentiment_score": "0.193092", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Veklury\u00ae Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations", "url": "https://investingnews.com/veklury-r-efficacy-and-safety-profile-further-demonstrated-in-vulnerable-patient-populations/", "time_published": "20230416T085706", "authors": [], "summary": "Phase 3 Clinical Trial Demonstrated the Safety Profile of Veklury in Patients with Severe Renal Impairment - - Real-World Evidence Demonstrated Veklury Reduced COVID-19- Associated Mortality and Readmission Rates in Immunocompromised Patients Across All Variants of Concern, Including Omicron -", "banner_image": "https://investingnews.com/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yNTg1ODg1NS9vcmlnaW4ucG5nIiwiZXhwaXJlc19hdCI6MTcwODY4MTIxOX0.Phin9ClvosnPNpkGRdBWHz_VFepTco5fqEYZcXCsZIQ/image.png?width=210", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.048393, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.138331", "ticker_sentiment_score": "0.010279", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Dividend Stocks to Buy and Hold for the Next Decade", "url": "https://www.fool.com/investing/2023/04/15/3-dividend-stocks-to-buy-and-hold-for-the-next-dec/", "time_published": "20230415T101400", "authors": ["David Jagielski", "and Prosper Junior Bakiny", "Keith Speights"], "summary": "Long-term investors looking for income should especially like these stocks.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F727606%2Fwarren-buffett-brka-brkb-berkshire-hathaway-motley-fool2.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.208251, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.324673", "ticker_sentiment_score": "0.093828", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.165883", "ticker_sentiment_score": "0.125557", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.286002", "ticker_sentiment_score": "0.192414", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023", "url": "https://investingnews.com/gilead-sciences-to-release-first-quarter-2023-financial-results-on-thursday-april-27-2023/", "time_published": "20230413T204228", "authors": [], "summary": "Gilead Sciences, Inc. ( Nasdaq: GILD ) announced today that its first quarter 2023 financial results will be released on Thursday, April 27, 2023 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's first quarter 2023 ...", "banner_image": "https://investingnews.com/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yNTg1ODg1NS9vcmlnaW4ucG5nIiwiZXhwaXJlc19hdCI6MTcwODY4MTIxOX0.Phin9ClvosnPNpkGRdBWHz_VFepTco5fqEYZcXCsZIQ/image.png?width=210", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.136983, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.742397", "ticker_sentiment_score": "0.212227", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "1 Sector Received $6.1 Billion in AI Investments Last Year: 3 Top Stocks to Buy", "url": "https://www.fool.com/investing/2023/04/13/ai-investments-top-stocks-to-buy/", "time_published": "20230413T095000", "authors": ["Keith Speights"], "summary": "These companies are leading the way in using AI in healthcare.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F727802%2Fman-pointing-upward-toward-a-rising-red-line-on-a-wall.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.340754, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.201944", "ticker_sentiment_score": "0.154985", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABCL", "relevance_score": "0.101797", "ticker_sentiment_score": "0.260105", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OSCR", "relevance_score": "0.051003", "ticker_sentiment_score": "0.148377", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.051003", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.051003", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.051003", "ticker_sentiment_score": "-0.033105", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.051003", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.101797", "ticker_sentiment_score": "-0.02333", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.250902", "ticker_sentiment_score": "0.22827", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead Sciences  ( GILD )  Dips More Than Broader Markets: What You Should Know", "url": "https://www.zacks.com/stock/news/2077884/gilead-sciences-gild-dips-more-than-broader-markets-what-you-should-know", "time_published": "20230412T220024", "authors": ["Zacks Investment Research"], "summary": "Gilead Sciences (GILD) closed at $82.16 in the latest trading session, marking a -0.46% move from the prior day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default117.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.184663, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.70749", "ticker_sentiment_score": "0.22206", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead Sciences: 4 Questions: Global Experts Convene To Identify Key Measures to Long-Term Success in HIV", "url": "https://investingnews.com/gilead-sciences-4-questions-global-experts-convene-to-identify-key-measures-to-long-term-success-in-hiv/", "time_published": "20230412T131618", "authors": [], "summary": "Dr. Jeffrey Lazarus was studying at New York University in the late 1980s when he saw first-hand the devastation of the HIV epidemic.", "banner_image": "https://investingnews.com/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yNTg1ODg1NS9vcmlnaW4ucG5nIiwiZXhwaXJlc19hdCI6MTcwODY4MTIxOX0.Phin9ClvosnPNpkGRdBWHz_VFepTco5fqEYZcXCsZIQ/image.png?width=210", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.166004, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.076115", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Could Gilead Sciences Stock Help You Become a Millionaire?", "url": "https://www.fool.com/investing/2023/04/12/could-gilead-sciences-stock-help-be-millionaire/", "time_published": "20230412T093100", "authors": ["Jim Halley"], "summary": "The company's dominant HIV therapies and growing oncology pipeline are delivering.", "banner_image": "https://media.ycharts.com/charts/7f74823170209c33b3eec5d5e8d98015.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999186"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.129357, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.112269", "ticker_sentiment_score": "0.122525", "ticker_sentiment_label": "Neutral"}]}, {"title": "P/E Ratio Insights for Gilead Sciences - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/23/04/31753993/pe-ratio-insights-for-gilead-sciences", "time_published": "20230411T181540", "authors": ["Benzinga Insights"], "summary": "In the current session, the stock is trading at $82.91, after a 0.38% increase. Over the past month, Gilead Sciences Inc. GILD stock increased by 3.94%, and in the past year, by 33.60%.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_6886.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}], "overall_sentiment_score": -0.021354, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.433523", "ticker_sentiment_score": "0.120975", "ticker_sentiment_label": "Neutral"}]}, {"title": "A Look Into Gilead Sciences' Debt - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/23/04/31752657/a-look-into-gilead-sciences-debt", "time_published": "20230411T180133", "authors": ["Benzinga Insights"], "summary": "Shares of Gilead Sciences Inc. GILD decreased by 3.87% in the past three months. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its financials.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": -0.116062, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.36472", "ticker_sentiment_score": "0.015832", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is SPDR Portfolio S&P 500 High Dividend ETF  ( SPYD )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2076692/is-spdr-portfolio-sp-500-high-dividend-etf-spyd-a-strong-etf-right-now", "time_published": "20230411T102008", "authors": ["Zacks Investment Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default15.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999998"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.297878, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PFG", "relevance_score": "0.114137", "ticker_sentiment_score": "0.066424", "ticker_sentiment_label": "Neutral"}, {"ticker": "STT", "relevance_score": "0.057215", "ticker_sentiment_score": "0.075944", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.114137", "ticker_sentiment_score": "0.066424", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.114137", "ticker_sentiment_score": "0.066424", "ticker_sentiment_label": "Neutral"}]}, {"title": "If You Invested $10,000 in Gilead Sciences in 2013, This Is How Much You Would Have Today", "url": "https://www.fool.com/investing/2023/04/10/if-you-invested-10000-in-gilead-sciences-in-2013/", "time_published": "20230410T131500", "authors": ["David Jagielski"], "summary": "Would you have been better off investing in the S&P 500?", "banner_image": "https://media.ycharts.com/charts/c4b931a9cda07774fc069c4c5fd348aa.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.87644"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.998962"}], "overall_sentiment_score": 0.219554, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.169676", "ticker_sentiment_score": "0.142574", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Dividend Stocks Billionaires Seem to Love", "url": "https://www.fool.com/investing/2023/04/09/3-dividend-stocks-billionaires-seem-to-love/", "time_published": "20230409T113000", "authors": ["Prosper Junior Bakiny"], "summary": "It sometimes pays to follow the lead of successful people.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F727340%2Fperson-looking-at-charts-on-a-computer-screen.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.289046, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ATVI", "relevance_score": "0.041755", "ticker_sentiment_score": "-0.048512", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.362505", "ticker_sentiment_score": "0.25565", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.399416", "ticker_sentiment_score": "0.295095", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.399416", "ticker_sentiment_score": "0.324225", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BRK-A", "relevance_score": "0.041755", "ticker_sentiment_score": "0.158862", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is Invesco Dynamic Biotechnology & Genome ETF  ( PBE )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2075894/is-invesco-dynamic-biotechnology-genome-etf-pbe-a-strong-etf-right-now", "time_published": "20230407T102011", "authors": ["Zacks Investment Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default195.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999965"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.27811, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BMRN", "relevance_score": "0.113866", "ticker_sentiment_score": "0.060813", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.113866", "ticker_sentiment_score": "0.060813", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.113866", "ticker_sentiment_score": "0.060813", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.170075", "ticker_sentiment_score": "0.222013", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Post-Pandemic Potential: Analysts Eye InflaRx COVID-19 Antibody For Market Breakthrough - InflaRx  ( NASDAQ:IFRX ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/04/31702239/post-pandemic-potential-analysts-eye-inflarx-covid-19-antibody-for-market-breakthro", "time_published": "20230406T174948", "authors": ["Vandana Singh"], "summary": "On Wednesday, the FDA granted emergency-use authorization to InflaRx NV's IFRX monoclonal antibody for hospitalized COVID patients when initiated within 48 hours of receiving artificial life support. Vilobelimab will be sold under Gohibic.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/06/ifrx.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.118545, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALIF", "relevance_score": "0.179788", "ticker_sentiment_score": "0.192971", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.350564", "ticker_sentiment_score": "0.232312", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "6 Reasons to Buy Gilead Sciences Stock", "url": "https://www.fool.com/investing/2023/04/06/6-reasons-to-buy-gilead-sciences-stock/", "time_published": "20230406T121500", "authors": ["David Jagielski"], "summary": "The healthcare stock could be a solid pillar to build your portfolio around.", "banner_image": "https://media.ycharts.com/charts/c2359632a8a3d635bb44c77d7c4e785f.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": 0.363729, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.127795", "ticker_sentiment_score": "0.267925", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead Sciences: Overcoming COVID-19 in Early 2020: Keith's Story - Investing News Network", "url": "https://investingnews.com/gilead-sciences-overcoming-covid-19-in-early-2020-keith-s-story/", "time_published": "20230405T125845", "authors": [], "summary": "Gilead Sciences: Overcoming COVID-19 in Early 2020: Keith's Story Investing News Network ...", "banner_image": null, "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.012285, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.343279", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead details promising early COVID antiviral data, setting up larger studies", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-details-promising-early-covid-antiviral-data-setting-up-larger-studies-2023-04-04/", "time_published": "20230404T223400", "authors": ["Deena Beasley"], "summary": "Gilead details promising early COVID antiviral data, setting up larger ... ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/ABIV5OHS3FOONCLVUTPIG425MQ.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.055405, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "0.081552", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.081552", "ticker_sentiment_score": "0.092739", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Gains But Lags Market: What You Should Know", "url": "https://www.zacks.com/stock/news/2073994/gilead-sciences-gild-gains-but-lags-market-what-you-should-know", "time_published": "20230403T215020", "authors": ["Zacks Investment Research"], "summary": "In the latest trading session, Gilead Sciences (GILD) closed at $83.24, marking a +0.33% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default269.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.219756, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.603594", "ticker_sentiment_score": "0.248627", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Should iShares Select Dividend ETF  ( DVY )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2073520/should-ishares-select-dividend-etf-dvy-be-on-your-investing-radar", "time_published": "20230403T102010", "authors": ["Zacks Investment Research"], "summary": "Style Box ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default258.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.208505, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.061315", "ticker_sentiment_score": "0.117018", "ticker_sentiment_label": "Neutral"}, {"ticker": "VLO", "relevance_score": "0.122269", "ticker_sentiment_score": "0.068311", "ticker_sentiment_label": "Neutral"}, {"ticker": "MO", "relevance_score": "0.122269", "ticker_sentiment_score": "0.068311", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.122269", "ticker_sentiment_score": "0.068311", "ticker_sentiment_label": "Neutral"}]}, {"title": "Texas Judge Obstructs Affordable Act Coverage Mandate For Some Cancer Screenings, Prophylaxis - GSK  ( NYSE:GSK ) , Pfizer  ( NYSE:PFE ) ", "url": "https://www.benzinga.com/general/biotech/23/03/31609651/texas-judge-obstructs-affordable-act-coverage-mandate-for-some-cancer-screenings-prophylaxis", "time_published": "20230331T144701", "authors": ["Vandana Singh"], "summary": "A Texas federal judge reportedly blocked Obamacare's mandate that health insurance plans cover preventive care, including screenings for certain cancers and pre-exposure prophylaxis against HIV ( PrEP ) , at no cost to patients.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/31/obamacare.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.073363, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.294093", "ticker_sentiment_score": "0.055333", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.428632", "ticker_sentiment_score": "0.184048", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.294093", "ticker_sentiment_score": "0.055333", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGIOF", "relevance_score": "0.149656", "ticker_sentiment_score": "0.033259", "ticker_sentiment_label": "Neutral"}]}, {"title": "COVID Remains A Global Threat - NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All - AstraZeneca  ( NASDAQ:AZN ) , Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/general/biotech/23/03/31608814/covid-remains-a-global-threat-nanoviricides-set-to-begin-clinical-trials-for-pan-coronavirus-drug", "time_published": "20230331T132955", "authors": ["David Willey"], "summary": "Effective treatments for COVID-19 remain very few and very limited in their capabilities, even after three years. As a result, there are still high rates of hospitalizations and COVID remains many times more deadly than influenza.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/31/screenshot_2023-03-31_at_6.11.42_pm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.096216, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.092569", "ticker_sentiment_score": "-0.028047", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.092569", "ticker_sentiment_score": "-0.119524", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.092569", "ticker_sentiment_score": "-0.119524", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.092569", "ticker_sentiment_score": "-0.119524", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.183895", "ticker_sentiment_score": "-0.103546", "ticker_sentiment_label": "Neutral"}]}, {"title": "ImmuneOnco Banks On Cutting-edge Cancer Drugs To Attract IPO Cash - AbbVie  ( NYSE:ABBV ) , Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/markets/penny-stocks/23/03/31608710/immuneonco-banks-on-cutting-edge-cancer-drugs-to-attract-ipo-cash", "time_published": "20230331T132356", "authors": ["The Bamboo Works"], "summary": "ImmuneOnco's main product pipeline is a cancer drug targeting a promising protein pathway, the first such drug to enter clinical tests in China, with more intensive trials due in the fourth quarter Eli Lilly ranks as the company's biggest institutional investor after six rounds of financing", "banner_image": "https://cdn.benzinga.com/files/immuneonco-biopharma.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.682689"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.070068, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.13459", "ticker_sentiment_score": "0.136324", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.067536", "ticker_sentiment_score": "0.091222", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.067536", "ticker_sentiment_score": "0.091222", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.033799", "ticker_sentiment_score": "-0.086146", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMAB", "relevance_score": "0.13459", "ticker_sentiment_score": "0.157981", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Should Franklin U.S. Low Volatility High Dividend Index ETF  ( LVHD )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2072829/should-franklin-us-low-volatility-high-dividend-index-etf-lvhd-be-on-your-investing-radar", "time_published": "20230331T102007", "authors": ["Zacks Investment Research"], "summary": "Style Box ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default362.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.576289"}], "overall_sentiment_score": 0.19952, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APD", "relevance_score": "0.121037", "ticker_sentiment_score": "0.064599", "ticker_sentiment_label": "Neutral"}, {"ticker": "PM", "relevance_score": "0.121037", "ticker_sentiment_score": "0.064599", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.121037", "ticker_sentiment_score": "0.064599", "ticker_sentiment_label": "Neutral"}]}, {"title": "USFDA approves Lupin's tablets for Hepatitis B infection treatment | The Financial Express", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/usfda-approves-lupins-tablets-for-hepatitis-b-infection-treatment/3028562/", "time_published": "20230331T095500", "authors": [], "summary": "USFDA approves Lupin's tablets for Hepatitis B infection treatment The Financial Express ...", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/01/Lupin_1642115046-1.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.029005, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.377142", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "IGM Biosciences, Inc.  ( IGMS )  Reports Q4 Loss, Misses Revenue Estimates", "url": "https://www.zacks.com/stock/news/2072686/igm-biosciences-inc-igms-reports-q4-loss-misses-revenue-estimates", "time_published": "20230330T220505", "authors": ["Zacks Investment Research"], "summary": "IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 22.22% and 0.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default277.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999687"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.121464, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IGMS", "relevance_score": "0.404563", "ticker_sentiment_score": "0.079791", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.209365", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Texas judge blocks Obamacare coverage mandate for PrEP, cancer screening", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/texas-judge-blocks-obamacare-coverage-mandate-prep-cancer-screening-2023-03-30/", "time_published": "20230330T144000", "authors": ["Brendan Pierson"], "summary": "Texas judge blocks Obamacare coverage mandate for PrEP, cancer ... ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/VL3SGBXV3NJK5IJU236JYVK42U.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.049751, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.174587", "ticker_sentiment_score": "0.130925", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.174587", "ticker_sentiment_score": "0.130925", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.174587", "ticker_sentiment_score": "0.130925", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGIOF", "relevance_score": "0.174587", "ticker_sentiment_score": "0.130925", "ticker_sentiment_label": "Neutral"}]}, {"title": "Arcellx, Inc.  ( ACLX )  Reports Q4 Loss, Misses Revenue Estimates", "url": "https://www.zacks.com/stock/news/2072068/arcellx-inc-aclx-reports-q4-loss-misses-revenue-estimates", "time_published": "20230329T212506", "authors": ["Zacks Investment Research"], "summary": "Arcellx, Inc. (ACLX) delivered earnings and revenue surprises of -7.04% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default260.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999687"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.112407, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.410059", "ticker_sentiment_score": "0.050304", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.212425", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is It Time to Buy These Ultra-Cheap Dividend Stocks?", "url": "https://www.fool.com/investing/2023/03/29/is-it-time-to-buy-these-ultra-cheap-dividend-stock/", "time_published": "20230329T200000", "authors": ["George Budwell"], "summary": "These two biopharma stocks aren't exciting growth plays, but they are reliable income vehicles.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F726320%2Fshopping-photo.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999998"}], "overall_sentiment_score": 0.063119, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "0.320557", "ticker_sentiment_score": "0.007002", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.195814", "ticker_sentiment_score": "0.073154", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.065866", "ticker_sentiment_score": "0.033374", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Are Cathie Wood's Ark ETFs Still Trailing Nasdaq Stocks? - ARK Innovation ETF  ( ARCA:ARKK ) ", "url": "https://www.benzinga.com/markets/cryptocurrency/23/03/31550425/why-are-cathie-woods-ark-etfs-still-trailing-nasdaq-stocks", "time_published": "20230329T194258", "authors": ["Piero Cingari"], "summary": "From their all-time highs towards the end of 2021, tech stocks have suffered a significant blow from the Federal Reserve's interest rate hike cycle. The sectors and industries that, before and during the pandemic, were the big winners in the wake of historically low borrowing costs, subsequently ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/29/cathie_wood_bz_ark_2.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.928769"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.026742, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TMUS", "relevance_score": "0.204072", "ticker_sentiment_score": "0.171828", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.102888", "ticker_sentiment_score": "0.174143", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ROKU", "relevance_score": "0.204072", "ticker_sentiment_score": "-0.092497", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.301933", "ticker_sentiment_score": "-0.226218", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "U", "relevance_score": "0.204072", "ticker_sentiment_score": "-0.092497", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEP", "relevance_score": "0.204072", "ticker_sentiment_score": "0.171828", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.204072", "ticker_sentiment_score": "0.171828", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVZ", "relevance_score": "0.102888", "ticker_sentiment_score": "0.111155", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.301933", "ticker_sentiment_score": "-0.211772", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "GILD: 3 of the Best Stocks in 1 of Wall Street's Worst-Rated Industry", "url": "https://stocknews.com/news/gild-vrtx-biib-crsp-sage-3-of-the-best-stocks-in-1-of-wall-streets/", "time_published": "20230329T145932", "authors": [], "summary": "The biotech industry thrived during the pandemic with rising demand for drugs, therapies, and vaccines. However, various macroeconomic and regulatory challenges have hampered the industry's growth since last year, prompting massive layoffs and shutdowns.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/WallSt_FBOpt.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99977"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.230653, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.196411", "ticker_sentiment_score": "0.159672", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SAGE", "relevance_score": "0.074306", "ticker_sentiment_score": "0.001033", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.267626", "ticker_sentiment_score": "0.178621", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.290894", "ticker_sentiment_score": "0.248232", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run", "url": "https://www.fool.com/investing/2023/03/29/up-463-this-sizzling-growth-stock-could-have-a-lot/", "time_published": "20230329T114500", "authors": ["George Budwell"], "summary": "Viking Therapeutics stock might in the midst of a historic run.", "banner_image": "https://media.ycharts.com/charts/1aab74f832e3934f36451a893136f24a.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.245454, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VKTX", "relevance_score": "0.09439", "ticker_sentiment_score": "0.171561", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.09439", "ticker_sentiment_score": "0.146904", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.141171", "ticker_sentiment_score": "0.171906", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDGL", "relevance_score": "0.09439", "ticker_sentiment_score": "0.171561", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.047278", "ticker_sentiment_score": "0.05616", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.047278", "ticker_sentiment_score": "0.045979", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.141171", "ticker_sentiment_score": "0.171906", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.09439", "ticker_sentiment_score": "0.054225", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.047278", "ticker_sentiment_score": "0.05616", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Gains As Market Dips: What You Should Know", "url": "https://www.zacks.com/stock/news/2071582/gilead-sciences-gild-gains-as-market-dips-what-you-should-know", "time_published": "20230328T215020", "authors": ["Zacks Investment Research"], "summary": "Gilead Sciences (GILD) closed at $80.99 in the latest trading session, marking a +1.77% move from the prior day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default138.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.173469, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.603594", "ticker_sentiment_score": "0.23282", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Bunge, Gilead Sciences And A Famous Chocolate Maker On CNBC's 'Final Trades' - Bunge  ( NYSE:BG ) , Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/23/03/31506228/bunge-gilead-sciences-and-a-famous-chocolate-maker-on-cnbcs-final-trades", "time_published": "20230327T123436", "authors": ["Priya Nigam"], "summary": "On CNBC's \"Halftime Report Final Trades,\" JP Morgan Private Bank's Anastasia Amoroso said she is sticking with Invesco QQQ Trust QQQ. Stephen Weiss of Short Hills Capital Partners named Bunge Limited BG. \"I think it trades between 90 and 100,\" he added.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/27/trader44.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.26566, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTS", "relevance_score": "0.188193", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BG", "relevance_score": "0.766141", "ticker_sentiment_score": "0.275786", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.188193", "ticker_sentiment_score": "0.390066", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.524949", "ticker_sentiment_score": "0.404345", "ticker_sentiment_label": "Bullish"}, {"ticker": "IVZ", "relevance_score": "0.188193", "ticker_sentiment_score": "0.390066", "ticker_sentiment_label": "Bullish"}, {"ticker": "SBNY", "relevance_score": "0.366061", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSY", "relevance_score": "0.659096", "ticker_sentiment_score": "0.454149", "ticker_sentiment_label": "Bullish"}]}, {"title": "Should You Invest in the VanEck Biotech ETF  ( BBH ) ?", "url": "https://www.zacks.com/stock/news/2070609/should-you-invest-in-the-vaneck-biotech-etf-bbh", "time_published": "20230327T102008", "authors": ["Zacks Investment Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default100.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999998"}], "overall_sentiment_score": 0.147758, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.136113", "ticker_sentiment_score": "0.07192", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.136113", "ticker_sentiment_score": "0.07192", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.136113", "ticker_sentiment_score": "0.07192", "ticker_sentiment_label": "Neutral"}]}, {"title": "Everest Medicines Receives Full Upfront Payment from Gilead for Trodelvy-Related Transaction, Boosting Pro Forma Cash Reserves", "url": "https://www.prnewswire.com/news-releases/everest-medicines-receives-full-upfront-payment-from-gilead-for-trodelvy-related-transaction-boosting-pro-forma-cash-reserves-301781641.html", "time_published": "20230327T001900", "authors": ["Everest Medicines"], "summary": "Everest Medicines Receives Full Upfront Payment from Gilead for ... PR ...", "banner_image": "", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.178456, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.075635", "ticker_sentiment_score": "0.089906", "ticker_sentiment_label": "Neutral"}]}, {"title": "Everest Medicines Receives Full Upfront Payment from Gilead for Trodelvy-Related Transaction, Boosting Pro Forma Cash Reserves", "url": "https://www.prnewswire.com/apac/news-releases/everest-medicines-receives-full-upfront-payment-from-gilead-for-trodelvy-related-transaction-boosting-pro-forma-cash-reserves-301781645.html", "time_published": "20230327T001500", "authors": ["Everest Medicines"], "summary": "Everest Medicines Receives Full Upfront Payment from Gilead for ... PR ...", "banner_image": "", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.178456, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.075635", "ticker_sentiment_score": "0.089906", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gordon Moore, credited for bringing PCs to millions of homes, dies at 94", "url": "https://www.business-standard.com/article/international/gordon-moore-credited-for-bringing-pcs-to-millions-of-homes-dies-at-94-123032500346_1.html", "time_published": "20230325T075800", "authors": ["Raghav Aggarwal"], "summary": "Gordon Moore came up with the 'Moore's Law' that would push semiconductor companies to put billions of dollars into research and develop the industry at breakneck speed ...", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-03/25/full/1679731019-7065.png?im=Resize,width=640", "source": "Business Standard", "category_within_source": "Top Stories", "source_domain": "www.business-standard.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.156505, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.052226", "ticker_sentiment_score": "-0.069021", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.052226", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval", "url": "https://www.zacks.com/stock/news/2069798/biotech-stock-roundup-alt-obesity-data-gild-exercises-option-incy-drug-approval", "time_published": "20230323T175100", "authors": ["Zacks Investment Research"], "summary": "Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default326.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.04131, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NRIX", "relevance_score": "0.03443", "ticker_sentiment_score": "-0.126266", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRTX", "relevance_score": "0.068797", "ticker_sentiment_score": "0.088636", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALT", "relevance_score": "0.137083", "ticker_sentiment_score": "-0.04596", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.103035", "ticker_sentiment_score": "0.099816", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.03443", "ticker_sentiment_score": "-0.003881", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.068797", "ticker_sentiment_score": "-0.130733", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.137083", "ticker_sentiment_score": "0.038663", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILD: 2 Biotech Stocks to Buy Hand Over Fist in March", "url": "https://stocknews.com/news/gild-vrtx-2-biotech-stocks-to-buy-hand-over-fist-in-march/", "time_published": "20230323T172452", "authors": [], "summary": "Despite macroeconomic challenges, the biotech industry has been performing relatively well. Government initiatives, rapid technology breakthroughs, and inelastic demand for healthcare are fostering the growth of the biotech industry.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/Biotech-Lg_FB.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999941"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": 0.215632, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.329866", "ticker_sentiment_score": "0.258818", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.41608", "ticker_sentiment_score": "0.365139", "ticker_sentiment_label": "Bullish"}]}, {"title": "Is iShares Select Dividend ETF  ( DVY )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2069414/is-ishares-select-dividend-etf-dvy-a-strong-etf-right-now", "time_published": "20230323T102008", "authors": ["Zacks Investment Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default246.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999996"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.271919, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.056674", "ticker_sentiment_score": "0.049928", "ticker_sentiment_label": "Neutral"}, {"ticker": "VLO", "relevance_score": "0.113062", "ticker_sentiment_score": "0.060653", "ticker_sentiment_label": "Neutral"}, {"ticker": "MO", "relevance_score": "0.113062", "ticker_sentiment_score": "0.060653", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.113062", "ticker_sentiment_score": "0.060653", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2069416/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now", "time_published": "20230323T102007", "authors": ["Zacks Investment Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default135.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999953"}], "overall_sentiment_score": 0.28271, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.061631", "ticker_sentiment_score": "0.068004", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.122894", "ticker_sentiment_score": "0.068464", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.122894", "ticker_sentiment_score": "0.068464", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.122894", "ticker_sentiment_score": "0.068464", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Dips More Than Broader Markets: What You Should Know", "url": "https://www.zacks.com/stock/news/2069298/gilead-sciences-gild-dips-more-than-broader-markets-what-you-should-know", "time_published": "20230322T215025", "authors": ["Zacks Investment Research"], "summary": "Gilead Sciences (GILD) closed at $77.81 in the latest trading session, marking a -1.68% move from the prior day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default115.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.122743, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.608634", "ticker_sentiment_score": "0.172566", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead  ( GILD )  Announces OS Data on Yescarta From ZUMA-7 Study", "url": "https://www.zacks.com/stock/news/2069257/gilead-gild-announces-os-data-on-yescarta-from-zuma-7-study", "time_published": "20230322T183800", "authors": ["Zacks Investment Research"], "summary": "Gileads Yescarta shows statistically significant improvement in overall survival for initial treatment of R/R LBCL patients versus historical standard of care in curative setting.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c9/2325.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.158897, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.110717", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.110717", "ticker_sentiment_score": "0.20835", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NRIX", "relevance_score": "0.110717", "ticker_sentiment_score": "-0.142925", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILD: 3 Stocks to Buy Now for More Potential Upside", "url": "https://stocknews.com/news/gild-teva-mgnx-3-stocks-to-buy-now-for-more-potential-upside/", "time_published": "20230322T163842", "authors": [], "summary": "The recent banking sector turmoil has soared investor anxieties and raised the odds of an impending recession.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/shutterstock_275184728-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.1428, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MGNX", "relevance_score": "0.19117", "ticker_sentiment_score": "-0.025808", "ticker_sentiment_label": "Neutral"}, {"ticker": "MORN", "relevance_score": "0.027571", "ticker_sentiment_score": "-0.109664", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.321673", "ticker_sentiment_score": "0.128735", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.296191", "ticker_sentiment_score": "0.142229", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBNY", "relevance_score": "0.027571", "ticker_sentiment_score": "-0.215178", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MS", "relevance_score": "0.027571", "ticker_sentiment_score": "-0.026345", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences' Debt Overview - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/23/03/31460358/gilead-sciences-debt-overview", "time_published": "20230322T161625", "authors": ["Benzinga Insights"], "summary": "Shares of Gilead Sciences Inc. GILD fell by 7.40% in the past three months. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its financials.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": -0.108774, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.281153", "ticker_sentiment_score": "-0.111064", "ticker_sentiment_label": "Neutral"}]}, {"title": "National AIDS Memorial Quilt Stops in Memphis to Break the Stigma and Change the Pattern Around AIDS in Black and Brown Communities", "url": "https://www.benzinga.com/pressreleases/23/03/g31460051/national-aids-memorial-quilt-stops-in-memphis-to-break-the-stigma-and-change-the-pattern-around-ai", "time_published": "20230322T160331", "authors": ["Globe Newswire"], "summary": "MEMPHIS, Tenn., March 22, 2023 ( GLOBE NEWSWIRE ) -- Memphis ranks eighth in the nation for new HIV cases per year among large cities in the United States, according to the Infectious Disease Society of America.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.16868, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.096671", "ticker_sentiment_score": "0.05561", "ticker_sentiment_label": "Neutral"}]}, {"title": "A Bull Market Is Coming: Load Up On These 3 Cheap Stocks Today", "url": "https://www.fool.com/investing/2023/03/22/a-bull-market-is-coming-load-up-on-3-cheap-stocks/", "time_published": "20230322T140700", "authors": ["David Jagielski"], "summary": "These stocks are all trading at less than 12 times their future profits.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F725221%2Fwarren-buffett-brka-brkb-berkshire-hathaway-motley-fool5.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999996"}, {"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.207186, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.358521", "ticker_sentiment_score": "0.145668", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCZ", "relevance_score": "0.358521", "ticker_sentiment_score": "0.289898", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.158173", "ticker_sentiment_score": "0.00404", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should SPDR Russell 1000 Yield Focus ETF  ( ONEY )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2068839/should-spdr-russell-1000-yield-focus-etf-oney-be-on-your-investing-radar", "time_published": "20230322T102007", "authors": ["Zacks Investment Research"], "summary": "Style Box ETF report for ONEY ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default316.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.231277, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HPQ", "relevance_score": "0.121037", "ticker_sentiment_score": "0.068013", "ticker_sentiment_label": "Neutral"}, {"ticker": "STT", "relevance_score": "0.060694", "ticker_sentiment_score": "0.108006", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.121037", "ticker_sentiment_score": "0.068013", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSX", "relevance_score": "0.121037", "ticker_sentiment_score": "0.068013", "ticker_sentiment_label": "Neutral"}]}, {"title": "Four Elements Of Healthcare Industry Leadership: China Summit", "url": "https://www.forbes.com/sites/forbeschina/2023/03/22/four-elements-of-healthcare-industry-leadership-forbes-china-summit/", "time_published": "20230322T045600", "authors": ["Russell Flannery"], "summary": "\"Healthcare can often be a very conservative industry because it's an industry that deals with very long timetables. However, playing it too safe and too careful can leave you behind competitors,\" Forbes Senior Editor Alex Knapp believes.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/641a86684534d42cd0ac6673/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.272087, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABCL", "relevance_score": "0.042876", "ticker_sentiment_score": "0.110706", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.042876", "ticker_sentiment_score": "-0.06925", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.042876", "ticker_sentiment_score": "0.0109", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.042876", "ticker_sentiment_score": "-0.06925", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.085629", "ticker_sentiment_score": "0.116594", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.042876", "ticker_sentiment_score": "-0.06925", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.042876", "ticker_sentiment_score": "0.193171", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "U.S.-China Collaboration Could Cut Development Time, Cost For New Cancer Treatments", "url": "https://www.forbes.com/sites/forbeschina/2023/03/22/us-china-collaboration-could-cut-development-time-cost-for-new-cancer-treatments/", "time_published": "20230322T041051", "authors": ["Russell Flannery"], "summary": "The world's current system for developing cancer drugs is unsustainable, Memorial Sloan Kettering oncologist Dr. Bob Li believes.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/641a7b6f7b3644404cbdef2f/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.022182, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.053153", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.053153", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.053153", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Harness Uncertainty To Overcome It In Today's Business World: China Summit", "url": "https://www.forbes.com/sites/forbeschina/2023/03/21/harness-uncertainty-to-overcome-it-in-todays-business-world-forbes-china-summit/", "time_published": "20230322T005442", "authors": ["Russell Flannery"], "summary": "In today's uncertain times, business leaders should focus on what is certain in their environment as a key approach to success, University of Michigan Business Professor told a Forbes China gathering last week ...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/641a4c7e6b19e283db4b2898/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.251334, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.06697", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.06697", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.06697", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead  ( GILD )  Exercises Option to License Nurix's Candidate", "url": "https://www.zacks.com/stock/news/2068682/gilead-gild-exercises-option-to-license-nurixs-candidate", "time_published": "20230321T184700", "authors": ["Zacks Investment Research"], "summary": "Gilead (GILD) exercises an option under its collaboration agreement with Nurix to license the latter???s investigational targeted protein degrader molecule NX 0479.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c9/2325.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.129253, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.069094", "ticker_sentiment_score": "0.093331", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.137671", "ticker_sentiment_score": "-0.117264", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.137671", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRIX", "relevance_score": "0.137671", "ticker_sentiment_score": "-0.117264", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILD: 3 Dividend Paying Stocks to Buy in March", "url": "https://stocknews.com/news/gild-cvs-mo-osh-3-dividend-paying-stocks-to-buy-in-march/", "time_published": "20230321T141851", "authors": [], "summary": "While the stock market has had a strong start to the year, macroeconomic concerns will likely keep it under pressure in the short term.", "banner_image": "https://stocknews.com/wp-content/uploads/2021/12/shutterstock_1271080456-1-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.99977"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.221506, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.305817", "ticker_sentiment_score": "0.306334", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MO", "relevance_score": "0.276561", "ticker_sentiment_score": "0.179131", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.362946", "ticker_sentiment_score": "0.232872", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OSH", "relevance_score": "0.062679", "ticker_sentiment_score": "0.188184", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Kite's Yescarta\u00ae CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma", "url": "https://investingnews.com/kite-s-yescarta-r-car-t-cell-therapy-demonstrates-a-statistically-significant-improvement-in-overall-survival-for-initial-treatment-of-relapsed-refractory-large-b-cell-lymphoma/", "time_published": "20230321T141145", "authors": [], "summary": "Kite, a Gilead Company ( Nasdaq: GILD ) , today announced the primary overall survival ( OS ) analysis results of the Phase 3 ZUMA-7 study.", "banner_image": "https://investingnews.com/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yNTg1ODg1NS9vcmlnaW4ucG5nIiwiZXhwaXJlc19hdCI6MTcwODY4MTIxOX0.Phin9ClvosnPNpkGRdBWHz_VFepTco5fqEYZcXCsZIQ/image.png?width=210", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": -0.114462, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.05387", "ticker_sentiment_score": "0.072982", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nurix's  ( NRIX )  Stock Up Due to License Option Exercise by Gilead", "url": "https://www.zacks.com/stock/news/2068549/nurixs-nrix-stock-up-due-to-license-option-exercise-by-gilead", "time_published": "20230321T140500", "authors": ["Zacks Investment Research"], "summary": "Nurix Therapeutics (NRIX) to earn an option fee of $20 million as partner Gilead exercised its option to exclusively license Nurix's investigational targeted protein degrader molecule NX 0479.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/21635.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.014697, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.128135", "ticker_sentiment_score": "-0.065329", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANVS", "relevance_score": "0.19117", "ticker_sentiment_score": "0.055112", "ticker_sentiment_label": "Neutral"}, {"ticker": "APTX", "relevance_score": "0.19117", "ticker_sentiment_score": "0.043279", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRIX", "relevance_score": "0.313218", "ticker_sentiment_score": "-0.107839", "ticker_sentiment_label": "Neutral"}]}, {"title": "What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years? - BioRestorative Therapies  ( NASDAQ:BRTX ) , Bristol-Myers Squibb  ( NYSE:BMY ) ", "url": "https://www.benzinga.com/general/biotech/23/03/31438097/what-is-autologous-cell-based-therapy-the-treatment-revolutionizing-regenerative-medicine-that-co", "time_published": "20230321T130708", "authors": ["Julian Richard"], "summary": "Autologous cell based therapies are personalized therapies using your own cells to target a disease or disorder. Personalized therapies targeting cancer such CAR-T cell therapies have generated impressive clinical results with complete remission rates in B-acute lymphoblastic leukemia in over ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/21/shutterstock_2125554068.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.186414, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SSTK", "relevance_score": "0.050044", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRTX", "relevance_score": "0.293506", "ticker_sentiment_score": "0.2403", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.09989", "ticker_sentiment_score": "0.203818", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.09989", "ticker_sentiment_score": "0.203818", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.050044", "ticker_sentiment_score": "0.190246", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Strength Seen in Nurix Therapeutics, Inc.  ( NRIX ) : Can Its 5.7% Jump Turn into More Strength?", "url": "https://www.zacks.com/stock/news/2068270/strength-seen-in-nurix-therapeutics-inc-nrix-can-its-57-jump-turn-into-more-strength", "time_published": "20230321T074900", "authors": ["Zacks Investment Research"], "summary": "Nurix Therapeutics, Inc. (NRIX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default287.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.17165, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PTGX", "relevance_score": "0.483888", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.103331", "ticker_sentiment_score": "0.076203", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRIX", "relevance_score": "0.483888", "ticker_sentiment_score": "0.182305", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "GILD: 3 Nasdaq Stocks That Could Carry Your Portfolio for Years", "url": "https://stocknews.com/news/gild-vrtx-adsk-3-nasdaq-stocks-that-could-carry-your-portfolio-for-years/", "time_published": "20230320T194636", "authors": [], "summary": "Nasdaq components Gilead Sciences, Inc. ( GILD ) , Vertex Pharmaceuticals Incorporated ( VRTX ) , and Autodesk, Inc.'s ( ADSK ) ever-improving performance could translate into impressive returns in the long run. In this piece, I have discussed several reasons I am bullish on these stocks despite ...", "banner_image": "https://stocknews.com/wp-content/uploads/2022/01/shutterstock_611856299-4-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999365"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.258744, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.236332", "ticker_sentiment_score": "0.205616", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.335928", "ticker_sentiment_score": "0.326397", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNCE", "relevance_score": "0.079832", "ticker_sentiment_score": "0.183452", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.053271", "ticker_sentiment_score": "0.067719", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRDA", "relevance_score": "0.079832", "ticker_sentiment_score": "0.125131", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADSK", "relevance_score": "0.158868", "ticker_sentiment_score": "0.177979", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "First Republic Bank's stock plummets and Peloton's stock falls while New York Community Bank shares soar, and other stocks on the move", "url": "https://www.marketwatch.com/story/new-york-community-bank-shares-surge-and-foot-lockers-stock-gains-but-first-republics-stock-hit-by-s-p-downgrade-b51e92d3", "time_published": "20230320T155600", "authors": ["", "Tomi Kilgore", "Jamie Chisholm"], "summary": "NYCB stock benefits from news it is snapping up some assets of failed Signature Bank.", "banner_image": "https://images.mktw.net/im-746997/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.101132, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACW", "relevance_score": "0.28387", "ticker_sentiment_score": "-0.355822", "ticker_sentiment_label": "Bearish"}, {"ticker": "ENPH", "relevance_score": "0.28387", "ticker_sentiment_score": "0.366415", "ticker_sentiment_label": "Bullish"}, {"ticker": "MDNDF", "relevance_score": "0.144275", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRIX", "relevance_score": "0.28387", "ticker_sentiment_score": "0.044546", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.28387", "ticker_sentiment_score": "0.044546", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBNY", "relevance_score": "0.144275", "ticker_sentiment_score": "0.156479", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NYCB", "relevance_score": "0.28387", "ticker_sentiment_score": "0.255041", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FLT", "relevance_score": "0.28387", "ticker_sentiment_score": "0.233511", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead Exercises First License Option Under Agreement With Nurix Therapeutics - Nurix Therapeutics  ( NASDAQ:NRIX ) , Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/general/biotech/23/03/31420626/gilead-exercises-first-license-option-under-agreement-with-nurix-therapeutics", "time_published": "20230320T141729", "authors": ["Vandana Singh"], "summary": "Gilead Sciences Inc GILD has exercised its option to license Nurix Therapeutics Inc's NRIX investigational targeted protein degrader molecule NX-0479 exclusively. This bivalent degrader, GS-6791, is the first development candidate from the previously announced Nurix-Gilead collaboration.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/20/gild.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.033853, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.410059", "ticker_sentiment_score": "-0.064556", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRIX", "relevance_score": "0.280615", "ticker_sentiment_score": "-0.299416", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Gilead Exercises Option to License Nurix's IRAK4 Targeted Protein Degrader Development Candidate, NX-0479", "url": "https://investingnews.com/gilead-exercises-option-to-license-nurix-s-irak4-targeted-protein-degrader-development-candidate-nx-0479/", "time_published": "20230320T130721", "authors": [], "summary": "-- IRAK4 Program Represents the First of Up to Five Degrader Programs Within the 2019 Discovery Collaboration Agreement -- -- Nurix to Receive a $20 Million Option Fee --", "banner_image": "https://investingnews.com/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yNTg1ODg1NS9vcmlnaW4ucG5nIiwiZXhwaXJlc19hdCI6MTcwODY4MTIxOX0.Phin9ClvosnPNpkGRdBWHz_VFepTco5fqEYZcXCsZIQ/image.png?width=210", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.055659, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.113169", "ticker_sentiment_score": "0.001163", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRIX", "relevance_score": "0.113169", "ticker_sentiment_score": "0.028543", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Exercises Option to License Nurix's IRAK4 Targeted Protein Degrader Development Candidate, NX-0479", "url": "https://www.globenewswire.com/news-release/2023/03/20/2630267/0/en/Gilead-Exercises-Option-to-License-Nurix-s-IRAK4-Targeted-Protein-Degrader-Development-Candidate-NX-0479.html", "time_published": "20230320T123000", "authors": ["Inc.", "Nurix Therapeutics"], "summary": "-- IRAK4 Program Represents the First of Up to Five Degrader Programs Within the 2019 Discovery Collaboration Agreement -- -- Nurix to Receive a $20 Million Option Fee ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/e95c30b7-0b40-4147-a34b-d48f933a63c7", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.058141, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.091772", "ticker_sentiment_score": "0.001076", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRIX", "relevance_score": "0.068896", "ticker_sentiment_score": "-0.009111", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences Unusual Options Activity - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/markets/options/23/03/31402802/gilead-sciences-unusual-options-activity", "time_published": "20230317T184556", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bullish stance on Gilead Sciences GILD. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.196236, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.737923", "ticker_sentiment_score": "0.308104", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Sensex gains 355 pts, Nifty ends at 17,100, VIX slumps 9%", "url": "https://www.business-standard.com/article/news-cm/sensex-gains-355-pts-nifty-ends-at-17-100-vix-slumps-9-123031700798_1.html", "time_published": "20230317T102200", "authors": ["Capital Market"], "summary": "Sensex gains 355 pts, Nifty ends at 17100, VIX slumps 9%s Business Standard ...", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/default/1230317/full-123031700798.jpg", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.10019, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AON", "relevance_score": "0.035138", "ticker_sentiment_score": "0.121576", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNEJF", "relevance_score": "0.035138", "ticker_sentiment_score": "0.133298", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.035138", "ticker_sentiment_score": "0.140151", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.035138", "ticker_sentiment_score": "0.140151", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.035138", "ticker_sentiment_score": "0.140151", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRC", "relevance_score": "0.105141", "ticker_sentiment_score": "0.077821", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.070207", "ticker_sentiment_score": "0.018306", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.035138", "ticker_sentiment_score": "-0.08031", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.035138", "ticker_sentiment_score": "0.004932", "ticker_sentiment_label": "Neutral"}]}, {"title": "Indices trade with minor gains, metal stocks shine", "url": "https://www.business-standard.com/article/news-cm/indices-trade-with-minor-gains-metal-stocks-shine-123031700671_1.html", "time_published": "20230317T090400", "authors": ["Capital Market"], "summary": "The domestic equity barometers pared losses and traded with minor gains in mid-afternoon trade. The Nifty traded above the 17,000 level after hitting day's low of 16,958.15 in afternoon trade. Realty, IT and metal stocks advanced while media, auto and FMCG stocks declined.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/default/1230317/full-123031700671.jpg", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.048152, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.076847", "ticker_sentiment_score": "0.04934", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRC", "relevance_score": "0.076847", "ticker_sentiment_score": "-0.08433", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.076847", "ticker_sentiment_score": "-0.08433", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.076847", "ticker_sentiment_score": "-0.08433", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.152983", "ticker_sentiment_score": "0.057584", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Gains But Lags Market: What You Should Know", "url": "https://www.zacks.com/stock/news/2066960/gilead-sciences-gild-gains-but-lags-market-what-you-should-know", "time_published": "20230316T214524", "authors": ["Zacks Investment Research"], "summary": "Gilead Sciences (GILD) closed at $79.85 in the latest trading session, marking a +0.25% move from the prior day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default38.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.164436, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.556576", "ticker_sentiment_score": "0.303418", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead  ( GILD )  Gains 34% in 12 Months: Will the Trend Sustain?", "url": "https://www.zacks.com/stock/news/2066925/gilead-gild-gains-34-in-12-months-will-the-trend-sustain", "time_published": "20230316T161000", "authors": ["Zacks Investment Research"], "summary": "Gilead (GILD) gains 34% in the past 12 months as its HIV business and rapidly growing oncology business maintain momentum despite volatility.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/388.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.276838, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.065506", "ticker_sentiment_score": "0.109163", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.130571", "ticker_sentiment_score": "0.088325", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.130571", "ticker_sentiment_score": "0.060577", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.130571", "ticker_sentiment_score": "0.07042", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Stock Moves -0.15%: What You Should Know", "url": "https://www.zacks.com/stock/news/2066402/gilead-sciences-gild-stock-moves--015-what-you-should-know", "time_published": "20230315T215021", "authors": ["Zacks Investment Research"], "summary": "In the latest trading session, Gilead Sciences (GILD) closed at $79.65, marking a -0.15% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default78.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.085282, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.659949", "ticker_sentiment_score": "0.128837", "ticker_sentiment_label": "Neutral"}]}, {"title": "First Drugs Facing Medicare Price Penalty Named", "url": "https://www.wsj.com/articles/first-drugs-facing-medicare-price-penalty-named-by-u-s-6453e7d9", "time_published": "20230315T162400", "authors": ["Stephanie Armour and Jared S. Hopkins"], "summary": "U.S. health officials listed 27 medications whose prices rose faster than inflation, triggering rebates under a new federal law.", "banner_image": "https://images.wsj.net/im-743043?size=1.5005861664712778&width=96&height=96", "source": "Wall Street Journal", "category_within_source": "Business", "source_domain": "www.wsj.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.272617, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.371523", "ticker_sentiment_score": "-0.171126", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GILD", "relevance_score": "0.371523", "ticker_sentiment_score": "-0.171126", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Drug Companies Raising Prices Greater Than Inflation? US Government Mulling Imposing Fines - AbbVie  ( NYSE:ABBV ) ", "url": "https://www.benzinga.com/general/biotech/23/03/31357344/drug-companies-raising-prices-greater-than-inflation-us-government-mulling-imposing-fines", "time_published": "20230315T123010", "authors": ["Vandana Singh"], "summary": "Under Joe Biden's signature Inflation Reduction Act, drugmakers for twenty-seven drugs will be penalized for charging prices that rise faster than inflation for people with disabilities or the elderly on the government's Medicare health program.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/15/accuse-image_by_tumisu_from_pixaby_.jpg?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.216921, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.423843", "ticker_sentiment_score": "-0.302104", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GILD", "relevance_score": "0.290607", "ticker_sentiment_score": "-0.472091", "ticker_sentiment_label": "Bearish"}, {"ticker": "SGEN", "relevance_score": "0.290607", "ticker_sentiment_score": "-0.472091", "ticker_sentiment_label": "Bearish"}, {"ticker": "PFE", "relevance_score": "0.147818", "ticker_sentiment_score": "0.221919", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "HOOKIPA Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook", "url": "https://www.globenewswire.com/news-release/2023/03/15/2627479/0/en/HOOKIPA-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-2023-Outlook.html", "time_published": "20230315T110000", "authors": ["HOOKIPA Pharma Inc"], "summary": "NEW YORK and VIENNA, March 15, 2023 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( NASDAQ: HOOK, 'HOOKIPA' ) , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and provided a corporate update for the fourth quarter ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/62ba88bb-8adc-44c4-9fd7-3f6ca365c93d", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.972756"}, {"topic": "Earnings", "relevance_score": "0.839681"}], "overall_sentiment_score": 0.162089, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HOOK", "relevance_score": "0.064319", "ticker_sentiment_score": "0.028103", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.016096", "ticker_sentiment_score": "0.080771", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is SPDR Russell 1000 Yield Focus ETF  ( ONEY )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2065878/is-spdr-russell-1000-yield-focus-etf-oney-a-strong-etf-right-now", "time_published": "20230315T102008", "authors": ["Zacks Investment Research"], "summary": "Smart Beta ETF report for ONEY ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default195.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.317402, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HPQ", "relevance_score": "0.113866", "ticker_sentiment_score": "0.059703", "ticker_sentiment_label": "Neutral"}, {"ticker": "STT", "relevance_score": "0.057079", "ticker_sentiment_score": "0.134964", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.113866", "ticker_sentiment_score": "0.059703", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSX", "relevance_score": "0.113866", "ticker_sentiment_score": "0.059703", "ticker_sentiment_label": "Neutral"}]}, {"title": "US to impose inflation fines on first set of drugs, lowering costs", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-impose-inflation-fines-first-set-drugs-lowering-costs-2023-03-15/", "time_published": "20230315T090500", "authors": ["Ahmed Aboulenein"], "summary": "WASHINGTON, March 15 ( Reuters ) - The U.S. government will subject 27 drugs to inflation penalties, it announced on Wednesday, meaning people on Medicare will pay less out-of-pocket by $2 to as high as $390 per average dose starting April 1.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/VMY4FFYTAVMRBCX5YM57HFKPWE.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.201141, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.12165", "ticker_sentiment_score": "-0.138131", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.12165", "ticker_sentiment_score": "-0.138131", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.12165", "ticker_sentiment_score": "-0.138131", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILD: 2 Smart Dividend Stocks to Buy Now for Steady Gains", "url": "https://stocknews.com/news/gild-mo-2-smart-dividend-stocks-to-buy-now-for-steady-gains/", "time_published": "20230314T135552", "authors": [], "summary": "While the stock market has seen a solid start to the year, macroeconomic concerns are expected to keep the market under pressure in the near term. With volatility expected to remain, I think dividend-paying stocks Gilead Sciences, Inc. ( GILD ) and Altria Group, Inc. ( MO ) could be worth buying ...", "banner_image": "https://stocknews.com/wp-content/uploads/2021/06/shutterstock_597023354-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.995077"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.999186"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.158825, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BAC", "relevance_score": "0.038284", "ticker_sentiment_score": "0.043308", "ticker_sentiment_label": "Neutral"}, {"ticker": "MO", "relevance_score": "0.368773", "ticker_sentiment_score": "0.171138", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.467372", "ticker_sentiment_score": "0.241156", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Global Antiviral Therapies Market Predicted to Generate a Revenue of $66,016.5 Million, Growing at a CAGR of 3.1% over the 2020-2027 Timeframe [208-Pages] | Explicated by Research Dive", "url": "https://www.benzinga.com/pressreleases/23/03/g31339569/global-antiviral-therapies-market-predicted-to-generate-a-revenue-of-66-016-5-million-growing-at-a", "time_published": "20230314T130500", "authors": ["Globe Newswire"], "summary": "New York, USA, March 14, 2023 ( GLOBE NEWSWIRE ) -- According to a report published by Research Dive, the global antiviral therapies market is projected to garner a revenue of $66,016.5 million and rise at a CAGR of 3.1% throughout the estimated period from 2020 to 2027.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.221134, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.068502", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VIR", "relevance_score": "0.068502", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.068502", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.068502", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?", "url": "https://www.zacks.com/stock/news/2065154/should-you-invest-in-the-ishares-biotechnology-etf-ibb", "time_published": "20230314T102011", "authors": ["Zacks Investment Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default340.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}], "overall_sentiment_score": 0.159936, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.067919", "ticker_sentiment_score": "0.034065", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.135347", "ticker_sentiment_score": "0.071708", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.135347", "ticker_sentiment_score": "0.071708", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.135347", "ticker_sentiment_score": "0.071708", "ticker_sentiment_label": "Neutral"}]}, {"title": "Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements", "url": "https://www.globenewswire.com/news-release/2023/03/13/2625713/0/en/Enochian-BioSciences-Achieves-Full-Compliance-with-NASDAQ-Filing-Requirements.html", "time_published": "20230313T123000", "authors": ["Enochian Bioscience"], "summary": "LOS ANGELES, March 13, 2023 ( GLOBE NEWSWIRE ) -- ( NASDAQ: ENOB ) . Enochian BioSciences Inc. ( the Company ) announced that it has achieved full compliance with NASDAQ filing requirements. The Annual Report on Form 10-K was filed on February 27, 2023, followed by the Quarterly Reports on Forms ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/6c0053ba-7c61-4e29-93f3-cc189b0327e4", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.172095, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ENOB", "relevance_score": "0.508593", "ticker_sentiment_score": "0.14648", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.109455", "ticker_sentiment_score": "0.157191", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements - Enochian BioSciences  ( NASDAQ:ENOB ) ", "url": "https://www.benzinga.com/pressreleases/23/03/g31318724/enochian-biosciences-achieves-full-compliance-with-nasdaq-filing-requirements", "time_published": "20230313T123000", "authors": ["Globe Newswire"], "summary": "LOS ANGELES, March 13, 2023 ( GLOBE NEWSWIRE ) -- ENOB. Enochian BioSciences Inc. ( the Company ) announced that it has achieved full compliance with NASDAQ filing requirements.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.16724, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ENOB", "relevance_score": "0.493128", "ticker_sentiment_score": "0.146816", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.105604", "ticker_sentiment_score": "0.155186", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Should IQ Chaikin U.S. Large Cap ETF  ( CLRG )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2064527/should-iq-chaikin-us-large-cap-etf-clrg-be-on-your-investing-radar", "time_published": "20230313T102009", "authors": ["Zacks Investment Research"], "summary": "Style Box ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default302.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Energy & Transportation", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.14302, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.12546", "ticker_sentiment_score": "0.065631", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.12546", "ticker_sentiment_score": "0.065631", "ticker_sentiment_label": "Neutral"}]}, {"title": "Everest Medicines Announces Silicon Valley Bank Developments Have Minimal Impact on Company", "url": "https://www.prnewswire.com/news-releases/everest-medicines-announces-silicon-valley-bank-developments-have-minimal-impact-on-company-301769704.html", "time_published": "20230312T234300", "authors": ["Everest Medicines"], "summary": "Everest Medicines Announces Silicon Valley Bank Developments ... PR ...", "banner_image": "", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.13556, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.082677", "ticker_sentiment_score": "0.032603", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 Best ETFs Tracking CRISPR Gene Editing", "url": "https://www.fool.com/investing/stock-market/market-sectors/healthcare/genomics-stocks/crispr-etfs/", "time_published": "20230310T204533", "authors": ["Keith Speights"], "summary": "These exchange-traded funds track companies in this biotech space.", "banner_image": "https://m.foolcdn.com/media/dubs/images/original_imageshttpsg.foolcdn.comeditorialimag.width-880_mOUIjpd.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.980509"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.17576, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SRPT", "relevance_score": "0.087503", "ticker_sentiment_score": "0.136786", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTLT", "relevance_score": "0.130926", "ticker_sentiment_score": "0.065929", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.087503", "ticker_sentiment_score": "0.094818", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.087503", "ticker_sentiment_score": "0.057183", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.043818", "ticker_sentiment_score": "0.05428", "ticker_sentiment_label": "Neutral"}, {"ticker": "DHR", "relevance_score": "0.087503", "ticker_sentiment_score": "0.049578", "ticker_sentiment_label": "Neutral"}, {"ticker": "PKI", "relevance_score": "0.087503", "ticker_sentiment_score": "0.049578", "ticker_sentiment_label": "Neutral"}, {"ticker": "BEAM", "relevance_score": "0.087503", "ticker_sentiment_score": "0.094818", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGMO", "relevance_score": "0.087503", "ticker_sentiment_score": "0.057183", "ticker_sentiment_label": "Neutral"}, {"ticker": "TECH", "relevance_score": "0.087503", "ticker_sentiment_score": "0.057183", "ticker_sentiment_label": "Neutral"}, {"ticker": "DTIL", "relevance_score": "0.087503", "ticker_sentiment_score": "0.049578", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.130926", "ticker_sentiment_score": "0.056825", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.087503", "ticker_sentiment_score": "0.049578", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.087503", "ticker_sentiment_score": "0.049578", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.130926", "ticker_sentiment_score": "0.061935", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.130926", "ticker_sentiment_score": "0.052824", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.087503", "ticker_sentiment_score": "0.136786", "ticker_sentiment_label": "Neutral"}, {"ticker": "WT", "relevance_score": "0.043818", "ticker_sentiment_score": "0.047067", "ticker_sentiment_label": "Neutral"}, {"ticker": "EVO", "relevance_score": "0.087503", "ticker_sentiment_score": "0.046284", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.130926", "ticker_sentiment_score": "0.133773", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILD: 4 Strong Buy Stocks to Buy in March 2023", "url": "https://stocknews.com/news/gild-hca-mck-lyts-cvs-4-strong-buy-stocks-to-buy-in-march-2023/", "time_published": "20230310T175545", "authors": [], "summary": "GILD: 4 Strong Buy Stocks to Buy in March ...", "banner_image": "https://stocknews.com/wp-content/uploads/2021/11/shutterstock_637209379-1-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.242237, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.040044", "ticker_sentiment_score": "0.188987", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.217568", "ticker_sentiment_score": "0.100174", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.119731", "ticker_sentiment_score": "0.137864", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.020028", "ticker_sentiment_score": "0.013535", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCA", "relevance_score": "0.159174", "ticker_sentiment_score": "0.136848", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYTS", "relevance_score": "0.23678", "ticker_sentiment_score": "0.192508", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks Delivering High-Dividend Yields - Gilead Sciences  ( NASDAQ:GILD ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/23/03/31295242/wall-streets-most-accurate-analysts-say-hold-these-3-health-care-stocks-delivering-high-dividend-yie", "time_published": "20230310T133613", "authors": ["Lisa Levin"], "summary": "During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/10/image15.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.082144, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BCS", "relevance_score": "0.10607", "ticker_sentiment_score": "-0.069083", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.10607", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.10607", "ticker_sentiment_score": "0.190022", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.10607", "ticker_sentiment_score": "0.144132", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.210274", "ticker_sentiment_score": "-0.096329", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences  ( GILD )  Stock Moves -1.55%: What You Should Know", "url": "https://www.zacks.com/stock/news/2063802/gilead-sciences-gild-stock-moves--155-what-you-should-know", "time_published": "20230309T224525", "authors": ["Zacks Investment Research"], "summary": "In the latest trading session, Gilead Sciences (GILD) closed at $78.96, marking a -1.55% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default107.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.088132, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.641573", "ticker_sentiment_score": "0.198783", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Shares of MacroGenics Jumped Thursday", "url": "https://www.fool.com/investing/2023/03/09/why-shares-of-macrogenics-jumped-thursday/", "time_published": "20230309T205900", "authors": ["Jim Halley"], "summary": "The company made a sale worth as much as $200 million for the royalty rights for its type-1 diabetes therapy.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F723519%2F2022-rivian-r1t-22.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.270974, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MGNX", "relevance_score": "0.754041", "ticker_sentiment_score": "0.429893", "ticker_sentiment_label": "Bullish"}, {"ticker": "ZLAB", "relevance_score": "0.131643", "ticker_sentiment_score": "0.202812", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.131643", "ticker_sentiment_score": "0.202812", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PRVB", "relevance_score": "0.131643", "ticker_sentiment_score": "0.202812", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Anti-Viral Therapies Market Growth  ( $82.92 Billion by 2028 )  Driven by Branded Drugs Segment during  ( 2022-2028 )  - Global Report by The Insight Partners", "url": "https://www.benzinga.com/pressreleases/23/03/g31276388/anti-viral-therapies-market-growth-82-92-billion-by-2028-driven-by-branded-drugs-segment-during-20", "time_published": "20230309T134617", "authors": ["Globe Newswire"], "summary": "New York, March 09, 2023 ( GLOBE NEWSWIRE ) -- According to The Insight Partners, \"Anti-Viral Therapies Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global Analysis by Type ( Generic Drugs and Branded Drugs ) , Mechanism of Action ( Nucleotide Polymerase ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.002392, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.049835", "ticker_sentiment_score": "0.05679", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.02493", "ticker_sentiment_score": "0.067196", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.02493", "ticker_sentiment_score": "0.067196", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.02493", "ticker_sentiment_score": "-0.003819", "ticker_sentiment_label": "Neutral"}, {"ticker": "RPNRF", "relevance_score": "0.02493", "ticker_sentiment_score": "-0.003819", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.02493", "ticker_sentiment_score": "0.067196", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGIOF", "relevance_score": "0.02493", "ticker_sentiment_score": "-0.003819", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Franklin U.S. Low Volatility High Dividend Index ETF  ( LVHD )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2063344/is-franklin-us-low-volatility-high-dividend-index-etf-lvhd-a-strong-etf-right-now", "time_published": "20230309T112009", "authors": ["Zacks Investment Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default285.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999996"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.239606, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APD", "relevance_score": "0.11123", "ticker_sentiment_score": "0.062494", "ticker_sentiment_label": "Neutral"}, {"ticker": "PM", "relevance_score": "0.11123", "ticker_sentiment_score": "0.062494", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.11123", "ticker_sentiment_score": "0.062494", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is IQ Chaikin U.S. Large Cap ETF  ( CLRG )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2063354/is-iq-chaikin-us-large-cap-etf-clrg-a-strong-etf-right-now", "time_published": "20230309T112006", "authors": ["Zacks Investment Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default282.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Energy & Transportation", "relevance_score": "0.5"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999965"}], "overall_sentiment_score": 0.232733, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.114956", "ticker_sentiment_score": "0.057692", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.114956", "ticker_sentiment_score": "0.057692", "ticker_sentiment_label": "Neutral"}]}, {"title": "Factbox: What's in Biden's budget: taxes on buybacks, rail safety, childcare", "url": "https://www.reuters.com/markets/rates-bonds/whats-bidens-budget-taxes-buybacks-rail-safety-childcare-2023-03-08/", "time_published": "20230308T234800", "authors": ["Reuters"], "summary": "Factbox: What's in Biden's budget: taxes on buybacks, rail safety ... ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/DT4OAXAAXVNSBA3ACB5BWNXLSI.jpg", "source": "Reuters", "category_within_source": "Markets", "source_domain": "www.reuters.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Blockchain", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.129028, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.046273", "ticker_sentiment_score": "0.130138", "ticker_sentiment_label": "Neutral"}]}, {"title": "Antifungal Drugs Market Worth  ( $13.99 Billion by 2028 )  at 3.3% CAGR - Global Analysis by Therapeutic Indication  ( Aspergillosis, Dermatophytosis, Candidiasis ) ", "url": "https://www.benzinga.com/pressreleases/23/03/g31257180/antifungal-drugs-market-worth-13-99-billion-by-2028-at-3-3-cagr-global-analysis-by-therapeutic-ind", "time_published": "20230308T135936", "authors": ["Globe Newswire"], "summary": "New York, March 08, 2023 ( GLOBE NEWSWIRE ) -- Latest Research Report by The Insight Partners, \"Antifungal Drugs Market Size, Share, Growth, Value and Global Forecast to 2028 - Global Analysis by Infection Type ( Superficial Fungal Infection and Systemic Fungal Infection ) , Drug Type ( ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.011984, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SCYX", "relevance_score": "0.033098", "ticker_sentiment_score": "0.098384", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.033098", "ticker_sentiment_score": "0.098384", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.033098", "ticker_sentiment_score": "0.098384", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.033098", "ticker_sentiment_score": "0.098384", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.033098", "ticker_sentiment_score": "0.098384", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.033098", "ticker_sentiment_score": "0.098384", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILD: 3 Stocks with Tremendous Growth Potential in 2023", "url": "https://stocknews.com/news/gild-coke-ooma-ko-3-stocks-with-tremendous-growth-potential-in-2023/", "time_published": "20230308T081115", "authors": [], "summary": "GILD: 3 Stocks with Tremendous Growth Potential in ...", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/shutterstock_275184728-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.247995, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.047797", "ticker_sentiment_score": "0.061176", "ticker_sentiment_label": "Neutral"}, {"ticker": "COKE", "relevance_score": "0.142706", "ticker_sentiment_score": "0.259277", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OOMA", "relevance_score": "0.280884", "ticker_sentiment_score": "0.265948", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.303175", "ticker_sentiment_score": "0.198935", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KO", "relevance_score": "0.071641", "ticker_sentiment_score": "0.191545", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "BMY: 2 Dividend Stocks That Could Pay You for the Rest of Your Life", "url": "https://stocknews.com/news/bmy-gild-jnj-2-dividend-stocks-that-could-pay-you-for-the-rest/", "time_published": "20230307T172348", "authors": [], "summary": "Investors' confidence has taken a hit due to macroeconomic issues. As bear-market risks remain, I think it is ideal to invest in quality dividend stocks, Bristol-Myers Squibb Company ( BMY ) and Gilead Sciences, Inc. ( GILD ) , that can ensure a steady income source.", "banner_image": "https://stocknews.com/wp-content/uploads/2021/10/shutterstock_468517802-1-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.99999"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.116522, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.253646", "ticker_sentiment_score": "0.186817", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.032251", "ticker_sentiment_score": "-0.212302", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BMY", "relevance_score": "0.372448", "ticker_sentiment_score": "0.156846", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.064449", "ticker_sentiment_score": "-0.035016", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Healthcare Stocks That Could Help Set You Up for Life", "url": "https://www.fool.com/investing/2023/03/07/2-healthcare-stocks-could-help-set-you-up-for-life/", "time_published": "20230307T143700", "authors": ["Prosper Junior Bakiny"], "summary": "Even seemingly boring businesses can deliver solid returns over long periods.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F723433%2Fnyse-wall-street-trading-new-york-financial-stock-market-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.404353, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "MDT", "relevance_score": "0.329237", "ticker_sentiment_score": "0.341687", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.495877", "ticker_sentiment_score": "0.58638", "ticker_sentiment_label": "Bullish"}]}, {"title": "A Look Into Gilead Sciences' Debt - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/23/03/31221891/a-look-into-gilead-sciences-debt", "time_published": "20230306T170145", "authors": ["Benzinga Insights"], "summary": "Shares of Gilead Sciences Inc. GILD moved lower by 9.56% in the past three months. Before having a look at the importance of debt, let's look at how much debt Gilead Sciences has.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": -0.137594, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.3007", "ticker_sentiment_score": "-0.157037", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Peering Into Gilead Sciences's Recent Short Interest - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/short-sellers/23/03/31220356/peering-into-gilead-sciencess-recent-short-interest", "time_published": "20230306T154524", "authors": ["Benzinga Insights"], "summary": "Gilead Sciences's GILD short percent of float has risen 3.28% since its last report. The company recently reported that it has 15.76 million shares sold short, which is 1.26% of all regular shares that are available for trading.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.267332, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.221819", "ticker_sentiment_score": "0.155473", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead Sciences  ( GILD )  Outpaces Stock Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2061733/gilead-sciences-gild-outpaces-stock-market-gains-what-you-should-know", "time_published": "20230303T224526", "authors": ["Zacks Investment Research"], "summary": "Gilead Sciences (GILD) closed the most recent trading day at $81.07, moving +1.82% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default347.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.154586, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.668563", "ticker_sentiment_score": "0.327787", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "GILD: 1 Resilient Growth Stock to Buy Now and Hold Forever", "url": "https://stocknews.com/news/gild-vrtx-biib-incy-1-resilient-growth-stock-to-buy-now-and-hold-forever/", "time_published": "20230303T170502", "authors": [], "summary": "After a brutal 2022, growth stocks are expected to stage a recovery amid cooling inflation, the Fed's downshift on monetary policy tightening, and recent economic data, including strong retail sales and job growth, hinting at the possibility of the economy getting a soft landing.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/shutterstock_275184728-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999922"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.276727, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.06623", "ticker_sentiment_score": "0.091152", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.06623", "ticker_sentiment_score": "0.091152", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.59404", "ticker_sentiment_score": "0.358087", "ticker_sentiment_label": "Bullish"}, {"ticker": "BIIB", "relevance_score": "0.06623", "ticker_sentiment_score": "0.091152", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILD: The 3 Best Biotech Stocks to Buy for Under $100", "url": "https://stocknews.com/news/gild-incy-taipy-the-3-best-biotech-stocks-to-buy-for-under-100/", "time_published": "20230303T150517", "authors": [], "summary": "GILD: The 3 Best Biotech Stocks to Buy for Under ...", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/Biotech-Lg_FB.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}], "overall_sentiment_score": 0.206632, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "INCY", "relevance_score": "0.241284", "ticker_sentiment_score": "0.192736", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.391311", "ticker_sentiment_score": "0.237799", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TAIPY", "relevance_score": "0.202028", "ticker_sentiment_score": "0.165088", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Jim Cramer's stock picks: Investors can now bet on or against them through two new funds | The Financial Express", "url": "https://www.financialexpress.com/investing-abroad/featured-stories/jim-cramers-stock-picks-investors-can-now-bet-on-or-against-them-through-two-new-funds/2999013/", "time_published": "20230303T143100", "authors": [], "summary": "Jim Cramer's stock picks: Investors can now bet on or against them ... The Financial Express ...", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/03/21.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.999997"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.115059, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.102013", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.102013", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.102013", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TDOC", "relevance_score": "0.102013", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "F", "relevance_score": "0.102013", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.102013", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOK", "relevance_score": "0.102013", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACN", "relevance_score": "0.102013", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.102013", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNAP", "relevance_score": "0.102013", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSCO", "relevance_score": "0.102013", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.102013", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASML", "relevance_score": "0.102013", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZI", "relevance_score": "0.102013", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PENN", "relevance_score": "0.102013", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VICI", "relevance_score": "0.102013", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VFC", "relevance_score": "0.102013", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.102013", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.102013", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.102013", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PANW", "relevance_score": "0.102013", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLTR", "relevance_score": "0.102013", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Thousands of Women, Dozens of Top Employers Gather in Silicon Valley to Discuss Women in the Workplace", "url": "https://www.benzinga.com/pressreleases/23/03/n31151581/thousands-of-women-dozens-of-top-employers-gather-in-silicon-valley-to-discuss-women-in-the-workpl", "time_published": "20230302T024700", "authors": ["PRNewswire"], "summary": "SANTA CLARA,Calif., March 1, 2023 /PRNewswire/ -- Amid layoffs, economic headwinds, and backsliding on women's rights in many parts of the world, thousands of people from dozens of top employers gathered today to address women in the workplace at the 2023 California Conference for Women.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}], "overall_sentiment_score": 0.277467, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TER", "relevance_score": "0.076602", "ticker_sentiment_score": "0.161138", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.076602", "ticker_sentiment_score": "0.161138", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UAL", "relevance_score": "0.076602", "ticker_sentiment_score": "0.161138", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNPR", "relevance_score": "0.076602", "ticker_sentiment_score": "0.161138", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.076602", "ticker_sentiment_score": "0.161138", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NYT", "relevance_score": "0.152499", "ticker_sentiment_score": "0.32409", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.076602", "ticker_sentiment_score": "0.161138", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SSNLF", "relevance_score": "0.076602", "ticker_sentiment_score": "0.161138", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HOLX", "relevance_score": "0.076602", "ticker_sentiment_score": "0.161138", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "STT", "relevance_score": "0.076602", "ticker_sentiment_score": "0.161138", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.076602", "ticker_sentiment_score": "0.161138", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ATVI", "relevance_score": "0.076602", "ticker_sentiment_score": "0.161138", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.076602", "ticker_sentiment_score": "0.161138", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DELL", "relevance_score": "0.076602", "ticker_sentiment_score": "0.161138", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "PFE: 2 COVID-19 Stocks That are Still Darlings in 2023", "url": "https://stocknews.com/news/pfe-gild-2-covid-19-stocks-that-are-still-darlings-in-2023/", "time_published": "20230228T173118", "authors": [], "summary": "PFE: 2 COVID-19 Stocks That are Still Darlings in ...", "banner_image": "https://stocknews.com/wp-content/uploads/2021/03/holx-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Earnings", "relevance_score": "0.999975"}], "overall_sentiment_score": 0.147809, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PFE", "relevance_score": "0.405378", "ticker_sentiment_score": "0.227315", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.358521", "ticker_sentiment_score": "0.247184", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pulmonary Arterial Hypertension Market Worth  ( $10.88 Billion by 2028 )  Lead by Asia Pacific Region  ( 6.5% CAGR )  - Global Report by The Insight Partners", "url": "https://www.benzinga.com/pressreleases/23/02/g31091255/pulmonary-arterial-hypertension-market-worth-10-88-billion-by-2028-lead-by-asia-pacific-region-6-5", "time_published": "20230228T140329", "authors": ["Globe Newswire"], "summary": "New York, Feb. 28, 2023 ( GLOBE NEWSWIRE ) -- According to The Insight Partners, \"Pulmonary Arterial Hypertension Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global Analysis By Drugs [Endothelin Receptor Antagonists ( ERAs ) , Prostacyclin and ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.077839, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LQDA", "relevance_score": "0.042159", "ticker_sentiment_score": "0.126267", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.021087", "ticker_sentiment_score": "0.076814", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.021087", "ticker_sentiment_score": "0.076814", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.021087", "ticker_sentiment_score": "0.112619", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.021087", "ticker_sentiment_score": "0.076814", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.021087", "ticker_sentiment_score": "0.076814", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.021087", "ticker_sentiment_score": "0.076814", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.021087", "ticker_sentiment_score": "0.076814", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.021087", "ticker_sentiment_score": "0.076814", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTHR", "relevance_score": "0.042159", "ticker_sentiment_score": "0.127257", "ticker_sentiment_label": "Neutral"}]}, {"title": "These 13 beaten-down stocks offer a 'margin of safety' from a possible credit shock, according to a top-1% fund manager", "url": "https://www.businessinsider.com/13-cheap-stocks-to-buy-recession-interest-rates-credit-shock-2023-2", "time_published": "20230228T130500", "authors": ["James Faris"], "summary": "13 Undervalued Stocks to Buy in a Recession: Top-1% Fund Manager - Business Insider ...", "banner_image": null, "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "www.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.857896"}], "overall_sentiment_score": 0.118454, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KMB", "relevance_score": "0.071677", "ticker_sentiment_score": "0.197786", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ZBH", "relevance_score": "0.071677", "ticker_sentiment_score": "0.236789", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CPB", "relevance_score": "0.071677", "ticker_sentiment_score": "0.197786", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SPR", "relevance_score": "0.071677", "ticker_sentiment_score": "0.069915", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLB", "relevance_score": "0.035875", "ticker_sentiment_score": "0.24258", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.071677", "ticker_sentiment_score": "0.214791", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FLS", "relevance_score": "0.071677", "ticker_sentiment_score": "0.069915", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.071677", "ticker_sentiment_score": "0.236789", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HXL", "relevance_score": "0.071677", "ticker_sentiment_score": "0.069915", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLX", "relevance_score": "0.071677", "ticker_sentiment_score": "0.197786", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.071677", "ticker_sentiment_score": "0.214791", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KEX", "relevance_score": "0.071677", "ticker_sentiment_score": "0.069915", "ticker_sentiment_label": "Neutral"}]}, {"title": "JNJ: The 4 Best Forever Stocks to Buy in February 2023", "url": "https://stocknews.com/news/jnj-gild-stla-cah-pltr-the-4-best-forever-stocks-to-buy-in-february-2023/", "time_published": "20230227T163254", "authors": [], "summary": "JNJ: The 4 Best Forever Stocks to Buy in February ...", "banner_image": "https://stocknews.com/wp-content/uploads/2022/01/shutterstock_1251939934-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.82617"}, {"topic": "Earnings", "relevance_score": "0.999999"}], "overall_sentiment_score": 0.160384, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LPLA", "relevance_score": "0.025817", "ticker_sentiment_score": "0.047001", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.025817", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.204287", "ticker_sentiment_score": "0.172725", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.253778", "ticker_sentiment_score": "0.095294", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.204287", "ticker_sentiment_score": "0.04087", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLTR", "relevance_score": "0.051607", "ticker_sentiment_score": "0.173495", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF  ( PBE ) ?", "url": "https://www.zacks.com/stock/news/2059096/should-you-invest-in-the-invesco-dynamic-biotechnology-genome-etf-pbe", "time_published": "20230227T112009", "authors": ["Zacks Investment Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default312.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.218745, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BMRN", "relevance_score": "0.133841", "ticker_sentiment_score": "0.071297", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.133841", "ticker_sentiment_score": "0.071297", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.133841", "ticker_sentiment_score": "0.071297", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.199584", "ticker_sentiment_score": "0.142469", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Stocks to Buy Right Now That Are Cash Cows", "url": "https://www.fool.com/investing/2023/02/25/3-stocks-to-buy-right-now-that-are-cash-cows/", "time_published": "20230225T112500", "authors": ["and Prosper Junior Bakiny", "Keith Speights", "David Jagielski"], "summary": "If cash is king, these three stocks should wear crowns.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F722052%2Fcash-cow.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.858979"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.248705, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.163631", "ticker_sentiment_score": "-0.031846", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.429956", "ticker_sentiment_score": "0.290415", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.041181", "ticker_sentiment_score": "0.06782", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.163631", "ticker_sentiment_score": "0.082121", "ticker_sentiment_label": "Neutral"}]}, {"title": "WHO panel is reviewing whether COVID vaccines need to be updated", "url": "https://www.marketwatch.com/story/who-panel-is-reviewing-whether-covid-vaccines-need-updating-as-agency-monitors-7-omicron-subvariants-3ff416a8", "time_published": "20230224T164000", "authors": ["Ciara Linnane"], "summary": "Most of the week's COVID news is focused on vaccines, including the big slide in Moderna's revenue caused by falling demand.", "banner_image": "https://images.mktw.net/im-731427?width=700&height=371", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": -0.040599, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.081691", "ticker_sentiment_score": "-0.001034", "ticker_sentiment_label": "Neutral"}, {"ticker": "NYT", "relevance_score": "0.040899", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.081691", "ticker_sentiment_score": "-0.001034", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Invesco S&P 500 High Dividend Low Volatility ETF  ( SPHD )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2058561/is-invesco-sp-500-high-dividend-low-volatility-etf-sphd-a-strong-etf-right-now", "time_published": "20230224T112004", "authors": ["Zacks Investment Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default125.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999986"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.229802, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MO", "relevance_score": "0.114956", "ticker_sentiment_score": "0.066606", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.114956", "ticker_sentiment_score": "0.066606", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.171688", "ticker_sentiment_score": "0.092075", "ticker_sentiment_label": "Neutral"}, {"ticker": "KMI", "relevance_score": "0.114956", "ticker_sentiment_score": "0.066606", "ticker_sentiment_label": "Neutral"}]}, {"title": "GSK/Pfizer-Backed ViiV Healthcare's HIV Treatment At Par With Gilead's: Study Shows - Pfizer  ( NYSE:PFE ) ", "url": "https://www.benzinga.com/news/large-cap/23/02/31022960/gskpfizer-backed-viiv-healthcares-hiv-treatment-at-par-with-gileads-study-shows", "time_published": "20230223T134336", "authors": ["Vandana Singh"], "summary": "ViiV Healthcare, majority-owned by GSK Plc GSK, Pfizer Inc PFE, and Shionogi Limited, announced 12-month findings from the SOLAR Phase 3b study of the long-acting injectable regimen Cabenuva ( cabotegravir, rilpivirine [CAB+RPV LA] ) compared against complete daily oral regimen Biktarvy ( ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/02/23/aapharma_1.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.019194, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BICEF", "relevance_score": "0.673107", "ticker_sentiment_score": "0.239382", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.305058", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.443626", "ticker_sentiment_score": "0.014539", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.443626", "ticker_sentiment_score": "0.014539", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGIOF", "relevance_score": "0.155451", "ticker_sentiment_score": "-0.054268", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILD: It's Time to Buy Up These 3 Growth Stocks In 2023", "url": "https://stocknews.com/news/gild-jazz-door-its-time-to-buy-up-these-3-growth-stocks-in/", "time_published": "20230223T125334", "authors": [], "summary": "GILD: It's Time to Buy Up These 3 Growth Stocks In ...", "banner_image": "https://stocknews.com/wp-content/uploads/2019/04/Growth-1.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.207742, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPGI", "relevance_score": "0.033421", "ticker_sentiment_score": "0.001993", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.32478", "ticker_sentiment_score": "0.23467", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GS", "relevance_score": "0.033421", "ticker_sentiment_score": "0.007821", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.198493", "ticker_sentiment_score": "0.302294", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DOOR", "relevance_score": "0.230704", "ticker_sentiment_score": "0.246966", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "4 Drug, Biotech Stocks Poised to Beat Q4 Earnings Estimates", "url": "https://www.zacks.com/stock/news/2057943/4-drug-biotech-stocks-poised-to-beat-q4-earnings-estimates", "time_published": "20230223T124600", "authors": ["Zacks Investment Research"], "summary": "We look at a few drug/biotech companies, TBPH, FGEN, AUPH, CYTK, which are poised to beat on earnings in the fourth quarter.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default295.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.163402, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TBPH", "relevance_score": "0.319488", "ticker_sentiment_score": "0.044096", "ticker_sentiment_label": "Neutral"}, {"ticker": "AUPH", "relevance_score": "0.275867", "ticker_sentiment_score": "0.222109", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CYTK", "relevance_score": "0.319488", "ticker_sentiment_score": "0.109702", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.046907", "ticker_sentiment_score": "0.097373", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.046907", "ticker_sentiment_score": "0.015914", "ticker_sentiment_label": "Neutral"}, {"ticker": "FGEN", "relevance_score": "0.319488", "ticker_sentiment_score": "0.097143", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.046907", "ticker_sentiment_score": "0.097373", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.046907", "ticker_sentiment_score": "0.097373", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should Invesco S&P 500 High Dividend Low Volatility ETF  ( SPHD )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2057910/should-invesco-sp-500-high-dividend-low-volatility-etf-sphd-be-on-your-investing-radar", "time_published": "20230223T112003", "authors": ["Zacks Investment Research"], "summary": "Style Box ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default342.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.152996, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MO", "relevance_score": "0.120733", "ticker_sentiment_score": "0.067941", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.120733", "ticker_sentiment_score": "0.067941", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.180236", "ticker_sentiment_score": "0.076588", "ticker_sentiment_label": "Neutral"}, {"ticker": "KMI", "relevance_score": "0.120733", "ticker_sentiment_score": "0.067941", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV", "url": "https://investingnews.com/gilead-presents-positive-proof-of-concept-data-for-investigational-combination-regimen-of-lenacapavir-with-broadly-neutralizing-antibodies-as-a-potential-twice-yearly-approach-for-the-treatment-of-hiv/", "time_published": "20230222T170727", "authors": [], "summary": "Study Demonstrates the Potential of Lenacapavir in Combination with Broadly Neutralizing HIV Antibodies Teropavimab and Zinlirvimab -", "banner_image": "https://investingnews.com/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yNTg1ODg1NS9vcmlnaW4ucG5nIiwiZXhwaXJlc19hdCI6MTcwODY4MTIxOX0.Phin9ClvosnPNpkGRdBWHz_VFepTco5fqEYZcXCsZIQ/image.png?width=210", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.091423, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.166551", "ticker_sentiment_score": "0.104726", "ticker_sentiment_label": "Neutral"}]}, {"title": "GSK's ViiV says study shows its long-acting HIV shot as effective as Gilead's daily pill", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/gsks-viiv-says-study-shows-its-long-acting-hiv-shot-effective-gileads-daily-pill-2023-02-22/", "time_published": "20230222T160800", "authors": ["Maggie Fick"], "summary": "GSK's ViiV says study shows its long-acting HIV shot as effective as ... ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/C3IJFZRAE5O3HBL6MNVRGWSEEM.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.037495, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.100729", "ticker_sentiment_score": "0.091522", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.100729", "ticker_sentiment_score": "0.061625", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.100729", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGIOF", "relevance_score": "0.100729", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Sciences Touts Encouraging Data From Real World Studies Of Its Flagship COVID-19 Treatment - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/general/biotech/23/02/31005994/gilead-sciences-touts-encouraging-data-from-real-world-studies-of-its-flagship-covid-19-treatment", "time_published": "20230222T143726", "authors": ["Vandana Singh"], "summary": "Gilead Sciences Inc GILD announced data from three retrospective real-world Veklury ( remdesivir ) studies for COVID-19 treatment.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/02/22/gild_logo_light__ebbb55419ca9273264e56cff479e848c.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.108788, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.410059", "ticker_sentiment_score": "0.191612", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Kite Completes Acquisition of Tmunity - Investing News Network", "url": "https://investingnews.com/kite-completes-acquisition-of-tmunity/", "time_published": "20230222T142322", "authors": [], "summary": "Kite Completes Acquisition of Tmunity Investing News Network ...", "banner_image": null, "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.083406, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.057352", "ticker_sentiment_score": "0.080949", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.057352", "ticker_sentiment_score": "0.080949", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.226477", "ticker_sentiment_score": "0.120834", "ticker_sentiment_label": "Neutral"}]}, {"title": "This Recession-Proof Company Has a Best-in-Class Dividend", "url": "https://www.fool.com/investing/2023/02/22/this-recession-proof-company-has-a-best-in-class-d/", "time_published": "20230222T123000", "authors": ["George Budwell"], "summary": "Pfizer's highly attractive valuation, rock-solid dividend program, and enormous yield put it at the top of its big pharma peer group.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F721691%2Fpills-dollar-symbol.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.904684"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}], "overall_sentiment_score": 0.166219, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JNJ", "relevance_score": "0.139265", "ticker_sentiment_score": "-0.114321", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.139265", "ticker_sentiment_score": "-0.114321", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.207571", "ticker_sentiment_score": "0.126829", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.139265", "ticker_sentiment_score": "-0.114321", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.339046", "ticker_sentiment_score": "0.41866", "ticker_sentiment_label": "Bullish"}, {"ticker": "PFE", "relevance_score": "0.339046", "ticker_sentiment_score": "0.229493", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.139265", "ticker_sentiment_score": "-0.114321", "ticker_sentiment_label": "Neutral"}]}, {"title": "Veklury\u00ae Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients", "url": "https://investingnews.com/veklury-r-reduced-risk-of-mortality-in-hospitalized-covid-19-patients-across-all-variant-time-periods-in-a-real-world-study-of-more-than-500000-hospitalized-patients/", "time_published": "20230221T225930", "authors": [], "summary": "Real-World Evidence from Clinical Practice Demonstrates Use of Veklury was Associated with a Statistically Significant Reduction in Mortality in an Overall Patient Population, Including Immunocompromised Patients -", "banner_image": "https://investingnews.com/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yNTg1ODg1NS9vcmlnaW4ucG5nIiwiZXhwaXJlc19hdCI6MTcwODY4MTIxOX0.Phin9ClvosnPNpkGRdBWHz_VFepTco5fqEYZcXCsZIQ/image.png?width=210", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.135841, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.142565", "ticker_sentiment_score": "0.081246", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies", "url": "https://investingnews.com/gilead-presents-new-data-from-hiv-cure-research-program-and-collaborations-exploring-novel-investigational-combinations-and-strategies/", "time_published": "20230221T202133", "authors": [], "summary": "Innovative Investigational Approaches Include Targeting of the HIV Viral Reservoir and Enhancing Immune Response in the Absence of Antiretroviral Therapy -", "banner_image": "https://investingnews.com/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yNTg1ODg1NS9vcmlnaW4ucG5nIiwiZXhwaXJlc19hdCI6MTcwODY4MTIxOX0.Phin9ClvosnPNpkGRdBWHz_VFepTco5fqEYZcXCsZIQ/image.png?width=210", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.162417, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.207826", "ticker_sentiment_score": "0.125778", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRTS", "relevance_score": "0.030026", "ticker_sentiment_score": "0.109383", "ticker_sentiment_label": "Neutral"}]}, {"title": "How Are Biotech ETFs Reacting to Q4 Earnings Releases?", "url": "https://www.zacks.com/stock/news/2057067/how-are-biotech-etfs-reacting-to-q4-earnings-releases", "time_published": "20230221T192100", "authors": ["Zacks Investment Research"], "summary": "The latest earnings from some of the big biotech players came in at mixed this reporting season.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default319.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}, {"topic": "Earnings", "relevance_score": "0.999953"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.053064, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.096671", "ticker_sentiment_score": "0.294335", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.144563", "ticker_sentiment_score": "-0.060782", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.096671", "ticker_sentiment_score": "-0.030346", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.096671", "ticker_sentiment_score": "-0.078435", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGN: 3 Biotech Stocks to Buy in 2023 That Could Help Set You up for Life", "url": "https://stocknews.com/news/amgn-gild-uthr-3-biotech-stocks-to-buy-in-2023-that-could-help/", "time_published": "20230221T140317", "authors": [], "summary": "AMGN: 3 Biotech Stocks to Buy in 2023 That Could Help Set You up ... ...", "banner_image": "https://stocknews.com/wp-content/uploads/2023/01/ISt_Biotechnology.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999956"}], "overall_sentiment_score": 0.233151, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.285829", "ticker_sentiment_score": "0.211241", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.260838", "ticker_sentiment_score": "0.169863", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.053094", "ticker_sentiment_score": "0.073022", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.053094", "ticker_sentiment_score": "0.282885", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UTHR", "relevance_score": "0.184296", "ticker_sentiment_score": "0.101429", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Global X SuperDividend U.S. ETF  ( DIV )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2056634/is-global-x-superdividend-us-etf-div-a-strong-etf-right-now", "time_published": "20230221T112006", "authors": ["Zacks Investment Research"], "summary": "Smart Beta ETF report for DIV ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default332.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}], "overall_sentiment_score": 0.238722, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SBR", "relevance_score": "0.113866", "ticker_sentiment_score": "0.063033", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.113866", "ticker_sentiment_score": "0.063033", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead  ( GILD )  Reports Positive Data From Urothelial Cancer Study", "url": "https://www.zacks.com/stock/news/2056487/gilead-gild-reports-positive-data-from-urothelial-cancer-study", "time_published": "20230220T165300", "authors": ["Zacks Investment Research"], "summary": "Gilead's (GILD) new and updated positive results from a phase II study show Trodelvy's rapid and durable responses for patients across a range of hard-to-treat types of mUC.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c9/2325.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.14081, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KALA", "relevance_score": "0.221313", "ticker_sentiment_score": "0.079666", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVAX", "relevance_score": "0.111747", "ticker_sentiment_score": "0.053783", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.111747", "ticker_sentiment_score": "-0.021746", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.111747", "ticker_sentiment_score": "0.190691", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Should SPDR Portfolio S&P 500 High Dividend ETF  ( SPYD )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2056184/should-spdr-portfolio-sp-500-high-dividend-etf-spyd-be-on-your-investing-radar", "time_published": "20230220T112007", "authors": ["Zacks Investment Research"], "summary": "Style Box ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default306.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.266571, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PFG", "relevance_score": "0.122894", "ticker_sentiment_score": "0.068464", "ticker_sentiment_label": "Neutral"}, {"ticker": "STT", "relevance_score": "0.061631", "ticker_sentiment_score": "0.111021", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.122894", "ticker_sentiment_score": "0.068464", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.122894", "ticker_sentiment_score": "0.068464", "ticker_sentiment_label": "Neutral"}]}, {"title": "If You Invested $100 In This Stock 20 Years Ago, You Would Have $2,100 Today - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/news/earnings/23/02/30964753/if-you-invested-100-in-this-stock-20-years-ago-you-would-have-2-100-today", "time_published": "20230217T190231", "authors": ["Benzinga Insights"], "summary": "Gilead Sciences GILD has outperformed the market over the past 20 years by 8.18% on an annualized basis producing an average annual return of 16.34%. Currently, Gilead Sciences has a market capitalization of $105.38 billion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.980595", "ticker_sentiment_score": "0.386944", "ticker_sentiment_label": "Bullish"}]}, {"title": "The Zacks Analyst Blog Highlights Tesla, Eli Lilly, Bank of America, QUALCOMM and Gilead Sciences", "url": "https://www.zacks.com/stock/news/2056015/the-zacks-analyst-blog-highlights-tesla-eli-lilly-bank-of-america-qualcomm-and-gilead-sciences", "time_published": "20230217T163900", "authors": ["Zacks Investment Research"], "summary": "Tesla, Eli Lilly, Bank of America, QUALCOMM and Gilead Sciences are part of the Zacks top Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/75/107.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.716023", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.716023", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.716023", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.716023", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.716023", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Trodelvy\u00ae Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer - Investing News Network", "url": "https://investingnews.com/trodelvy-r-demonstrates-positive-efficacy-treating-both-platinum-ineligible-and-rapidly-progressing-post-platinum-metastatic-urothelial-cancer/", "time_published": "20230217T143000", "authors": [], "summary": "Trodelvy\u00ae Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer Investing News Network ...", "banner_image": null, "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": -0.132078, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.061473", "ticker_sentiment_score": "0.048159", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILD: The 3 Hottest Biotech Stocks to Own in 2023 and 1 to Avoid", "url": "https://stocknews.com/news/gild-uthr-jazz-bngo-the-3-hottest-biotech-stocks-to-own-in-2023-and/", "time_published": "20230216T183332", "authors": [], "summary": "Despite macro uncertainties, the biotech industry has fared relatively well over the past year thanks to consistent breakthroughs and inelastic demand. Along with increasing opportunities to serve an aging population, the Biden Administration's National Biotechnology and Biomanufacturing ...", "banner_image": "https://stocknews.com/wp-content/uploads/2023/01/ISt_Biotechnology.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99999"}], "overall_sentiment_score": 0.164341, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.048969", "ticker_sentiment_score": "0.056359", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNGO", "relevance_score": "0.146173", "ticker_sentiment_score": "0.10887", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.287481", "ticker_sentiment_score": "0.098936", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.146173", "ticker_sentiment_score": "0.08436", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTHR", "relevance_score": "0.146173", "ticker_sentiment_score": "0.065169", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top Analyst Reports for Tesla, Eli Lilly & Bank of America", "url": "https://www.zacks.com/research-daily/2055447/top-analyst-reports-for-tesla-eli-lilly-bank-of-america", "time_published": "20230216T160000", "authors": ["Zacks Investment Research"], "summary": "Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), Eli Lilly and Company (LLY) and Bank of America Corporation (BAC).", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default183.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.196944, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.303175", "ticker_sentiment_score": "0.184961", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABB", "relevance_score": "0.123844", "ticker_sentiment_score": "0.09851", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.123844", "ticker_sentiment_score": "0.09851", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.303175", "ticker_sentiment_score": "0.184961", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAC", "relevance_score": "0.184834", "ticker_sentiment_score": "0.126117", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.123844", "ticker_sentiment_score": "0.09851", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 Least-Hurt Biotech ETFs of the Last Week", "url": "https://www.zacks.com/stock/news/2054858/5-least-hurt-biotech-etfs-of-the-last-week", "time_published": "20230215T180000", "authors": ["Zacks Investment Research"], "summary": "Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default289.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.818451"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.107558, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VYNT", "relevance_score": "0.060848", "ticker_sentiment_score": "0.012023", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.121343", "ticker_sentiment_score": "0.207713", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVZ", "relevance_score": "0.060848", "ticker_sentiment_score": "0.157036", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.121343", "ticker_sentiment_score": "0.166173", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FNCH", "relevance_score": "0.060848", "ticker_sentiment_score": "0.012023", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILD: 3 Genius Dividend Stocks to Buy Now and Hold Forever", "url": "https://stocknews.com/news/gild-hmc-syy-3-genius-dividend-stocks-to-buy-now-and-hold-forever/", "time_published": "20230214T163603", "authors": [], "summary": "The Federal Reserve has been steadily increasing interest rates to draw money out of the economy and ease inflationary pressures. Inflation slowed down in December 2022 to an annual rate of 6.5% and is expected to tick down to 6.2% in January, continuing the disinflation trend that began last ...", "banner_image": "https://stocknews.com/wp-content/uploads/2021/08/shutterstock_1271080456-1-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.999999"}], "overall_sentiment_score": 0.17959, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SYY", "relevance_score": "0.199037", "ticker_sentiment_score": "0.228733", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.281261", "ticker_sentiment_score": "0.157093", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HMC", "relevance_score": "0.25416", "ticker_sentiment_score": "0.186474", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023 - Investing News Network", "url": "https://investingnews.com/gilead-demonstrates-transformative-potential-impact-of-antiviral-innovation-at-croi-2023/", "time_published": "20230214T141136", "authors": [], "summary": "Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023 Investing News Network ...", "banner_image": null, "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.093344, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DSSMY", "relevance_score": "0.016227", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.097128", "ticker_sentiment_score": "0.104594", "ticker_sentiment_label": "Neutral"}]}, {"title": "Lattice Semiconductor To Rally 33%? Here Are 10 Other Analyst Forecasts For Tuesday - Belden  ( NYSE:BDC ) , Cadence Design Sys  ( NASDAQ:CDNS ) ", "url": "https://www.benzinga.com/news/23/02/30895885/lattice-semiconductor-to-rally-33-here-are-10-other-analyst-forecasts-for-tuesday", "time_published": "20230214T123008", "authors": ["Lisa Levin"], "summary": "Goldman Sachs boosted the price target for Kaiser Aluminum Corporation KALU from $70 to $80. Goldman Sachs analyst Emily Chieng maintained a Sell rating on the stock. Kaiser Aluminum shares rose 1.7% to close at $85.33 on Monday. Needham raised the price target for Cadence Design Systems, Inc.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/02/14/image_5.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.99793"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.211067, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BDC", "relevance_score": "0.290033", "ticker_sentiment_score": "0.318665", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.290033", "ticker_sentiment_score": "0.18088", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "C", "relevance_score": "0.195814", "ticker_sentiment_score": "0.054514", "ticker_sentiment_label": "Neutral"}, {"ticker": "LSCC", "relevance_score": "0.290033", "ticker_sentiment_score": "0.430962", "ticker_sentiment_label": "Bullish"}, {"ticker": "HON", "relevance_score": "0.290033", "ticker_sentiment_score": "-0.05663", "ticker_sentiment_label": "Neutral"}, {"ticker": "MGA", "relevance_score": "0.290033", "ticker_sentiment_score": "0.189321", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GS", "relevance_score": "0.195814", "ticker_sentiment_score": "0.200656", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COIN", "relevance_score": "0.290033", "ticker_sentiment_score": "0.322545", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SHOP", "relevance_score": "0.290033", "ticker_sentiment_score": "-0.021779", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.195814", "ticker_sentiment_score": "0.239818", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CDNS", "relevance_score": "0.290033", "ticker_sentiment_score": "0.137213", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.195814", "ticker_sentiment_score": "0.215754", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KALU", "relevance_score": "0.290033", "ticker_sentiment_score": "0.271486", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Amarin Shareholders Vote \"AGAINST\" All of Sarissa's Proposals - Amarin Corp  ( NASDAQ:AMRN ) ", "url": "https://www.benzinga.com/pressreleases/23/02/g30891615/leading-independent-proxy-advisory-firm-glass-lewis-recommends-that-amarin-shareholders-vote-again", "time_published": "20230214T004744", "authors": ["Globe Newswire"], "summary": "Glass Lewis Recognizes that Change Led by Amarin's New Board is Already Underway, and Sarissa Representation is Not Warranted Report Notes that Sarissa's Underqualified Slate of Nominees Include \"Redundant\" Skillsets Amarin Board Urges Shareholders to Vote \"AGAINST\" Sarissa's Proposals on the ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.088, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMRN", "relevance_score": "0.551009", "ticker_sentiment_score": "0.134787", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.025166", "ticker_sentiment_score": "0.052092", "ticker_sentiment_label": "Neutral"}]}, {"title": "Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Amarin Shareholders Vote \"AGAINST\" All of Sarissa's Proposals", "url": "https://www.globenewswire.com/news-release/2023/02/14/2607198/18362/en/Leading-Independent-Proxy-Advisory-Firm-Glass-Lewis-Recommends-that-Amarin-Shareholders-Vote-AGAINST-All-of-Sarissa-s-Proposals.html", "time_published": "20230214T004700", "authors": ["Amarin Corporation plc"], "summary": "Glass Lewis Recognizes that Change Led by Amarin's New Board is Already Underway, and Sarissa Representation is Not Warranted ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/00eeab93-e634-4279-86b3-7973c2a21623?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.095191, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMRN", "relevance_score": "0.533678", "ticker_sentiment_score": "0.128973", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.026415", "ticker_sentiment_score": "0.019443", "ticker_sentiment_label": "Neutral"}]}, {"title": "Regenerative Medicine Market to Surpass USD 153.05 Billion by 2029, With 26.3% CAGR", "url": "https://www.benzinga.com/pressreleases/23/02/g30874563/regenerative-medicine-market-to-surpass-usd-153-05-billion-by-2029-with-26-3-cagr", "time_published": "20230213T124547", "authors": ["Globe Newswire"], "summary": "Pune, India, Feb. 13, 2023 ( GLOBE NEWSWIRE ) -- The regenerative medicine market size was valued at USD 23.65 billion in 2021. The market is expected to grow from USD 29.86 billion in 2022 to USD 153.05 billion by 2029 with a CAGR of 26.3% during the forecast period.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Mergers", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.262539, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLUE", "relevance_score": "0.039548", "ticker_sentiment_score": "0.033177", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.039548", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IART", "relevance_score": "0.039548", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.039548", "ticker_sentiment_score": "0.033177", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.039548", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.039548", "ticker_sentiment_score": "0.033177", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.039548", "ticker_sentiment_score": "0.083153", "ticker_sentiment_label": "Neutral"}]}, {"title": "Antifungal Drugs Market Report will Surpass USD 25.04 Billion by 2030 at a CAGR of 4.2% Till 2030 : GreyViews", "url": "https://www.benzinga.com/pressreleases/23/02/g30860017/antifungal-drugs-market-report-will-surpass-usd-25-04-billion-by-2030-at-a-cagr-of-4-2-till-2030-g", "time_published": "20230210T190000", "authors": ["Globe Newswire"], "summary": "Pune India, Feb. 10, 2023 ( GLOBE NEWSWIRE ) -- Antifungal Drugs Market Size By Drug Class ( Allylamines, Azoles, Polyenes, Echinocandins, and Others ) , By Route of Administration ( Parenteral, Oral and Topical ) , By Indication ( Candidiasis, Dermatophytosis, Aspergillosis and Others ) , ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.168828, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALPMF", "relevance_score": "0.032251", "ticker_sentiment_score": "0.125042", "ticker_sentiment_label": "Neutral"}, {"ticker": "HKMPF", "relevance_score": "0.064449", "ticker_sentiment_score": "0.132162", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.032251", "ticker_sentiment_score": "0.125042", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.064449", "ticker_sentiment_score": "0.132162", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHC", "relevance_score": "0.032251", "ticker_sentiment_score": "0.125042", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.032251", "ticker_sentiment_score": "0.125042", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead  ( GILD )  Kite Reports Positive Data on CAR T-Cell Therapy", "url": "https://www.zacks.com/stock/news/2052947/gilead-gild-kite-reports-positive-data-on-car-t-cell-therapy", "time_published": "20230210T160300", "authors": ["Zacks Investment Research"], "summary": "Gilead (GILD) reports positive long-term results from the phase I/II study on Tecartus (brexucabtagene autoleucel) for acute lymphoblastic leukemia.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c9/2325.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.263223, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GSK", "relevance_score": "0.137671", "ticker_sentiment_score": "0.210422", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.137671", "ticker_sentiment_score": "0.145248", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update", "url": "https://www.globenewswire.com/news-release/2023/02/09/2605512/0/en/Nurix-Therapeutics-Reports-Fourth-Quarter-and-Fiscal-Year-2022-Financial-Results-and-Provides-a-Corporate-Update.html", "time_published": "20230209T211500", "authors": ["Nurix Therapeutics", "Inc."], "summary": "Demonstrated NX-2127 overcomes BTK inhibitor resistance mutations and provides clinical benefit to patients with hematological malignancies ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/e95c30b7-0b40-4147-a34b-d48f933a63c7?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.081249, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.085997", "ticker_sentiment_score": "0.020712", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRIX", "relevance_score": "0.051663", "ticker_sentiment_score": "0.033991", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.103109", "ticker_sentiment_score": "0.021694", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILD: 3 High-Value Stocks to Buy and Hold for a Lifetime", "url": "https://stocknews.com/news/gild-stla-bvh-3-high-value-stocks-to-buy-and-hold-for-a-lifetime/", "time_published": "20230209T171825", "authors": [], "summary": "The Fed raised its interest rates by 25 basis points at the first Federal Open Market Committee ( FOMC ) meeting of 2023, bringing the federal funds rate to a target range of 4.5% to 4.75%.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/shutterstock_245520088-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}], "overall_sentiment_score": 0.278469, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACLX", "relevance_score": "0.075715", "ticker_sentiment_score": "0.235282", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACHR", "relevance_score": "0.050519", "ticker_sentiment_score": "0.150296", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.3426", "ticker_sentiment_score": "0.24131", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BVH", "relevance_score": "0.200066", "ticker_sentiment_score": "0.101342", "ticker_sentiment_label": "Neutral"}]}, {"title": "Kite's Tecartus CAR T-Cell Therapy Demonstrates Durable Overall Survival Benefit In Leukemia Settings - Gilead Sciences  ( NASDAQ:GILD ) ", "url": "https://www.benzinga.com/general/biotech/23/02/30839751/kites-tecartus-car-t-cell-therapy-demonstrates-durable-overall-survival-benefit-in-leukemia-setti", "time_published": "20230209T171732", "authors": ["Vandana Singh"], "summary": "Kite, a Gilead Sciences Inc GILD company, announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus ( brexucabtagene autoleucel ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/02/09/gild_logo_light__ebbb55419ca9273264e56cff479e848c.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.227456, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.501398", "ticker_sentiment_score": "0.170037", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update", "url": "https://www.zacks.com/stock/news/2052486/biotech-stock-roundup-amgn-gild-bmy-regns-q4-results-kprx-up-on-study-update", "time_published": "20230209T170000", "authors": ["Zacks Investment Research"], "summary": "Earnings results from Amgen (AMGN), Gilead (GILD) and others are the key highlights from the biotech sector during the past week.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default125.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.9545"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.196867, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KPRX", "relevance_score": "0.042876", "ticker_sentiment_score": "0.031433", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.128135", "ticker_sentiment_score": "0.116537", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.128135", "ticker_sentiment_score": "0.1827", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Regenerative Medicine Market Growth Report  ( $37.48 Billion )  Lead by Increasing Adoption of Gene Therapies | The Insight Partners", "url": "https://www.benzinga.com/pressreleases/23/02/g30833795/regenerative-medicine-market-growth-report-37-48-billion-lead-by-increasing-adoption-of-gene-thera", "time_published": "20230209T140800", "authors": ["Globe Newswire"], "summary": "New York, Feb. 09, 2023 ( GLOBE NEWSWIRE ) -- According to The Insight Partners, \"Regenerative Medicine Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global Analysis by Type ( Cell-Based Immunotherapy and Cell Therapy Products, Tissue-Engineered Products, ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.177379, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AUTL", "relevance_score": "0.030408", "ticker_sentiment_score": "0.04152", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDXG", "relevance_score": "0.030408", "ticker_sentiment_score": "0.100066", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYK", "relevance_score": "0.030408", "ticker_sentiment_score": "0.100066", "ticker_sentiment_label": "Neutral"}, {"ticker": "IART", "relevance_score": "0.060771", "ticker_sentiment_score": "0.156279", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVS", "relevance_score": "0.030408", "ticker_sentiment_score": "0.100066", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.030408", "ticker_sentiment_score": "0.100066", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.030408", "ticker_sentiment_score": "0.100066", "ticker_sentiment_label": "Neutral"}, {"ticker": "VCEL", "relevance_score": "0.030408", "ticker_sentiment_score": "0.100066", "ticker_sentiment_label": "Neutral"}]}, {"title": "Starburst Unveils Inaugural Data Rebel and Partner Award Winners at Datanova Conference", "url": "https://www.prnewswire.com/in/news-releases/starburst-unveils-inaugural-data-rebel-and-partner-award-winners-at-datanova-conference-301742770.html", "time_published": "20230209T140000", "authors": ["Starburst Data"], "summary": "Starburst Unveils Inaugural Data Rebel and Partner Award Winners ... PR ...", "banner_image": "", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.434195, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VMW", "relevance_score": "0.062271", "ticker_sentiment_score": "0.216633", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CCZ", "relevance_score": "0.062271", "ticker_sentiment_score": "0.216633", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.062271", "ticker_sentiment_score": "0.031158", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.062271", "ticker_sentiment_score": "0.031158", "ticker_sentiment_label": "Neutral"}, {"ticker": "DASH", "relevance_score": "0.062271", "ticker_sentiment_score": "0.216633", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Starburst Unveils Inaugural Data Rebel and Partner Award Winners at Datanova Conference", "url": "https://www.prnewswire.com/news-releases/starburst-unveils-inaugural-data-rebel-and-partner-award-winners-at-datanova-conference-301742770.html", "time_published": "20230209T140000", "authors": ["Starburst Data"], "summary": "Starburst Unveils Inaugural Data Rebel and Partner Award Winners ... PR ...", "banner_image": "", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.434195, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VMW", "relevance_score": "0.062271", "ticker_sentiment_score": "0.216633", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CCZ", "relevance_score": "0.062271", "ticker_sentiment_score": "0.216633", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.062271", "ticker_sentiment_score": "0.031158", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.062271", "ticker_sentiment_score": "0.031158", "ticker_sentiment_label": "Neutral"}, {"ticker": "DASH", "relevance_score": "0.062271", "ticker_sentiment_score": "0.216633", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Starburst Unveils Inaugural Data Rebel and Partner Award Winners at Datanova Conference", "url": "https://www.newswire.ca/news-releases/starburst-unveils-inaugural-data-rebel-and-partner-award-winners-at-datanova-conference-844575743.html", "time_published": "20230209T140000", "authors": ["Starburst Data"], "summary": "Starburst Unveils Inaugural Data Rebel and Partner Award Winners ... Canada ...", "banner_image": "", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.434195, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VMW", "relevance_score": "0.062271", "ticker_sentiment_score": "0.216633", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CCZ", "relevance_score": "0.062271", "ticker_sentiment_score": "0.216633", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.062271", "ticker_sentiment_score": "0.031158", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.062271", "ticker_sentiment_score": "0.031158", "ticker_sentiment_label": "Neutral"}, {"ticker": "DASH", "relevance_score": "0.062271", "ticker_sentiment_score": "0.216633", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "GILD: 1 Dividend Stock You'll Be Thankful to Own in 2023", "url": "https://stocknews.com/news/gild-vrtx-biib-uthr-1-dividend-stock-youll-be-thankful-to-own-in-2023/", "time_published": "20230209T135309", "authors": [], "summary": "GILD: 1 Dividend Stock You'll Be Thankful to Own in ...", "banner_image": "https://stocknews.com/wp-content/uploads/2022/01/shutterstock_1274515525-1-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999997"}, {"topic": "Earnings", "relevance_score": "0.992549"}], "overall_sentiment_score": 0.241827, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.074345", "ticker_sentiment_score": "0.079659", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.598987", "ticker_sentiment_score": "0.369852", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNCE", "relevance_score": "0.111315", "ticker_sentiment_score": "0.203191", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UTHR", "relevance_score": "0.074345", "ticker_sentiment_score": "0.079659", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.074345", "ticker_sentiment_score": "0.079659", "ticker_sentiment_label": "Neutral"}]}, {"title": "Mind the Gap: Understanding the 3 Types of Price Gaps", "url": "https://www.zacks.com/commentary/2051869/mind-the-gap-understanding-the-3-types-of-price-gaps", "time_published": "20230209T134000", "authors": ["Zacks Investment Research"], "summary": "Large price gaps can mark the end of a major price moves or be the signature of a future winning stock. Andrew Rocco explains the difference through historical examples.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default66.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999995"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.769861"}], "overall_sentiment_score": 0.135275, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MANU", "relevance_score": "0.094762", "ticker_sentiment_score": "0.106429", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.094762", "ticker_sentiment_score": "0.062846", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.234006", "ticker_sentiment_score": "0.207646", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GME", "relevance_score": "0.094762", "ticker_sentiment_score": "-0.019555", "ticker_sentiment_label": "Neutral"}]}]}